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ABSTRACT 
Cytotoxic T lymphocytes are able to identify malignant cells by scanning for aberrant 
peptides presented on cell surface human leukocyte antigen (HLA) Class I molecules 
by virtue of an antigen binding receptor called the T-cell receptor (TCR). Peptides 
presented by HLA Class I complexes represent the largest array of tumour associated 
antigens (TAAs) and are therefore ideal targets for immunotherapeutic reagents. 
Cancer patients frequently mount T-cell responses to tumour-specific antigens, but 
these are in most cases ineffective at clearing the tumour. This is in part due to the 
low affinity of TCRs for self-antigens coupled with low-level expression of target 
peptides on the surface of cancer cells. To harness the exquisite antigen recognition 
property of TCRs for use as potential therapeutic proteins, the principal goal of this 
thesis was to generate ultra-high affinity TCRs against three clinically relevant HLA 
Class I melanoma-specific epitopes, including peptides derived from Melan-
A/MART-1(26-35), gp100(280-288) and MAGE-A3(168-176). TCRs are membrane-bound 
disulphide (ds)-linked heterodimers consisting of an alpha and a beta chain. Each 
chain comprises three hypervariable or complementarity-determining region (CDR) 
loops, which assemble to form the antigen binding domains. As a general rule the 
CDR3 loops, and to a lesser extent the CDR1 loops, contact the peptide bound in the 
HLA groove and as such specificity is largely attributable to the CDR3 loops. The 
remaining CDR loops interact with the HLA surface and not the bound peptide. Each 
CDR loop was mutagenised using degenerative NNK oligonucleotides and expressed 
on the surface of bacteriophage as fusions to the phage coat protein pIII. Through a 
Darwinian process of in vitro evolution using pHLA ligand as the target molecule, 
mutated TCRs with improved affinity for pHLA were identified. TCRs engineered by 
phage display were produced as soluble ds-linked proteins and the contribution to 
affinity of each mutated CDR was measured by surface plasmon resonance (SPR). 
Using a combinatorial strategy, individual mutated CDRs were spliced into the same 
TCR molecule in a stepwise manner to further increase binding affinity. The final 
combination of mutated CDRs was shown to bind their cognate pHLA antigen with 
substantially improved KD values of 18 pM (Melan-A/MART-1(26-35)), 11 pM 
(gp100(280-288)) and 58 pM (MAGE-A3(168-176)), representing an increase over the wild-
type TCR of approximately 1.8 million-fold, 1.7 million-fold and 3.7 million-fold 
respectively. In addition, having discovered an off-target binding profile for the high 
affinity MAGE-A3 TCR, the phage display methodologies were explored to 
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reestablish the specificity of this molecule. These results are significant because this 
has provided a platform on which, for the first time, to make TCR-based therapeutics. 
For example, the affinity enhanced gp100 TCR is currently undergoing clinical 
evaluation in a Phase I/II trial.  
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1.1 Introduction  
The mainstay of cancer treatment, except in cases where the disease is too far 
progressed, has for many decades been surgery. More recently, this has been 
combined with chemo- or radiation therapy which, although it does not have 
spectacular efficacy and is associated with severe toxicity, has improved survival and 
time to progressive disease in many indications. Most chemo- and radiation therapies 
attempt to exploit the highly proliferative characteristic of cancer cells by inducing 
damage in the replicating cell ultimately leading to cell death. This is rarely a targeted 
approach and typically highly proliferative normal, healthy cells such as those in the 
bone marrow, digestive tract and hair follicles are also affected.  
The limited efficacy and severe side-effects of chemo- and radiation type therapies 
has in recent decades prompted considerable efforts to develop therapies that are 
targeted more specifically to cancer cells. Extensive research has uncovered 
molecules that are specifically involved in tumour survival and growth. Many proteins 
have also been identified that, although of unknown function, are characteristic to a 
smaller or larger extent of cancer cells, because they are overexpressed or, in some 
cases, exclusively expressed, in these. All these molecules represent potential targets 
for anti-cancer drugs.  
Targeted cancer therapies raise the possibility of more efficacious and less toxic 
treatment and include small molecule drugs and monoclonal antibodies that act in a 
variety of ways: blocking signal transduction pathways involved in the proliferation 
of cancer cells, sequestering proteins required for tumour spread and apoptosis of 
malignant cells via a toxic ‘pay load’ or by recruitment of components of the immune 
system e.g. bispecific antibodies which target the cancer cell via one arm and T-cells 
via the other. In recent years immunotherapy more than any other type of therapy has 
begun to show the capacity to eradicate tumours leading to long-term clinical 
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remission and the potential promise of a cure. In the majority of patients however, a 
cure remains elusive due to active immune evasion by cancers. 
Cancer cells arise from normal tissue cells and, despite the devastating threat they 
pose to a patient’s health, differ only marginally from their parental origin. However, 
they do contain gene mutations and exhibit abnormal expression of certain genes that 
make them stand out from ‘self’. A group of potential cancer targets are the tumour 
associated antigens (TAAs) which can elicit an immune response by antibodies or by 
T-cells. Cancer antigens vary in the pattern of their expression and can be divided into 
several distinct groups. Overexpressed antigens are expressed in normal tissue but are 
upregulated in tumours. Mutated self-antigens arise from random point mutations 
within genes that can be specific to a particular tumour of a particular individual. 
Cancer/testis antigens are widely spread in many different cancers but their normal 
expression is restricted to male germline cells in the testis. Expression of 
differentiation antigens is restricted to one particular tissue-type and by cancer cells 
derived from that tissue-type. 
The dominant immunotherapeutic protein scaffold in clinical development is 
antibody-based. The last two decades has seen notable successes with this type of 
framework, such as trastuzumab (Herceptin) in metastatic breast cancer, bevacizumab 
(Avastin) in metastatic colorectal cancer and rituximab (Rituxan) in Non-Hodgkin’s 
lymphoma. The targets for antibody-based therapies against cancer cells are integral-
membrane proteins; however, the majority of TAAs are intracellular and therefore 
inaccessible to antibodies. Therefore, the continued development of these types of 
drugs may be hindered by the limited number of amenable cancer targets. 
Cellular proteins, including TAAs, are continuously undergoing a process of 
degradation in the cytosol and are loaded onto major histocompatibility complexes 
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(MHC in the murine system and human leukocyte antigen, HLA in the human system) 
as short peptide fragments. The surface presentation of peptides provides the immune 
surveillance system a means to scan and screen the protein composition of the cell. 
Cytotoxic CD8
+
 T-cells recognise endogenously-derived peptide fragments presented 
in the context of MHC molecules via a surface-bound protein called the T-cell 
receptor (TCR); a molecule homologous both in structure and function to the B-cell 
receptor (BCR) displayed on the surface of B-cells.  
A number of clinical observations have provided evidence supporting the role of 
natural immunity to cancer. Although rare, in some cases, spontaneous regression of 
melanoma lesions accompanied by the clonal expansion of T-cells has been observed 
as reviewed in (Bindea, Mlecnik et al. 2010; Vesely, Kershaw et al. 2011). These anti-
tumour responses manifest in the absence of specific immunotherapy supporting the 
role of the immune system in the detection of malignant cells. Further evidence for 
cancer immunosurveillance (i.e. the recognition and destruction of cancerous cells by 
the immune system) is provided by reports that have identified tumour-reactive T-
cells in human cancer patients (Bindea, Mlecnik et al. 2010; Vesely, Kershaw et al. 
2011). Additionally, studies of melanoma, ovarian and colon cancer have 
demonstrated that improved prognosis correlates with increased numbers of 
intratumoural infiltrating lymphocytes (TILs). More specifically, it is the T-cell 
phenotype, quantity and location within the tumour that collectively are associated 
with patient survival (Bindea, Mlecnik et al. 2010; Vesely, Kershaw et al. 2011). 
However, in the majority of cancer cases presented T-cells are ineffective at 
controlling tumour growth. Failure to eliminate cancer cells is due in part to the 
depletion of T-cells that recognise self-peptides with high affinity during the process 
of negative selection in the thymus. T-cells that move into the periphery will present 
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TCRs with low antigen-binding affinity for self-antigen and as a result may fail to 
recognise and destroy malignant cells presenting these peptides. 
Whilst antibodies cannot recognise intracellular TAAs, the unique ability of TCRs 
to do so, makes this class of molecule an ideal candidate for therapeutic tumour 
targeting. For TCRs to be suitable as cancer therapeutic agents several challenges 
have to be addressed. TCRs are naturally membrane-bound and would therefore have 
to be produced as a soluble molecule. The number of tumour associated peptide 
antigens TAPAs presented on the surface of tumour cells is low necessitating 
engineering of the TCR for high affinity for which there is no precedent. 
 
1.2 Antibody structure and function 
Since the Nobel Prize-winning achievements of Georges Kohler and Cesar Milstein in 
1975 (Kohler and Milstein 1975) in generating monoclonal antibody hybridomas, this 
class of molecule has proven invaluable in both the research and clinical arena. The 
literature on this subject is almost endless, providing numerous lessons in areas such 
as protein engineering, design and expression, tumour targeting and drug 
development. 
The lessons learned from the engineering of antibody fragments are very relevant 
when exploring the engineering of TCRs. Both TCRs and antibodies are members of 
the immunoglobulin superfamily and retain a good degree of structural homology. 
Strategies devised for antibody stabilisation, reconfiguration and expression have the 
potential to inform or be directly applied to TCR engineering. 
Antibodies play a crucial role in the body’s response to encounters with foreign 
antigens; they are used by the immune system to identify and neutralise foreign 
pathogens. Antibodies can be secreted in a soluble form from activated B-cells called 
plasma cells or remain membrane bound. There are 5 classes (or isotypes) of 
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antibodies called immunoglobulins: IgA, IgD, IgE, IgG and IgM which differ in size 
and antigen-binding capacity (Murphy, Travers et al. 2008). The intact format of IgG 
is used by almost all approved antibody drugs (Beck, Wurch et al. 2011). Figure 1.1 
depicts an IgG molecule.  
The principal unit is Y-shaped (150 kilodaltons, KDa), bivalent (can bind two 
identical antigens) and has a modular structure containing a total of twelve domains 
(Padlan 1994). It comprises four chains: two identical heavy (H) chains and two 
identical light (L) chains (either a lambda-λ or a kappa-κ light chain) held together by 
disulphide bonds. 
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Figure 1.1. Schematic representation of an antibody IgG structure. An IgG 
molecule comprises two distinct modules in relation to activity: an antigen-binding 
end (the Fab region) and a biological mediated end (the Fc region). The IgG molecule 
consists of two identical heavy (H) chains and two identical light (L) chains (either an 
lambda  chain or a kappa chain) held together by disulphide bonds. The H chain is 
formed by one variable (V) domain and three constant (C) domains (CH1, CH2 and 
CH3). The light chain consists of one V domain and only a single C domain. The Fv 
fragment consists of a covalently bonded variable heavy (VH) and variable light (VL) 
domain. The N-terminus of the V domains contain three hypervariable loops or 
complementarity determining regions (CDR1, 2 and 3) where the highest level of 
sequence variability is concentrated; the most variable part is the third CDR. The 
pairing of the two V domains creates a single hypervariable site called the antigen-
binding site. Adapted from (Brekke and Sandlie 2003; Holliger and Hudson 2005).  
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The heavy chains of IgG comprise three constant (CH1, CH2, CH3) domains and one 
variable (VH) domain, whilst the light chains contain a constant (CL) domain and a 
single variable (VL) domain. Each domain comprises two -sheets packed tightly 
against each other in an antiparallel -barrel to form the so-called immunoglobulin 
(Ig) fold. The smallest unit of an antibody that still retains the antigen-binding site is 
the Fv (fragment, variable) domain which encompasses the variable region of the 
heavy and light chain. The antibody is divided into two distinct function-related 
portions. The Fab (fragment, antigen-binding) domain comprises of one variable 
domain and one constant domain from each of the two chains. The variable region is 
responsible for antigen recognition and binding affinity. The “tip” (N-terminus) of the 
VL and VH domains is formed from a total of six hypervariable loops or 
complementarity determining regions (CDRs); three loops from the variable domain 
of each chain (VH-CDR1, CDR2, CDR3 and VL-CDR1, CDR2, CDR3). Each set of 
loops is supported by nine -strands arranged in two sheets of four and five strands. 
The enormous diversity in antigen-binding capacity is generated by genetic 
recombination events that occur during B-cell maturation and somatic hypermutation 
of the variable regions in the activated B-cell. Recombination events in the precursor 
B-cell lead to a single heavy chain and a single light chain gene, each with a specific 
V region. Whilst antigen specificity of VH CDR3 results from the recombination of 
variable (V), diversity (D) and junctional (J) gene segments, VL CDR3 antigen 
specificity results from VJ gene recombination (Storb, Shen et al. 2001). Antigen-
binding capability is also derived from germline encoded CDR1s and CDR2s. There 
are seven human kappa ( ) light chains and eleven human lambda ( ) light chains. 
Further diversity is generated through variation in CDR-L1, CDR-H1 and CDR-H2 
lengths (Tomlinson, Walter et al. 1992; Lefranc, Giudicelli et al. 1999). The tail of the 
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molecule (domains two and three of each of the heavy chain constant regions), is 
termed the Fc (fragment, crystallisable) region and mediates effector functions 
through  interaction with Fc receptors expressed on various effector cells, including 
macrophages and natural killer (NK) cells or with components of the complement 
system leading to the destruction of antibody-coated target cells. 
 
1.3 Engineered Antibody fragments  
The modular structure of antibodies with the scaffold-like properties of the Ig fold 
lends itself to reconfiguration into various other simplified structural formats, 
including Fab (Fragment of antigen-binding), Fv (Fragment variable) and scFv 
(Single-chain Fv). The reduced size of these fragments confers a number of 
advantages, in certain circumstances over the parent IgG. For example, Fab fragments 
are more easily crystallised and in the context of molecular evolution strategies, Fab 
and other antibody fragments are better expressed in microbial systems. In terms of 
therapeutic potential, the smaller formats exhibit improved pharmacokinetics allowing 
a more rapid and efficient penetration of tissues inaccessible to intact IgGs. Numerous 
approaches have been devised to generate alternative recombinant antibody scaffolds 
for facile expression in microbial systems (yeast and E. coli). There are various ways 
of employing subunits of the antibody complex for engineering smaller fragments that 
can be used therapeutically; a number of which are undergoing preclinical and clinical 
evaluation (Holliger and Hudson 2005). 
 
1.3.1 Fragment of antigen-binding (Fabs) 
The Fab fragment (50 KDa), at one-third the size of the complete IgG, retains the 
antigen-binding capacity of the parent antibody making it an attractive molecule in 
terms of expression and potential therapeutic application. Chimeric mouse-human 
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Fabs that comprise mouse V domains fused to human C domains have been expressed 
as functional fragments in both yeast (Horwitz, Chang et al. 1988) and E. coli (Better, 
Chang et al. 1988; Skerra and Pluckthun 1991). 
 
1.3.2 Single-chain Fvs (scFvs) 
A smaller engineered antibody fragment is called Fv (Fragment variable). Variable 
VH and VL domains which are expressed as separate polypeptides assemble into Fv 
fragments through non-covalent association (Skerra and Pluckthun 1988; Pluckthun 
and Skerra 1989; Ward, Gussow et al. 1989). The production of Fv fragments, 
however, was hampered by improper folding and a tendency to form aggregates. In an 
effort to overcome the issues of instability and poor yields, the VH and VL domains of 
an Fv fragment can be linked to generate molecules called single-chain Fvs (scFvs) 
via a flexible peptide linker (Bird, Hardman et al. 1988; Huston, Levinson et al. 
1988), typically between 10 and 25 amino acids in length or by introducing a 
disulphide bond in the framework region of the VH and VL domains (disulphide-
stabilised Fvs; dsFvs) (Brinkmann, Reiter et al. 1993).  
 
1.3.3 Multivalent scFvs  
In terms of therapeutic promise, antibody molecules need to fulfil certain 
pharmacokinetic requirements such as low antigen dissociation rates and high 
retention times on the target tumour. Whilst monovalent antibody fragments such as 
scFvs, dsFvs and Fvs do not satisfy these criteria, they can be multimerised  (scFv 
dimers, trimers and tetramers) as a means to increase functional affinity (avidity) 
(Holliger and Hudson 2005). Multivalency can be achieved by varying the length of 
the linker between the VH and VL domains. Shortening the linker to between 5-15 
(Holliger, Prospero et al. 1993; Kortt, Lah et al. 1997; Arndt, Muller et al. 1998; 
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Nielsen, Adams et al. 2000), <5 or between 0-2 residues forces the scFv to self-
associate into dimeric (dimer), trimeric (trimer) or tetrameric (tetramer) antibody 
fragments respectively (Dolezal, De Gori et al. 2003).  
 
1.4 In vitro affinity maturation of antibodies 
It is not fully understood what affinity is necessary to deliver maximal therapeutic 
potential in terms of potency and efficacy. Although it has been shown that 
improvements in affinity correlate with greater antibody-mediated cytotoxicity and 
target cell lysis (McCall, Shahied et al. 2001), it has also been demonstrated that 
lower affinity antibodies are capable of efficient tumour targeting and tumour 
retention (Adams, Schier et al. 1998). Additionally, ultra-high affinity antibodies may 
not always be desired as, in some cases, diffusion from the vasculature into solid 
tumours, is impaired. It therefore seems apparent that an affinity plateau is reached 
above which tumour retention reduces (Adams, Schier et al. 2001).  
Display technologies have proven to be a powerful and efficient method to isolate 
and engineer antibodies in vitro. An examination of the techniques and strategies used 
to improve the affinity of antibodies has direct implications for the directed evolution 
of TCRs for high affinity. The in vitro directed evolution of antibody affinity follows 
a well-defined process akin to Darwinian evolution that starts with genetically 
manipulating the antibody sequence to generate huge libraries of variants from which 
binders with improved affinity for the target antigen are selected. A variety of display 
formats have been employed to engineer tighter binding antibodies each with 
advantages and disadvantages. The three major display formats are shown in Figure 
1.2 and include cell-free systems such as ribosomal display and cell-based systems 
such as yeast display and phage display. The fundamental principal of each display 
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strategy is the link between the phenotype (protein) and the genotype (genetic 
information) (Bradbury, Sidhu et al. 2011).  
Ribosome display was established by Hanes and Pluckthun (Hanes and Pluckthun 
1997) as a technique to identify scFv fragments specific for target ligands. The DNA 
construct for ribosomal display includes a T7 promoter, the gene to be displayed and a 
spacer region near the codon for the carboxy-terminus lacking a terminal stop codon. 
The library DNA is transcribed and translated in vitro (cells are not used any stage). 
The spacer domain enables the complete exit of the nascent polypeptide from the 
ribosomal tunnel whilst absence of a 3’ stop codon leaves the protein tethered to the 
ribosome accessible for interaction with antigen. Using this approach, scFvs against 
bovine insulin with affinities up to 82 pM (Hanes, Schaffitzel et al. 2000) and scFvs 
against the human death-receptor Fas with 22-fold affinity gains (Chodorge, Fourage 
et al. 2008) have been engineered. The major attraction of ribosomal display is the 
size of the libraries that can be generated. Because there is no transformation step, 
diversity is not restricted as in cell-based systems; libraries of more than 1x10
13
 
members are routinely produced. Cell-free systems such as ribosomal display are, 
however, limited to the display of antibody scFv fragments and have not been 
successful in the display of intact full-length IgGs. Ribosomal display of antibodies 
has been recently reviewed (Pluckthun 2012). 
In yeast display recombinant proteins are displayed on the surface of S. cerevisiae 
as fusions to the a-agglutinin yeast adhesion cell surface receptor (Boder and Wittrup 
1997). The receptor comprises two proteins, Aga1 and Aga2. Aga1 is embedded in 
the cell membrane and Aga2 binds Aga1 through two disulphide bonds. Recombinant 
antibodies are fused in frame to the AGA2 gene. 
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Figure 1.2. In vitro display formats. (A). Phage display. The recombinant protein (in 
this case an scFv) is displayed on the surface of a bacteriophage particle fused to a 
phage coat protein (in this case pIII). (B). Ribosome display. The DNA library is 
fused to a spacer sequence lacking a stop codon. The spacer sequence when translated 
remains tethered to the ribosome allowing the protein of interest (e.g. an scFv) to 
protrude out of the ribosome and interact with target antigen. The genetic information 
is recovered by reverse transcriptase PCR. (C). Yeast display. The gene of interest is 
fused to the Aga2 gene. The fusion cassettes are transformed into a strain of S. 
cerevisiae (producing endogenous Aga1 protein). Association of Aga1 and Aga2-scFv 
fusion through two disulphide (S-S) bonds results in display on the yeast cell surface. 
Expression is monitored using antibodies to the HA or c-Myc tags. Adapted from 
(Weisser and Hall 2009).  
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In the yeast display cloning vector the gene of interest is flanked with a C-terminal 
c-myc and N-terminal HA epitope tag. This facilitates monitoring of the level of 
recombinant antibody display through FACS-sorting using fluorescently labelled 
antibodies recognising either of the epitope tags. Flow cytometry techniques also 
allow the isolation and enrichment of populations of yeast cells displaying antibodies 
with desired antigen-binding characteristics. Although yeast display library size is 
limited by the relatively low transformation efficiency of yeast cells, there have been 
numerous antibody engineering successes.  In addition to affinity maturing an anti-
fluorescein scFv more than 17,000-fold to 48 fM (one of the highest affinity 
antibodies reported) (Boder, Midelfort et al. 2000), the Wittrup lab has also evolved 
the dissociation half-life of an anti-carcinoembryonic antigen (CEA) antibody up to 7 
days at 37ºC (Graff, Chester et al. 2004). Application of yeast display over the past 15 
years for engineering of antibodies has been recently summarised (Boder, 
Raeeszadeh-Sarmazdeh et al. 2012). 
Although both ribosome and yeast display have been used successfully to engineer 
antibodies, phage display technology remains the most widely used method of 
improving antibody affinity and binding properties; both are pivotal to the 
development of effective therapeutic molecules. 
Antibody fragments can be displayed on the surface of filamentous bacteriophage 
fused to one of the phage coat proteins, commonly protein III (pIII). A detailed 
description of the phage display machinery will be discussed in section 1.5. The 
antibody fragments can be displayed as Fab fragments, in which one of the two 
domains is fused to bacteriophage pIII and expressing the other unfused and secreting 
into the periplasm of E. coli (Hoogenboom, Griffiths et al. 1991; Barbas, Bjorling et 
al. 1992; Barbas, Crowe et al. 1992), as Fv fragments (Riechmann and Weill 1993) 
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and as scFv fragments (Marks, Hoogenboom et al. 1991). The increased stability of 
the Fab fragment compared to scFv and Fv fragments, presumably a consequence of 
the additional constant region interface, has seen it become the more popular display 
scaffold in recent libraries. 
An antibody phage library is a population of phage that displays on their surface a 
repertoire of antibody variants. Novel antibody clones specific for a particular target 
antigen can be isolated from several types of phage library including immunised, 
naïve and synthetic and will be discussed in section 1.5.4. In terms of in vitro affinity 
maturation (lead optimisation), which aims to mimic in vivo somatic hypermutation 
and clonal selection, sequence diversity is introduced into an antibody clone in a 
number of ways. The most commonly used are CDR walking (site directed 
mutagenesis), light and heavy chain shuffling and random mutagenesis of the variable 
domains. Molecular evolution techniques follow three steps: first, generation of 
diversity, second, introduction of a selective pressure and third, amplification of 
improved variants. 
 
1.4.1 CDR walking 
CDR walking is a targeted approach to introduce diversity within regions of the 
molecule that are known to interact with the antigen, principally the CDR loops. 
Affinity improvements can be achieved using a parallel or sequential approach.  
In a parallel strategy, Fab antibody libraries have been constructed in which every 
residue in all of the CDRs is separately mutated, one at a time. Using degenerative 
NNS oligonucleotides (where N = nucleotides G, A, T or C in an equal molar ratio 
and S = nucleotides G or C in an equal molar ratio) (Wu, Beuerlein et al. 1998) or 
NNK oligonucleotides (where K = nucleotides T or G in an equal molar ratio) (Wu, 
Pfarr et al. 2005) each residue is targeted. Combinations of individual mutations 
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selected from these libraries often confer a step wise improvement in affinity into the 
low nanomolar range.  
A parallel (Yang, Green et al. 1995) and a sequential (Schier, McCall et al. 1996) 
approach have been used to affinity mature an antibody for the HIV gp120 antigen. 
The parallel approach involved building five Fab libraries targeting four CDRs (Yang, 
Green et al. 1995) and combining independently isolated mutations. Whilst not all 
mutations combined in an additive manner, a 420-fold affinity improvement was 
achieved over the parent antibody. Marks and colleagues (Schier, McCall et al. 1996) 
addressed the non-cooperation frequently observed between mutants by using a 
sequential library strategy. Firstly, a high affinity clone was isolated from an NNS 
designed LCDR3 library. Using this clone as template for mutagenesis of the HCDR3, 
further variants were identified. Recruitment of mutated HCDR3 segments into the 
already high affinity LCDR3 segment conferred a 1230-fold improvement in affinity 
over the parent clone. In this example, the sequential approach proved to be a more 
efficient means of achieving high affinity compared with the parallel approach. 
There are numerous examples of CDR mutagenesis for the isolation of high 
affinity antibodies, including Fab-based libraries where affinity improvements of 228-
fold are observed from CDR3 targeting (Lowe, Gerhardt et al.) and 5000-fold from 
LCDR3 and HCDR2 targeting (Steidl, Ratsch et al. 2008).  
Affinity improvements are also possible through extending the length of germ line 
encoded HCDR2 loops (Lamminmaki, Pauperio et al. 1999). Inserting two, three or 
four NNS-encoded residues into the loop of HCDR2 created new antigen-binding 
contacts and conferred up to 12-fold improvements in affinity over the wild-type 
antibody. 
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1.4.2 Chain shuffling 
Chain shuffling exploits the enormous natural sequence diversity of antibody variable 
chains (Tomlinson, Walter et al. 1992; Timmers, Hermans et al. 1993; Williams and 
Winter 1993) and is another strategy for selecting high affinity antibodies. In this 
approach, one of the chains is replaced by a repertoire of genes and combined with the 
static partner (Marks, Griffiths et al. 1992; Kwong, Baskar et al. 2008). A chain 
shuffling strategy was used to improve the affinity of an already high affinity anti-
HIV gp120 antibody (Thompson, Pope et al. 1996). Whilst shuffling the light chain 
yielded little improvement in affinity, two residues in HCDR2 and one in the heavy 
chain framework, resulted in reduced off-rate from the gp120 antigen. Subsequently, 
the HCDR3 was randomised by a synthetic oligonucleotide spiking approach. Finally, 
the residues in the heavy chain each conferring a reduction in off-rate were 
randomised by site-directed mutagenesis to yield a mutant with a 7-fold improvement 
over the parent antibody. 
 
1.4.3 Guided mutagenesis 
Further strategies to engineer improvements in affinity rely on either antibody-antigen 
structural information or on protein alignment of antibody germline sequences to 
identify hot spots frequently mutated in the natural antibody repertoire. Structural 
information can guide the identification of contact points at the antibody-antigen 
interface and so can direct the engineering of antibodies through a targeted approach 
(Chen, Wiesmann et al. 1999). In this study, the wild-type antibody crystal structure 
identified the HCDR3 loop as making greatest contact with antigen. Focusing 
mutagenesis within this region uncovered variants with between two and five-fold 
improvements in affinity compared to the parent molecule with a further improvement 
in affinity when combined. In a  similar approach, instructed by crystallography, a hot 
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spot of amino acids in the contact zone were targeted using degenerative 
oligonucleotides that yielded mutated antibodies with improved potency both in vitro 
and in vivo over the wild-type antibody (Li, Xi et al. 2009). 
Ho et al. (Ho, Kreitman et al. 2005) used NNS-directed mutagenesis of residues 
frequently mutated in vivo by somatic mutation to identify two hot-spots within 
LCDR1 that conferred a 7-fold improvement over the wild-type antibody.  Whilst this 
study failed to demonstrate additivity of the mutations, Ducancel and co-workers 
(Muller, Savatier et al. 2011) successfully showed that independently identified CDR 
hot-spot mutations combined to bestow further affinity improvements over the parent 
antibody. 
 
1.4.4 Random mutagenesis 
Affinity maturation can also be accomplished using a non-targeted approach. 
Mutations are randomly introduced into either the variable genes or framework 
regions using error-prone PCR (Foote and Winter 1992; Hawkins, Russell et al. 1992) 
or using a bacterial mutator strain (Irving, Kortt et al. 1996; Low, Holliger et al. 
1996). Hawkins et al. (Hawkins, Russell et al. 1992) introduced mutations randomly 
into the antibody genes of an anti-hapten antibody using error prone PCR and 
identified mutations with a 4.5-fold increase in affinity over the parent molecule. 
Winter and co-workers (Low, Holliger et al. 1996) used a similar approach to isolate 
mutations with up to 100-fold improvement in affinity over the wild-type antibody. 
From the studies reported here, it appears that the CDR walking approach is most 
successful in generating the largest increases in antibody affinity and as such deserves 
consideration as a strategy to engineer TCRs for high affinity.  
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1.5 Phage Display 
Phage display is an in vitro selection technique that allows the isolation and 
enrichment of proteins and peptides with particular biochemical characteristics from 
vast pools (libraries) of variants. Phage display was first reported over twenty-five 
years ago in George Smith’s seminal paper (Smith 1985) that demonstrated that 
peptides, fused to one of the phage coat proteins could be enriched over normal phage 
through binding to a target antibody. It was later shown that antibody fragments could 
also be displayed on phage opening up the technology to antibody engineering 
(McCafferty, Griffiths et al. 1990).  
 
1.5.1 Filamentous phage structure 
The filamentous bacteriophages are a group of viruses capable of infecting many 
Gram negative bacteria.  The best studied filamentous phages belong to Ff class of 
phages (f1, M13, fd) whose genomes are more than 98% homologous. The Ff phage 
particle is approximately 6.5 nm in diameter and 930 nm in length (see Figure 1.3). 
The 6440-nucleotide circular single-stranded DNA genome (ssDNA) encodes eleven 
proteins, of which five are the coat proteins (pIII, pVI, pVII, pVIII and pIX) and the 
remainder are the non-structural proteins involved in DNA replication (pII, pV and 
pX) and virion assembly (pI, pIV and pXI). The filament-shaped structure which 
encapsulates the phage DNA comprises almost 2700 copies of the major coat protein, 
pVIII. One end of the particle is capped by five copies each of pVII and pIX. The 
other end of the particle consists of between four to five copies each of pIII and pVI.  
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Figure 1.3. Filamentous phage Ff structure. Filamentous phage are cylindrical 
structures with a diameter of about 6.5 nm and a length of about 900 nm containing a 
circular single-stranded (ss) DNA genome comprising 6407 nucleotides, encapsulated 
by approximately 2700 copies of the major coat protein pVIII. The particle is capped 
at the pointed end by five copies each of pIII and pVI. The blunt end contains three to 
five copies of pVII and pIX. 
 
 
1.5.2 The life cycle of filamentous phage 
Ff phages most efficiently infect male bacteria as they use the E. coli F pilus (encoded 
by the F plasmid) as a receptor during the infection process. The infection and 
assembly process is illustrated in Figure 1.4. Infection is mediated through the 
interaction of pIII and the F pilus. The pIII consists of three domains: two N-terminal, 
N1 and N2 (which are intramolecularly linked) and one C-terminal, CT. The three 
domains are connected by a flexible glycine-rich linker. Infection is initiated when the 
N2 domain binds to the F pilus on an E. coli cell. The pilus subsequently retracts 
bringing the phage particle to the E. coli periplasm. Interaction of the pilus with pIII 
leads to the dissociation of N1 from N2 allowing it to bind with the bacterial TolA 
protein. The F pilus acts as a receptor and the TolA protein as a co-receptor for pIII 
binding and infectivity. The presence of pIII in the bacterial membrane confers the 
cell with resistance to further infection from filamentous phage. Two additional 
bacterial proteins, TolQ and TolR, are essential for phage infectivity facilitating the 
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disassembly of the phage coat proteins into the cytoplasmic membrane and injection 
of the phage ssDNA into the bacterial cytoplasm, although the exact mechanism of 
this process remains unclear. Once in the cytoplasm, the viral (+) ssDNA is converted 
into a double-stranded, supercoiled molecule that is referred to as the Replicative 
Form (RF) DNA. The (-) strand of the RF DNA acts as the template for transcription 
and the synthesis of all eleven phage proteins. Of particular importance to further 
phage genome replication is pII which serves as a nicking-closing enzyme. It first 
nicks the (+) strand of the RF in a non-coding intergenic region. The (-) strand of the 
RF acts as a template to elongate the nicked (+) strand via a rolling-circle mode of 
action. Once a round of replication has finished, the nicked (+) strand is recircularised 
by pII and converted into RF. The process of RF DNA synthesis continues until a 
level of pV is reached where it starts to bind to viral (+) ssDNA blocking its 
conversion to RF DNA. All phage proteins are synthesised simultaneously. Each of 
the eight proteins involved in phage assembly are inserted into the cytoplasmic (pIII, 
pVI, pVII, pVIII, pIX, pI and pXI) or outer membrane (pIV). The remaining three 
phage proteins (pII, pX and pV) are located in the cytoplasm. Assembly of the virus 
particle is a multi-step process that takes place in the cytoplasmic membrane. It 
involves the removal of pV from phage genomic DNA and encapsulation by the 
phage capsid proteins. The eventual extrusion of phage particles from the bacterial 
cell occurs via the assembly point (comprising pI, pXI and pIV) where the 
cytoplasmic and outer membrane become in close contact and a pIV-mediated 
channel is formed. Once the end of the DNA is reached, as the phage particle exits 
through the pIV channel, assembly is terminated by the addition of pIII and pVI. 
During the first hour about 1000 phage progeny are secreted from the bacterial cell 
(Webster 2001). 
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Figure 1.4. Life cycle of filamentous Ff phage. Sequential binding of the N2 domain 
of pIII with the E. coli F pilus and the Tol A protein leads to retraction of the pilus 
and transfer of the phage genome (the + strand) into the cytoplasm of the bacterial 
cell. The major pVIII coat protein integrates into the inner membrane. The viral 
ssDNA is converted to a double-stranded Replicative Form (RF) DNA mediated by 
host enzymes and acts as the template for the phage gene expression. Newly 
synthesised viral ssDNA is coated with pV (except the packaging sequence hairpin 
(PS) which protrudes from one end) preventing conversion to RF. The pV/ssDNA 
complex is the substrate for phage assembly. Phage proteins are expressed 
simultaneously. Multiple copies of pIV assemble in the outer membrane of the 
bacteria host cell, whilst pI and pXI proteins assemble in the inner membrane. An 
assembly point is formed where the inner and outer membrane come into close 
proximity. The formation of the pI, pXI, pIV (thioredoxin) transport complex 
provides a route through which the phages are secreted from the E. coli cell. 
Interaction of pIX and pVII with the pV/ssDNA complex at the PS leads to the 
replacement of pV with pVIII. Secretion is terminated by capping of the phage 
particle with pIII and pVI. Adapted from (Russel, Lowman et al. 2004).  
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1.5.3 Phage display formats 
Whilst all of the phage coat proteins have been used to display various peptides, 
antibodies and other proteins (Velappan, Fisher et al. 2010) the most widely used 
phage proteins for display are pIII and pVIII. Phage vectors that encode foreign DNA 
as pIII or pVIII fusions are called type 3 or type 8 respectively (Smith and Petrenko 
1997). In type 3 or 8, the foreign DNA is inserted into the phage genome as N-
terminal fusions so that all copies of either pIII (five copies) or pVIII (2700 copies) 
display the foreign peptide. With regards to type 8 vectors the number of peptides that 
can be displayed is dependent on the size of the peptide and is restricted to short 
fragment insertions (5-6 residues), possibly due to the space constraints resulting from 
the tight packing of the pVIII coat proteins or because large pVIII fusions may be 
unable to pass through the pIV pore during virion assembly (Greenwood, Hunter et al. 
1991). Display on pIII molecules can accommodate larger insertions although 
infectivity can be affected.  
To overcome the size restriction of the foreign peptide (about six residues) in type 
8 vectors there is a second group of phage vector, type 3 3 or 8 8, in which the phage 
genome contains two copies of genes III or VIII, one wild-type and one recombinant. 
This gives rise to phage particles displaying a mixture of wild-type and recombinant 
pIII or pVIII molecules (with the majority of pIII or pVIII molecules being wild-
type).  
Type 3+3 or 8+8 is different from 3 3 or 8 8 in that the wild-type and recombinant 
genes III or VIII are encoded by two separate genomes. Type 3 or 8 and 3 3 or 8 8 
vectors are termed phage vectors and type 3+3 and 8+8 vectors are called phagemid 
vectors or just phagemids.  
Phage vectors bear the entire phage genome and so possess all the necessary viral 
machinery for the replication and assembly of new virus particles. Foreign peptides 
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are inserted in frame at the C-terminus of the coat protein signal peptide sequence and 
at the N-terminus of the coat protein (pIII or pVIII) sequence. This results in 
polyvalent display in which all copies of the coat proteins display the foreign peptide 
(Scott and Smith 1990; McLafferty, Kent et al. 1993).  
In contrast, phagemids do not contain the genes required for the production of new 
virus particles. A phagemid is a small plasmid that contains an antibiotic resistance 
gene to allow the selection of plasmid-bearing cells, an E. coli origin of replication for 
plasmid propagation in bacteria and a filamentous phage (Ff) origin of replication 
which enables the synthesis of single-stranded vector DNA. The Ff origin remains 
inactive until the phagemid-bearing E. coli cells are superinfected with a helper 
phage.  
A helper phage is a phage particle which provides all the necessary genetic 
information for the assembly and propagation of new virus particles including the 
wild-type coat proteins. The phage replication protein encoded by the helper phage 
acts in trans on both the helper phage and phagemid Ff origin of replication. The 
foreign peptide is cloned between the coat protein signal sequence, and the fusion coat 
protein sequence is under the control of a weak promoter. Phagemid-bearing E. coli 
are grown in glucose-containing media to repress the expression of pIII which would 
prevent superinfection with helper phage. Helper phage contain an antibiotic selection 
marker (commonly kanamycin) different from that encoded by the phagemid allowing 
the selection of E. coli cells that contain both the helper phage and phagemid 
genomes. In the E. coli cell proteins from both the helper phage (wild-type) and the 
phagemid (recombinant) are produced. Wild-type pIII competes with recombinant 
pIII for incorporation into the assembling virus particle. The majority of phage 
produced from the phagemid system will display only wild-type pIII on their surface 
Chapter 1 
 41 
derived from the helper phage (referred to as bald phage), with less than 10% 
displaying one copy of the fusion, resulting in monovalent display. This is due to the 
excess expression of wild-type pIII and its preferential assembly into the virus particle 
over the recombinant version. However, it is important to note that helper phage 
contain a defective Ff origin of replication and packaging signal and so phagemid 
DNA is preferentially packaged over helper phage DNA so that the link between the 
phenotype and the genotype of the protein displayed is maintained.  
It is possible to increase the valency of display with the phagemid system by using 
a modified gene III-deleted helper phage called Hyperphage (Rondot, Koch et al. 
2001). Such phages display the pIII phenotype but contain a phage vector that does 
not code the gene III sequence. So the phage particles have to be produced in an E. 
coli cell line that provides pIII for helper phage assembly. This means that the only 
source of pIII is from the phagemid vector and so multivalent display is possible.  
The type of phage display system employed dictates the number of recombinant 
fusion proteins displayed on the phage surface that are accessible to interaction with 
the target antigen. Polyvalency of the phage vector system in which 3-5 identical 
copies of the fusion protein are displayed leads to the selection of low affinity binders 
(by virtue of avidity effects). In contrast, the monovalent phagemid system, due to the 
lack of avidity effects, more often select for high affinity binders and as such are 
typically used in affinity maturation projects.  
An overview of the processes involved in the construction of and selection from 
TCR phage display libraries is illustrated in Figure 1.14 (page 99). 
 
1.5.4 Isolation of antibody variable domains  
In addition to the affinity maturation of antibodies, phage display has proven an 
effective tool for the generation and isolation of antibodies with particular binding 
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specificities. Antibodies are a naturally diverse group of molecules and so provide an 
excellent scaffold for engineering. A variety of strategies have been employed to 
isolate V domains against any given antigen. These include isolating antibodies from 
immunised animals, from repertoire (naïve) libraries or from synthetic or semi-
synthetic libraries.  
Antibody libraries can be constructed from an immunised source by firstly 
challenging the animal with a particular antigen and then amplifying the VL and VH 
domains from reverse-transcribed splenocyte RNA (Clackson, Hoogenboom et al. 
1991). A drawback, in addition to the time demands and technical challenges of 
animal immunization, is that the antibody specificities are restricted to that of the 
antigen used and so new libraries have to be built for each new antigen.  
The construction of naïve libraries from repertoires of V-genes addresses this 
limitation. Oligonucleotide primer sets for each of the VL and VH genes are used to 
PCR amplify the repertoire of V-genes from a non-immunised source of PBMCs. The 
random combination of variable chains generates a library of diverse antibodies with 
the potential to recognise any target antigen. Libraries with a relatively limited 
diversity of >10
7
 have yielded antibodies with affinities in the low micromolar range 
(Marks, Hoogenboom et al. 1991). By comparison, naïve libraries with 10
10 
clones 
(Vaughan, Williams et al. 1996) and 6.5 x 10
10
 clones (Griffiths, Williams et al. 1994) 
have yielded antibodies with subnanomolar and low nanomolar affinities respectively. 
Synthetic VH/VL libraries are constructed by design and can vary from being semi-
synthetic to fully synthetic depending on the ratio of antibody genes of synthetic or 
natural origin. The Winter lab has utilised semi-synthetic and fully synthetic libraries 
to select antibodies against desired antigens by introducing randomised mutations into 
HCDR3 of all 49 VH genes; either 5-8 residues (Hoogenboom and Winter 1992) or 4-
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12 residues (Nissim, Hoogenboom et al. 1994) and combining with a single VL 
domain. 
Knappik et al. (Knappik, Ge et al. 2000) constructed fully synthetic Human 
combinatorial antibody libraries (HuCAL). They combined 7 VH and 7 VL chain 
genes to generate 49 VH/VL (E. coli optimised) frameworks and then randomised the 
CDR3 loops. A recent permutation is the HuCAL GOLD library in which all six 
CDRs are randomised (Rothe, Urlinger et al. 2008). The quality of the CDR 
randomisation libraries was optimised using trinucleotides where there is a greater 
control over the inserted mutations compared to the more common mononucleotides. 
There are many further examples of synthetic libraries in which the number of 
antibody frameworks is restricted. The ETH-2 library built on one germline heavy 
chain and two germline light chains, diversified through random mutagenesis of 
HCDR3 (4-6 positions) and LCDR3 (6 positions) (Viti, Nilsson et al. 2000) has been 
mined for  anti-CEA antibodies (Pavoni, Flego et al. 2006). Another synthetic library 
was constructed by combining 49 germline VH chains and 7 light chains coupled with 
randomisation of HCDR3 (de Kruif, Boel et al. 1995). Additionally, libraries have 
been devised that combine repertoire-derived variable CDR3 genes with synthetically 
engineered variable CDR1 and CDR2 domains (Hoet, Cohen et al. 2005). 
 
1.5.5 In vitro selection methods 
In theory it should be possible to directly screen antigen-binding phage-displayed 
particles from the original phage display library but this is impractical because of the 
number of phage particles that would have to be analysed. For this reason methods 
have been developed to enrich for antigen-binding molecules over non-binding phage 
particles. Because the genotype encoding the displayed protein is carried within the 
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phage particle, once proteins have been selected, the DNA sequence can be readily 
determined by sequencing. 
The selection process called “biopanning” involves multiple steps: incubation of 
phage antibodies with their target, washing to remove clones that do not bind, elution 
of antigen-binding phage antibodies from their target and infection of E. coli cells 
with the eluted phage (Figure 1.5).  
Each of these steps can be performed in a variety of ways. The selection step is the 
process whereby antigen-binding phage is separated from non-binding phage; this 
requires purified antigen. The quality of antigen is paramount in order to prevent the 
selection of antibodies to antigens other than the target peptide. Selections are 
performed in a blocking media such as bovine serum albumin, milk powder or gelatin 
to reduce the binding of non-specific phage. To maximise the capture of antigen 
binders the first selection cycle (“pan”) is usually carried out under conditions that are 
not too stringent. The antigen is immobilised onto solid supports such as petri dishes 
or plastic tubes (Marks, Hoogenboom et al. 1991) or can be tagged, biotinylated and 
captured in solution as phage-antigen complexes with streptavidin-coated 
paramagnetic beads and a magnet (Hawkins and Winter 1992).  
Several features of the process can be fine-tuned to enrich for clones with the 
desired binding properties, including antigen concentration, the number of washes, the 
type of elution agent and the total number of panning cycles. The selection efficiency 
is also dependent on other factors such as folding of the protein in the periplasm 
during phage assembly and potential toxicity of the protein to the bacterial host cell. 
Both of these can affect the level of display on the phage surface.  
Antigen concentration can be decreased and the number of washes increased 
through each round of panning to encourage the selection of higher affinity antigen 
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binders. The selection of higher affinity antibodies from an already high affinity 
parent molecule requires greater stringency (i.e. panning of second generation 
libraries). In off-rate selection antibody-phage is mixed with biotinylated antigen until 
equilibrium is reached. A molar excess of non-biotinylated antigen is added to capture 
antibodies with faster dissociation times. Antibodies with slower off-rates remain 
bound to the biotinylated antigen and are isolated (Hawkins, Russell et al. 1992).  
A number of treatments can be used to elute antibodies bound to antigen: acidic 
(0.1 M HCl or 0.2 M Glycine, pH 2.5) (De Pascalis, Gonzales et al. 2003), basic (0.1 
M triethylamine) (van Wyngaardt, Malatji et al. 2004) or enzymatic (a trypsin 
protease cleavage site is engineered between antibody and pIII) (Kristensen and 
Winter 1998). In the next step, the eluted phage is then used to infect E. coli cells and 
plated onto selective agar. The selective output is amplified through several rounds of 
replication in liquid media and the enriched antigen-binding phage particles re-enter 
the panning cycle. Following several rounds of panning (typically three to five) 
individual antibiotic-resistant colonies are picked, phage prepared and screened for 
antigen-binding by ELISA.   
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Figure 1.5. Schematic representation of the biopanning process. A phagemid 
vector that encodes a recombinant protein (in this example a TCR) fused to pIII is 
propagated in E. coli with a helper phage. The library of protein variants is displayed 
on the surface of the phage particles and is incubated with the target antigen in a 
binding step. Antigen is either immobilised onto a solid surface or is tagged 
(biotinylated) and added in solution (as shown here). In solution panning, antigen-
binding phages are rescued using streptavidin-coated beads and a magnet. Following a 
wash step to remove non-specific phage particles, specific antigen-binding phage are 
eluted from the binding matrix and used to re-infect E. coli and re-enter the next 
round of panning. Following several rounds of enrichment individual clones are 
analysed by ELISA and sequencing.  
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1.6 Cellular immune responses 
The potent capacity of the immune system to combat diseases is demonstrated by its 
ability to prevent infection from the barrage of pathogens we are exposed to during 
our lifetime. The human body is protected from infection with foreign pathogens and 
from the growth of tumour cells by a collection of interdependent cells that comprise 
the immune system. The immune system comprises two main subdivisions, the innate 
and the adaptive immune system. The innate system which is the first line of defence 
provides a physical barrier (skin and mucosal epithelia) to many pathogenic agents 
but also includes cells such as macrophages and neutrophils that eliminate pathogens 
through an active process called phagocytosis. Only when this barrier is breached 
does the second line of defence, the adaptive immune system, come into play. The 
adaptive immune response is distinguished from the innate system in a number of 
ways. First, the innate system acts immediately to protect against invading pathogens, 
whereas the adaptive response requires sufficient time for the clonal expansion and 
differentiation of antigen-specific lymphocytes. Second, whereas the cells of the 
adaptive immune system use highly diverse antigen-specific receptors that have 
undergone genetic rearrangement, the innate receptors are germ-line encoded and 
recognise surface molecules displayed on pathogens. Third, the adaptive system 
affords immunological memory against re-infection with the same pathogen, whereas 
the innate system does not result in lasting memory of specific pathogens. The 
adaptive immune response is characterised by specific recognition of foreign 
pathogens by T and B lymphocytes. B-cells contribute to the humoral response by 
secreting antigen-specific antibodies that recognise, inactivate and destroy pathogens. 
T-cells recognise antigens presented on the surface of cells bound to MHC molecules. 
T-cells are the key players in cell-mediated immune response. Recognition of antigen 
fragments bound to MHC molecules is through the heterodimeric T-cell receptor 
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(TCR) which consists of and an alpha and a beta (  or ) chain. The work described 
in this thesis is focused on the recognition of peptide-MHC by the  TCR and so  
TCRs will not be considered further. 
Effector T-cells are divided into two distinct subsets: cytotoxic T-cells (Tc) and 
helper T-cells (TH). Cytotoxic T-cells express on their surface the CD8 co-receptor 
and recognise and kill pathogen-infected or tumour cells largely through two 
mechanisms.  First, perforin/granzyme-mediated killing: perforin molecules released 
from the Tc insert into the target cell membrane to form a pore through which granule 
proteases (granzymes) pass. Granzymes cleave intracellular substrates to activate 
signalling pathways leading to apoptosis. Second, Fas Ligand (FasL)/Fas protein 
killing: activated Tc upregulate the expression of a transmembrane protein designated 
FasL. Target cells express a receptor for FasL called the Fas protein. Interaction of 
FasL and Fas leads to apoptosis of the target cell. The work described in this thesis is 
focussed on CD8
+
 T-cells as these have the ability to recognise intracellular antigens. 
CD4 T-cells orchestrate the immune system by recognising MHC class II and will not 
be considered further.  T-cells also express on their surface CD3, which contains the 
γ, δ, ε and ζ proteins used for cell signalling when a T-cell encounters cognate antigen 
presented on MHC molecules. In the context of cancer, many components of the 
immune response are not recruited and consequently the disease progresses. 
Therapeutic approaches that are designed to harness some or all of these mechanisms 
have great promise to provide potent long-term effective treatment. 
 
1.7 The Major Histocompatibility Complex   
There are two classes of MHC molecules: class I and class II. The genes that encode 
the MHC class I and class II molecules are clustered on the short arm of human 
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chromosome 6 occupying 4-6 megabases. The  chain of MHC class I and the  and 
 chains of MHC class II are tightly linked within the MHC region of chromosome 6 
whilst the 2-microglobulin ( 2-m) of class I molecules is located on chromosome 15. 
There are three “classical” MHC class I genes in humans: Human Leukocyte Antigen 
(HLA)-A, -B and -C which are highly polymorphic, and three “non-classical” class I 
genes HLA-E, -F and -G which are far less polymorphic. MHC class I molecules are 
present on almost all nucleated cells.  
The class II molecules (HLA-DR, -DQ and -DP) are encoded by a cluster of genes 
located within the MHC class II region of the MHC on human chromosome 6. The 
HLA-DR, -DQ and -DP chain genes are all highly polymorphic. The cellular 
distribution of MHC class II molecules is more restricted than for class I molecules 
being normally found on B lymphocytes, dendritic cells and macrophages but not on 
other cells. 
The function of the MHC molecule is to capture peptides and display them on the 
cell surface for recognition by T-cells. MHC class I molecules present peptides that 
are derived from the cytosol and are recognised by cytotoxic T-cells expressing the 
CD8 co-receptor. MHC class II molecules present peptides produced in intracellular 
vesicles and are recognised by helper T-cells expressing the CD4 co-receptor. T-cells 
only recognise antigens presented on the cell surface bound to MHC in the form of 
short peptides (on average 9 amino acids in length). Binding of T-cells to peptide-
MHC (pMHC) molecules evoke cytotoxic and helper T-cell responses. 
Class I molecules are formed from the association of a membrane-bound heavy 
chain and soluble 2-m. Class II molecules comprise a membrane-bound  and  
chain. The class II heterodimer is formed by a non-covalent association of an  chain 
( 1 and 2 domains) and a chain ( 1 and 2 domains). The peptide-binding groove 
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is formed from the dimer of the membrane-distal domains 1 and . Structurally the 
1 and 2-m of class I molecules are similar to the 1 and 2 domains of class II 
molecules. Likewise the 2 and 3 domains of class I are similar to the 1 and 2 
domains. One main difference between the structure of the peptide-binding grooves is 
that in class I molecules it is blocked at both ends by bulky amino acid side chains 
whereas  in class II molecules it is open ended and able to accommodate longer 
peptides (15 amino acids) (Madden 1995). 
Our lab is focused on the engineering of MHC class I-restricted T-cell receptors 
and therefore the structural analysis sections will be restricted to these molecules.  
 
1.7.1 Structure of MHC molecules  
The first three-dimensional structure of the MHC class I HLA-A2 protein was 
determined to 3.6-Å and provided information on the domain arrangement of MHC 
class I molecules (Bjorkman, Saper et al. 1987; Bjorkman, Saper et al. 1987). MHC 
class I molecules comprise a heavy chain (43 KDa), which spans the membrane, 
complexed non-covalently to a light chain known as 2-m (12 KDa). The heavy chain 
consists of three domains, called 1, 2 and 3 (each of ~90 amino acids). The 
structure of the pMHC class I complex ectodomain is shown in Figure 1.7.  
The 3 and 2-m are fairly conserved and form immunoglobulin-like folds. The 1 
and 2 membrane-distal domains comprise of two  helices that rest on a seven-
stranded beta sheet to form a cleft or groove (~30 Å long and 12 Å wide) (Figure 1.6). 
It was presumed, from the initial solved structure (Bjorkman, Saper et al. 1987) that 
electron density within the groove that was not of heavy chain origin represented 
bound antigen. 
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Figure 1.6. Structure of the ectodomain of the class I molecule HLA-A*0201-NY-
ESO-1(157-165) (SLLMWITQC). The HLA heavy chain consists of three domains: 
alpha 1 ( 1 red), alpha 2 ( 2 purple) and alpha 3 ( 3 green); 1 and 2 associate as a 
dimer comprising two -helices to form the antigen-binding groove. The peptide 
(brown) is positioned between the two -helices extending the whole length of the 
cleft. The light chain or 2-m (pale blue) is linked to the heavy chain through non-
covalent interactions. The figure is based on the crystal structure reported in (Chen, 
Stewart-Jones et al. 2005) and was constructed in PyMOL version 1.5. (PDB: 2BNR). 
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1.7.2 Peptide-MHC binding  
Further crystal structures of the MHC class I complex confirmed the presence of 
peptide bound in the cleft of the molecule (Madden, Gorga et al. 1991; Saper, 
Bjorkman et al. 1991; Fremont, Matsumura et al. 1992; Silver, Guo et al. 1992). All 
crystal structures showed that the peptide lies the length of the 1 2 groove in an 
elongated conformation in a constrained orientation. Whether a peptide will bind to 
the groove depends on the amino acids that line the groove. Because class I molecules 
are polymorphic, different class I molecules will bind different peptides. Variations of 
the residues lining the pockets along the peptide-binding groove that are conferred by 
different class I alleles alter the peptide-binding specificity or binding motif of each 
MHC molecule. 
There are six specificity pockets (A to F) that line the class I peptide-binding 
groove creating an irregular surface necessary to accommodate a plethora of peptide 
side chains. Although the peptide-binding groove is highly polymorphic, at either end 
of the cleft reside two clusters of residues (pockets A and F) that are conserved 
between most class I molecules. The amino acid residues forming pockets B to E are 
not as conserved and are described as being polymorphic in sequence. Hydrogen 
bonds form between the conserved residues of the A pocket and the N-terminus of the 
bound peptide. Likewise hydrogen bonds form between conserved residues lining the 
F pocket and the C-terminus of the peptide. A network of hydrogen bonds form 
between the peptide main chain and the conserved residues at either end of the MHC 
cleft so-called side chain sequence-independent interactions. Hydrogen bonds also 
form between polymorphic residues in the groove and the peptide main chain. 
Additional contacts form between the MHC and the side chains of the central peptide 
residues. In combination, this extensive network of interactions account for the tight 
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binding affinity between peptide and the MHC molecule (Stern and Wiley 1994; 
Madden 1995). The stability of peptide binding is achieved through water-mediated 
hydrogen bonds between the peptide and the MHC molecule. The importance of 
groove-based water molecules to fill the gap between the floor of the binding cleft and 
the peptide has been demonstrated (Meng, von Grafenstein et al. 1997). 
Although class I molecules can accommodate a vast spectrum of peptide sequences 
(with a strong preference for nonameric peptides), peptides must fulfil certain criteria 
to bind into the groove. MHC molecules show a preference for certain amino acid 
residues at particular positions in the peptide before binding will occur. So-called 
anchor residues in the peptide, in most cases at or near the amino and carboxy-
terminal end of the peptide, are buried deep in the peptide-binding groove and 
stabilise the complex. Anchor residues are usually at position 2 (P2) at the N-terminus 
and the C-terminal (PC) residue but can also be the third (P3) or fifth (P5) residue 
depending on the class I allele. HLA-A*0201 (HLA-A2) has a preference for leucine 
or methionine at P2 and with a preference for leucine or valine at PC (Hunt, 
Henderson et al. 1992; Parker, Bednarek et al. 1992). HLA-A*0101 preferentially 
binds nonapeptides with the anchor residues asparagine or glutamic acid at P3 and 
tyrosine at P9 (DiBrino, Tsuchida et al. 1993; Falk, Rotzschke et al. 1994). 
In addition to binding of nonomeric peptides, the class I peptide-binding groove 
can accommodate longer peptides of 11 (Guo, Jardetzky et al. 1992) and 13 (Tynan, 
Borg et al. 2005) amino without loss of the fixed binding at the N- and C-terminus. 
This is achieved by a significant conformational change in the central region of the 
peptide which points out of the groove. The central core of the peptide is exposed for 
direct interaction with the TCR. It is therefore the peptide that dictates the antigenic 
identity of the MHC complex.  
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A structural comparison of five different peptides bound to the class I HLA-A2 
molecule showed that although the peptide amino and carboxy-termini bound 
similarly within the groove, the conformation of the central peptide core varied 
greatly in relation to its sequence. The central peptide residue side chains can point up 
for some peptides, down or sideways for others (Madden, Garboczi et al. 1993). This 
demonstrated that both the length and sequence of the peptide is important for 
creating unique structural landscapes that can be recognised by specific T-cell 
receptors and moreover, the driving force of TCR recognition is the central core of the 
peptide. 
A remarkable feature of the pMHC complex is that whilst a high level of 
polymorphism exists within the residues lining the antigen-binding groove 
(Bjorkman, Saper et al. 1987), the overall architecture of MHC class I molecules is 
conserved. This structural conservation is demonstrated in Figure 1.7. Figure 1.7 A-C 
depict the HLA-A*0201 heavy chain in complex with three different peptides, 
demonstrating the capacity of the HLA complex to accommodate peptide variation 
within the groove with minimal alteration to the global organisation of the structure. 
Figure 1.7 D shows the HLA-B*0801 heavy chain in complex with an EBV-derived 
peptide, illustrating that the fold structure is maintained throughout. Moreover, it 
demonstrates the remarkable capacity of TCRs to distinguish between different 
antigenic targets that vary by only a handful of amino acid residues.  
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Figure 1.7. Comparison of the structure of two different HLA class I molecules 
in complex with four different peptides. (A). HLA-A2-GAG (77-85) (SLYNTVATL) 
(PDB: 1T21) (Martinez-Hackert, Anikeeva et al. 2006). (B). HLA-A2-GAG (77-85) 
variant (SLFNTIAVL) (PDB: 1T1W) (Martinez-Hackert, Anikeeva et al. 2006). (C). 
HLA-A2-NY-ESO-1 (157-165) (SLLMWITQC) (PDB: 2BNR) (Chen, Stewart-Jones et 
al. 2005). (D). HLA-B8-Epstein Barr nuclear Ag 3A (193-201) (FLRGRAYGL) (PDB: 
1M05) (Kjer-Nielsen, Clements et al. 2002). MHC class molecules comprise a three 
domain heavy chain ( 1 shown in red, 2 shown in blue and 3 shown in green) and 
a light 2-m chain (shown in pale blue). The peptide-binding groove is formed from 
two -helices and the peptide shown in brown lies in the cleft. The configuration of 
the MHC class I molecule is largely unchanged irrespective of the MHC isoform 
(HLA-A or HLA-B) or the sequence of the bound peptide. The figure was constructed 
in PyMOL version 1.5. 
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1.8 Antigen processing and presentation: Class I pathway 
The ability of T-cells to distinguish between healthy and diseased cells (pathogen-
infected or tumour cells) is pivotal to their protective immune function. Antigens are 
processed within the cell into peptide fragments through two distinct pathways (class I 
and class II). The work described in this thesis is focussed on the  TCR recognition 
of MHC class I derived peptides and so the peptide loading of MHC class II 
molecules will not be discussed further. MHC class I molecules transport endogenous 
peptides originating from the cytosol to the cell surface. Proteins, both normal self-
proteins and foreign or abnormal proteins are degraded in the cytoplasm. This 
constant turnover provides an abundance of potential MHC class I peptides. MHC 
class I heavy chains assemble into a complex with 2-m in the lumen of the ER where 
they are retained until they are loaded with a peptide. Proteins are degraded in the 
cytosol by a mutlicatalytic protease complex called the proteasome. Two subunits of 
the proteasome are encoded within the MHC by the LMP2 and LMP7 genes and are 
inducible by IFN- . Incorporation of these subunits alters the enzymatic specificity of 
the complex favouring the cleavage of peptides after hydrophobic residues and 
inhibiting cleavage after acidic residues, thus producing peptides that are suited to 
binding MHC class I molecules. The TAP (transporter associated with antigen 
processing) complex transports peptides from the cytosol to the ER. The complex 
forms a peptide-binding channel through which peptides can pass (peptides of 8-13 
residues are favoured). The TAP complex associates with the MHC class I molecule 
and peptides are loaded into the peptide-binding groove to complete the folding and 
assembly of the MHC class I complex. The peptide-MHC complex then leaves the ER 
and is transported to the cell surface.   
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1.9 T-cell receptors  
T-cell receptors recognise both the bound peptide and the polymorphic variation 
within the MHC molecule; a feature of T-cell antigen-binding termed MHC 
restriction (Zinkernagel and Doherty 1974). T-cell receptors (TCRs) share many 
common structural and functional characteristics with antibodies. The domain 
structures of TCRs are very similar to those of antibodies and so are classified as 
members of the immunoglobulin superfamily. As antigen-specific receptors TCR and 
antibodies also share a common function. The organisation of the variable domains of 
the TCR into an antigen-recognition site resembles the Fab fragment of antibodies. 
Although they share these features, TCRs differ in several ways from antibodies. 
First, they only exist as membrane-bound proteins expressed on the surface of T-cells 
and are not found in a soluble form as antibodies are. Second, antibodies have two 
antigen-binding sites whereas TCRs only have one. Third, the affinity of interaction 
between TCR and its antigen is far weaker than for antibodies. Fourth, TCRs have to 
recognise both the antigen and the MHC molecule into which it is bound.  
 
1.9.2 T-cell receptor gene rearrangement 
As with Ig light and heavy chains, TCR  and  chains contain a variable (V), a 
joining (J) and a constant (C) region. The TCR  chain, like the Ig heavy chain, also 
contain diversity (D) segments (Davis and Bjorkman 1988). The gene encoding the 
TCR  chain is found on chromosome 14 and has 47 V  gene segments  (TRAV, 
nomenclature assigned by the immunogenetics database, IMGT (Lefranc, Giudicelli 
et al. 1999)), 61 J  segments (TRAJ) and 1 C segment. The  chain locus is on 
chromosome 7 and has 54 V  (TRBV) segments, 2 D  (TRBD) segments, 14 J  
(TRBJ) segments and 2 C segments.  
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Functional TCRs result from and  chain gene rearrangement, in which a TCR  
protein chain comprises only one V, J and C segment and the TCR   protein chain 
consists of only one V, D, J and C segments spliced together (Figure 1.8). TCR 
diversity is generated, as with Igs, through the CDRs. CDRs 1 and 2 are encoded by 
the germline V gene itself, whereas CDR3 is formed by the junction of V and J for 
chains and V, D and J for  chains. For the  chain a V gene segment rearranges to 
a J gene segment to create a functional V  region exon. The  chain undergoes a two-
step rearrangement: first, D to J and then V to DJ to form the functional V  region 
exon. The rearranged V gene segments are transcribed and spliced with the constant 
segment to yield the TCR  and  chains. This process takes places in the thymus.  
The mechanics of rearrangement and splicing of TCR and Ig DNA are similar. TCR 
diversity is generated not only by a combinatorial process of V(D)J gene segment 
rearrangement, but also through addition of nucleotides at the junctions between V, D 
and J segments during rearrangement. Palindrome (P) and non-template-encoded (N) 
nucleotides can be added or deleted.  
As a consequence of VDJ gene rearrangement occurring in immature thymocytes, 
in the thymus a theoretical pool of 10
15
 TCRs with differing specificities could 
generated in the mouse (Davis and Bjorkman 1988). The theoretical number of 
possible TCR in humans is likely to be substantially larger due to the larger number of 
TCR V  genes (Sewell 2012). To prevent mounting an immune response to self-
antigens whilst maintaining recognition of self-MHC, naïve T-cells proliferate and 
then undergo a process of clonal selection in the thymus (Starr, Jameson et al. 2003) 
that substantially reduces the TCR diversity in the circulation to perhaps 25 million 
(Arstila, Casrouge et al. 1999).   
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Figure 1.8. T-cell receptor  and  chain gene recombination and expression. For 
the chain, a V segment rearranges to a J segment to create a V region exon. 
Transcription and splicing to a C segment generates the final mRNA encoding the 
TCR  chain protein. For the  chain, D-J rearrangement takes place first. The 
selection of C 1 or C 2 is determined by the selection of the J 1 or J 2 gene.  In the 
second step, the V segment rearranges with the DJ segment. The V-DJ exon is 
transcribed and spliced to a C segment to produce the final mRNA sequence encoding 
the TCR  chain protein. The  and  chain proteins pair to form the TCR 
heterodimer. Not all V and J segments are shown and the V segment leader sequences 
are omitted for simplicity. Adapted from (Janeway, Travers et al. 2001).   
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1.9.3 Selection of the T-cell repertoire 
Upon entering the thymus TCR  and  chain genes are rearranged to produce a 
functional TCR heterodimer. The earliest population of thymocytes do not express 
CD4, CD8 or TCRs and are called “double-negative” (DN: CD4- CD8-) T-cells. 
Productively rearranged  chains are expressed on the T-cell surface and associate 
with the pre-TCR invariant surrogate  chain (pT ) to form the pre-TCR 
heterodimer. Thymocytes undergo rapid proliferation and CD4 and CD8 are co-
expressed on the same cell. The  chain genes rearrange and are expressed on the cell 
surface where they pair with the  chain. These cells are called “double-positive” 
(DP: CD4
+
 CD8
+
) thymocytes. Successive attempts at rearranging a productive  
chain continue until positive selection takes place.  
In positive selection (or MHC restriction) T-cells that bind self-MHC molecules 
expressed on cortical thymic epithelial cells (cTECs) are retained. Thymocytes that 
express a rearranged TCR and fail to recognise self-MHC (does not bind or binds 
too weakly) are deleted by apoptosis (Kisielow and Miazek 1995). Thymocytes that 
interact with MHC class I molecules will express only CD8 and T-cells that bind 
MHC class II molecules express only CD4 and are known as “single-positive” (SP: 
CD4
-
 CD8
+
 or CD4
+
 CD8
-
) T-cells. 
In negative selection SP-T-cells are screened for recognition of self-peptides 
associated with self-MHC to prevent autoimmune disorders (Finkel, Cambier et al. 
1989). SP-T-cells migrate from the cortex to the medulla where they encounter self-
MHC displaying a spectrum of peripheral self-peptides on medullary thymic epithelial 
cells (mTECs). So called self-reactive T-cells that bind with too high affinity for self-
peptides are deleted presumably leaving a repertoire of T-cells with low affinity for 
self-antigens but with the potential to recognise foreign antigens with higher affinity. 
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Those T-cells that do not bind the self-peptide MHC molecules are retained and 
allowed to further mature. 
 
1.9.4 Structure of the  T-cell receptor  
This work will focus on the  TCRs. A wealth of structural data of the TCR 
molecule alone or in complex with cognate pHLA have provided an insight into the 
domain organisation of the molecule; this is reviewed extensively in (Rudolph, 
Stanfield et al. 2006).  
TCRs were predicted to have a Fab-like structure and it was presumed that as they 
shared a high degree of similarity in the organisation of their protein domains they 
would also possess a similar folding pattern (Claverie, Prochnicka-Chalufour et al. 
1989). As predicted from sequence homologies, subsequent three-dimensional 
structures of a monomeric TCR chain (Bentley, Boulot et al. 1995) and a V  
domain homodimer (Fields, Ober et al. 1995) confirmed structural homology to 
immunoglobulins (Igs) with the hypervariable region forming loops all pointing in 
one direction.  
Amino-terminal V domains, which comprise VDJ gene encoded protein (as 
discussed earlier) are formed from the association of six CDR loops; three from both 
 and  chains. Collectively the CDRs form the antigen-binding site at the 
membrane-distal end of the molecule.  A carboxy-terminal constant (C) region with 
homology to the Ig C domain is positioned at the membrane-proximal end of the 
protein. Each chain contains a short stalk region including a cysteine proximal to the 
transmembrane domain that forms an inter-chain disulphide bond followed by a 
positively charged transmembrane domain and a cytoplasmic tail (Figure 1.9).  
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Figure 1.9. Cartoon structure of the membrane-bound TCR. The TCR comprises 
four domains: variable alpha (V ), constant alpha (C ), variable beta (V ) and 
constant beta (C ). The  TCR heterodimer is tethered to the T-cell through a 
transmembrane domain. The V  and V  regions form the antigen-binding surface. 
The alpha and beta chains are stabilised by a membrane-proximal disulphide bond 
(ds-bond) (highlighted in red).  
 
 
 
 
 
To date, the structures of ten (free) TCRs have been solved (uncomplexed to 
pMHC). The structural information obtained from the first TCRs to be solved, an  
murine TCR designated 2C (in complex with H-2K
b
-dEV8 peptide) (Garcia, Degano 
et al. 1996) and a human  TCR designated A6 (in complex with HLA-A2-Tax 
peptide) (Garboczi, Utz et al. 1996) provided a structural template that subsequent 
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antiparallel  strands held together by disulphide bonds (Figure 1.10). Three of the 
four domains, V , V  and C  are related to Ig domains; the C  domain however, is 
structurally unrelated to the normal Ig fold and represents the most disordered region 
of the TCR. The C  c, f and g strands that comprise the top  sheet are structurally 
unrelated to Ig C-type folds. The C  domain consists of one half of the classical -
barrel with the remainder of the domain exhibiting random coils. The buried interface 
between the C -C  domains is more extensive than in antibodies. The interface is 
highly polar with a high proportion of acidic residues on C  and basic residues on 
C . Carbohydrate moieties associated with the C  domain form hydrogen bonds with 
the C  domain. The relatively parallel association of the C  and C  domains gives 
the TCR its ‘squat’ structure. The V and C domains interact extensively. The V -C  
interaction is highly polar with many interdomain hydrogen bonds whilst the V -C  
contact area is mainly through van der Waals’ interactions. The CDR loops align 
fairly closely with antibody loops, with the exception of CDR2  which is almost at 
right angles to the equivalent loop in antibodies. The antigen-binding surface is 
relatively flat lacking protruding side chains presumably facilitating closer contact 
between TCR and pMHC. It does contain a hydrophobic cleft formed between the two 
CDR3s which is believed to accommodate side chains extending from the peptide 
bound into the MHC antigen-binding groove. 
Although all TCRs share these common features subtle differences can be 
observed between TCRs including, variation in the CDR loop length (Bulek, Cole et 
al.; Reiser, Gregoire et al. 2002) and at the interface between the  and  chains of 
different V-region families, which can alter the local structure and affect the 
orientation of the two chains respectively.   
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Figure 1.10. Domain organisation of the ectodomain of the  TCR. The TCR 
depicted is the 1G4 TCR. The TCR consists of four domains characterised by a series 
of antiparallel  strands: two variable (V  and V ) and two constant (C  and C ) 
regions. The truncated membrane-proximal domain is highlighted. The antigen-
binding portion of the molecule (highlighted with a dashed circle) is formed from the 
six complimentarity determining region (CDR) loops: CDR1  (dark blue), CDR2  
(magenta), CDR3  (dark green), CDR1  (orange), CDR2  (red), CDR3  (yellow). 
This figure was constructed in PyMOL version 1.5. (PDB: 2BNR) (Chen, Stewart-
Jones et al. 2005). 
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1.9.5 Structure of the T-cell receptor-peptide-MHC complex 
An extensive collection of structural data has amassed over the last 15 years on the 
complex of TCR bound to peptide-MHC (pMHC) molecules and a number of 
common features have emerged (Rudolph, Stanfield et al. 2006). These include the 
mode of docking onto the pMHC, the positioning of the CDR loops in relation to the 
MHC helices and the peptide and the significant interface between the TCR and MHC 
that buries the peptide beneath the TCR footprint.  
The first TCR-pMHC complexes were published in quick succession over 15 years 
ago; the A6 TCR/HLA-A2-Tax complex from the Wilson lab (Garcia, Degano et al. 
1996) and the 2C TCR/ H-2K
b
-dEV8 complex from the Wiley lab (Garboczi, Utz et 
al. 1996). In general, the mode of interaction between TCR and pMHC is similar 
irrespective of the MHC allele or class. The TCR docks on the pMHC in a conserved 
diagonal to orthogonal binding orientation relative to the peptide-binding groove 
(Figure 1.11). The maintained docking orientation is demonstrated by two TCRs in 
complex with the same pHLA. The A6 (Garboczi, Ghosh et al. 1996) and B7 (Ding, 
Smith et al. 1998) TCRs bind the HLA-A2-Tax complex in a similar diagonal docking 
orientation across the peptide-binding groove despite sharing only one contact residue 
at the TCR-HLA interface.  
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Figure 1.11. Architecture of the complex formed between class I HLA and  
TCR. The TCR depicted is the 1G4 TCR in complex with HLA-A*0201 tumour 
epitope NY-ESO-1(157-165) (SLLMWITQC). The TCR sits directly on top of the HLA 
molecule in a diagonal orientation with the primary contacts between the TCR and the 
HLA mediated through the CDR alpha (CDR  pink) and CDR beta (CDR  pale 
purple) loops which point down towards the HLA alpha helices (green) and the bound 
peptide (brown). The binding interface is formed between the TCR CDR loops and 
the HLA heavy chain  helices and peptide. The 2-microglobulin ( 2-m) is shown in 
pale blue. This figure was constructed in PyMOL version 1.5. (PDB: 2BNR) (Chen, 
Stewart-Jones et al. 2005). 
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The V  domain lies more over the N-terminal end of the peptide and the V  over 
the C-terminal end. V  CDR1 is positioned over the N-terminal end of the pMHC 1 
helix and over the N-terminal end of the peptide. V  CDR2 lies predominantly over 
the C-terminal end of the pMHC 2 helix. V  CDR2 mainly lies over the C-terminal 
end of the pMHC 1 helix with slight contact with the C-terminal end of the peptide. 
V  CDR1 mostly covers the N-terminal end of the pMHC 2 helix with some contact 
with the C-terminal end of the peptide. The most diverse loops of the TCR (CDR3  
and CDR3 ) predominantly make contact with the peptide making minimal contact 
with the MHC framework (Figure 1.12).  
Positioning of the less diverse germline encoded CDR1 and CDR2 loops over the 
MHC helices coupled with the placement of the more diverse CDR3 loops over the 
peptide provide a possible structural explanation for MHC restriction and moreover, 
indicate that specificity of antigen-binding is largely governed by the CDR3  and 
CDR3  loops. Whilst this suggests that engineering of the CDR1 and CDR2 loops for 
improved binding to the MHC helices may lead to diminished peptide specificity, a 
recent study by Dunn et al. (Dunn, Rizkallah et al. 2006) demonstrated that affinity 
enhancing mutations in CDR2 loops retained specificity for their cognate pMHC.   
A further pattern that characterises TCR-pMHC complex formation is the large 
buried surface area at the TCR-pMHC interface (~1200-2000 Å
2
). The V  and V  
contribution to this footprint varies widely between different TCRs. It can be split 
equally between the  and  chains as seen with the 1G4 TCR in complex with HLA-
A2-NY-ESO 9C (47% and 53% respectively), skewed towards the  chain with the 
A6 TCR/HLA-A2-Tax (Y8A) (65% and 35%) or towards the  chain with the 
BM3.3/H-2K
b
-pBM1 complex (37% and 63%) (Rudolph, Stanfield et al. 2006). 
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Whilst the orientation of TCR-pMHC docking is stringently conserved with 
respect to the positioning of the CDR loops relative to the bound peptide and MHC 
helices, examples exist that vary from this generality. The BM3.3-H2Kb-pBM1 TCR 
complex is one such example (Reiser, Darnault et al. 2000). The CDR3  loop, rather 
than aligning over the peptide, flares out from the peptide binding groove; the cavity 
being occupied by ~30 water molecules. It can be envisaged that engineering of the 
BM3.3 TCR for high affinity may require extension of the CDR3  loop to facilitate 
contact with the pMHC complex. 
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Figure 1.12. A view of 1G4 TCR binding to HLA-A*0201 tumour epitope NY-
ESO-1(157-165) (SLLMWITQC) from beneath the peptide binding groove. The 
TCR contains six CDR loops: CDR1  (dark blue), CDR2  (magenta), CDR3  (dark 
green), CDR1  (orange), CDR2  (red), CDR3  (yellow). As a general rule the CDR3 
loops and to a lesser extent the CDR1 loops contact the peptide bound in the HLA 
groove and as such it is the CDR3 loops that largely confer specificity. The CDR2 
loops interact predominantly with the HLA surface and not the bound peptide. Whilst 
the V  domain interacts predominantly with the N-terminus of the peptide, the V  
contacts the C-terminus. The peptide amino and carboxy termini are shown with an N 
and a C respectively. This figure was constructed in PyMOL version 1.5. (PDB: 
2BNR) (Chen, Stewart-Jones et al. 2005). 
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1.9.6 T-cell receptor conformational changes upon ligand binding 
Although the crystallographic database contains more than 40 TCR-pMHC 
complexes, only ten free TCR structures have been solved. Nonetheless, using this 
limited set of uncomplexed structures, has revealed the conformational changes that 
occur following TCR-pMHC ligation (Armstrong, Piepenbrink et al. 2008).  
Many reports have shown that the CDR loops possess a degree of flexibility or 
plasticity in order to bind pMHC. This has been exemplified by studies of a single 
TCR bound to different peptides (Garcia, Degano et al. 1996; Ding, Baker et al. 1999; 
Degano, Garcia et al. 2000). In general, moderate changes in the orientation of the 
CDR loops are sufficient to generate a degree of cross-reactivity or TCR degeneracy. 
Conformational differences are predominantly within the CDR3 loops that make 
adjustments to accommodate the varying peptide side chains.   
For example, the CDR3  loop of the LC13 TCR undergoes a 2.5 Å rigid body shift 
accompanied by a 38º rotation that increases the contact with the peptide. Upon 
ligation, the CDR3  loop undergoes an 8Å  shift to form a “crumpled” structure that 
enables contact with the HLA 1 helix (Kjer-Nielsen, Clements et al. 2003). A 
similar degree of  repositioning  of the CDR3  and CDR3  loops (~5 Å each) has 
also been reported for the JM22 TCR (Ishizuka, Stewart-Jones et al. 2008). More 
dramatically, a  ~15.1 Å conformational shift of the (unusually long) CDR3  loop has 
been observed for the KB5-C20 TCR upon pMHC engagement (Reiser, Gregoire et 
al. 2002).  
Whilst the majority of TCR-pMHC complexes studied to date have shown that 
greatest conformational changes occur in the hypervariable CDR3 loops, examples 
exist that break from this convention. For the LC13 TCR-HLA-B8-EBV complex, 
major conformational shifts also occur in the germline encoded CDR1  and CDR2  
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loops (in addition to the CDR3 loops) with the CDR2  loop pointing in the opposite 
direction upon ligation (Kjer-Nielsen, Clements et al. 2003).  
Significant conformational disruption of the CDR3s is not always observed. The 
CDR3 loops of the 1G4 TCR undergo only minor shifts upon pMHC binding. Here, 
accommodation of the peptide is achieved through a preexisting cavity formed 
between the CDR1 , CDR3  and CDR3  domains (Chen, Stewart-Jones et al. 2005). 
It can be surmised that upon TCR-pMHC ligation, the CDR3  loop undergoes 
greatest shift in conformation and the CDR1  loop undergoes the least. To generalise, 
the following magnitude of conformational shift occurs: CDR3  > CDR3  > CDR1  
> CDR2  > CDR2  > CDR1  (Armstrong, Piepenbrink et al. 2008).  
 
1.9.7 TCR degeneracy 
It has been estimated that  there are >10
15
 potential peptides that can be presented on 
MHC dwarfing the 2.5 x 10
7
 different TCRs within the naïve T-cell pool (Arstila, 
Casrouge et al. 1999). This poses a significant conundrum for the immune system 
assuming the clonal selection theory that one T-cell is specific for a single pMHC 
antigen. One theory to satisfy this predicament is that significant TCR degeneracy 
exists in the immune system that enables the limited diversity of TCRs in the naïve 
pool to respond to the multitude of displayed peptides (Mason 1998). Indeed, it has 
recently been estimated that a single TCR (designated 1E6) isolated from a patient 
with type I diabetes can respond to more than 1 million distinct peptides (Wooldridge, 
Ekeruche-Makinde et al. 2012). 
A number of mechanisms have been proposed that permit this degree of 
promiscuity; a perspective of which has been presented recently (Sewell 2012). One 
solution that focuses on the TCR molecule, argues that it is the considerable flexibility 
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of the TCR antigen-binding loops (most strikingly in the CDR3 regions), that enables 
binding to an array of divergent peptides. The conformational plasticity of the TCR 
facilitates inspection of different pMHC landscapes and is supported by numerous 
TCR crystal structures in their bound and unbound states (Rudolph, Stanfield et al. 
2006; Armstrong, Piepenbrink et al. 2008).  
However, flexibility of the CDR loops does not satisfy the degeneracy of the 1E6 
TCR, which upon pMHC ligation does not undergo conformational adjustment 
(Bulek, Cole et al. 2012; Wooldridge, Ekeruche-Makinde et al. 2012). Rather, 
degeneracy is achieved through a conserved pair of residues within the peptide that is 
sufficient for TCR engagement; permitting inclusion of divergent residues at all other 
positions (so-called peptide-centric binding). 
Molecular mimicry that allows a TCR to bind to molecularly similar peptides has 
also been advocated (Borbulevych, Piepenbrink et al. 2011). The A6 TCR binds both 
the Tax peptide (sequence LLFGYPVYV) from the HTLV-1 virus and a self-peptide 
from the neuronal protein HuD (sequence LGYGFVNYI). It has been postulated that 
if T-cells react with a foreign peptide that shares sufficient sequence homology to a 
self-peptide, autoimmune pathologies may ensue. Baker and colleagues 
(Borbulevych, Piepenbrink et al. 2011) showed that shared homology of the Tax and 
HuD peptides at positions 4, 5 and 8 permitted recognition of both, by the A6 TCR, 
albeit with a 70-fold reduced binding affinity.  
In addition to conformational changes occurring in the TCR, structural adjustments 
of the pMHC complex upon ligation have also been observed (Garboczi, Utz et al. 
1996; Tynan, Reid et al. 2007) and more recently have been implicated  as a potential 
mechanism of TCR cross-reactivity (Borbulevych, Piepenbrink et al. 2009). Cross-
reactive binding of the A6 TCR towards the yeast peptide mimic Tel1p (sequence 
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MLWGYLQYV) is mediated through cooperative conformational changes in the 
TCR CDR3 loops, the peptide and the HLA- 2 helix. The phrase ‘conformational 
melding’ has been introduced to describe the process of structural adjustments 
occurring at the pMHC-TCR interface that allows the TCR to sample all 
conformational variations searching for a suitable fit.  
It therefore appears likely that a cooperative flexibility and subsequent structural 
rearrangement of the TCR, the peptide and the HLA molecule all contribute to a level 
of T-cell promiscuity that is essential for an effective cellular immune response. 
 
1.9.8 T-cell receptor binding affinities and kinetics 
Until the advent of techniques to produce high levels of soluble TCR, studies of the 
interactions of the TCR and the pMHC were difficult. Over the last twenty years 
technologies, such as surface plasmon resonance (SPR), have been developed as a 
powerful tool to measure protein-protein interactions. TCR-pMHC interactions are 
characterised by a low affinity (0.1-400 M) compared to antibodies. Since the first 
determined TCR/pMHC affinity measurements were published using BIAcore 
(Matsui, Boniface et al. 1994), a wealth of data has accumulated and is reviewed in 
(Willcox, Gao et al. 1999; van der Merwe and Davis 2003; Cole, Pumphrey et al. 
2007; Stone, Chervin et al. 2009; Bridgeman, Sewell et al. 2011). The interaction of 
TCR and pMHC is a reversible reaction involving an association rate constant (kon) 
(which measures the binding speed), a dissociation rate (koff) (which measures the 
dissociation speed), a half-life of interaction (t1/2) calculated from the koff and a 
dissociation constant (KD, affinity) determined by a ratio of koff/kon.  
A recent study by Cole et al. (Cole, Pumphrey et al. 2007) directly compared the 
binding affinity of 8 class I and 6 class II MHC-restricted TCRs. Their data supports 
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the body of work that demonstrates that low affinity is the result of a fast dissociation 
rate constant and a slow association rate constant (van der Merwe and Davis 2003). 
The mean kon values of the class I MHC (TCR-I) and the class II MHC (TCR-II)-
restricted TCRs for their cognate antigen were 3.3 x 10
4
 M
-1
 s
-1 
and 4.1 x 10
4
 M
-1
 s
-1 
respectively. The mean TCR-I koff was 0.22 s
-1 
and the mean TCR-II koff was 0.3 s
-1
. 
The slow on rates may be a consequence of the conformational changes that take 
place in the antigen-binding CDR loops upon pMHC ligation prior to stabilisation of 
the complex (Willcox, Gao et al. 1999).  
From the accumulated data it is possible to propose a number of common features 
regarding the biophysical properties of the TCR-pMHC interaction. First, TCRs bind 
to MHC class I molecules with a higher affinity (five times greater affinity) compared 
to MHC class II-restricted TCRs. This may indicate that CD4
+
 T-cells have a lower 
activation threshold compared with CD8
+
 T-cells or that the signal mediated by the 
TCR-pMHC class II is stronger than by the TCR-MHC class I interaction. Second, 
class I TCRs demonstrate faster on rates than class II TCRs, with conserved off rates 
irrespective of the MHC restriction and antigenic origin (Cole, Pumphrey et al. 2007). 
The faster on rates conferred by the class I molecules may suggest that the interaction 
with TCR is more favourable than for class II complexes. The class I peptides tend to 
bulge from the peptide binding groove providing a structural feature on which to bind. 
The conserved off rates is consistent with crystal structures that shows the number of 
contacts between TCR/MHC class I and class II are similar (Rudolph, Stanfield et al. 
2006). Third, self-reactive TCRs bind with lower affinity and shorter half-lives 
compared to TCRs binding to non-self-peptides (Aleksic, Liddy et al. 2012).  In this 
recent report the binding of 24 TCRs to their cognate pMHC complexes were 
analysed, of which 10 peptides were of viral origin and 14 were tumour associated 
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peptide antigens (TAPAs). The mean KD = ~108 M and mean t1/2 <1.9 s for TCRs 
binding to cancer associated peptides; mean KD = ~8 M and mean t1/2 8.4 s for TCRs 
binding to viral peptides).  This clear correlation in binding parameters between self-
reactive and non-self-reactive TCRs could be the consequence of clonal selection in 
the thymus. Those T-cells bearing TCRs that bind too tightly to self-pMHC are 
deleted in a process of negative selection thus leaving TCRs with low affinity for self-
pMHC in the periphery. In contrast, T-cells will not have encountered virally-derived 
peptides during thymic selection, and so high affinity TCRs for these non-self-
antigens will be present in the periphery.   
 
1.10 Engineering T-cell receptors 
TCRs have been engineered for improvements in stability and antigen-binding affinity 
using a variety of display platforms previously applied to antibody engineering. TCRs 
and antibodies share a similar domain organisation. This structural relatedness would 
imply that the display strategies employed successfully for antibodies would be 
amenable to TCRs (e.g. yeast display, mammalian display and phage display). 
However, the success of surface-displayed TCRs has been limited. The difficulties 
may be related to the inherent instability of the TCR molecule in which the  and  
chains have a reduced ability to associate (i.e. a low affinity for each other) as 
compared to the heavy and light antibody chain counterparts. Symptomatic of this is 
the tendency of TCRs to misfold and form aggregates. 
 
1.10.1 Yeast display of TCRs 
The Kranz lab pioneered TCR engineering using yeast display (Kieke, Shusta et al. 
1999). Whilst antibodies are readily displayed on the surface of yeast, TCRs are not. 
In general, wild-type TCRs cannot be detected on the yeast cell surface and must be 
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engineered to identify a variant exhibiting improved folding properties. In this study, 
an E. coli mutator strain was used to introduce random mutations throughout both 
chains of the murine 2C TCR. The mutant single chain V -linker-V  TCRs 
(scTCRs), analogous to the VH-linker-VL scFv, were transfected into yeast and mutant 
scTCRs with improved folding properties were selected with clonotypic anti-TCR 
antibodies by flow cytometry. The majority of mutations that improved the level of 
display were concentrated at the V /V  interface away from the antigen-binding 
regions and so had little effect on antigen-binding kinetics. 
To further improve the stability and soluble expression efficiency of the murine 2C 
TCR a directed-evolution strategy using the yeast display system was devised (Shusta, 
Holler et al. 2000). A mixture of the wild-type 2C scTCR and four stabilised mutant 
2C scTCRs previously identified (Kieke, Shusta et al. 1999) were subjected to random 
mutagenesis using error-prone PCR. The yeast-displayed mutant scTCR library was 
screened in parallel at two temperatures: a 46°C incubation library sort to isolate 
mutants with improved stability and a 37°C incubation induction step to screen for 
higher expression. Mutants isolated from both strategies were combined and 
demonstrated an additive effect in improving thermal stability, display levels and 
solubility of purified protein. 
In addition to the murine 2C TCR, the yeast cell format has been successfully used 
to display correctly folded human TCRs as an scTCR (Aggen, Chervin et al. 2011). 
Three high affinity TCRs (previously identified by phage display) were used in the 
study: the A6 TCR, the 1G4 TCR (Li, Moysey et al. 2005; Dunn, Rizkallah et al. 
2006) and the 868 TCR (Varela-Rohena, Molloy et al. 2008). In contrast to the 
selection of yeast-displayed 2C TCR where a clonotypic antibody capable of 
recognising correctly folded V  and V  domains is available; here they used soluble 
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peptide-HLA-A2 tetramers. Remarkably, the 868 scTCR was detected on the yeast 
cell surface without necessitating a random mutagenesis step; the first time this had 
been observed for a TCR. However, random mutagenesis of the A6 scTCR was 
required to select mutants that folded properly in yeast cells, but was not sufficient to 
isolate yeast-displayed 1G4 scTCR. Because the A6 and 1G4 TCRs share the 
TRBV6-5  chain, the V  mutations that permitted display of the A6 TCR were 
transferred into the 1G4 TCR framework but were not sufficient to allow surface 
display of the 1G4 TCR.  
In spite of the efforts to identify common mutations within the V-domains that 
allow the surface expression of TCRs (Weber, Donermeyer et al. 2005; Richman, 
Aggen et al. 2009; Aggen, Chervin et al. 2011), the results were ineffectual, 
suggesting that an in vitro evolution strategy, employing scattergun muatagenesis, is 
the most effective approach to select TCRs that can be displayed on the surface of 
yeast. 
Yeast display has also been used to select mutated TCRs with improved binding 
affinity for their cognate peptide-MHC. In the first example the CDR3  loop of the 
murine 2C TCR was targeted for mutagenesis using NNS oligonucleotides to mutate 
five codons (Holler, Holman et al. 2000). Using the stabilised mutant 2C TCR 
previously isolated (Kieke, Shusta et al. 1999) as the template, a library of 10
5
 
variants was constructed from which CDR3  mutants with up to 100-fold higher 
affinity for the pMHC were isolated. As a continuation of this work, the other CDR 
loops (CDR1 , CDR2 , CDR1 , CDR2  and CDR3 ) of the 2C scTCR were 
subjected to mutagenesis using NNS oligonucleotides (Chlewicki, Holler et al. 2005). 
In the context of the CDR3  clone, mutants were isolated in CDR2 , CDR1  and 
Chapter 1 
 78 
CDR3  that conferred up to 750-fold affinity improvements over the wild-type 2C 
scTCR with no loss of peptide specificity.  
Isolation of high-affinity class II-restricted murine (3.L2) TCR mutants has also 
been demonstrated (Weber, Donermeyer et al. 2005). Using a yeast display stabilised 
mutant (mutated in CDR1 ) as a template for mutagenesis of the CDR3 loops, 
mutants were selected with up to an 800-fold improvement in affinity compared to the 
TCR containing no CDR mutations.  
 
1.10.2 Mammalian cell surface display of TCRs 
There have been two reports of the display and engineering of TCRs on the surface of 
TCR-negative T-cells using retroviral transduction (Kessels, van Den Boom et al. 
2000; Chervin, Aggen et al. 2008). An advantage of this technique over yeast display 
is that the TCRs are expressed as full-length heterodimeric proteins in their native 
conformation rather than in a single-chain format. A significant drawback, however, 
is the limited sequence diversity that can be generated as a consequence of low 
retroviral transformation efficiency (~10
4
 surface TCR-expressing cells). An 
additional technical challenge in the process is the ability to tightly control the 
transformation conditions in order to minimise the number of target cells containing 
multiple TCRs.  
Whilst the first report (Kessels, van Den Boom et al. 2000) was successful in 
demonstrating surface TCR display, mutants were isolated on the basis of altered 
binding specificity rather than with improved binding affinity. In a subsequent study 
reported from the Kranz lab (Chervin, Aggen et al. 2008), high affinity variants of the 
murine 2C TCR were isolated using retroviral display. The CDR3  loop was targeted 
for mutagenesis using a single five codon NNS degenerative oligonucleotide. 
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Following only two cycles of sorting, enrichment of a single clone (m100) was 
achieved. Interestingly, the m100 clone was distinct from a 2C TCR mutant (m33) 
isolated from a CDR3  yeast display library (Holler and Kranz 2003). Whilst both 
clones contained a conserved proline indicating its importance to the binding affinity, 
the determined equilibrium binding constants showed the yeast display isolate (m33) 
to exhibit a ~50-fold higher affinity compared to the mammalian display isolate 
(m100); KD value of 32 nM for m33 and 1.8 M for m100. These experiments 
illustrate the influence of the display format on the selection output.    
 
1.10.3 Phage display of TCRs   
Green and co-workers first described the phage display of TCRs (Onda, LaFace et al. 
1995). An atypical TCR V  chain was fused to the N-terminus of the bacteriophage 
coat protein pVIII. It was shown that the TCR V  chain could be enriched from a 
library “spiked” with an irrelevant TCR indicating the promise of this display 
strategy. In a later study, a 3-domain single-chain murine DO11.10 TCR (V -linker-
V C ) was displayed on the surface of phage fused separately to the N-terminus of 
pIII and pVIII (Weidanz, Card et al. 1998). Display of the TCR on the phage surface 
was confirmed with an anti-TCR antibody. The DO11.10 phage-displayed TCR was 
“spiked” into a phage display single-chain antibody library. Selections using anti-
TCR antibodies or an anti-V -specific antibody resulted in a 2,500-fold enrichment in 
the percentage of phage displaying the DO11.10 scTCR. In this study, however, 
neither affinity maturation nor functionality of the TCR was demonstrated. 
Li et al. (Li, Moysey et al. 2005) first demonstrated phage display directed 
evolution of human TCRs for high-affinity. This approach used V C /V C  
heterodimers and included the stabilising non-native disulphide bond introduced into 
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the C-domains, so-called monoclonal TCRs (mTCRs) (Boulter, Glick et al. 2003). 
The CDR3 loops of the A6 TCR, specific for the human T-cell lymphotrophic virus 
type 1 (HTLV-1) tax11-19 peptide-HLA-A*0201, and the 1G4 TCR, specific for the 
NY-ESO-1157-165 peptide-HLA-A*0201, were targeted for mutagenesis using 
degenerative NNK oligonucleuotides. Libraries of mutated TCRs were fused to the N-
terminus of the bacteriophage protein pIII. Following on from this work the germline-
encoded CDR2 loops of the 1G4 TCR were targeted for mutagenesis using 
degenerative oligonucleuotides (Dunn, Rizkallah et al. 2006). The highest-affinity A6 
TCR after a single round of selection had a KD of 2.5 nM representing a >700-fold 
improvement over the wild-type TCR. The highest-affinity 1G4 TCR obtained 
following a second round of engineering had a KD of 26 pM equating to >1 million-
fold increase over the wild-type counterpart. 
The display of TCRs on the surface of bacteriophage has recently been further 
interrogated with the hope to optimise the levels of display (Loset, Lunde et al. 2007). 
The TCR fusion format (scTCR, Fab and dsTCR), fusion mode (  or  domain fused 
to pIII) and phage system (phage vector and phagemid vector) were explored. In total, 
six constructs were generated: scTCR (V V -pIII or V V -pIII), cFab (chimeric Fab 
V CH/V CL-pIII or V CL/V CH-pIII) and dsTCR (V C /V C -pIII or 
V C /V C -pIII). It was demonstrated that in addition to the format and domain 
orientation, the primary sequence of the TCR greatly influences the level of display. 
 
1.10.4 Production of soluble TCRs 
The production of soluble TCRs in sufficient quantities and of consistent quality has 
been a considerable challenge. Although many expression systems and TCR 
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constructs have been explored no single method was applicable to all TCRs (Fremont, 
Rees et al. 1996; Rudolph, Stanfield et al. 2006).  
An early approach took advantage of the shared structural homology of antibodies 
and TCRs by making chimeric TCR-Ig proteins (V CL and V CL) but failed to 
produce correctly folded heterodimer (Gascoigne, Goodnow et al. 1987). To facilitate 
the production of properly folded heterodimer the TCR constant (C) domains were 
included in the TCR-Ig constructs (V C CL and V C CL) (Gregoire, Rebai et al. 
1991). Another approach was to mimic the scFv antibody format and refold single-
chain scTCRs (V -linker-V ) (Novotny, Ganju et al. 1991; Hoo, Lacy et al. 1992; 
Hilyard, Reyburn et al. 1994) or disulphide-stabilised scTCRs (Reiter, Kurucz et al. 
1995) from E. coli inclusion bodies. Alternatively scTCRs have been expressed in the 
periplasm of E. coli (Ward 1991; Wulfing and Pluckthun 1994). Three-domain single-
chain scTCRs (V -linker-V C ) have also been expressed on the surface of TCR-
negative T-cells linked to a glycosyl phosphatidylinositol (GPI) anchor with soluble 
TCR obtained by enzymatic cleavage with a phosphatidylinositol-specific 
phospholipase (Chung, Wucherpfennig et al. 1994).  
Although the single-chain format did show promise in the production of soluble 
TCR, it is far from ideal because they do not include the entire extracellular region of 
the TCR. Soluble heterodimeric V C /V C TCRs have been produced in a number 
of expression systems: in Drosophila melanogaster cells (Garcia, Degano et al. 1996), 
secreted from Chinese hamster ovary (CHO) cells (Strong, Penny et al. 1994) or 
refolded from E. coli inclusion bodies (Garboczi, Hung et al. 1992; Garboczi, Utz et 
al. 1996; Ding, Smith et al. 1998). These methods rely on weak noncovalent 
interactions between the  and  chains and so the TCRs tend to be rather unstable. 
To stabilise the TCR structure Wilcox et al. (Willcox, Gao et al. 1999) attached the 
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jun/fos heterodimerisation domains to the C-terminal end of the  and  chains, 
respectively, and refolded the TCR from E. coli inclusion bodies. The TCR was 
shown to be correctly folded and specific for its cognate peptide-HLA ligand as 
measured by surface plasmon resonance. Whilst this method is highly successful in 
producing a wide variety of different TCRs the inclusion of the non-native leucine 
zipper fusion partners makes it unsuitable for use as a therapeutic reagent. Boulter et 
al. (Boulter, Glick et al. 2003) introduced a non-native inter-chain disulphide bond 
between the C  and C  domains and TCRs were refolded from E. coli inclusion 
bodies (mTCRs). Soluble TCRs produced with either the engineered disulphide bond 
or the jun/fos coiled coil fusion showed comparable binding affinities to their cognate 
peptide-HLA molecules. This approach provides a generic method to produce soluble, 
stable and functional TCRs and has been used extensively as a research tool (Chen, 
Stewart-Jones et al. 2005; Tynan, Borg et al. 2005; Cole, Pumphrey et al. 2007; 
Purbhoo, Li et al. 2007). It has also been shown that the high-affinity A6c134 TCR 
(Li, Moysey et al. 2005) can be produced as a functional, soluble, disulphide-linked 
protein in the cytoplasm of trxB gor mutant E. coli strains (Liddy, Molloy et al. 
2010).   
 
1.11 Bispecific antibodies 
As has been alluded to earlier, multispecific antibodies offer numerous advantages 
over their monospecific counterparts. Bispecific antibody molecules can bind two 
targets at the same time; either two different antigens or two different epitopes on the 
same antigen i.e. dual binding specificity in a single construct. Antibody fragments 
can be engineered with two different antigen specificities by connecting each separate 
scFv polypeptide via a middle peptide linker (tandem scFv or bispecific scFv) 
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(Mallender and Voss 1994; Korn, Nettelbeck et al. 2004).  Bivalent (scFv)2 antibodies 
can also be produced by introducing C-terminal cysteines (Adams, McCartney et al. 
1993; Kipriyanov, Dubel et al. 1994) commercialised by Macrogenics as Dual-
Affinity Re-Targeting (DART) platform antibodies (Moore, Zhang et al. 2011). 
However, they have no or, at best, limited therapeutic potential because they are 
devoid of the Fc region of a full-IgG and require reformatting to interact either with 
Fc-related or cytotoxic effector cells. Single-chain Fv IgG-like antibodies have been 
produced by fusing an scFv fragment with one antigen-binding specificity to a full-
length IgG molecule with a second antigen-binding specificity. Fusion of the scFv can 
either be at the N-terminus (Alt, Muller et al. 1999; Michaelson, Demarest et al. 2009) 
or C-terminus (Orcutt, Ackerman et al.; Coloma and Morrison 1997; Dong, Sereno et 
al. 2011) of either the IgG heavy or light chain. Fusion to a full-IgG molecules 
ensures that the Fc effector function of the antibody is retained. Whilst fusion to an Fc 
domain confers an effector function through triggering a multifaceted cellular immune 
cascade leading to target cell death, a more direct killing approach is through 
conjugation of the antibody to molecules such as cellular toxins, radioisotopes and 
cytokines.  
 
1.11.1 Anti-TCR/Anti-tumour antibody bispecifics 
Almost three decades ago it was first demonstrated by two groups that bispecific or 
“hybrid” antibodies with dual specificity for the T-cell receptor and a chosen target 
antigen could redirect T-cells to the target site (Perez, Hoffman et al. 1985; Staerz, 
Kanagawa et al. 1985). In subsequent studies it was shown that cross-linked anti-
tumour/anti-TCR antibody bispecifics could specifically lyse target tumour cells 
(Perez, Titus et al. 1986) and that T-cell triggering was dependent on dual antibody 
binding to both TCR and target antigen (Roosnek and Lanzavecchia 1989). More 
Chapter 1 
 84 
recently, bispecific anti-tumour antigen/anti-CD3 scFvs showed great promise in 
redirecting T-cells to specifically lyse tumour cells in vitro (Loffler, Kufer et al. 2000; 
Withoff, Bijman et al. 2001; Dreier, Lorenczewski et al. 2002). 
This approach has been exploited commercially by German biotech Micromet 
(recently acquired by Amgen) who have developed a new class of bispecific antibody 
called bispecific T-cell engager (BiTE) antibodies which comprise the VH and VL 
domain from an anti-CD3 IgG antibody attached to a VH and VL domain from an anti-
tumour IgG antibody via a peptide linker (Figure 1.13). Dual engagement of a T-cell 
and a tumour cell results in T-cell activation and tumour cell killing through apoptosis 
(Baeuerle and Reinhardt 2009). Several BiTE molecules have demonstrated 
significant efficacy in controlling and in some cases eradicating tumour tissue using 
human xenograft mouse models. Anti-tumour efficacy has been confirmed using 
BiTE molecules targeting different tumour antigens, e.g. epithelial cell adhesion 
molecule (Ep-CAM) (Schlereth, Fichtner et al. 2005) and EpHA2 receptor tyrosine 
kinase (Hammond, Lutterbuese et al. 2007). Blinatumomab (MT103), a bispecific 
antibody targeting CD19 positive cells of various B-cell malignancies is currently 
undergoing clinical appraisal for a number of indications. In a Phase I study for the 
treatment of Non-Hodgkin’s Lymphoma (NHL) a median duration of response in all 
patients of 508 days was observed (Dhimolea and Reichert 2012). A Phase II clinical 
trial evaluating the efficacy of blinatumomab for the treatment of patients with 
minimal residual disease B-cell acute lymphoblastic leukaemia (MRD B-ALL) 
showed an 80% complete molecular response rate (Topp, Kufer et al. 2011).  
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Figure 1.13. The BiTE antibody structure and mode of action. The BiTE molecule 
comprises the VH and VL domains from two different mAbs, one specific for a tumour 
associated antigen (TAA) and one specific for the CD3 moiety of the T-cell receptor 
complex. The TAA-specific arm binds to the target antigen and the anti-CD3 arm 
binds to T-cells. Interaction of both arms with their targets leads to T-cell activation 
and redirected lysis of the attached tumour cell. Adapted from (Baeuerle and 
Reinhardt 2009)). 
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1.12 Tumour associated antigens 
1.12.1 Antibody TAA targets 
A key challenge has been the identification of suitable antigen targets. Genomic, 
proteomic and bioinformatic databases in combination with serology and 
immunohistochemistry have identified antigens that are overexpressed in cancer cells 
or expressed in a modified form compared with normal tissues. Many TAAs targeted 
by therapeutic monoclonal antibodies are growth factors and growth factor receptors 
that are overexpressed on tumour cells and can be divided into distinct groups 
(reviewed in (Scott, Wolchok et al. 2012). (1) Haematopoietic differentiation 
antigens, usually associated with cluster of differentiation (CD) antigens: CD20, 
CD30, CD33 and CD52; (2) Glycoproteins expressed on solid tumours: EpCAM, 
CEA (carcinoembryonic antigen) and PSMA (prostate specific membrane antigen); 
(3) Angiogenesis-related antigens: VEGF (vascular endothelial growth factor) and 
VEGFR (vascular endothelial growth factor receptor); (4) Growth and differentiation 
signalling antigens: EGFR (epidermal growth factor receptor) and Her2; (5) Stromal 
and extracellular matrix antigens: FAP (fibroblast activation protein) and Tenascin. A 
total of twelve mAbs targeting many of these surface proteins have being given FDA 
approval for the treatment of various solid and haematological tumours and a 
multitude of others are being analysed in early and late-stage clinical trials (Scott, 
Wolchok et al.).  
Whilst the overall clinical benefit of these mAbs has in general been fairly modest, 
several have become blockbusters. Trastuzumab (Herceptin) is a humanised IgG used 
in the treatment of breast cancer. It targets the HER2 gene which is amplified in 25-
30% of breast cancers and the encoded protein is expressed in abnormally elevated 
levels in tumour cells. In combination with chemotherapy, trastuzumab can prolong 
the life of patients by 4-5 months compared to patients on chemotherapy alone 
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(Slamon, Leyland-Jones et al. 2001). Bevacizumab (Avastin) is a humanised mAb 
against VEGF and is used in the treatment of metastatic colorectal cancer and can 
prolong the survival of patients by 4-5 months compared to patients on chemotherapy 
and placebo (Hurwitz, Fehrenbacher et al. 2004). Rituximab is a chimeric mAb that 
targets CD20 on B-cells and is used for the treatment of Non-Hodgkin’s Lymphoma. 
Treatment with rituximab significantly improved time to progressive disease (3.7 
versus 1.3 years) compared to treatment with chemotherapy alone (van Oers, Van 
Glabbeke et al. 2010).  
  
1.12.2 T-cell TAA targets 
It is over 100 years since Paul Ehrlich proposed his magic bullet theory to selectively 
target tumour cells (Ehrlich 1906) and whilst there have been a number of success 
stories for the treatment of cancer, there still remains a clear unmet need for more 
effective targeted therapies. 
A major limitation of antibody-based therapies against cancer cells is the nature 
and location of the target antigens. The majority of TAAs are expressed as 
intracellular proteins and are therefore inaccessible to antibodies. This greatly reduces 
the pool of potential antigens that antibodies can target.  Modification to the protein 
makeup of the cell that results from genetic mutations and altered gene expression, 
distinguishes cancer cells from normal cells. These differences are reflected at the cell 
surface in the degradation products (epitopes) presented by MHC molecules, thus 
providing a mechanism for T-cells to distinguish between normal and malignant cells. 
Aberrant peptides can be recognised by cytotoxic T-cells resulting in target cell lysis. 
Several strategies have been employed to identify tumour associated T-cell 
antigens/epitopes (reviewed in (Paschen 2009)). The first is to generate tumour-
specific T-cells. Tumour-specific cytotoxic T-cells can be isolated by stimulating 
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lymphocytes from a cancer patient with an autologous tumour cell line. Stimulated T-
cells are then used to screen HLA-matched target cells transfected with tumour-
derived cDNA libraries. The second approach is to use reverse immunology. 
Computer software using predictive algorithms analyse proteins of interest for HLA-
binding motifs. Predicted peptides are synthesised and their ability to bind MHC 
measured. Dendritic cells loaded with the candidate peptides are used to prime 
autologous T-cells. Peptide-specific T-cells are used to confirm reactivity against the 
predicted peptide by lysis of pulsed antigen presenting cells or peptide-matched 
tumour cells. A third method elutes the repertoire of peptides bound to MHC from the 
surface of cancer cells. Eluted peptides are separated by a combination of 
chromatography with mass spectroscopy and the peptide tissue distribution on normal 
and malignant cell analysed. A fourth strategy uses DNA microarray technology to 
compare gene expression profiles in normal and tumour cells (Paschen 2009). These 
methods have been used to identify four main classes of human tumour antigens: 
cancer-testis antigens, differentiation antigens, overexpressed antigens and unique 
antigens and are reviewed in (Linley, Ahmad et al.; Novellino, Castelli et al. 2005; 
Lucas and Coulie 2008; Paschen 2009).  
The focus of this study is the engineering for high affinity three HLA class I-
restricted TCRs targeting peptides derived from Melan-A/MART-1, gp100 and 
MAGE-3 antigens and as such each will be discussed in detail. 
 
1.12.2.1 Cancer testis antigens 
The cancer-testis (CT) antigens or tumour-specific shared antigens are the products of 
genes that are silent in normal cells and are reactivated in malignant cells. Expression 
of these antigens in normal tissue is restricted to MHC-negative testicular germ cells 
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and placenta trophoblasts which cannot present antigens to T-cells. For this reason the 
CT antigens represent ideal candidates for targeted immunotherapy.  
 
1.12.2.1.1 MAGE 
Van der Bruggen et al. (van der Bruggen, Traversari et al. 1991) identified the gene 
encoding the TAA MAGE-1 and demonstrated that the antigen, initially called MZ2-
D was recognised by CTLs from a melanoma patient. They subsequently identified a 
nonapeptide presented by HLA-A1 recognised by the same CTLs (Traversari, van der 
Bruggen et al. 1992). They later reported that a structurally-related antigen (73 % 
sequence homology to MAGE-1) is expressed on the same tumour, named MAGE-3 
(Gaugler, Van den Eynde et al. 1994). 
The MAGE-3 nonapeptide presented in the context of HLA-A1 corresponded to 
codons 168-176 (EVDPIGHLY) of the large open reading frame and is the best 
characterised MAGE-3 epitope (Celis, Tsai et al. 1994). Since it is HLA-A1-restricted 
it is commonly referred to as MAGE-3.A1. T-cells specific for the MAGE-3 peptide 
elicits cytotoxic activity toward peptide-pulsed, HLA-A1 positive target cells and 
toward two MAGE-3-expressing HLA-A1 melanoma cell lines (Celis, Tsai et al. 
1994).   
The expression of the MAGE-3 gene by tumour tissues was measured by RT-PCR 
(Gaugler, Van den Eynde et al. 1994). It was shown that it is expressed in a variety of 
tumour samples and tumour cell lines including in 69 % (72 out of 105) of 
melanomas, 81 % (50/62) of melanoma cell lines, 82 % (18/22) of head and neck 
squamous cell carcinoma tumour samples, 30 % (14/46) non small cell lung 
carcinoma tumour samples, 2 out 3 small cell lung carcinoma tumour samples and in 
82 % (18/22) of cell lines. 
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MAGE-A3 has also been detected in the bone marrow of multiple myeloma (MM) 
patients (Jungbluth, Ely et al. 2005; Atanackovic, Luetkens et al. 2009). In these 
studies the percentage of MAGE-A3 positive samples from Stage III MM patients 
was higher compared to Stage I/II (50-100 % compared to 33-50 % respectively). 
Thus there appears to be a correlation between cancer progression and MAGE-A3 
expression. It has also been shown that a CTL clone (CTL 434/1) that recognises 
MAGE-A3 can specifically lyse a MM cell line (EJM) which is both HLA-A1+ and 
MAGE-A3 + (van Baren, Brasseur et al. 1999). 
The identification of the MAGE family of CT antigens paved the way for the 
discovery of a multitude of other CT gene families, including BAGE, GAGE and NY-
ESO, and are reviewed in (Scanlan, Simpson et al. 2004).  
 
1.12.2.2 Differentiation antigens 
This group describes TAAs that are shared between tumours and the normal tissue 
from which the tumour arose. They are also called shared lineage antigens and are 
mainly found on melanomas and normal melanocytes (Anichini, Maccalli et al. 1993). 
Following oncogenic transformation the antigens are significantly overexpressed.  
 
1.12.2.2.1 Melan A/MART-1 
The Melan-A (melanoma antigen A) or MART-1 (melanoma antigen recognised by 
T-cells 1) was one of the first TAAs to be cloned. CTLs were isolated from either 
peripheral blood mononuclear cells from a melanoma patient (Coulie, Brichard et al. 
1994) or from tumour infiltrating lymphocytes (TILs) from metastatic melanoma 
patients (Kawakami, Eliyahu et al. 1994). To identify potential immunogenic peptides 
twenty-three peptides from MART-1 were synthesised (Kawakami, Eliyahu et al. 
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1994). Specific lysis of peptide-pulsed T2 cells by more than ten TIL populations 
identified two HLA-A2 overlapping peptides mapped to residues 27-35 
(AAGIGILTV) and 26-35 (EAAGIGILTV); it has been argued that the decapeptide 
(EAAGIGILTV) represents the major HLA-A2 epitope (Romero, Gervois et al. 
1997). They showed that the decapeptide was more efficiently recognised by 
polyclonal tumour-infiltrated lymph nodes (TILNs) and monoclonal CTL clones 
derived from a melanoma patient than the nonapeptide. Mass spectrometry later 
identified the nonapeptide (AAGIGILTV) but not the decapeptide  (EAAGIGILTV) 
on the surface of melanoma cells eluted from HLA-A2 molecules (Skipper, Gulden et 
al. 1999). 
On the basis that both of these peptides contain a nonoptimal P2 alanine anchor 
residue, artificial variants, substituting alanine for leucine, were designed (Valmori, 
Fonteneau et al. 1998). Artificial variant (or heteroclitic) peptides of the nonapeptide 
(ALGIGILTV) and decapeptide (ELAGIGILTV) were synthesised (the substituted 
alanine for leucine are underlined). Recognition of the peptide analogues by either 
Melan-A-specific tumour infiltrated lymph node cells (TILNs) or Melan-A-specific 
CTL were in agreement. Although the Ala28Leu nonapeptide variant bound with 
higher affinity to HLA-A2, recognition by Melan-A-specific TILNs and CTLs was 
greatly diminished. In contrast, the Ala27Leu decapeptide variant which also bound 
with higher affinity to HLA-A2, was more efficiently recognised by Melan-A-specific 
TILNs and CTLs than both the wild-type and variant nonapeptides.    
Overexpression of Melan-A/MART-1 in tumour tissue has been extensively 
evaluated. It has been demonstrated that, at the mRNA level as measured by RT-PCR, 
that 100 % of (26/26) melanoma samples were positive for Melan-A/MART-1 
(Coulie, Brichard et al. 1994). Immunohistochemistry (IHC) using anti-MART-1 
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antibodies has also been a valuable technique to measure the level of Melan-
A/MART-1 expression. Positive staining of melanoma tumour samples for Melan-
A/MART-1 has been 89 % (193 out of 217 samples) (Cormier, Hijazi et al. 1998); 82 
% (103 out of 126 samples) (Zubovits, Buzney et al. 2004) and 83 % (285 out of 345 
samples) (Reinke, Koniger et al. 2005).  
 
1.12.2.2.2 gp100 
A second melanoma differentiation antigen, called gp100 (also known as Pmel17) that 
shares a similar expression pattern in normal and malignant tissue to that of Melan-
A/MART-1 has also been identified (Bakker, Schreurs et al. 1994; Kawakami, 
Eliyahu et al. 1994).  
Multiple HLA-A2 naturally-processed gp100 epitopes have been detected on the 
surface of melanoma cells by mass spectrometry and includes a peptide mapped to 
residues 280-288, G9
280
 (YLEPGPVTA) (Cox, Skipper et al. 1994; Skipper, Gulden 
et al. 1999). Several of these peptides, including the G9
280
 peptide were used to 
generate CTL derived from peripheral blood lymphocytes (PBLs) of HLA-A2
+
 
melanoma patients. These CTLs were shown to kill both peptide-pulsed T2 cells and 
HLA-A2
+
, gp100
+
 melanoma cell lines (Salgaller, Afshar et al. 1995). 
As was observed with the Melan-A/MART-1 wild-type peptides, the G9
280
 peptide 
also contains a nonoptimal HLA-A2 anchor residue. In the case of the G9
280
 peptide it 
contains an alanine at P9. Through peptide-binding assays it was determined that the 
G9
280
 has an intermediate binding affinity to HLA-A*0201 (Kawakami, Eliyahu et al. 
1995). To improve both the HLA-binding affinity and immunogenicity, the alanine 
was substituted for a valine at this position (Parkhurst, Salgaller et al. 1996). The 9V 
variant bound HLA-A*0201 with a ten-fold increase in affinity compared to the 
Chapter 1 
 93 
parent peptide. This correlated with enhanced immunogenicity and CTLs were 
induced against the modified peptide more efficiently than against the unmodified 
peptide. Stimulation of melanoma patient PBMCs with the G9
280
 peptide induced 
tumour-specific CTL from only one of seven patients, compared to six out of seven 
with the 9V variant.  
Overexpression of gp100 in malignant melanoma has been well documented. 
Expression has been assessed by RT-PCR and has shown that 100 % (10 out of 10) 
(Jager, Ringhoffer et al. 1996) and (6 out of 6) (Spagnoli, Schaefer et al. 1995) of 
melanoma samples were positive for gp100 mRNA. IHC staining with anti-gp100 
antibodies has also been used to analyse gp100 expression in melanoma tissue with 
reports of 76 % (165 out of 217 samples) (Cormier, Hijazi et al. 1998) and 82 % 
(Trefzer, Hofmann et al. 2006) gp100 positive staining. 
 
1.12.2.3 Overexpressed antigens 
Overexpression can mean two different things: either a gene is expressed at higher 
levels in malignant cells than in normal cells or that a higher percentage of tumour 
cells express the antigen compared to normal cells so that at the single cell level the 
amount of gene expression is the same. Tumour overexpressed antigens include HER-
2/neu, PRAME, telomerase, surviving, MUC-1 and WT-1. Each of these proteins are 
expressed in both normal and tumour cells and although they represent potential 
targets for immunotherapy the possibility for autoimmunity against normal cells must 
be considered (Lucas and Coulie 2008; Paschen 2009; Linley, Ahmad et al. 2011).  
 
Chapter 1 
 94 
1.12.2.4 Unique antigens 
Unique antigens in tumour cells arise from somatic mutations in normal genes and as 
such can be considered tumour-specific. This group of TAAs is exemplified by Ras 
where the peptide is altered by point mutations. These TAAs are ideal for 
immunotherapy targeting because of their truly tumour-specific localisation. 
However, because the mutations are generally restricted to the tumour of a particular 
individual, immunotherapeutic agents would be needed for each patient, i.e. 
personalised medicine (Lucas and Coulie 2008; Paschen 2009; Linley, Ahmad et al. 
2011). 
 
1.13 Considerations on TCRs as bispecifics  
In order to exploit the exquisite antigen recognition capacity of the TCR for use as a 
soluble immunotherapeutic reagent, three properties of the TCR molecule need 
addressing: first, TCRs are naturally membrane-bound proteins; second, soluble 
versions of TCRs would be devoid of effector domains; third, TCRs have an intrinsic 
low affinity for cognate pMHC. 
The challenge of producing soluble TCR has been successfully achieved by 
expressing the  and  chains paired by a non-native ds-bond in E. coli (Boulter, 
Glick et al. 2003) and has been discussed earlier in Section 1.10.4.  
The choice of effector domain has been largely influenced by the recent success of 
the bispecific scFv antibodies (BiTES) which possess dual specificity for target 
antigen and the CD3 domain of the TCR complex (Baeuerle, Kufer et al. 2009; 
Baeuerle and Reinhardt 2009).  Fusing a human anti-CD3 scFv to the TCR would 
facilitate the redirection and activation of T-cells to lyse tumour cells in a mode of 
action analogous to the BiTE molecules. 
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In the context of my thesis, the third and most relevant feature of the TCR that 
limits its therapeutic potential is the inherent low affinity of interaction with pMHC. 
The repertoire of T-cells is generated during thymic selection. T-cells in the periphery 
express TCRs with low affinities for pMHC to minimise autoreactivity. The majority 
of T-cells that recognise self-antigen presented on MHC with too high an affinity will 
have been deleted during negative selection. Many TAAs are derived from self-
antigens and so those T-cells that are present in the periphery will express TCRs with 
low affinity for these TAAs reducing their targeting and killing capabilities.   
Engagement of a T-cell with a cognate antigen presenting cell (APC) leads to 
substantial reorganisation of receptors involved in antigen recognition and adhesion. 
It is at the T-cell:APC contact interface that supramolecular activation clusters 
(SMAC) or bullseye-shaped immunological synapses are formed (Monks, Freiberg et 
al. 1998; Grakoui, Bromley et al. 1999). Clustered within the central region, cSMAC, 
are molecules for T-cell signalling such as CD28 or cytotoxic T-lymphocyte antigen-4 
(CTLA-4) on the T-cell that bind pMHC and CD80/CD86 on the APC respectively. 
This is surrounded by a peripheral ring, pSMAC, of adhesion molecules such as 
leukocyte function associated antigen-1 (LFA-1) and intracellular adhesion molecule-
1 (ICAM-1) on T-cell and APC respectively, that function to strengthen the T-
cell:APC interaction. Phosphorylation of TCR/CD3 intracellular domains following 
ligation of the TCR with pMHC initiates a signalling cascade that regulates gene 
expression of immune modulating cytokines that ultimately determines cell fate. 
Although the mechanisms responsible for triggering these signalling cascades are not 
fully understood, several models exist as reviewed in (van der Merwe and Dushek 
2011). The aggregation model proposes that the aggregation of more than one TCR-
CD3 molecule increases the proximity of signalling proteins (e.g. Lck) with their 
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substrate. The conformational change model proposes that ligation of TCR with 
cognate pMHC leads to conformational changes that are transmitted to the CD3 
domain enhancing phosphorylation events. The segregation model suggests that 
exclusion from the TCR:pMHC contact zone of large ectodomain inhibitory 
phosphatases, CD45 and CD148, favours phosphorylation and thus signalling to 
occur.    
In a cellular context, the low affinity TCR-pMHC interaction is adequate to induce 
cytotoxicity of target cells bearing as few as three pMHC complexes (Purbhoo, Irvine 
et al. 2004). Whilst the processes that permit such remarkable sensitivity are not fully 
understood, the role of the co-receptor CD8 expressed on the surface of cytotoxic T-
cells is pivotal. The CD8 effect described by Cole et al. in a recent review (Cole, 
Laugel et al. 2012) suggests that at low TCR-pMHC affinity T-cell activation is 
dependent on CD8 cooperation, whereas at high TCR-pMHC affinity T-cell 
stimulation is CD8 independent. This hypothesis has direct implication on the 
biological activity of a soluble TCR reagent in which the antigen-binding function is 
uncoupled from the intrinsic co-receptor participation. Binding to pMHC through a 
soluble high affinity TCR may negate the absolute requirement for CD8 contribution; 
a parameter that has as yet not been explored.  
In addition to abrogating the complete requirement for CD8 co-receptor assistance, 
engineering a soluble TCR reagent for high affinity could also compensate for loss of 
avidity effects necessary to target low numbers of pMHC. Antigen expression on 
tumour cells that act as targets for antibody therapeutics is in great contrast to the 
number of peptide epitopes available for recognition by TCR therapeutics. For 
example, Baeuerle and colleagues have determined the level of Ep-CAM expression 
on the surface of several tumour cell lines and included: Kato III (gastric cell line) 
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900,000 sites per cell, SW480 (colon) 510,000 sites per cell and PC3 (prostate) 
114,000 sites per cell (Brischwein, Schlereth et al. 2006). The number of pMHC 
complexes on the cell surface has been estimated using a variety of methods each in 
agreement that the level of presented epitopes is extremely low. Peptides bound to 
HLA-A*0201 have been eluted from the surface of tumour cells and quantified by 
mass spectrometry with estimates of 85 to 125 copies per cell of the YLDPQQNL 
epitope (derived from an unknown member of the zinc finger protein) (Wang, Gulden 
et al. 1997) and 18 copies per cell for the KVLEYVIKV epitope (derived from the 
MAGE-A1 protein) (Pascolo S Cancer Res 2001 61:4072). Antibody fragments 
isolated from nonimmunised phage-Fab libraries with anti-pHLA specificity have also 
been used to quantitate the cell surface expression of peptide antigens (Chames, 
Hufton et al. 2000; Cohen, Hoffmann et al. 2002). More recently, tetramers of soluble 
TCRs (Laugel, Boulter et al. 2005) or high-affinity TCR monomers (Purbhoo, Sutton 
et al. 2006) have been used. In the latter study, Jakobsen and colleagues determined 
by single-molecule fluorescence microscopy, that SK-MEL-37 and Mel-264 
melanoma cells presented an average of ~25 and ~45 target antigens per cell 
respectively.  
Although tumour cells can be recognised and killed by the body’s cytotoxic T-
cells, most tumours are not eliminated. Cancer cells have developed escape 
mechanisms that enable evasion of the immune system. The display of peptides on 
MHC are targets for T-cells; aberrant peptides will be recognised and the cell 
destroyed. Down-regulation or complete loss of expression of MHC on tumour cells 
provides a method to avoid detection by T-cells and therefore a survival advantage. 
The mechanisms for loss of MHC include 2-m mutations, alterations in the antigen 
Chapter 1 
 98 
processing machinery, HLA class I mutations and deletion of segments of 
chromosome 6 and are reviewed in (Tait 2000). 
T-cell avidity is a measure of the strength of interaction between a T-cell and its 
target antigen and is affected by TCR expression levels, TCR-pMHC binding affinity 
and expression of other co-stimulatory and co-inhibitory receptors on T-cells. 
Although for some, binding affinity provides the most important contribution, there 
does not appear to be a clear relationship between binding affinity, avidity and tumour 
cell killing. High avidity T-cells can have TCRs of low affinity and conversely, low 
avidity T-cells can have high affinity TCR. Both populations of T-cells still retain the 
capacity to recognise tumour cells as reviewed in (McKee, Roszkowski et al. 2005).  
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Figure 1.14. Schematic representation  of the processes involved in the affinity 
maturation of TCRs by phage display. 
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1.14 Aims of the thesis 
Peptides presented by HLA Class I complexes represent antigenic barcodes that T-
cells scan to distinguish malignant cells from healthy cells and are therefore ideal 
targets for immunotherapeutic reagents. Although natural T-cell immunity can lead to 
regression of malignant lesions in a minority of patients, these are in most cases 
ineffective at clearing the tumour. An effectual anti-tumour T-cell-mediated immune 
response is hampered in part by the low affinity of TCRs for self-antigens and by the 
low-level expression of target antigens presented on cancer cells. To harness the 
inherent antigen recognition property of TCRs for use as potential therapeutic 
proteins, the principal goal of this thesis was to generate ultra-high affinity TCRs.  
The specific aims include: 
1. Using phage display to engineer for high affinity TCRs that recognise peptides 
derived from Melan-A/MART-126-35, gp100280-288 and MAGE-A3168-176. 
2. Developing a generic and robust phage display process for the targeted 
mutagenesis and in vitro selection of TCRs with improved binding kinetics. 
3. Exploring the phage display methodologies to isolate high affinity TCRs, 
including 
a.  The format of the TCR; investigating the effect of the position of the 
inter-chain constant region cysteines (native versus mTCR).  
b. The number of consecutive CDR residues randomised (5-NNK versus 
6-NNK). 
c. The use of subtractive panning of phage libraries on mammalian cells 
to remove off-target binders and enrich for target-specific binders. 
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2.1 Reagents and buffers 
2.1.1 Bacterial culture media 
 
Media Ingredients 
Luria Bertani Medium (LB) Tryptone 10 g/l (Oxoid) 
Yeast Extract 5 g/l (Sigma) 
NaCl 10 g/l (Sigma) 
 
Super Optimal Broth (SOB) 
 
Tryptone 20 g/l  
Yeast Extract 5 g/l  
NaCl 10 g/l  
KCl 2.5 mM (Sigma) 
 
TYP Medium 
 
Tryptone 16 g/l  
Yeast Extract 16 g/l  
NaCl 5 g/l 
K2HPO4 1 g/l (Sigma) 
 
2xYeast Extract Tryptone Medium (2xYT) 
 
Tryptone 16 g/l  
Yeast Extract 10 g/l  
NaCl 5 g/l 
 
LB Agar 
 
LB medium + BactoAgar 16 
g/l (Appleton Woods) 
 
YTE Agar 
 
2xYT medium + BactoAgar 
16 g/l  
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2.1.2 Bacterial strains and vectors 
 
Strain Product details 
E. coli XL1-Blue Agilent Technologies: RecA endA1 gyrA96 thi-1 
hsdR17supE44 relA1 lac (F proAB lacIq
Z
 M15 Tn10 (Tet
r
) 
 
E. coli TG1 Lucigen: [F´ traD36 proAB lacIq
Z
 Δ M15] supE 
 thi-1 Δ (lac-proAB) Δ (mcrB-hsdSM)5(rK-mK-) 
 
E. coli BL21 
(DE3) pLysS 
Novagen: F
–
 ompT hsdSB (rB-, mB-) dcm gal λ(DE3) pLysS 
Cm
r 
 
 
E. coli Rosetta  
(DE3) pLysS 
Novagen: F
–
 ompT hsdSB (rB-, mB-) dcm gal λ(DE3) pLysS 
RARE2 Cm
r 
 
 
Plasmid Description 
pLitmus28 NEB: pUC19 origin of replication bla (Ap
R
) M13 origin of 
replication promoter lacZ  
ab
pEX922 Wild-type A6  TCR  
ac
pG484 Undisclosed TCR  
ab
pG125 Wild-type Mel-5 TCR  
ab
pG396 Enhanced-affinity Mel-5 TCR clone MELa1  
ab
pG397 Enhanced-affinity Mel-5 TCR clone MELa1c   
ab
pGPb7 Enhanced-affinity gp100 TCR clone GPb7  
ac
pIM160 Wild-type MAGE-A3 TCR (native format) 
ac
pIM194 Enhanced-affinity MAGE-A3 TCR clone MAGEa6a  
ac
pIM195 Enhanced-affinity MAGE-A3 TCR clone MAGEb2a 
ab
pLAS0282 Wild-type MAGE-A3 TCR  
pEX954 pGMT7-based vector for T7 driven bacterial expression 
containing the  chain constant region including the 
introduced mutant cysteine at position TRAC48 (Boulter, 
Glick et al. 2003) 
pEX821 pGMT7-based vector for T7 driven bacterial expression the 
 chain constant region including the introduced mutant 
cysteine at position TRBC57 (Boulter, Glick et al. 2003) 
pG190 pEX954-based vector encoding wild-type Mel-5 TCR  
chain 
pG176 pEX821-based vector encoding wild-type Mel-5 TCR  
chain 
pG246 pEX954-based vector encoding enhanced-affinity MELa1 
Mel-5 TCR  chain 
 
a
pLitmus28-based phagemid vector; 
b
mTCR format; 
c
Native format  
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2.1.3 Buffer compositions: E. coli inclusion body preparation and TCR refolds 
 
Buffer Ingredients 
Lysis buffer EDTA (pH 8) 10 mM (Sigma) 
Tris-HCl (pH 8.1) 10 mM (Sigma) 
NaCl 150 mM (Sigma) 
Glycerol 10% (v/v) (Sigma) 
 
Triton wash buffer EDTA (pH 8) 10 mM 
Tris-HCl (pH 8.1) 50 mM 
NaCl 100 mM 
Triton X-100 0.5% (v/v) (Sigma) 
 
Resuspension buffer EDTA (pH 8) 10 mM 
Tris-HCl (pH 8.1) 50 mM 
NaCl 100 mM 
 
Guanadine Buffer Guanadine-HCl 6 M (Apollo Scientific) 
EDTA (pH 8) 10 mM 
Tris-HCl (pH 8.1) 50 mM 
NaCl 100 mM 
 
TCR refold Buffer Urea 5 M (VWR) 
Tris (pH 8.1) 100 mM 
L-arginine HCl 400 mM (Sigma) 
-mercaptoethylamine 6.5 mM (Sigma) 
Cystamine 3.7 mM (Sigma) 
 
 
2.2 Preparation of phagemid vectors pEX922 and pG484 
E. coli TG1 glycerol stocks bearing the phagemid vectors pEX922 (Li, Moysey et al. 
2005) (kindly provided by Dr. Y. Li) and pG484 (kindly provided by Dr. R. Webster) 
were used to inoculate 50 ml 2xYT media (in a sterile 250 ml conical flask) 
supplemented with 100 g/ml ampicillin (Fisher Scientific) and 2% (w/v) glucose 
(media designated 2xYTag) and incubated with shaking at 250 rpm (Innova 4430 
incubator) for 16 hours at 37ºC. DNA was isolated from the overnight culture using a 
QIAprep spin miniprep kit (Qiagen). Overnight cultures were pelleted at 3,360 x g for 
10 minutes at room temperature. The pellets were thoroughly respuspended in 400 l 
resuspension buffer. Cells were lysed by inverting with 400 l cell lysis buffer and 
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neutralised by inverting with 560 l neutralisation buffer. The cell lysate was 
centrifuged at 16,200 x g for 10 minutes at room temperature and the supernatant 
applied to a Qiagen miniprep spin column. Following a 1 minute centrifugation at 
16,200 x g at room temperature, the column was washed with 400 l binding buffer 
followed by two washes with 750 l wash buffer. After the second wash step, the 
columns were re-centrifuged at 16,200 x g for 1 minute at room temperature to 
remove residual buffer. The DNA was eluted from the column using 50 l nuclease-
free water (Qiagen) into a clean 1.5 ml sterile centifugation tube. The absorbance of 
the eluted DNA was measured at 260 nm using a Nanodrop ND-1000 
spectrophotometer (Thermo Scientific) and the concentration calculated using the 
Beer-Lambert law. 
 
2.3 Generating phagemid TCR templates 
2.3.1 PCR oligonucleotides 
The oligonucleotides used to PCR amplify the variable (V) and constant (C) regions 
specific to the Mel-5 and MAGE-A3 TCRs are listed below. Primers Nat22 and J185 
were used to PCR amplify the Mel-5 TRAV12-2 and TRBV30 genes respectively. 
Primers J135 and J155 were used to PCR amplify the MAGE-A3 TRAV21 and 
TRBV5-1 genes respectively. The phagemid vector, pGPb7, encoding the first-
generation enhanced-affinity gp100 TCR mutant GPb7 was kindly provided by Dr. N. 
Harewood. High purity salt free (HPSF) oligonucleotides were ordered from Eurofins 
MWG. 
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Phagemid molecular cloning primers 
Nat22   5’-gcccagccggccatggcccaaaaagaagttgaa-3’ 
J185   5’-ctattctcacagcgcgcagtctcagactattcatcaatgg-3’ 
J135    5’-gcccagccggccatggccaaacaggaggtgacgcaga-3’ 
J155   5’-ctattctcacagcgcgcagaaggctggagtcactcaaac-3’ 
YOL236  5’-ccgtgtaccagctgagagactc-3’ 
YOL237  5’-gagtctctcagctggtacacgg-3’ 
YOL238  5’-gcgcgctgtgagaatagaaag-3’ 
YOL239  5’-cacacccaaaaggccacact-3’ 
YOL240  5’-agtgtggccttttgggtgtg-3’ 
YOL13  5’-tcacacaggaaacagctatg-3’ 
YOL22  5’-cattttcagggatagcaagc-3’ 
J195   5’-tccagaagacaccttcttcc-3’ 
MAGEa6aFwd 5’-ttagtgcgtccgtatcagag-3’ 
MAGEa6aRev 5’-ctctgatacggacgcactaacagagatgtgag-3’ 
MAGEb2aFwd 5’-acgttgagaaacaaaggaaacttc-3’ 
MAGEb2aRev 5’-gtttcctttgtttctcaacgtcatatccgtgtattc-3’ 
 
2.3.2 PCR of TCR  and  chains  
With the exception of the MAGE-A3 TCR  and  chains which were amplified from 
the cDNA isolated from the MAGE-A3-EB103 T-cell clone (kindly provided by Dr. 
B. Cameron), the TCR V regions were amplified from E. coli expression plasmids 
containing the TCR  and  chains. The TCR constant regions were amplified from 
either phagemid vector pEX922 containing TCR  chains including the non-native 
constant domain cysteines at position TRAC threonine 48 and TRBC serine 57 
(Boulter, Glick et al. 2003) (engineered mTCR format) or from phagemid vector 
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pG484 containing TCR  chains including the native membrane-proximal cysteines 
at position TRAC 95 and TRBC 131 and the wild-type residue at positions TRAC 48 
and TRBC 57 (native format). V  PCR fragments were designated fragment A; V  
PCR fragments were designated fragment B; C  PCR fragments were designated 
fragment C; C  PCR fragments were designated fragment D. For the Mel-5 TCR the 
 chain E. coli expression vector was pG190 and the  chain E. coli expression was 
pG176 (both vectors kindly provided by E. Gostick). In addition to wild-type  and  
chains, several affinity enhanced and  chains were cloned into the phagemid 
vector. The Mel-5 TCR V  region (fragment A) encoding the enhanced-affinity 
CDR3  clone MELa1c was amplified from E. coli expression vector pG246 (Section 
2.6.3). MAGE-A3 TCR V  (MAGEa6a) and V  (MAGEb2a) mutations were 
introduced into the wild-type MAGE-A3 TCR using two pairs of complimentary 
primers to generate fragments E and F and will be described separately. All 
phagemid-TCR vectors were constructed with the mTCR constant regions with the 
exception of the MAGE-A3 TCR-phagemids which were prepared with both mTCR 
and native constant regions. All reactions were performed in sterile PCR tubes. The 
reaction components and volumes for the amplification of the TCR V  and C  
domains were as follows: Fragment A (TCR V ): 1 l 
a
DNA, 1 l dNTP mix (10 mM 
each; NEB), 1 l 
b
V  forward primer (10 pmol/ l), 1 l YOL237 (10 pmol/ l), 5 l 
10 X Polymerase buffer (Roche), 3.5 U Expand DNA polymerase (Roche) in a final 
volume of 50  l. Fragment B (TCR V ): 1 l 
c
DNA, 1 l dNTP mix (10 mM each), 
1 l 
d
V  forward primer (10 pmol/ l), 1 l YOL240 (10 pmol/ l), 5 l 10 X 
Polymerase buffer, 3.5 U Expand DNA polymerase  in a final volume of 50 l. 
Fragment C (TCR C ): 5 ng 
e
DNA, 1 l dNTP mix (10 mM each), 1 l YOL236 (10 
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pmol/ l), 1 l YOL238 (10 pmol/ l), 5 l 10 X Polymerase buffer, 3.5 U Expand 
DNA polymerase  in a final volume of 50 l. Fragment D (TCR C ): 5 ng 
f
DNA, 1 l 
dNTP mix (10 mM each), 1 l YOL239 (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 
10 X Polymerase buffer, 3.5 U Expand DNA polymerase  in a final volume of 50 l.   
 
a
TCR V  templates were: E. coli expression plasmid pG190 for the wild-type Mel-5  chain; E. coli 
expression plasmid pG246 for the MELa1c CDR3  enhanced-affinity clone; cDNA isolated from the 
MAGE-A3-EB103 T-cell clone for the wild-type MAGE-A3  chain; 
b
TCR V  specific forward 
primers were: Nat22 for the Mel-5 TCR; J135 for the MAGE-A3 TCR; 
c
TCR V  templates were: E. 
coli expression plasmid pG176 for the Mel-5  chain; cDNA isolated from the MAGE-A3-EB103 T-
cell clone for the wild-type MAGE-A3  chain; 
d
TCR V  specific forward primers were: J185 for the 
Mel-5 TCR; J155 for the MAGE-A3 TCR; 
e
TCR C  templates were: phagemid plasmid pEX922 for 
the mTCR constant domains; phagemid plasmid pG484 for the native constant domains; 
f
TCR C  
templates were: phagemid plasmid pEX922 for the mTCR constant domains; phagemid plasmid pG484 
for the native constant domains; 
a,c
E. coli expression plasmids were diluted to 5 ng/ l and the T-cell 
clone was diluted 1:10 in nuclease-free H2O. 
 
 
MAGEa6a and MAGEb2a   
All reactions were performed in sterile PCR tubes. The reaction components and 
volumes were as follows: Fragment E: 5 ng pIM160 (Section 2.1.2), 1 l dNTP mix 
(10 mM each), 1 l YOL13 (10 pmol/ l), 1 l 
a
Reverse primer (10 pmol/ l), 10 l 5 
X Phusion Polymerase buffer (NEB), 2 U Phusion DNA polymerase (NEB) in a final 
volume of 50 l. Fragment F: 5 ng pIM160, 1 l dNTP mix (10 mM each), 1 l 
b
Forward primer (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 10 l 5 X Phusion 
Polymerase buffer, 2 U Phusion DNA polymerase  in a final volume of 50 l.  
 
a
Reverse primer either MAGEa6aRev or MAGEb2aRev; 
b
Forward primer either MAGEa6aFwd or 
MAGEb2aFwd. 
 
 
The PCR conditions to amplify the TCR fragments (A-F) were as follows using a 
Biometra PCR thermocycler: Step 1: 94ºC for 2 min; Step 2: 94ºC for 16 sec; Step 3: 
53ºC for 16 sec; Step 4: 72ºC for 50 sec/kbp (Expand; Roche) or 25 sec/kbp (Phusion; 
NEB); Step 5: 4ºC pause. Step 2 to 4 repeated 26 times. 
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2.3.3 Purification of TCR variable and constant domains for cloning into the 
phagemid vector 
PCR amplified TCR gene fragments were resolved on a 1.5% (w/v) agarose (Bio-
Rad) gel containing 2.5 l ethidium bromide (Sigma) in 50 ml agarose gel. DNA 
bands of the expected size were excised from the gel and purified using the 
Zymoclean DNA gel recovery kit (Zymo Research). The gel slices were weighed and 
three times the volume of the excised gel slice was added. Following melting of the 
gel slices at 50ºC using a heating block, each mixture was added to a separate Zymo 
column. The columns were centrifuged at 16,200 x g for 30 seconds at room 
temperature and the flow through discarded. The columns were washed with 500 l 
wash buffer and centrifuged at 16,200 x g for 30 seconds at room temperature. The 
washing step was repeated with 250 l wash buffer and the columns were centrifuged 
at 16,200 x g for 30 seconds at room temperature. After the second wash step, the 
columns were centrifuged at 16,200 x g for 1 minute at room temperature to remove 
residual buffer. The DNA was eluted from the column using 15 l nuclease-free water 
into a clean 1.5 ml sterile centrifugation tube. The concentration of the eluted DNA 
was determined using a Nanodrop ND-1000 spectrophotometer. 
 
2.3.4 Generating full-length  TCR constructs using splice by overlap extension 
PCR (SOE-PCR) for cloning into phagemid vector 
The DNA fragments (A, B, C and D or E and F) were assembled using SOE-PCR to 
generate a 1700-1800 bp fragment. The primers for the ABCD SOE-PCR were the 
TCR V  specific forward primer (used to generate fragment A) and YOL22 and for 
the EF SOE-PCR were primers YOL13 and YOL22. The fragments were diluted to 
give an equimolar ratio in a 1 l volume of each. Fragment A/B/C/D: 2-6 ng each of 
fragments A, B, C and D, 1 l dNTPs (10 mM each), 1 l 
a
V  forward primer (10 
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pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X polymerase buffer, 3.5 U Expand 
polymerase in a final volume of 50 l.  
 
a
TCR V  specific forward primers were: Nat22 for the Mel-5 TCR and J135 for the MAGE-A3 TCR.  
 
Fragment E/F: 2 ng each of fragments E and F, 1 l dNTPs (10 mM each), 1 l 
YOL13 (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 10 l 5 X polymerase buffer, 1 U 
Phusion polymerase in a final volume of 50 l. The cycling parameters are outlined in 
Section 2.3.2 except with an extension time of 80 seconds (A/B/C/D) or 45 seconds 
(E/F) and repeating steps 2 to 4 thirty times. The amplified SOE-PCR 1700-1800 bp 
product was resolved on a 1% (w/v) agarose gel and gel-purified using the Zymoclean 
DNA gel recovery kit. DNA was eluted using 15-20 l nuclease-free water. 
 
2.3.5 Restriction digests of the SOE-PCR product and pEX922 and ligation into 
phagemid vector 
The SOE-PCR fragment and phagemid vector pEX922 were mixed with 10 U each of 
the restriction enzymes NcoI and NotI (NEB) and buffer according the manufacturer’s 
recommendations in a final volume of 40-50 l and incubated at 37ºC for 3 hours. 
Following incubation at 37ºC, the digested DNA fragments were resolved on a 1% 
(w/v) agarose gel. Bands of the expected size were excised from the gel and purified 
using the Zymoclean DNA gel recovery kit. The concentration of the eluted DNA was 
determined using a Nanodrop ND-1000 spectrophotometer. The purified SOE-PCR 
product was ligated (using the Rapid ligation kit; Roche) into the purified phagemid 
vector pEX922 using a molar ratio of 3:1 (insert to vector) following conditions: 
typically, 40 ng pEX922, 40 ng SOE-PCR fragment, 1 l DNA Dilution Buffer 5 X, 
5 l DNA Ligation Buffer 2 X, 5 U T4 DNA ligase in a final volume of 10 l. 
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Following incubation at room temperature for 10 minutes, residual salt was removed 
from the ligation mixture using the DNA clean and concentrator kit (Zymo research). 
The ligation mixture was mixed with 100 l DNA binding buffer and added to a 
Zymo spin column. The columns were centrifuged at 16,200 g for 30 seconds at room 
temperature and the flow through discarded. The columns were washed with 500 l 
wash buffer and centrifuged at 16,200 x g for 30 seconds at room temperature. The 
washing step was repeated with 250 l wash buffer and the columns were centrifuged 
at 16,200 x g for 30 seconds at room temperature. After the second wash step, the 
columns were centrifuged at 16,200 x g for 1 minute at room temperature to remove 
residual buffer. The DNA was eluted from the column using 12 l nuclease-free water 
into a clean 1.5 ml sterile centrifugation tube. 
 
2.3.6 Preparation of electrocompetent E. coli TG1 cells 
A 40 ml volume of LB medium was inoculated with a single E. coli TG1 colony 
picked from a freshly streaked minimal salt agar plate and grown overnight at 37ºC at 
250 rpm. From the overnight starter culture, 12 ml was used to inoculate 800 ml LB 
medium (in a 2 litre flask). The culture was incubated at 37ºC at 250 rpm until the 
optical density (OD600) reached 0.2; at which point the culture was transferred to an 
incubator set at 18ºC and grown for a further 1 hour with shaking (250 rpm). 
Incubation at 18ºC continued until the OD600 reached 0.7. The conical flasks were 
then chilled on ice for 30 minutes with gentle swirling. The culture was then split 
between two 500 ml centrifuge bottles and centrifuged at 3,360 g for 20 minutes at 
4ºC. The supernatant was discarded and the pellets were resuspended (by gentle 
agitation) in 50 ml ice-cold sterile molecular grade water. Once the cells were 
resuspended, the volume was increased to 400 ml (the original culture volume) ice-
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cold sterile molecular grade water. The samples were centrifuged at 3,360 x g for 20 
minutes at 4ºC. The supernatant was discarded and the pellets were resuspended (by 
gentle agitation) in 50 ml ice-cold sterile molecular grade water. Once the cells were 
resuspended, the volume was increased to 400 ml (the original culture volume) ice-
cold sterile molecular grade water. The samples were centrifuged at 3,360 x g for 20 
minutes at 4ºC. The supernatant was discarded and each pellet was resuspended in 40 
ml (1/10
th
 the original volume) ice-cold filter-sterilised 10% (v/v) glycerol (Sigma) 
solution. The cell suspension (80 ml volume) was transferred to four sterile 50 ml 
centrifuge tubes and centrifuged at 3,360 x g for 20 minutes at 4ºC. The supernatant 
was discarded and each pellet was resuspended in 0.5 ml ice-cold filter-sterilised 10% 
(v/v) glycerol solution (2 ml final volume). Following 20 minutes incubation on ice, 
the cells were transferred to sterile 1.5 ml centrifugation tubes, flash frozen in liquid 
nitrogen and stored at -80ºC.      
 
2.3.7 Electroporation of E. coli TG1 cells with a TCR-containing phagemid 
vector   
Electrocompetent E. coli TG1 cells were transformed with the purified ligation 
reaction (Section 2.3.5) using a MicroPulser electroporation system (Bio-Rad). The E. 
coli TG1 cells were thawed on ice and 40 l was transferred to a sterile 1.5 ml 
centrifugation tube containing 2.5-3 l of the purified ligation mixture. After gentle 
mixing with a pipette tip, the E. coli TG1 cell/DNA mixture was transferred into a 
chilled electroporation cuvette without introducing bubbles. The electroporation 
cuvette was gently tapped to deposit the cells across the bottom of the chamber and 
then placed in the ShockPod (Bio-Rad) and the lid closed. A 1.8 kV pulse was passed 
through the cell suspension and 0.96 ml of prewarmed (37ºC) SOC media (Sigma) 
was used to collect the contents of the chamber into a sterile 50 ml centrifugation 
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tube. The transformed cells were incubated at 37ºC at 250 rpm for 1 hour. Using a 
sterile inoculation loop the transformed E. coli TG1 cells were streaked onto an YTE 
agar plate supplemented with 100 g/ml ampicillin and 2% glucose (w/v) to obtain 
single colonies. The plate was incubated at 30ºC overnight. 
 
2.3.8 Colony PCR screen of E. coli TG1 cells transformed with a TCR-containing 
phagemid vector 
A total of 8 colonies were screened. Five ml 2xYTag media was inoculated with a 
single ampicillin-resistant E. coli TG1 colony and incubated at 37ºC at 250 rpm until 
the culture was visibly cloudy. At this point, 1 l of each was screened by colony 
PCR with primers YOL13 and YOL22. The cultures were incubated at 37ºC at 250 
rpm until reaching the desired cell density (OD600 ~0.8). Bacterial stocks were 
prepared for each of the 8 cultures by mixing in a sterile 1.5 ml centrifugation tube 0.6 
ml of culture with 0.4 ml 50% glycerol-supplemented media; 20% (v/v) glycerol final. 
Tubes were snap frozen on dry-ice and stored at -80ºC.  The PCR mixture for each 
colony was assembled as follows: 1 l E. coli culture (or E. coli colony), 1 l dNTP 
mix (10 mM each), 1 l YOL13 (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X 
Polymerase buffer (NEB), 2.5 U Taq DNA polymerase (NEB) in a final volume of 50 
l. The cycling parameters are outlined in Section 2.3.2 with an extension time of 
120 seconds and repeating steps 2 to 4 thirty times. The PCR products were purified 
using the DNA clean and concentrator kit. DNA was eluted in 30 l of nuclease-free 
water and purified DNA sequenced with primers YOL13, YOL22 and J195 using the 
Sanger sequencing method (GATC Biotech).  
 
Chapter 2 
 114 
2.4 Construction of TCR phage display libraries 
Phagemid vector DNA (listed in Section 2.3.1) was isolated from the E. coli TG1 
bacterial stock of a sequence verified phagemid vector-TCR clone (Section 2.3.8). 20 
ml of 2xYTag media was inoculated with 5 l of the E. coli TG1 bacterial stock and 
incubated at 26ºC overnight at 250 rpm. DNA was isolated from the overnight culture 
using a QIAprep spin miniprep kit (Qiagen). The eluate was re-purified using the 
DNA clean and concentrator kit (Zymo research). The concentration of the eluted 
DNA was determined using a Nanodrop ND-1000 spectrophotometer. As a 
modification to the Mel-5 TCR library construction, phagemid vector templates, 
pGPb7 (gp100 TCR) and pIM160, pIM194, pIM195 and pLAS0282 (MAGE-A3 
TCR) were linearised separately with NcoI and NotI. Restriction digests were 
typically performed using ~1.5 μg DNA, 25 U of the required enzyme and buffer in 
accordance with manufacturer’s guidelines (NEB) in a final volume of 20 μl. 
Digestions were incubated at 37 °C for 2-4 hours. After incubation DNA was resolved 
on a 1% (w/v) agarose gel and bands of the predicted size were purified using the 
Zymoclean DNA gel recovery kit. The concentration of the eluted DNA was 
determined using a Nanodrop ND-1000 spectrophotometer. 
 
2.4.1 Mel-5 TCR phage display libraries 
Mutagenised Mel-5 TCR libraries were constructed in which the DNA encoding the 
CDRs was mutated with degenerative 4- or 5-NNK oligonucleotides (where N = 25% 
mix each of nucleotides A, C, G and T; K = 50% mix each of nucleotides G or T). 
High purity salt free (HPSF) oligonucleotides were ordered from Eurofins MWG. 
First-generation libraries were built in the context of the wild-type Mel-5 TCR 
framework and all 6 CDRs were targeted. Second-generation libraries were 
constructed in the context of two enhanced-affinity CDR3  frameworks (MELa1 and 
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MELa1c) and only CDR1 , CDR2 , CDR2  and CDR3  regions were mutated. The 
methods used to identify the enhanced-affinity templates (MELa1 and MELa1c) will 
be described in Section 2.6.3. This section will focus on phage display library 
construction. The primers are shown below and the PCR strategies employed for the 
first and second-generation library construction are depicted in Figure 2.1 and Figure 
2.2.  
 
Mel-5 TCR library primers 
Nat1  5’-gtcactgtaagtgcagttgag-3’ 
Nat2  5’-aactgcacttacagtgacNNKNNKNNKNNKTccttcttctggtacagacaa-3’ 
Nat3  5’-tccttcttctggtacagacaatat-3’ 
Nat4  5’-gaacattatcaactcagggca-3’ 
Nat5  5’-cctgagttgataatgttcNNKNNKNNKNNKggtgacaaagaagatgg-3’ 
Nat6  5’-ggtgacaaagaagatggaaggttt-3’ 
Nat29  5’-agccacctacctctgtNNKNNKNNKNNKNNKggcaaatcaacctttg-3’ 
Nat30  5’-cacctacctctgtgccNNKNNKNNKNNKNNKaaatcaacctttgggg-3’ 
Nat31  5’-cctctgtgccgtgaacNNKNNKNNKNNKNNKacctttggggatggga-3’ 
Nat32  5’-ctgtgccgtgaacgttNNKNNKNNKNNKNNKtttggggatgggacta-3’ 
Nat37  5’-acagaggtaggtggctgaatc-3’ 
Nat38  5’-ggcaaatcaacctttggggat-3’ 
Nat39  5’-ggcacagaggtaggtggctga-3’ 
Nat40  5’-aaatcaacctttggggatggg-3’ 
Nat41  5’-gttcacggcacagaggtaggt-3’ 
Nat42  5’-acctttggggatgggactacg-3’ 
Nat43  5’-aacgttcacggcacagaggta-3’ 
Nat44  5’-tttggggatgggactacgctc-3’ 
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Nat23  5’-tccctccacagtgcactccagaga-3’ 
Nat24  5’-tgcactgtggagggaNNKNNKNNKNNKaacctatactggtaccga-3’ 
Nat25  5’-aacctatactggtaccgacaggct-3’ 
Nat26  5’-ggagtagaagagcagctggaggcc-3’ 
Nat27  5’-ctgctcttctactccNNKNNKNNKNNKcagatcagctctgaggtg-3’ 
Nat28  5’-cagatcagctctgaggtgccccag-3’ 
Nat33  5’-tggcttctatctctgtNNKNNKNNKNNKNNKgggttaggcaccgggg-3’ 
Nat34  5’-ctatctctgtgcctggNNKNNKNNKNNKNNKggcaccggggagctgt-3’ 
Nat35  5’-ctgtgcctggtccgagNNKNNKNNKNNKNNKggggagctgttttttg-3’ 
Nat36  5’-gtccgagacagggttaNNKNNKNNKNNKNNKttttttggagaaggct-3’ 
Nat45  5’-acagagatagaagccagagtc-3’ 
Nat46  5’-gggttaggcaccggggagctg-3’ 
Nat47  5’-ccaggcacagagatagaagcc-3’ 
Nat48  5’-ggcaccggggagctgtttttt-3’ 
Nat49  5’-ctcggaccaggcacagagata-3’ 
Nat50  5’-ggggagctgttttttggagaa-3’ 
Nat51  5’-taaccctgtctcggaccaggc-3’ 
Nat52  5’-ttttttggagaaggctctagg-3’ 
Nat209 5’-actgtaagtgcagttgagaga-3’ 
Nat212   5’-caactgcacttacagtNNKNNKNNKNNKcagtccttcttctggt-3’ 
Nat215 5’-cagtccttcttctggtacaga-3’ 
Nat227   5’-ggagtgcactgtggagNNKNNKNNKNNKcccaacctatactggt-3’ 
Nat224 5’-ctccacagtgcactccagaga-3’ 
Nat230 5’-cccaacctatactggtaccga-3’ 
Nat239   5’-tgcctggtccgagacaNNKNNKNNKNNKNNKgagctgttttttggag-3’ 
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Nat242 5’-tgtctcggaccaggcacagag-3’ 
Nat245 5’-gagctgttttttggagaaggc-3’ 
Nat241  5’-cgagacagggttaggcNNKNNKNNKNNKNNKtttggagaaggctcta-3’ 
Nat244 5’-gcctaaccctgtctcggacca-3’ 
Nat247 5’-tttggagaaggctctaggctg-3’ 
 
 
2.4.1.1 Generating ‘black’ and ‘red’ library PCR fragments 
First-generation library PCRs used phagemid vector pG125 (wild-type Mel-5 TCR) as 
the template. Second-generation  chain library PCRs used either phagemid vector 
pG396 (MEla1) or pG397 (MELa1c) as template. Second-generation  chain library 
PCRs used phagemid vector pG125 as template. All reactions were performed in 
sterile PCR tubes. The reaction components and volumes for the amplification of the 
Mel-5 TCR alpha and beta ‘black’ and ‘red’ PCR fragments (Figure 2.1 and Figure 
2.2) are shown below. 
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A. 
 
 
 
 
 
 
 
 
 
 
YOL13 Nat3 a1 a2 
Nat2 
YOL238 Nat1 
CDR1
YOL13 Nat6 a4 a5 
Nat5 
YOL238 Nat4 
CDR2
YOL13 Nat38 a7 a8 
Nat29 
YOL238 Nat37 
CDR3 -1
YOL13 Nat40 a10 a11 
Nat30 
YOL238 Nat39 
CDR3 -2
YOL13 Nat42 a13 a14 
Nat31 
YOL238 Nat41 
CDR3 -3
YOL13 Nat44 a16 a17 
Nat32 
YOL238 Nat43 
CDR3 -4
a3 
a6 
a9 
a12 
a15 
a18 
Stitch name 
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B. 
 
Figure 2.1. Schematic representation of the strategy for constructing first-
generation mutagenised Mel-5 TCR fragments. (A).  chain library. (B).  chain 
library. Two PCR fragments are generated for each CDR library (a black and a red 
fragment). The two fragments are assembled by addition of an NNK oligonucleotide 
(bright green corresponds to the mutagenised NNK region; black and red sections will 
anneal to the corresponding coloured fragments) and amplification with the external 
primers. The  chain fragments are named: a1, a2, a4, a5, a7, a8, a10, a11, a13, a14, 
a16 and a17. The  chain fragments are named: b1, b2, b4, b5, b7, b8, b10, b11, b13, 
b14, b16 and b17.  chain SOE-PCR fragments are named: a3, a6, a9, a12, a15 and 
a18.  chain SOE-PCR fragments are named: b3, b6, b9, b12, b15 and b18. 
J195 Nat25 b1 b2 
Nat24 
YOL22 Nat23 
CDR1
J195 
 
Nat28 b4 b5 
Nat27 
YOL22 Nat26 
CDR2
J195 
 
Nat46 b7 b8 
Nat33 
YOL22 Nat45 
CDR3 -1
J195 
 
Nat48 b10 b11 
Nat34 
YOL22 Nat47 
CDR3 -2
J195 
 
Nat50 b13 b14 
Nat35 
YOL22 Nat49 
CDR3 -3
J195 Nat52 b16 b17 
Nat30 
YOL22 Nat51 
CDR3 -4
b3 
b6 
b9 
b12 
b15 
b18 
Stitch name 
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A. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YOL13 Nat215 a1 a2 or à2 
Nat212 
YOL238 Nat209 
CDR1 -1
YOL13 Nat3 a4 a5 or à5 
Nat2 
YOL238 Nat1 
CDR1 -2
YOL13 Nat6 a7 a8 or à8 
Nat5 
YOL238 Nat4 
CDR2
a3 or à3 
a6 or à6 
a9 or à9 
Stitch name 
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B.
 
J195 Nat230 b1 b2 
Nat227 
YOL22 Nat224 
CDR1 -1
J195 
 
Nat25 b4 b5 
Nat24 
YOL22 Nat23 
CDR1 -2
J195 
 
Nat237 b7 b8 
Nat235 
YOL22 Nat233 
CDR2 -1
J195 
 
Nat28 b10 b11 
Nat27 
YOL22 Nat26 
CDR2 -2
J195 
 
Nat46 b13 b14 
Nat33 
YOL22 Nat45 
CDR3 -1
J195 Nat48 b16 b17 
Nat34 
YOL22 Nat47 
CDR3 -2
b3 
b6 
b9 
b12 
b15 
b18 
Stitch name 
J195 Nat50 b19 b20 
Nat35 
YOL22 Nat49 
CDR3 -3 b21 
J195 Nat245 b22 b23 
Nat239 
YOL22 Nat242 
CDR3 -4 b24 
J195 Nat52 b25 b26 
Nat36 
YOL22 Nat51 
CDR3 -5 b27 
J195 Nat247 b28 b29 
Nat241 
YOL22 Nat244 
CDR3 -6 b30 
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Figure 2.2. Schematic representation of the strategy for constructing second-
generation mutagenised Mel-5 TCR fragments by overlapping PCR. (A).  chain 
library schematic. (B).  chain library schematic. Two PCR fragments were generated 
for each CDR library (a black and a red fragment). The two fragments were 
assembled by addition of an NNK oligonucleotide and amplified with the external 
primers. The  chain fragments are named: a1, a2 or à2, a4, a5 or à5, a7, a8 or à8. 
Fragments generated using pG396 (MELa1) as template are shown as “a” and 
fragments generated using pG397 (MELa1c) as template are shown as “à”. The 
chain fragments are named: b1, b2, b4, b5, b7, b8, b10, b11, b13, b14, b16, b17, 
b19, b20, b22, b23, b25, b26, b28 and b29.  chain SOE-PCR fragments are named: 
a3, a6 and a9.  chain SOE-PCR fragments are named: b3, b6, b9, b12, b15, b18, b21, 
b24, b27 and b30. 
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Alpha chain ‘black’ PCR fragments: 
Component    Volume 
a
Phagemid vector ~2 ng/ l  1 l 
dNTP mix (10 mM each)  1 l 
YOL13 (10 pmol/ l)   1 l 
b
Nat Rev primer (10 pmol/ l)  1 l 
10 X Polymerase buffer  5 l 
Expand DNA polymerase   1 l 
Nuclease-free H2O   40 l 
     50 l 
a
First-generation libraries: pG125; second-generation  chain libraries: pG396 or pG397; 
b
First-
generation libraries: Nat Rev primer refers to the following primers (Figure 2.1A): Nat1, Nat4, Nat37, 
Nat39, Nat41 and Nat43; 
b
Second-generation libraries: Nat Rev primer refers to the following primers 
(Figure 2.2A): Nat209, Nat1, Nat4.  
 
 
Alpha chain ‘red’ PCR fragments: 
Component    Volume 
a
Phagemid vector ~2 ng/ l  1 l 
dNTP mix (10 mM each)  1 l 
b
Nat Fwd primer (10 pmol/ l) 1 l 
YOL238 (10 pmol/ l)   1 l 
10 X Polymerase buffer  5 l 
Expand DNA polymerase   1 l 
Nuclease-free H2O   40 l 
     50 l 
a
First-generation libraries: pG125; second-generation  chain libraries: pG396 or pG397; 
b
First-
generation libraries: Nat Fwd primer refers to the following primers (Figure 2.1A): Nat3, Nat6, Nat36, 
Nat40, Nat42 and Nat44; 
b
Second-generation libraries: Nat Fwd primer refers to the following primers 
(Figure 2.2A): Nat215, Nat3, Nat6.  
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Beta chain ‘black’ PCR fragments: 
Component    Volume 
a
Phagemid vector ~2 ng/ l  1 l 
dNTP mix (10 mM each)  1 l 
J195 (10 pmol/ l)   1 l 
b
Nat Rev primer (10 pmol/ l)  1 l 
10 X Polymerase buffer  5 l 
Expand DNA polymerase   1 l 
Nuclease-free H2O   40 l 
     50 l 
a
First and second-generation libraries: pG125; second-generation  chain libraries: pG125; 
b
First-
generation libraries: Nat Rev primer refers to the following primers (Figure 2.1B): Nat23, Nat26, 
Nat45, Nat47, Nat49 and Nat51; 
b
Second-generation libraries: Nat Rev primer refers to the following 
primers (Figure 2.2B): Nat224, Nat23, Nat233, Nat26, Nat45, Nat47, Nat49, Nat242, Nat51, and 
Nat244.  
 
Beta chain ‘red’ PCR fragments: 
Component    Volume 
a
Phagemid vector ~2 ng/ l  1 l 
dNTP mix (10 mM each)  1 l 
b
Nat Fwd (10 pmol/ l)  1 l 
YOL22 (10 pmol/ l)   1 l 
10 X Polymerase buffer  5 l 
Expand DNA polymerase   1 l 
Nuclease-free H2O   40 l 
     50 l 
a
First-generation libraries: pG125; second-generation  chain libraries: pG125; 
b
First-generation 
libraries: Nat Fwd primer refers to the following primers (Figure 2.1B): Nat25, Nat28, Nat46, Nat48, 
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Nat50 and Nat52; 
b
Second-generation libraries: Nat Fwd primer refers to the following primers (Figure 
2.2B): Nat230, Nat25, Nat237, Nat28, Nat46, Nat48, Nat50, Nat245, Nat52 and Nat247.  
 
 
PCR extension times were adjusted according to the expected size based on the 
manufacturer’s (Roche) recommended extension times. The reactions were performed 
using the following PCR cycling conditions: Step 1: 94ºC for 2 min; Step 2: 94ºC for 
16 sec; Step 3: 55ºC for 16 sec; Step 4: 72ºC for 40 sec/kbp; Step 5: 4ºC pause. Step 2 
to 4 repeated 25 times. 
 
Following PCR cycling, 20 U of DpnI (NEB) endonuclease were added to each PCR 
tube, mixed by gentle pipetting and incubated at 37ºC for 2 hours using a Biometra 
PCR thermocycler. PCR amplified Mel-5 TCR ‘black’ and ‘red’ alpha and beta 
fragments were resolved on a 1.6% (w/v) agarose gel. DNA bands of the expected 
size were excised from the gel and purified using the Zymoclean DNA gel recovery 
kit. The DNA was eluted from the column using 10-30 l nuclease-free water into a 
clean 1.5 ml sterile centrifugation tube. The concentration of the eluted DNA was 
determined using a Nanodrop ND-1000 spectrophotometer. Additionally, to assess 
purity of the excised bands 1 l of each was resolved on a 1-1.5% (w/v) agarose gel. 
 
2.4.1.2 Generating full-length Mel-5 TCR  and  chain library PCR fragments 
Full-length  and  chain library PCR fragments were assembled by SOE-PCR using 
the mutagenic NNK oligonucleotides (Section 2.3.1) to join the ‘black’ and the ‘red’ 
PCR fragments and amplification with primers YOL13 and YOL238 for the  chain 
fragments and J195 and YOL22 for the  chain fragments. In addition, control PCRs 
were set up, identical except for the omission of the linking NNK primer. ‘Black’ and 
‘red’ purified PCR fragments were diluted to a concentration so that 1 l of each 
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would give a 1:1 molar ratio in a total of 10-12 ng DNA. The reaction components 
and volumes for the amplification of the full-length Mel-5 TCR  and  PCR 
fragments were as follows (note that the components of the control PCRs are not 
provided). Alpha chain: 1 l each of ‘black’ and ‘red’ fragments, 1 l dNTPs (10 mM 
each), 1 l YOL13 (10 pmol/ l), 1 l YOL238 (10 pmol/ l), 1 l
 a
NNK 
oligonucleotide (1 pmol/ l), 5 l 10 X polymerase buffer, 3.5 U Expand polymerase 
in a final volume of 50 l. Beta chain: 1 l each of ‘black’ and ‘red’ fragments, 1 l 
dNTPs (10 mM each), 1 l J195 (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 1 l
 a
NNK 
oligonucleotide (1 pmol/ l), 5 l 10 X polymerase buffer, 3.5 U Expand polymerase 
in a final volume of 50 l.   
 
a
The nomenclature of the NNK oligonucleotides are shown in Figure 2.1 and Figure 2.2.  
 
The reactions were performed using the PCR cycling conditions outlined in Section 
2.4.1.1 using an extension time of 80 seconds and repeating steps 2 to 4 thirty times. 
After successful amplification, the full-length mutagenised Mel-5 TCR  and  chain 
fragments were resolved on a 1% (w/v) agarose gel and DNA bands of the expected 
size were excised from the gel and purified using the Zymoclean DNA gel recovery 
kit. The DNA was eluted from the column using 20-50 l nuclease-free water. The 
concentration of the eluted DNA was determined using a Nanodrop ND-1000 
spectrophotometer. To assess purity of the excised bands 1 l of each was resolved on 
a 1.4% (w/v) agarose gel. 
 
2.4.1.3 Restriction digests of the Mel-5 TCR SOE-PCR products and pG125  
First-generation libraries were cloned into pG125 as SfiI fragments for the  chains 
and as BssHII-NotI fragments for the  chain fragments. Second-generation  chain 
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libraries (built on either MELa1 or MELa1c DNA templates) were cloned into pG125 
as SfiI fragments. Second-generation  chain libraries were cloned into both pG396 
and pG397 as BssHII-NotI fragments. Restriction digests of 2-3 g of SOE-PCR 
fragments were set up with 20-30 U each of the appropriate enzyme(s), using the 
manufacturer’s recommended buffer in a final volume of 50-60  l. Restriction digest 
of 60-100 g of phagemid vectors were set up with 300-500 U each of the appropriate 
enzyme(s), using the manufacturer’s recommended buffer in a final volume of 600-
700 l  and incubating at 37ºC (NotI) or 50ºC (BssHII or SfiI).  SfiI digests were 
performed at 50ºC for 6 hours. NotI digests were performed at 50ºC for 6 hours 
followed by incubation with BssHII for a further 6 hours at 50ºC.  
 
2.4.1.4 Transformation and electroporation of Mel-5 TCR libraries 
Digested DNA were gel-purified from a 1% (w/v) agarose gel using the Zymoclean 
DNA gel recovery kit and the concentrations determined on a Nanodrop ND-1000 
spectrophotometer. To assess purity of the excised bands 1 l of each was resolved on 
a 1% (w/v) agarose gel. For the first-generation libraries the efficiency of the insert 
and vector digests was monitored by small-scale pilot ligations using the Rapid 
ligation kit (Roche) and a total of ~80 ng DNA based on a ratio of 3:1 (insert to 
vector) following the conditions described in Section 2.3.5. Control ligations of 
digested vector only were also set up. Subsequently, large-scale ligations were 
prepared using T4 DNA ligase (NEB) overnight at 16ºC as shown below and in Table 
2.1. 
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First-generation libraries 
Alpha chain libraries : 4 g pG125, 1.4 g  chain fragment, l 10 X ligase buffer, 
2000 U T4 DNA ligase (NEB) in a final volume of 120 l.  
Beta chain libraries : 5 g pG125, 2 g  chain fragment, l 10 X ligase buffer, 
2000 U T4 DNA ligase (NEB) in a final volume of 150 l.  
 
Library Ligation CDR SOE-PCR fragment 
1 
1 CDR1  a3 
2 CDR2  a6 
2 
3 
CDR3  
a9 
4 a12 
5 a15 
6 a18 
3 
7 CDR1  b3 
8 CDR2  b6 
4 
9 
CDR3  
b9 
10 b12 
11 b15 
12 b18 
 
Table 2.1. Mel-5 TCR first-generation affinity maturation library ligations. Refer 
to Figure 2.1 for nomenclature of fragments. 
 
 
 
 
Second-generation libraries 
Second-generation library ligations were set up using a ratio of 3:1 (insert:vector) 
with the total amount of DNA indicated in Table 2.2 according to the following ratio 
of reagents: 300 U T4 ligase (NEB) for 1 g of total DNA in a final volume of 100 l 
and incubating overnight at 16ºC. 
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Library  Ligation Framework CDR 
SOE-PCR 
fragments 
Phagemid  
V + I 
( g) 
1 
1 MELa1 CDR1 a3, a6 pG125 7 
2 MELa1 CDR2 a9 pG125 4 
2 
3 MELa1c CDR1 à3, à6 pG125 6.5 
4 MELa1c CDR2 à9 pG125 4 
- 
a
5 MELa1 CDR1 b3, b6 pG396 5.6 
a
6 MELa1 CDR2 b9, b12 pG396 7 
3 
7 MELa1c CDR1 b3, b6 pG397 5.1 
8 MELa1c CDR2 b9, b12 pG397 6.8 
- 
a
9 MELa1 CDR3
b15, b18, b21, 
b24, b27, b30 
pG396 11 
4 10 MELa1c CDR3
b15, b18, b21, 
b24, b27, b30 
pG397 15 
 
Table 2.2. Mel-5 TCR second-generation affinity maturation library ligations. 
Refer to Figure 2.2 for nomenclature of fragments. 
a
The chain libraries, 
CDR1 CDR2  and CDR3  (ligations 5, 6 and 9), built on the MELa1 framework 
were contaminated with the MELa1 template and were not taken forward into the 
phage panning experiments. V = vector; I = insert.  
 
 
After ligation, the mixtures were purified using the Zymo DNA clean and 
concentrator kit. DNA was eluted in 20-40 l of nuclease-free water. Transformation 
of electrocompetent E. coli TG1 cells followed the protocol described in Section 2.3.7 
except that following recovery at 37ºC the entire 1 ml suspension volume was spread 
uniformly onto YTE agar (Square BioAssay dish 245 mm x 245 mm; Corning) 
supplemented with 100 g/ml ampicillin and 2% glucose (w/v). For second-
generation libraries, commercially prepared electrocompetent E. coli TG1 cells were 
used (≥4 x 1010 cfu/ g; Lucigen). For the first-generation libraries, 1 electroporation 
for each ligation was performed. For the second-generation libraries, 2 
transformations for each ligation were performed except for ligation 9 and ligation 10 
in which 6 and 10 transformations were performed respectively. Serial dilutions of the 
transformed library were performed by diluting the library in SOC media and 
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spreading 100 μl of each dilution on YTE agar plates supplemented with 100 g/ml 
ampicillin and 2% glucose (w/v). The plates were incubated at 30ºC overnight. 
Individual colonies were counted on the dilution plates and the library sizes were 
calculated. Individual ampicillin-resistant colonies from each library were screened by 
PCR with Taq polymerase (NEB) using primers YOL13 and YOL22 and following 
the protocol described in Section 2.3.8. PCR products were purified using the DNA 
clean and concentrator kit and were sequenced with primers YOL13 and YOL22 
(GATC Biotech). The transformed colony large plates were scraped using a spreader 
into 15% (v/v) glycerol-supplemented 2xTY media. The scraped bacterial suspension 
from multiple transformations belonging to the same CDR library were pooled and 
incubated on ice for ~15 minutes with gentle mixing. The 12 first-generation 
individual transformations were pooled into 4 libraries (Table 2.1). The 10 second-
generation ligation transformations were pooled into 6 libraries (Table 2.2). All 
bacterial library stocks were transferred to sterile 1.5 ml centrifugation tubes and snap 
frozen on dry-ice. The cell stocks were stored at -80ºC.  
 
2.4.2 gp100 TCR phage display libraries 
First-generation gp100 TCR libraries were constructed by Dr. N. Harwood who 
provided the phagemid-gp100 TCR vector (pGPb7) encoding the enhanced-affinity 
clone GPb7 (Section 2.4). Second-generation libraries were built using pGPb7 as 
template targeting CDR2 , CDR3  and CDR3  regions for mutagenesis. Second-
generation libraries were constructed according to the protocols outlined in Section 
2.4-2.4.1.4 with some modifications. The primers are shown below and the PCR 
strategy employed for the library construction is depicted in Figure 2.3.  
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gp100 TCR library primers 
Nat53 5’-taaaattaggtggacaag 
Nat54 5’-cttgtccacctaattttaNNKNNKNNKNNKNNKagagagaaacacagtggaag-3’ 
Nat55 5’-cttgtccacctaattttaataNNKNNKNNKNNKNNKgagaaacacagtggaag 
Nat56 5’-acagaagtaagaagcagtgtc 
Nat57 5’-gacactgcttcttacttctgtNNKNNKNNKNNKNNKacacctcttgtctttgg 
Nat58 5’-cgtagcacagaagtaagaagc 
Nat59 5’-gcttcttacttctgtgctacgNNKNNKNNKNNKNNKcttgtctttggaaagggcacaag-3’ 
Nat60 5’-tccgtccgtagcacagaagtaag 
Nat61 5’-cttacttctgtgctacggacggaNNKNNKNNKNNKNNKtttggaaagggcacaag-3’ 
Nat62 5’-acagagatagaaagctgtcgg 
Nat63 5’-ccgacagctttctatctctgtNNKNNKNNKNNKNNKggcccctacgagcagtac 
Nat64 5’-actggcacagagatagaaagctgtc 
Nat65 5’-gacagctttctatctctgtgccagtNNKNNKNNKNNKNNKtacgagcagtacttcg 
Nat66 5’-tatactactggcacagagatag 
Nat67 5’-ctatctctgtgccagtagtataNNKNNKNNKNNKNNKcagtacttcgggccgg 
Nat68 5’-gccccctatactactggcacag 
Nat69 5’-ctgtgccagtagtatagggggcNNKNNKNNKNNKNNKttcgggccgggcaccaggctc-3’ 
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Figure 2.3. Schematic representation of the strategy for constructing second-
generation mutagenised gp100 TCR fragments by overlapping PCR. Two PCR 
fragments are generated for each CDR library (a black and a red fragment). The red 
fragment is generated with a forward primer containing the NNK motif. The two 
fragments are assembled by SOE-PCR with primers YOL13-YOL22 (bright green 
primer segment corresponds to the mutagenised NNK region and the black primer 
region will anneal to the corresponding black PCR fragment). The  and  chain 
fragments are denoted by the letter a or b respectively. NcoI-NotI restriction sites are 
shown in purple. 
YOL13 a1 a2 
Nat54 
Nat53 
CDR2 -1
a3 
Stitch name 
YOL22 
YOL13 a1 a5 
Nat55 
Nat53 
CDR2 -2
a6 
YOL22 
YOL13 a7 a8 
Nat57 
Nat56 
CDR3 -1
a9 
YOL22 
YOL13 a10 a11 
Nat59 
Nat58 
CDR3 -2
a12 
YOL22 
YOL13 a13 a14 
Nat61 
Nat60 
CDR3 -3
a15 
YOL22 
YOL13 b1 b2 
Nat63 
Nat62 
CDR3 -1
b3 
YOL22 
YOL13 b4 b5 
Nat65 
Nat64 
CDR3 -2
b6 
YOL22 
YOL13 b7 b8 
Nat67 
Nat66 
CDR3 -3
b9 
YOL22 
YOL13 b10 b11 
Nat69 
Nat68 
CDR3 -4
b12 
YOL22 
NcoI NotI 
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2.4.2.1 Generating ‘black’ and ‘red’ library PCR fragments 
Second-generation library PCRs used NcoI or NotI linearised phagemid vector pGPb7 
(Section 2.4) as the template. ‘Black’ fragments: 2 ng pGPb7 (NotI linearised), 1 l 
dNTPs (10 mM each), 1 l YOL13 (10 pmol/ l), 1 l 
a
Nat Rev primer (10 pmol/ l), 
5 l 10 X polymerase buffer, 3.5 U Expand polymerase in a final volume of 50 l. 
‘Red’ fragments: 2 ng pGPb7 (NcoI linearised), 1 l dNTPs (10 mM each), 1 l bNat 
Fwd primer (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X polymerase buffer, 3.5 
U Expand polymerase in a final volume of 50 l.  
 
a
Nat Rev primer refers to the following primers shown in Figure 2.3: Nat53, Nat56, Nat58, Nat60, 
Nat62, Nat64, Nat66, Nat68. 
b
Nat Fwd primer refers to the following primers shown in Figure 2.3: 
Nat54, Nat55, Nat57, Nat59, Nat61, Nat63, Nat65, Nat67, Nat69.  
 
 
The reactions were performed using the following PCR cycling conditions: Step 1: 
94ºC for 2 min; Step 2: 94ºC for 16 sec; Step 3: 53ºC for 16 sec; Step 4: 72ºC for 50 
sec/kbp; Step 5: 4ºC pause. Step 2 to 4 repeated 26 times. DpnI treatment and gel-
purification of PCR fragments followed the protocol described in Section 2.4.1.1. To 
assess purity of the excised bands 1 l of each was resolved on a 1% (w/v) agarose 
gel. 
 
2.4.2.2 Generating full-length gp100 TCR library PCR fragments 
In contrast to the three-fragment SOE-PCR assembly of the Mel-5 TCR libraries, 
gp100 TCR libraries were assembled by two-fragment SOE-PCR. Full-length 
TCR library fragments were assembled using SOE-PCR amplification of the 
‘black’ and ‘red’ PCR fragments with primers YOL13 and YOL22. ‘Black’ and ‘red’ 
purified PCR fragments were diluted to a concentration so that 1 l of each would 
give a 1:1 molar ratio in a total of 10-12 ng DNA. Multiple PCRs were set up for each 
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stitch reaction to generate sufficient PCR product required for ligations. Control PCRs 
were set up using only the ‘black’ or ‘red’ fragment as template; the composition of 
the control PCRs is not provided. The PCR mixture for the SOE-PCRs was assembled 
as follows: 1 l ‘black’ fragment, 1 l ‘red’ fragment, 1 l dNTP mix (10 mM 
each), 1 l YOL13 (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X Polymerase 
buffer (NEB), 2.5 U Taq DNA polymerase (NEB) in a final volume of 50 l. The 
reactions were performed using the PCR cycling conditions outlined in Section 
2.4.2.1 with an extension time of 80 seconds and repeating steps 2 to 4 thirty rimes. 
PCR products were resolved by agarose gel electrophoresis and bands of the expected 
size were purified using the Zymoclean DNA gel recovery kit. To assess purity of the 
excised bands 1 l of each was resolved on a 1% (w/v) agarose gel. To monitor the 
integrity of the library PCR fragments, purified PCRs were sequenced with primers 
YOL13 and J195 (GATC) (‘polyclonal sequencing’).  
 
2.4.2.3 Restriction digests of the gp100 TCR SOE-PCR products and pEX922  
Purified SOE-PCR fragments: typically, 6-8 g DNA, 50 U each of NcoI and NotI 
(both NEB), buffer in accordance with manufacturer’s guidelines (NEB) in a final 
volume of 80 l. Phagemid vector pEX922: typically, 100 g DNA, 500 U each of 
NcoI and NotI (both NEB), buffer in accordance with manufacturer’s guidelines 
(NEB) in a final volume of 1 ml and incubation at 37ºC for 5 hours. 
 
2.4.2.4 Ligation and transformation of gp100 TCR libraries 
Digested DNA were gel-purified from a 1% (w/v) agarose gel using the Zymoclean 
DNA gel recovery kit and the concentrations determined on a Nanodrop ND-1000 
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spectrophotometer. To assess purity of the excised bands 1 l of each was resolved on 
a 1% (w/v) agarose gel. Transformations were prepared using T4 DNA ligase 
overnight at 16ºC. Alpha chain libraries : ~5 g pEX922, ~5 g 
a
 chain 
fragments, l 10 X ligase buffer, 4000 U T4 DNA ligase (NEB) in a final volume 
of 800 l. Beta chain libraries : ~10 g pEX922, ~10 g 
b
 chain fragments, l 
10 X ligase buffer, 8000 U T4 DNA ligase (NEB) in a final volume of 1.6 ml.  
 
a
 chain library fragments: library 1 (CDR2 ) comprised PCR fragments a3 and a6; library 2 (CDR3 ) 
comprised PCR fragments a9, a12 and a15; 
b
 chain library fragments: library 3 (CDR3 ) comprised 
PCR fragments b3, b6, b9 and b12. 
 
 
After ligation, the mixtures were purified using the Zymo DNA clean and 
concentrator kit. DNA was eluted in 20 l of nuclease-free water. Multiple 
transformations of electrocompetent E. coli TG1 cells (Lucigen) were performed for 
each library (library 1: 12; library 2: 12; library 3: 20) as described in Section 2.4.1.4. 
Preparation of bacterial glycerol stocks and sequencing of library clones followed the 
methods described in Section 2.4.1.4. 
 
2.4.3 MAGE-A3 TCR phage display libraries 
First-generation libraries were built in the context of the wild-type MAGE-A3 TCR 
framework and all 6 CDRs were targeted. Second-generation libraries targeted only 
CDR3 regions and were constructed in the context of two enhanced-affinity 
frameworks (MAGEa6a and MAGEb2a) (Section 2.3). Construction of first and 
second-generation libraries followed the protocols outlined in Section 2.4.2. The 
template for amplification of the ‘black’ and ‘red’ fragments (Figure 2.4 and Figure 
2.5) was NcoI or NotI linearised phagemid vector pIM160 (for first-generation 
libraries), pIM194 and pIM195 (for second-generation libraries). ‘Black’ fragments: 2 
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ng phagemid vector (NotI linearised), 1 l dNTPs (10 mM each), 1 l YOL13 (10 
pmol/ l), 1 l 
a
Nat Reverse primer (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U 
Phusion polymerase (NEB) in a final volume of 50 l. ‘Red’ fragments: 2 ng 
phagemid vector (NcoI linearised), 1 l dNTPs (10 mM each), 1 l 
b
Nat Forward 
primer (10 pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U 
Phusion polymerase in a final volume of 50 l.
 a
Nat Reverse and
 b
Nat Forward 
primers see Figure 2.4 and 2.5. PCR cycling as shown in Section 2.4.2 (extension 
time of 25 seconds/kbp). Assembly of  TCR fragments by SOE-PCR followed the 
protocol outlined in Section 2.4.2.2 (extension time of 45 seconds). Construction of 
second-generation Strategy 2 libraries followed a unique set of protocols and will be 
described separately. The primers are shown below and the PCR strategies employed 
for the first and second-generation library construction are depicted in Figure 2.4, 
Figure 2.5 and Figure 2.6. Second-generation Strategy 3 libraries were kindly 
provided by Dr. Y. Li.  
 
MAGE-A3 TCR library primers 
Nat70  5’-ctcaactgcagtttcactNNKNNKNNKNNKNNKaacctccagtggtttaggcag-3’ 
Nat71  5’-agtgaaactgcagttgagaacc-3’ 
Nat72  5’-caactgcagtttcactgatNNKNNKNNKNNKNNKctccagtggtttaggcaggac-3’ 
Nat73  5’-atcagtgaaactgcagttgag-3’ 
Nat74  5’-ggtctcacatctctgttgNNKNNKNNKNNKNNKcagagagagcaaacaagtggaag-3’ 
Nat75  5’-caacagagatgtgagacctttccc-3’ 
Nat76  5’-gccacctacctctgtgctNNKNNKNNKNNKNNKgctgggagttaccaactcac-3’ 
Nat77  5’-agcacagaggtaggtggctgag-3’ 
Nat78  5’-cctacctctgtgctgtgaggNNKNNKNNKNNKNNKagttaccaactcactttcggg-3’ 
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Nat79  5’-cctcacagcacagaggtagg-3’ 
Nat80  5’-cctctgtgctgtgaggccgNNKNNKNNKNNKNNKtaccaactcactttcgggaagg-3’ 
Nat81  5’-cggcctcacagcacagaggtagg-3’ 
Nat82  5’-gtgctgtgaggccgggagggNNKNNKNNKNNKNNKctcactttcgggaaggggacc-3’ 
Nat83  5’-ccctcccggcctcacagcacag-3’ 
Nat84 5’-gaggccgggaggggctgggNNKNNKNNKNNKNNKttcgggaaggggaccaaactc-3’ 
Nat85  5’-cccagcccctcccggcctcac-3’ 
Nat86  5’-ctgagctgctcccctatcNNKNNKNNKNNKNNKgtatcctggtaccaacagacc-3’ 
Nat87  5’-gataggggagcagctcagtgtc-3’ 
Nat88  5’-ccttcagttcctctttgaaNNKNNKNNKNNKNNKcagagaaacaaaggaaacttccc-3’ 
Nat89  5’-ttcaaagaggaactgaaggcc-3’ 
Nat90  5’-cttcagttcctctttgaatacNNKNNKNNKNNKNNKagaaacaaaggaaacttccctg-3’ 
Nat91  5’-gtattcaaagaggaactgaagg-3’ 
Nat92  5’-gccctttatctttgcgccNNKNNKNNKNNKNNKgccgacgagcagtacttcggg-3’ 
Nat93  5’-ggcgcaaagataaagggccgagtc-3’ 
Nat94  5’-ctttatctttgcgccagcagcNNKNNKNNKNNKNNKgagcagtacttcgggccgggc-3’ 
Nat95  5’-gctgctggcgcaaagataaagg-3’ 
Nat96  5’-ctttgcgccagcagcccgNNKNNKNNKNNKNNKcagtacttcgggccgggcacc-3’ 
Nat97  5’-cgggctgctggcgcaaagataaag-3’ 
Nat98  5’-cgccagcagcccgaacatgNNKNNKNNKNNKNNKttcgggccgggcaccaggctc-3’ 
Nat99  5’-catgttcgggctgctggcgcaaag-3’ 
Nat100 5’-ctcagccacctacctctgtNNKNNKNNKNNKNNKggggctgggagttaccaactc-3’ 
Nat101 5’-acagaggtaggtggctgagtc-3’ 
Nat102 5’-ctcggccctttatctttgcNNKNNKNNKNNKNNKatggccgacgagcagtacttc-3’ 
Nat103 5’-gcaaagataaagggccgagtc-3’ 
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A. 
 
 
  
 
 
 
 
 
 
 
 
YOL13 a1 a2 
Nat70 
Nat71 
CDR1 -1
a3 
Stitch name 
YOL22 
YOL13 a4 a5 
Nat72 
Nat73 
CDR1 -2
a6 
YOL22 
YOL13 a7 8a 
Nat74 
Nat75 
CDR2 -1
a9 
YOL22 
YOL13 a10 a11 
Nat76 
Nat77 
CDR3 -1
a12 
YOL22 
YOL13 a13 a14 
Nat78 
Nat79 
CDR3 -2
a15 
YOL22 
YOL13 a16 a17 
Nat80 
Nat81 
CDR3 -3
a18 
YOL22 
YOL13 a19 a20 
Nat82 
Nat83 
CDR3 -4
a21 
YOL22 
YOL13 a22 a23 
Nat84 
Nat85 
CDR3 -5
a24 
YOL22 
NcoI NotI 
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B.  
 
 
 
 
Figure 2.4. Schematic representation of the strategy for constructing first-
generation mutagenised MAGE-A3 TCR fragments by overlapping PCR. (A).  
chain library schematic. (B).  chain library schematic. Two PCR fragments are 
generated for each CDR library (a black and a red fragment). The red fragment is 
generated with a forward primer containing the NNK motif. The two fragments are 
assembled by SOE-PCR with primers YOL13-YOL22 (bright green primer segment 
corresponds to the mutagenised NNK region and the black primer region will anneal 
to the corresponding black PCR fragment). The  and  chain fragments are denoted 
with an a or b respectively. 
 
 
 
YOL13 b1 b2 
Nat86 
Nat87 
CDR1 -1
b3 
Stitch name 
YOL22 
YOL13 b4 b5 
Nat88 
Nat89 
CDR2 -1
b6 
YOL22 
YOL13 b7 ba 
Nat90 
Nat91 
CDR2 -2
b9 
YOL22 
YOL13 b10 b11 
Nat92 
Nat93 
CDR3 -1
b12 
YOL22 
YOL13 b13 b14 
Nat94 
Nat95 
CDR3 -2
b15 
YOL22 
YOL13 b16 b17 
Nat96 
Nat97 
CDR3 -3
b18 
YOL22 
YOL13 b19 b20 
Nat98 
Nat99 
CDR3 -4
b21 
YOL22 
NcoI NotI 
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YOL13 a1 or á1 a2 or á2  
Nat100 
Nat101 
CDR3 -1
a3 or á3 
Stitch name 
YOL22 
YOL13 a4 or á4 a5 or á5 
Nat76 
Nat77 
CDR3 -2
a6 or á6 
 YOL22 
YOL13 a7 or á7 a8 or á8 
Nat78 
Nat79 
CDR3 -3
a9 or á9 
 YOL22 
YOL13 a10 or á10 a11 or á11 
Nat80 
Nat81 
CDR3 -4
a12 or á12 
 YOL22 
YOL13 a13 or á13 a14 or á14 
Nat82 
Nat83 
CDR3 -5
a15 or á15 
 YOL22 
YOL13 a16 or á16 a17 or á17 
Nat84 
Nat85 
CDR3 -6
a18 or á18 
 YOL22 
NcoI 
NotI 
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B. 
 
 
 
 
Figure 2.5. Strategy 1: schematic representation of the strategy used for 
constructing mutagenised second-generation MAGE-A3 TCR CDR3 fragments 
in the context of the enhanced-affinity CDR2 mutant clones MAGEa6a and 
MAGEb2a. (A). CDR3  library schematic. (B). CDR3  library schematic. Two PCR 
fragments are generated for each CDR library (a black and a red fragment). The red 
fragment is generated with a forward primer containing the NNK motif. The two 
fragments are assembled by SOE-PCR with primers YOL13-YOL22 (bright green 
primer segment corresponds to the mutagenised NNK region and the black primer 
region will anneal to the corresponding black PCR fragment). The  and  chain 
library fragments are amplified from either phagemid vector template pIM194 
(encoding the CDR2  MAGEa6a back-mutant) or pIM195 (encoding the CDR2  
MAGEb2a back-mutant). The  chain PCR products generated from pIM194 and 
pIM195 template are named “a” and “á” respectively. The  chain PCR products 
generated from pIM194 and pIM195 template are named “b” and “b” respectively. 
Phagemid vector templates pIM194 and pIM195 contain constant region cysteines 
located in the native format. 
 
 
 
 
YOL13 b1 or b1  b1 or b1 
Nat102 
Nat103 
CDR3 -1
b3 or b3 
Stitch name 
YOL22 
YOL13 b4 or b4 b5 or b5 
Nat92 
Nat93 
CDR3 -2
b6 or b6 
YOL22 
YOL13 b7 or b7 b8 or b8 
Nat94 
Nat95 
CDR3 -3
b9 or b9 
YOL22 
YOL13 b10 or b10 b11 or b11 
Nat96 
Nat97 
CDR3 -4
b12 or b12 
YOL22 
YOL13 b13 or b13 b14 or b14 
Nat98 
Nat99 
CDR3 -5
b15 or b15 
YOL22 
NcoI 
NotI 
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2.4.3.1 Ligation and transformation of MAGE-A3 TCR libraries 
Digests were performed according to the conditions outlined in Section 2.4.2.3: 2-7 
g of each SOE-PCR fragment, 5 U/ g DNA each of NcoI and NotI (both NEB), 
buffer in accordance with manufacturer’s guidelines (NEB) in a final volume of 30-50 
l. Ligations were set up using a 3:1 ratio of insert to vector with 400 U T4 DNA 
ligase (NEB) per 1 g total DNA and 1X T4 ligase buffer in a final volume of 80 l 
and incubated overnight at 16ºC. The total amount of vector and library insert DNA 
used in the ligation reactions is outlined below: 
 
First-generation library ligations (total DNA shown) 
Library 1: CDR1  (PCR fragment a3, a6) 10 g  
Library 2: CDR2  (PCR fragment a9) 5 g  
Library 3: CDR3  (PCR fragment a12, a15, a18, a21, a24) 20 g  
Library 4: CDR1  (PCR fragment b3) 5 g  
Library 5: CDR2  (PCR fragment b6, b9) 10 g  
Library 6: CDR3  (PCR fragment b12, b15, b18, b21) 20 g  
Refer to Figure 2.4 for nomenclature of PCR fragments. 
 
Second-generation Strategy 1 library ligations 
Library 1: CDR3 :MAGEa6a (PCR fragment a3, a6, a9, a12, a15, a18) 6 g 
Library 2: CDR3 :MAGEb2a (PCR fragment à3, à6, à9, à12, à15, à18) 6 g 
Library 3: CDR3 :MAGEa6a (PCR fragment b3, b6, ba9, b12) 5 g  
Library 4: CDR3 :MAGEb2a (PCR fragment b3, b6, ba9, b12) 5 g 
Refer to Figure 2.5 for nomenclature of PCR fragments. 
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After ligation, the mixtures were purified using the Zymo DNA clean and 
concentrator kit. DNA was eluted in 20 l (first-generation) or 12 l (second-
generation) of nuclease-free water. Multiple transformations of electrocompetent E. 
coli TG1 cells (Lucigen) were performed following the protocol described in Section 
2.4.1.4. For the first-generation libraries: 6 each for library 2 and 4; 10 each for 
library 1 and 5; 20 each for library 3 and 6. Five transformations of each second-
generation library were performed. Preparation of bacterial glycerol stocks and 
sequencing of library clones followed the methods described in Section 2.4.1.4. The 
scraped bacterial suspension from multiple transformations belonging to the same 
library were pooled.  
 
2.4.3.2 Construction of MAGE-A3 TCR first-generation CDR2 :CDR2  
crossing libraries 
The Pan 3 mutated CDR2  and CDR2  regions that were selected from first-
generation libraries 2 and 5 (Section 2.4.3.1) were spliced by SOE-PCR to generate a 
library of TCRs mutated in both CDR2 loops. TG1 E. coli glycerol stocks of first-
generation Pan 3 library 2 and library 5 (Section 2.4.3.1) were used to inoculate 
separately 25 ml 2xYT media to an OD600 of ~1.0. Cell suspensions were pelleted at 
3,360 x g for 10 minutes at room temperature. The pellets were thoroughly 
respuspended in 25 ml STE buffer (10 mM Tris, pH 8.1, 1 M EDTA, pH 8.0, 100 mM 
NaCl). After a second wash step (under the same conditions) DNA was isolated from 
the cultures using the QIAprep spin miniprep kit (Qiagen). The concentration of the 
eluted DNA was determined using a Nanodrop ND-1000 spectrophotometer. DNA 
isolated from library 2 and library 5 (10 g) was digested with 50 U each of 
restriction enzymes NcoI and AvrII (both NEB) and buffer in accordance with 
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manufacturer’s guidelines (NEB) in a final volume of 270 μl. Digestions were 
incubated at 37ºC for 5 hours. Digested library fragments were resolved on a 1% 
(w/v) agarose gel and a ~640 bp band from library 2 and ~6200 bp from library 5 
DNA were gel-purified using the Zymo DNA clean and concentrator kit. Ligation 
reactions using appropriately digested (gel-purified) DNA insert and vector were set 
up using a 3:1 molar ratio of insert:vector (5 g total DNA), 2000 U of T4 DNA 
Ligase (NEB), 1X ligation buffer in a final volume of 400 μl and incubated overnight 
at 16ºC. Three transformations of electrocompetent TG1 E. coli cells (Lucigen) were 
performed with 2.5 l of the PCR-purified ligation as described in Section 2.4.1.4. 
The scraped cell suspension from each of the 3 transformations was pooled and stored 
at -80Cº. 
   
2.4.3.3 Construction of MAGE-A3 TCR second-generation Strategy two libraries 
Four previously constructed MAGE-A3 TCR libraries (Section 2.4.3.1) were 
converted from the native to the engineered disulphide C-region cysteine framework 
(mTCR). These were the preselected (Pan 0) first-generation library 3 and library 6 
and the Pan 0 second-generation library 1 and library 4 (Section 2.4.3.1). DNA was 
isolated from the scraped bacterial glycerol stocks as described in Section 2.4.3.2. The 
concentration of the eluted DNA was determined using a Nanodrop ND-1000 
spectrophotometer. The primers used to introduce the mTCR constant region 
cysteines are shown below and the PCR library construction strategy is depicted in 
Figure 2.6. 
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Figure 2.6. Schematic representation of the strategy to convert MAGE-A3 TCR 
CDR3 libraries from native format into mTCR format. (A). TCR  and  chains 
containing membrane proximal C domain cysteines (*) in native format. (B). TCR  
and  chains containing introduced constant domain cysteines (*) (membrane 
proximal cysteines removed) in mTCR format. (C). Introduction of mTCR  chain 
cysteine into CDR3  library segments. Templates: library 3 CDR3  built on wt 
framework (section 5.2.2) and library 1 CDR3  built on MAGEa6a framework 
Alpha Beta gIII 
mTCRaF 
* 
* 
Nat87 
* 
* * Alpha Beta gIII 
YOL13 
mTCRaR 
* 
NNK 
CDR3 
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(section 5.8.2) (both containing native cysteine). (D).  PCR amplification of MAGE-
A3 TCR C  domain. Template: wt MAGE-A3 TCR in mTCR format. (E). 
Introduction of mTCR  chain cysteine into CDR3  library segments. Templates: 
library 6 CDR3  built on wt framework (section 5.2.2) and library 4 CDR3  built on 
MAGEb2a framework (section 5.8.2) (both containing native cysteine). (F). PCR 
amplification of MAGE-A3 TCR C  domain. Template: wt MAGE-A3 TCR in 
mTCR format. SOE-PCR fragment from (C) and (D) generates full-length V /C  
product including the mTCR cysteines. Digested (E) and (F) SOE-PCR product 
generates full-length V /C  product including the mTCR cysteines. gIII, M13 
geneIII. 
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MAGE-A3 TCR second-generation Strategy 2 library primers 
mTCRaR 5’-gtctagcacacatttgtctgtgatatacacatc-3’ 
mTCRbR 5’-cgggtctgtgcagaccccactgtgcacctccttc-3’ 
mTCRaF 5’-gacaaatgtgtgctagacatgaggtctatg-3’ 
mTCRbF 5’-ggggtctgcacagacccgcagcccctcaag-3’ 
 
The reaction components and volumes were as follows:  Fragment C: 15 ng 
a
phagemid library, 1 l dNTPs (10 mM each), 1 l YOL13 (10 pmol/ l), 1 l 
mTCRaR (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U Phusion polymerase in a 
final volume of 50 l. Fragment D: 2 ng 
b
pLAS0282, 1 l dNTPs (10 mM each), 1 l 
mTCRaF (10 pmol/ l), 1 l Nat87 (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U 
Phusion polymerase in a final volume of 50 l. Fragment E: 15 ng 
c
phagemid library, 
1 l dNTPs (10 mM each), 1 l J195 (10 pmol/ l), 1 l mTCRbR (10 pmol/ l), 5 l 
10 X polymerase buffer, 1 U Phusion polymerase in a final volume of 50 l. 
Fragment F: 2 ng 
b
pLAS0282, 1 l dNTPs (10 mM each), 1 l mTCRbF (10 
pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U Phusion 
polymerase in a final volume of 50 l.  
 
a
MAGE-A3 TCR-phagemid library template (Section 2.4.3.1): library 3 (first-generation) or library 1 
(second-generation); 
b
pLAS0282 (wild-type MAGE-A3 TCR mTCR format) from Section 2.4; 
c
MAGE-A3 TCR-phagemid library template (Section 2.4.3.1): library 6 (first-generation) or library 4 
(second-generation).  
 
 
The reactions were performed using the PCR cycling conditions outlined in Section 
2.4.2.1 (20 second extension time). PCR products (C, D, E, F) were resolved on a 
1.5% (w/v) agarose gel and bands of the expected size were gel-purified using the 
Zymo DNA clean and concentrator kit. Full-length  (C/D) or  (E/F) chains were 
assembled as follows: Fragment C/D: 10 ng fragment C, 5 ng fragment D, 1 l dNTPs 
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(10 mM each), 1 l YOL13 (10 pmol/ l), 1 l Nat87 (10 pmol/ l), 5 l 10 X 
polymerase buffer, 1 U Phusion polymerase in a final volume of 50 l. Fragment E/F: 
10 ng fragment E, 5 ng fragment F, 1 l dNTPs (10 mM each), 1 l J195 (10 
pmol/ l), 1 l YOL22 (10 pmol/ l), 5 l 10 X polymerase buffer, 1 U Phusion 
polymerase in a final volume of 50 l. The reactions were performed using the PCR 
cycling conditions outlined in Section 2.4.2.1 (30 second extension time). SOE-PCR 
products (C/D and E/F) were resolved on a 1.5% (w/v) agarose gel and bands of the 
expected size were gel-purified using the Zymo DNA clean and concentrator kit. 
Fragment C/D was digested with restriction enzymes NcoI and AvrII (both NEB); 
Fragment E/F was digested with restriction enzymes AvrII and NotI (both NEB). 
Phagemid pLAS0282 (20 g) was digested separately with NcoI-AvrII and AvrII-
NotI. Restriction digests were performed using 10 U (for the inserts) or 50 U (for the 
vector) of the required enzymes and buffer in accordance with manufacturer’s 
guidelines (NEB) in a final volume of 50 μl (inserts) or 300 μl (vector). Digestions 
were incubated at 37ºC for 5 hours. Digested vector and PCR fragments were 
resolved on a 1% (w/v) agarose gel and bands of the expected size were gel-purified 
using the Zymo DNA clean and concentrator kit. Fragments C/D and E/F (1 g) were 
ligated separately into phagemid vector pLAS0282 using T4 DNA ligase at a ratio of 
3:1 (insert:vector) overnight at 16ºC following the conditions described in Section 
2.4.3.1. Electrocompetent E. coli TG1 cells (Lucigen) were transformed with PCR-
purified ligations as described in Section 2.3.7 to generate 4 libraries: library 1, 
CDR3  on the wild-type MAGE-A3 TCR framework; library 2, CDR3  on the 
MAGEa6a TCR framework; library 3, CDR3  on the wild-type MAGE-A3 TCR 
framework; library 2, CDR3  on the MAGEb2a TCR framework. 
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2.5 Phage selections and screening 
2.5.1 Rescue of TCR-displaying phages  
For the rescue of TCR-displaying phages, 250 ml 2xYTag media in a conical flask 
was inoculated with an aliquot of the phage glycerol stocks to an initial OD600 ~0.05-
0.08 and incubated at 37ºC with shaking at 250 rpm until the mid-exponential growth 
phase (OD600 ~0.4-0.5) was reached. At which point, helper phage M13K07 (>1 x 
10
11
 pfu/ml; Invitrogen) was added to 50 ml of culture at an infection ratio of 20:1 
(phage:bacteria), mixed by inversion and incubated at 37ºC in a water-bath for 30 
minutes (without shaking). The cultures were pelleted at 2,900 g for 10 minutes at 
16ºC and the supernatant discarded. The pellets were resuspended in 100 ml 2xYT 
media in a conical flask supplemented with ampicillin (100 g/ml) and kanamycin 
(Apollo Scientific Limited) (25 g/ml) (helper phage resistance gene) (designated 
2xYTak) and incubated overnight at 26ºC with shaking at 250 rpm. The quantity of 
reagents was adjusted according to the culture volume. Monoclonal phage TCRs were 
rescued from panning master-plates (Section 2.5.4) by inoculating 100 l 2xYTag 
media in a sterile 96-well tissue culture plate (Falcon) with 5 l of each well of the 
master-plate and incubating at 37ºC with shaking for 2-3 hours. Helper phage 
M13K07 was added 20:1 (phage:bacteria) and incubated at 37ºC for 1 hour without 
shaking. The cultures were centrifuged, the supernatant discarded and the pellets 
resuspended in 400 l 2xYTak media and incubated overnight at 26ºC with shaking at 
250 rpm. 
 
2.5.2 Precipitation of phage-displayed fragments using PEG/NaCl 
The 100 ml culture was centrifuged at 11,200 x g for 20 minutes at 4ºC and the 
bacterial pellet discarded. The supernatant was transferred to a fresh centrifugation 
tube and the phage was precipitated by adding 20 ml polyethylene glycol (PEG)/NaCl 
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(20% w/v PEG 8000; Sigma, 2.5 M NaCl), mixing thoroughly by inversion and 
incubating on ice for 1 hour. Following incubation the tubes were centrifuged for 10 
minutes at 3,360 x g at 4ºC. The supernatant was discarded and the tubes briefly 
respun to remove the remaining supernatant. The TCR-phage pellet was resuspended 
in 10 ml phosphate buffered saline (PBS; Sigma) and spun at 11,200 x g for 10 
minutes at 4ºC. The supernatant was transferred to a fresh tube and the phage was 
precipitated once more by adding 2.5 ml PEG/NaCl solution, mixing thoroughly by 
inversion and incubating on ice for 20-30 minutes. After incubation the tubes were 
spun for 10 minutes at 3,360 x g at 4ºC and the supernatant discarded. Following a 
final brief spin to remove the remaining supernatant the TCR-phage pellets were 
resuspended in 1 ml PBS and transferred to a sterile 1.5 ml centrifuge tube. The TCR-
phage solution was centrifuged twice at 16,200 x g for 15 minutes at 4ºC; TCR-phage 
supernatant was transferred to fresh tubes between spins. The supernatant containing 
phage TCR was stored on ice at 4ºC until required for panning experiments. The 
quantity of reagents was adjusted accordingly for the precipitation of TCR-displaying 
phages from other culture volumes.  
 
2.5.3 Preparation of debiotinylated Marvel (db-M) solution 
BioMag streptavidin-coated magnetic beads (2 ml) (Qiagen) were washed 5 times 
with 1 ml PBS using a magnet to collect the beads between each wash. The washed 
beads were added to 3% (w/v) Marvel dried milk powder and incubated at room 
temperature for 2 hours with mixing. After the incubation the beads were collected 
using a magnet. The milk solution was transferred to a fresh tube and place on the 
magnet. This step was repeated at least 5 times to remove the remaining beads. To the 
db-M 1.5 ml 0.5 M EDTA, pH 8.0 was added and transferred to prewashed dialysis 
tubing and dialysed against 5 litres of PBS. The dialysis buffer was changed to fresh 
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PBS and stored overnight at 4ºC. The next day, the dialysis buffer was changed to 
fresh PBS and dialysed for a further 2-3 hours. After dialysis the db-M was filter 
sterilised through a 0.22 M filter (Sartorius Stedim Biotech) and divided into 1 ml 
aliquots for storage at -20ºC. 
 
2.5.4 Selection of antigen-binding TCR-displaying phage using solution-based 
biopanning 
Rescued phage (from Section 2.5.2) (50-100 l) was added to 1 ml 3% db-M and 
incubated at room temperature for 90 minutes with rotation
a
. After this blocking step 
1 l Tween-20 (Sigma) together with biotinylated pHLA (kindly provided by Dr. B. 
Cameron) at the desired concentration and incubated at room temperature for 1 hour 
with gentle rotation
b
. Dynabeads M-280 streptavidin-coated magnetic beads 
(Invitrogen) were washed 5 times with PBS and 50-100 l was used to rescue the 
phage-TCR-pHLA complexes. Following a 7 minute incubation at room temperature 
with rotation the bead-phage-TCR-pHLA complexes were captured using a magnet. 
The collected beads were washed by resuspension using a fresh pipette tip and a fresh 
centrifuge tube between each wash. The washing conditions for the first cycle of 
panning were typically: 2 times with 3% (w/v) Marvel-PBS (MPBS); 3 times PBS-
Tween-20 (PBST) (0.1%, v/v final); 2 times PBS. After discarding the final wash 
solution the TCR phage were eluted by adding 0.5 ml triethylamine (Sigma) and 
incubating at room temperature for 8 minutes with rotation. The beads were collected 
using a magnet and the supernatant containing eluted phage TCRs transferred to a 
sterile 1.5 ml centrifuge tube containing 0.25 ml 1 M Tris-HCl, pH7.4 (Sigma) for 
neutralisation purposes. Ten ml mid-exponential growth phase (OD600 ~0.4-0.5) TG1 
E. coli cells (grown in 2xYT supplemented with 2%, w/v glucose) were infected with 
0.6 ml of the eluted phage, mixed by inversion and incubated at 37ºC for 30 minutes 
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in a water-bath (without shaking). After incubation the culture was centrifuged at 
2,900 x g for 10 minutes at room temperature and the pellet respuspended in 1 ml 
fresh 2xYT media and spread onto YTE agar plates (Square BioAssay dish 245 mm x 
245 mm; Corning) supplemented with ampicillin (100 g/ml) and 2% (w/v) glucose 
and incubated at 30ºC overnight. Input and output titres of phage were performed by 
infecting TG1 E. coli cells and performing serial dilutions of the phage. The infected 
cells were incubated for 30 min at 37ºC and 100 μl of each dilution spread on 2xYT 
agar plates containing ampicillin (100 g/ml) and 2% (w/v) glucose and incubated at 
30ºC overnight. Alternatively, input phage titres were determined using an absorbance 
at 260 nm based method (Lee, Iorno et al. 2007). Precipitated input phage was diluted 
50-fold in PBS and the OD260nm measured. Using the empirical formula: phage ml
-1
 = 
OD260 x phage dilution x 22.14 x 10
10
 the phage titre was estimated (Lee, Iorno et al. 
2007). The input and output titres were calculated by counting the number of cells 
present on the dilution plates. The stock plates containing the eluted phage were 
scraped using 2xYT media containing 20% (v/v) glycerol for the next cycle of 
panning. After the final round of panning individual ampicillin-resistant TG1 E. coli 
cells were used to inoculate 100 l 2YT media containing ampicillin (100 g/ml) and 
2% (w/v) glucose in a sterile 96-well tissue culture plate (Falcon) and incubated at 
37ºC overnight with shaking. Following incubation 30 l 2xYT media containing 
50% (v/v) glycerol was added to each well and stored at -80ºC until required for 
monoclonal phage ELISAs (master-plate).  
 
a
Subtractive panning on human primary cells: before selection on biotinylated pHLA the TCR-phage 
was subjected to a depletion step. The 1 ml blocked TCR-phage solution was used to resuspend ~2 x 
10
6
 HEP2 (human hepatocyte) or HDMEC3 (human microvascular endothelial) cells (kindly provided 
by Dr. N. Hassan). After 1 hour room temperature incubation with rotation the tubes were centrifuged 
at 3,360 g for 10 minutes at room temperature to remove the human cell pellet. 
b
Off-rate selections: 
after 45 minutes incubation with biotinylated pHLA, 0.1-1 M of nonbiotinylated pHLA (same 
antigenic identity as the biotinylated pHLA) was added and incubated for a further 15 minutes with 
rotation. 
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2.5.5 Phage ELISA - Monoclonal and inhibition  
An ELISA plate was incubated with 100 l streptavidin (5 g/ml final; Sigma) 
overnight at 4ºC. All subsequent steps were performed at room temperature. The plate 
was washed 2 times with PBS, 100 l biotinylated pHLA (5 g/ml final) added and 
incubated for 30 minutes with shaking. After 3 washes with PBS the plate was 
blocked with 400 l 3% (w/v) MPBS for 1 hour. In a separate sterile 96-well plate 70 
l phage supernatant
a
 was mixed with 70 l 6% (w/v) MPBS
b
 and incubated for 1 
hour with shaking. The blocked ELISA plate was washed 3 times with PBS and 100 
l blocked rescued monoclonal phage TCRs were added and the plate incubated for 1 
hour with shaking. After incubation the plate was washed 3 times with PBST. After 
washing the wells 4 times with PBST, 100 l of 1:1,000 dilution of a anti-M13 
antibody (Sigma) in 1% (w/v) BSA-PBS was added and the plate incubated for 1 hour 
with shaking. After washing the wells 5 times with PBST, 100 l of 1:15,000 dilution 
of a phosphatase-labelled anti-rabbit IgG monoclonal antibody (Sigma) in 1% (w/v) 
BSA-PBS was added and the plate incubated for 1 hour with shaking. Antigen-
binding phage was detected using 100 l BluePhos (KPL) as substrate for alkaline 
phosphatase. This solution was left to develop for 20-30 minutes and the absorbance 
was read at 650 nm.  
 
a
Phage: phage supernatant was used neat; PEG precipitated phage was first diluted in PBS before 
adding to 6% (w/v) MPBS. 
b
Inhibition ELISA: nonbiotinylated pHLA was added to 6% (w/v) MPBS at 
a concentration that was twice the desired final concentration to account for the diluting effect from 
adding an equal volume of the phage solution.     
 
 
2.6 Protein expression 
2.6.1 Making chemically competent bacterial cells 
Bacterial cells were streaked out onto an LB agar plate and incubated overnight at 
37ºC. 200 ml of SOB media (supplemented with tetracycline Sigma, 12.5 g/ml final 
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and 300 mM NaCl) was inoculated with a single colony and grown to an OD600 of 
~0.4. Cells were pelleted by centrifugation at 3,360 x g for 10 minutes in a Heraeus 
Megafuge 2.0 R centrifuge at 4ºC. The pellet was resuspended in 68 ml of ice-cold 
FSB, pH 6.4 (10 mM KOAc, 44 mM MnCl2, 100 mM KCl, 10 mM CaCl2, 3 mM 
HACoCl3 and 10% v/v glycerol) and incubated on ice for 15 minutes. After pelleting 
by centrifugation at 840 x g for 10 minutes at 4ºC, the bacterial cells were 
resuspended in 16 ml ice-cold FSB (containing 3.5% v/v DMSO; Sigma). Cells were 
then aliquoted into pre-chilled centrifugation tubes, snap frozen on dry-ice and stored 
at -80ºC. 
 
2.6.2 Transformation of chemically competent E. coli cells 
Aliquots of competent bacteria were thawed on ice. 100-200 ng of plasmid DNA (E. 
coli BL21-DE3 pLysS) or 10 l ligation reaction mixture (E. coli XL1-Blue) was 
added to 100 μl thawed competent bacteria, incubated on ice for 20 minutes, before 
being transferred to 42ºC for 45 seconds and replaced on ice for 2 minutes. Following 
heat-shock, the cells were streaked out on LB agar plates supplemented with 100 
μg/ml ampicillin and incubated overnight at 37ºC. 
 
2.6.3 Cloning mutated Mel-5 TCR CDR3  chains into E. coli expression vector 
The Mel-5 TCR CDR3  mutants (MELa1-MEL-a9) were amplified from the E. coli 
TG1 Pan 3 master-plate (Section 2.5.4) and the Mel-5 TCR CDR3  back-mutants 
(MELa1a-MELa1d) were amplified from E. coli expression vector pG161 (encoding 
MELa1) using the primers listed below:  
 
Mel-5 TCR E. coli expression vector primers 
TRAV12-2  5’-agatataatgcatgcaaaaagaagttgaacaaaattctggacccc-3’ 
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SalI Rev  5’-ttgtcagtcgacttagagtctctcagctggtacacg-3’ 
Nat102 5’-acgacccccaacgttcacggcacagaggtag -3’ MELalaR 
Nat103 5’-gccgtgaacgttgggggtcgtcttacctttg-3’ MELalaF 
Nat104 5’-aagacgacccgcatcgttcacggcacagagg -3’ MELalbR 
Nat105 5’-cgtgaacgatgcgggtcgtcttacctttgggg-3’ MELalbF 
Nat106 5’-aaaggtaagtttacccccatcgttcacggcac-3’ MELalcR 
Nat107 5’-cgatgggggtaaacttacctttggggatggg-3’ MELalcF 
Nat108 5’-cccaaaggtagaacgacccccatcgttcacg-3’ MELaldR 
Nat109 5’-gggggtcgttctacctttggggatgggactac-3’ MELaldF 
T7  5’-taatacgactcactataggg-3’ 
OX281 5’-cagcaaaaaacccctcaag-3’ 
 
MELa1-MELa9: 1 l E. coli culture, 1 l dNTPs (10 mM each), 1 l TRAV12-2 (10 
pmol/ l), 1 l SalI Rev (10 pmol/ l), 5 l 10 X polymerase buffer, 3.5 U Expand 
polymerase in a final volume of 50 l. MELa1a-MELa1c: Fragment A: 5 ng pG161, 1 
l dNTPs (10 mM each), 1 l T7 (10 pmol/ l), 1 l 
a
Reverse primer (10 pmol/ l), 5 
l 10 X polymerase buffer, 3.5 U Expand polymerase in a final volume of 50 l. 
Fragment B: 5 ng pG161, 1 l dNTPs (10 mM each), 1 l 
b
Forward primer (10 
pmol/ l), 1 l OX281 (10 pmol/ l), 5 l 10 X polymerase buffer, 3.5 U Expand 
polymerase in a final volume of 50 l.  
 
a
Reverse primer: Nat102, Nat104, Nat106, Nat108. 
b
Forward primer: Nat103, Nat105, Nat107, Nat109. 
PCR amplification parameters followed those outlined in Section 2.3.2.  
 
 
All PCR products were resolved by agarose gel electrophoresis and bands of the 
expected size were purified using the Zymoclean DNA gel recovery kit. MELa1a-
MEa1c fragments A/B were assembled by SOE-PCR using 10 ng each of fragment A 
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and B, 1 l dNTPs (10 mM each), 1 l T7 (10 pmol/ l), 1 l OX281 (10 pmol/ l), 5 
l 10 X polymerase buffer, 3.5 U Expand polymerase in a final volume of 50 l and 
using PCR cycling parameters outlined in 2.3.2. DNA was resolved agarose gel 
electrophoresis and purified using the Zymoclean DNA gel recovery kit. Restriction 
enzymes ClaI-SalI or XbaI-HindIII were used to digest fragments MELa1-a9 and 
MELa1a-MELa1d respectively. Vector pEX954 was separately digested with ClaI-
XhoI and XbaI-HindIII 2 μg DNA, 20 U of the required enzymes and buffer in 
accordance with manufacturer’s guidelines (NEB) in a final volume of 40 μl. 
Digestions were incubated at 37ºC for ~6 hours. Ligation reactions using 
appropriately digested (gel-purified) DNA insert and vector were set up using a 3:1 
molar ratio of insert:vector (typically 100 ng insert DNA, 70 ng vector) as outlined in 
Section 2.3.5 and ligations were transformed into chemically competent XL1-Blue E. 
coli cells (as described in Section 2.6.2). Sequence-verified plasmid DNA was used to 
transform E. coli BL21-DE3 pLysS bacteria as described above. 
 
2.6.4 Expression of TCR  and  chains in bacterial cell culture 
A single colony from freshly transformed BL21 (DE3) pLysS bacteria was used to 
inoculate 10 ml TYP media supplemented with 100 μg/ml ampicillin and incubated 
for 4 hours at 37ºC with shaking. The 10 ml starter culture was used to inoculate 1 
litre of TYP media supplemented with 100 μg/ml ampicillin and incubated for ~7 
hours at 37ºC with shaking until the OD600 reached 0.6-1.0. Protein expression was 
induced by adding 0.5 ml 1 M isopropyl-1-thio-β-D-galactopyranoside (IPTG; 
Generon). The culture was incubated overnight at 37ºC with shaking. The following 
morning, the culture was pelleted at 3,360 x g for 30 minutes at 4ºC and the 
supernatant discarded.  
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2.6.5 Inclusion body preparation 
The composition of all buffers is listed in Section 2.1.3. Inclusion bodies were 
purified from 1 litre IPTG-induced E. coli as follows. The bacterial pellet was 
resuspended in 40 ml lysis buffer supplemented 2 mM dithiothreitol (DTT; Sigma), 
DNAse (Sigma) to a final concentration of 0.2 mg/ml and 200 mM MgCl2 and 
incubated at room temperature with mixing for 30 minutes. The bacterial suspension 
was transferred to a 50 ml centrifuge tube (Falcon) and subjected to 2-3 repeated 
freeze/thaw cycles. The bacteria was pelleted at 3,360 x g for 30 minutes at 4ºC and 
the supernatant discarded. Inclusion bodies were purified in 50 ml triton wash buffer 
supplemented with 2 mM DTT using a homogeniser to resolubilise the pellet. 
Inclusion bodies were pelleted at 3,360 x g for 30 minutes at 4ºC and the supernatant 
containing bacterial cell debris discarded. This step was repeated 2-3 times and the 
inclusion body pellet resuspended in 5 ml resuspension buffer supplemented with 2 
mM DTT using a homogeniser.  
 
2.6.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Mel-5 TCR  chain inclusion bodies (MELa1a-MELa1c) were prepared for SDS-
PAGE analysis as follows: 80 l of purified inclusion bodies was pelleted, the 
supernatant discarded and then resuspended in 0.32 ml Laemmli sample buffer (Bio-
rad) containing 5% -mercaptothanol (Bio-rad). Refolded TCR samples collected 
from anion exchange and size exclusion chromatography were mixed at a ratio of 1:1 
in Laemmli sample buffer with and without reducing agent. The inclusion body 
samples (5 l and 10 l) or refolded TCR anion exchange and size exclusion samples 
(15 l) and molecular weight marker (Prestained SDS-PAGE marker, Bio-Rad) were 
loaded into separate wells of a Novex 4-20% Tris-Glycine SDS-PAGE gel 
Chapter 2 
 158 
(Invitrogen). Gels were run at 200 volts for 1 hour and subsequently stained with 
Coomasie Blue staining solution (40% methanol (Fisher), 7% acetic acid (Sigma), 
0.025% Brilliant Blue R (Sigma) for 1 hour with mixing. Gels were destained with 
destain solution (10% methanol, 10% acetic acid) for at least 1 hour with mixing.       
 
2.6.7 Estimating protein concentration by UV spectrophotometry 
Samples were diluted 1 in 100 in 6 M guanidine buffer (Section 2.1.3) for inclusion 
bodies and undiluted for refolded TCR proteins. Absorbance at 280 nm was measured 
using either 6 M guanidine buffer or PBS accordingly as reference blanks. 
Concentrations were calculated using the predetermined extinction coefficient values 
calculated from the amino acid sequence of the proteins using Vector NTI 
(Invitrogen).   
 
2.6.8 Production of soluble Mel-5 TCRs 
For the preparation of soluble TCRs, 15 mg of TCR  chain (MELa1a-MELa1c) and 
7.5 mg of wild-type TCR  chain inclusion bodies were denatured in 10 ml 6 M 
guanidine buffer (Section 2.1.3) supplemented with 10 mM DTT at 37ºC for 30 
minutes. Refolding was initiated by adding the denatured  chain mixture to 0.5 litre 
of pre-chilled TCR refold buffer (Section 2.3.1) and mixing vigorously for 2 hour at 
4ºC. The refold solution was poured into 12 kDa dialysis tubing and dialysed against 
20 litres of distilled H2O overnight then 20 litres 10 mM Tris, pH 8.1 for 24 hours 
(with 2 changes of 10 mM Tris, pH 8.1). The refold was filtered through a 0.8 M 
filter (Whattman) and loaded onto a Poros50HQ column equilibrated with 10 mM 
Tris, pH 8.1 and the protein eluted with a salt gradient (0-500 mM NaCl over 10 
minutes/10 mM Tris, pH 8.1). After analysis of the eluted samples by SDS-PAGE, the 
fraction containing correctly folded TCR was purified by gel-filtration (size 
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exclusion) on a Superdex 75PG 26/60 (S75) column equilibrated with HEPES-
buffered-saline-EP (HBS-EP, GE Healthcare) solution. HBS contains 10 mM HEPES 
(pH 7.4), 150 mM NaCl, 3.4 mM EDTA and 0.005% surfactant P20. Fractions 
containing correctly folded TCR, as checked by SDS-PAGE, were pooled and stored 
at 4ºC until required for biophysical analysis by surface plasmon resonance (SPR) 
using a BIAcore 3000. Production of all TCR and  chains followed a similar 
method. 
 
2.7 Surface plasmon resonance (SPR) kinetic studies  
2.7.1 SPR equilibrium analysis 
Streptavidin was covalently linked to Research Grade CM-5 sensor chips (BIAcore) 
via primary amines using the standard amino-coupling kit according to the 
manufacturer’s instructions (BIAcore). Streptavidin was injected at 0.2 mg/ml in 10 
mM sodium acetate (pH 4.5) until a saturation of response units (RU) was achieved. 
Biotinylated pHLA proteins were diluted to ~5 g/ml and flowed over the relevant 
sensor flow cells at a flow rate of 10 l/min. Approximately 1000 RU of pHLA ligand 
were bound to each flow cell. TCRs were concentrated to approximately 5 to 10-fold 
above the expected KD. Ten serial doubling dilutions of TCR were prepared and 
injected (5 l/min) over the relevant flow cells at 25ºC and the response values at 
equilibrium for each protein concentration measured using the BIAevaluation 3.1 
software. Using Origin 6.1 software the equilibrium binding constant (KD) values 
were determined using a non-linear curve fit (y = (P1 x)/(P2 + x)).    
  
2.7.2 SPR kinetic analysis 
Chip and reagent preparation was the same as for equilibrium analysis. Flow cells 
were coated with ~100 RU of pHLA ligand. TCRs were concentrated to 
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approximately 5 to 10-fold above the expected KD and were flowed over the sensor 
surface at 50 l/min in a total volume of 300 l using a kinetic injection. Kinetic 
binding parameters Kon and Koff were determined assuming 1:1 Langmuir binding 
using BIAevaluation 3.1 software.  
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3.1 Introduction 
This chapter describes in detail the processes involved in engineering TCRs for high 
affinity through directed molecular evolution using phage display. The chapter is 
divided into three principal sections: (1) isolating high affinity TCRs from first 
generation phage display libraries; (2) identifying a suitable clone from the first 
generation libraries on which to build subsequent libraries; (3) isolating high affinity 
TCRs from second generation libraries.      
In this chapter, the affinity maturation of the Mel-5 TCR that recognises the 
melanoma-specific epitope derived from Melan-A/MART-126-35 (Kawakami, Eliyahu 
et al. 1994) will be described. The Mel-5 TCR was isolated from a Melan-A-specific 
CD8
+
 T cell clone that recognises the ELAGIGILTV peptide in complex with HLA-
A*0201 and was kindly provided by Andy Sewell (Cardiff University, UK) (Cole, 
Yuan et al. 2009). The wild-type Mel-5 TCR binds to HLA-A*0201-Melan-
A/MART-126-35 with an affinity of 18 M as determined by surface plasmon 
resonance (SPR) equilibrium binding measurements (Cole, Pumphrey et al. 2007). 
Affinity maturation of the Mel-5 TCR involved targeted mutagenesis of each of the 
six CDR loops using degenerative NNK oligonucleotides. Mutated TCR chains were 
expressed on the surface of bacteriophage as fusions to the phage coat protein pIII to 
facilitate selection on soluble pHLA antigen. Enrichment for enhanced-affinity clones 
was measured by phage inhibition ELISA. Affinity maturation of the Mel-5 TCR 
required the construction of second generation libraries, using as template an 
improved affinity clone from the first generation libraries. The CDR-walking 
mutagenesis approach which has been successfully used for the affinity maturation of 
antibodies was adopted here to isolate mutations in further CDRs (Yang, Green et al. 
1995; Schier, McCall et al. 1996).     
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3.2 Design and construction of first generation Mel-5 TCR libraries 
 
3.2.1 Cloning the wild-type Mel-5 TCR into the phagemid vector 
The phagemid/helper phage system was used to isolate high affinity TCRs. Unlike in 
a phage vector system where recombinant protein is expressed as fusion proteins to all 
5 copies of  pIII, in the phagemid vector system only  1 to 3 copies of  recombinant 
protein are displayed. Whereas a phage vector system, through multivalent display, 
supports the selection of low-affinity binders, the phagemid vector system encourages 
the enrichment for high affinity binders through, predominantly, monovalent display.  
Although scFvs have been successfully engineered by phage display, the phage 
display of scTCRs has proved more challenging (probably due to problems of folding) 
(Weidanz, Card et al. 1998). We hypothesised that the introduced inter-chain ds-bond 
at the constant region interface would overcome these folding problems and facilitate 
the display of full-length TCR on the phage surface.  
The phagemid vector pG125 for the phage display of the Mel-5 TCR was 
constructed by splicing by overlap extension PCR (SOE-PCR) as described in Section 
2.3 of Materials and Methods. A four-way PCR stitch product was assembled as 
follows: the TCR V  domain (TRAV12-2, nomenclature according to (Lefranc, 
Giudicelli et al. 1999)) was amplified from the E. coli expression vector pG190 
(cloned by E. Gostick) containing the TCR  chain with forward primer Nat22 (to 
introduce an NcoI restriction site) (Section 2.3.1 of Materials and Methods) and 
reverse primer YOL237 to generate fragment A; TCR C  plus the bacteriophage 
geneIII leader sequence was amplified from the phagemid vector, pEX922 (pLitmus 
28a, based on pUC19 phagemid vector containing the  and  A6 TCR genes) (Li, 
Moysey et al. 2005) with forward primer YOL236 and reverse primer YOL238 to 
generate fragment C; the TCR V  (TRBV30, nomenclature according to (Lefranc, 
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Giudicelli et al. 1999) was amplified from the E. coli expression vector pG176 
(cloned by E. Gostick) containing the TCR chain with forward primer J185 and 
reverse primer YOL240 to generate fragment B; TCR C  plus ~200 base pairs (bp) of 
bacteriophage geneIII  was amplified from pEX922 with forward primer YOL239 and 
reverse primer YOL22 to generate fragment D (encoding a NotI site). The TCR  and 
 constant regions include the introduced cysteines at position TRAC threonine 48 
and TRBC serine 57 (Boulter, Glick et al. 2003). The PCR fragments were resolved 
on a 1.6 % (w/v) agarose gel (Figure 3.1 A). The fragments migrated to the expected 
sizes: PCR fragment A ~390 base pairs (bp); fragment B ~450 bp; fragment C ~370 
bp; fragment D ~550 bp. A four-way SOE-PCR was performed with equimolar 
amounts of purified fragments A, B, C and D and amplified with external primers 
Nat22 and YOL22 to generate the desired ~1700 bp fragment (Figure 3.1 B).  
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A. 
 
 
 
B. 
 
 
Figure 3.1. Generating the wild-type Mel-5 TCR PCR fragment for cloning into 
the phagemid vector. (A). Photo of ethidium bromide agarose gel electrophoresed 
wild-type Mel-5 TCR PCR products were gel-purified and 1 l loaded onto a 1.6 % 
(w/v) agarose gel for quantitation. Lane 1, Hyperladder (HYP) IV size of bands in bp; 
lane 2, PCR fragment A; lane 3, fragment B; lane 4, fragment C; lane 5, fragment D. 
(B). Ethidium bromide stained agarose gel photo of the PCR-assembled Mel-5 wt 
TCR. A four-way SOE-PCR was set up with equimolar amounts of each of the 
fragments (A-D). Lane 1, HYP I; lane 2, assembled PCR product (A/B/C/D). Stitch 
PCR was resolved on a 1 % (w/v) agarose gel.   
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Both the PCR-assembled full-length Mel-5 TCR fragment and the phagemid 
vector, pEX922 (containing a human  TCR) were digested with the restriction 
enzymes NcoI and NotI and resolved on a 1.4 % (w/v) agarose gel (Figure 3.2 A). 
Digestion of the pEX922 vector excised a ~1500 bp fragment corresponding to a full-
length TCR. The upper band, equating to the linearised phagemid vector was gel-
purified. Digestion of the Mel-5 TCR stitch PCR product generated two fragments: 
one of ~1500 bp, corresponding to the Mel-5 TCR fragment and one of ~200 bp, 
corresponding to the NotI-YOL22 fragment. Following gel-purification, 1 l of each 
digested DNA fragment was resolved on a 1.2 % (w/v) agarose gel for quantitation 
(Figure 3.2 B). Using a molar ratio of 1:3 of vector:insert and T4 ligase, the Mel-5  
TCR fragment was ligated into pEX922. 
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A. 
 
 
 
 
B.  
 
 
Figure 3.2. Generating the digested Mel-5 wild-type TCR PCR fragment and 
phagemid vector. (A). Ethidium bromide stained agarose gel photo of the NcoI-NotI 
digested Mel-5 TCR PCR and phagemid vector, pEX922. Lane 1, HYP I; lane 2, 
NcoI-NotI digest of pEX922 vector; lane 3, NcoI-NotI digest of the Mel-5 TCR PCR 
fragment. The high molecular weight band for both digests (indicated with an arrow) 
was excised and gel-purified. (B). Ethidium bromide stained agarose gel photo of gel-
purified NcoI-NotI digested Mel-5 TCR PCR and pEX922. Lane 1, HYP I; lane 2, 
NcoI-NotI pEX922 vector fragment; lane 3, NcoI-NotI Mel-5  TCR fragment.    
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Following transformation of chemically-competent E. coli XL1-Blue cells, DNA 
from ampicillin-resistant colonies was isolated and sequenced with primers YOL13 
and YOL22 (Figure 3.4). Figure 3.3 shows the DNA and protein sequence of the Mel-
5 TCR cloned into the phagemid vector, named pG125. The Mel-5 TCR  chain V 
domain is encoded by TRAV12-2*01 and TRAJ27*01 gene segments. The C  region 
is encoded by the TRAC*01 gene segment (International Immunogenetics (IMGT) 
nomenclature (Lefranc, Giudicelli et al. 1999)). The Mel-5 TCR  chain V domain is 
encoded by TRBV30, TRBJ2-2*01 and TRBD1*01 gene segments. The C  region is 
encoded by the TRBC1*01 gene segment. The locations of the six CDR loops are 
highlighted. 
In the final pG125 construct, the TCR  chain contains the engineered ds-bond 
mutation and is truncated N-terminal of the natural membrane-proximal cysteine. The 
TCR  chain contains the ds-bond mutation and is truncated at the equivalent 
position. The 3’ end of the  chain is fused in frame to the 5’ end of the geneIII coat 
protein of bacteriophage M13. The pelB and geneIII leader sequences are fused to the 
5’ end of the  and  chains, respectively, and expression of both chains is under the 
control of the same lacZ promoter (Figure 3.4 A). Figure 3.4 B illustrates the location 
of the primers and restriction sites used for cloning the mutagenic libraries into the 
phagemid vector pEX922.  
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             SfiI 
         ~~~~~~~~~~~~~~ 
                                                              NcoI 
                    pelB leader gene                  ~~ 
  M  K  Y  L   L  P  T   A  A  A   G  L  L  L   L  A  A   Q  P  A 
       1 ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTCGCGGC CCAGCCGGCC 
 TACTTTATGG ATAACGGATG CCGTCGGCGA CCTAACAATA ATGAGCGCCG GGTCGGCCGG 
 
 NcoI 
 ~~~~ 
  M  A  Q  K   E  V  E   Q  N  S   G  P  L  S   V  P  E   G  A  I 
      61 ATGGCCCAAA AAGAAGTTGA ACAAAATTCT GGACCCCTCA GTGTTCCAGA GGGAGCCATT 
 TACCGGGTTT TTCTTCAACT TGTTTTAAGA CCTGGGGAGT CACAAGGTCT CCCTCGGTAA 
 
                                         CDR1  
  A  S  L  N   C  T  Y   S  D  R   G  S  Q  S   F  F  W   Y  R  Q 
     121 GCCTCTCTCA ACTGCACTTA CAGTGACCGA GGTTCCCAGT CCTTCTTCTG GTACAGACAA 
 CGGAGAGAGT TGACGTGAAT GTCACTGGCT CCAAGGGTCA GGAAGAAGAC CATGTCTGTT 
 
                                                 CDR2  
  Y  S  G  K   S  P  E   L  I  M   F  I  Y  S   N  G  D   K  E  D 
     181 TATTCTGGGA AAAGCCCTGA GTTGATAATG TTCATATACT CCAATGGTGA CAAAGAAGAT 
 ATAAGACCCT TTTCGGGACT CAACTATTAC AAGTATATGA GGTTACCACT GTTTCTTCTA 
 
  G  R  F  T   A  Q  L   N  K  A   S  Q  Y  V   S  L  L   I  R  D 
     241 GGAAGGTTTA CAGCACAGCT CAATAAAGCC AGCCAGTATG TTTCTCTGCT CATCAGAGAC 
 CCTTCCAAAT GTCGTGTCGA GTTATTTCGG TCGGTCATAC AAAGAGACGA GTAGTCTCTG 
 
                                      CDR3  
  S  Q  P  S   D  S  A   T  Y  L   C  A  V  N   V  A  G   K  S  T 
     301 TCCCAGCCCA GTGATTCAGC CACCTACCTC TGTGCCGTGA ACGTTGCAGG CAAATCAACC 
 AGGGTCGGGT CACTAAGTCG GTGGATGGAG ACACGGCACT TGCAACGTCC GTTTAGTTGG 
 
  F  G  D  G   T  T  L   T  V  K   P  N  I  Q   N  P  D   P  A  V 
     361 TTTGGGGATG GGACTACGCT CACTGTGAAG CCAAATATCC AGAACCCTGA CCCTGCCGTG 
 AAACCCCTAC CCTGATGCGA GTGACACTTC GGTTTATAGG TCTTGGGACT GGGACGGCAC 
 
  Y  Q  L  R   D  S  K   S  S  D   K  S  V  C   L  F  T   D  F  D 
     421 TACCAGCTGA GAGACTCTAA ATCCAGTGAC AAGTCTGTCT GCCTATTCAC CGATTTTGAT 
 ATGGTCGACT CTCTGAGATT TAGGTCACTG TTCAGACAGA CGGATAAGTG GCTAAAACTA 
 
  S  Q  T  N   V  S  Q   S  K  D   S  D  V  Y   I  T  D   K  C  V 
     481 TCTCAAACAA ATGTGTCACA AAGTAAGGAT TCTGATGTGT ATATCACAGA CAAATGTGTG 
 AGAGTTTGTT TACACAGTGT TTCATTCCTA AGACTACACA TATAGTGTCT GTTTACACAC 
 
  L  D  M  R   S  M  D   F  K  S   N  S  A  V   A  W  S   N  K  S 
     541 CTAGACATGA GGTCTATGGA CTTCAAGAGC AACAGTGCTG TGGCCTGGAG CAACAAATCT 
 GATCTGTACT CCAGATACCT GAAGTTCTCG TTGTCACGAC ACCGGACCTC GTTGTTTAGA 
 
  D  F  A  C   A  N  A   F  N  N   S  I  I  P   E  D  T   F  F  P 
     601 GACTTTGCAT GTGCAAACGC CTTCAACAAC AGCATTATTC CAGAAGACAC CTTCTTCCCC 
 CTGAAACGTA CACGTTTGCG GAAGTTGTTG TCGTAATAAG GTCTTCTGTG GAAGAAGGGG 
 
                            SfiI 
                        ~~~~~~~~~~~~~~ 
  S  P  E  S   S  *  * 
     661 AGCCCAGAAA GTTCCTAATA AGGCCGTAGT GGCCTTAATT AAGAATTCTT TAAGAAGGGG 
 TCGGGTCTTT CAAGGATTAT TCCGGCATCA CCGGAATTAA TTCTTAAGAA ATTCTTCCCC 
 
                                    gIII leader gene 
          M   K  K  L   L  F  A  I   P  L  V   V  P  F   Y  S  H  S  
     721 ATATACATAT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC TATTCTCACA 
 TATATGTATA CTTTTTTAAT AATAAGCGTT AAGGAAATCA ACAAGGAAAG ATAAGAGTGT 
 
 BssHII 
 ~~~~~~ 
 ·  A  Q  S   Q  T  I   H  Q  W  P   A  T  L   V  Q  P   V  G  S  P  
     781 GCGCGCAGTC TCAGACTATT CATCAATGGC CAGCGACCCT GGTGCAGCCT GTGGGCAGCC 
 CGCGCGTCAG AGTCTGATAA GTAGTTACCG GTCGCTGGGA CCACGTCGGA CACCCGTCGG 
 
                             CDR1  
 ·  L  S  L   E  C  T   V  E  G  T   S  N  P   N  L  Y   W  Y  R  Q  
     841 CGCTCTCTCT GGAGTGCACT GTGGAGGGAA CATCAAACCC CAACCTATAC TGGTACCGAC 
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 GCGAGAGAGA CCTCACGTGA CACCTCCCTT GTAGTTTGGG GTTGGATATG ACCATGGCTG 
 
                                   CDR2  
 ·  A  A  G   R  G  L   Q  L  L  F   Y  S  V   G  I  G   Q  I  S  S  
     901 AGGCTGCAGG CAGGGGCCTC CAGCTGCTCT TCTACTCCGT TGGTATTGGC CAGATCAGCT 
 TCCGACGTCC GTCCCCGGAG GTCGACGAGA AGATGAGGCA ACCATAACCG GTCTAGTCGA 
 
 ·  E  V  P   Q  N  L   S  A  S  R   P  Q  D   R  Q  F   I  L  S  S  
     961 CTGAGGTGCC CCAGAATCTC TCAGCCTCCA GACCCCAGGA CCGGCAGTTC ATCCTGAGTT 
 GACTCCACGG GGTCTTAGAG AGTCGGAGGT CTGGGGTCCT GGCCGTCAAG TAGGACTCAA 
 
                                         CDR3  
 ·  K  K  L   L  L  S   D  S  G  F   Y  L  C   A  W  S   E  T  G  L  
    1021 CTAAGAAGCT CCTCCTCAGT GACTCTGGCT TCTATCTCTG TGCCTGGTCC GAGACAGGGT 
 GATTCTTCGA GGAGGAGTCA CTGAGACCGA AGATAGAGAC ACGGACCAGG CTCTGTCCCA 
 
 ·  G  T  G   E  L  F   F  G  E  G   S  R  L   T  V  L   E  D  L  K  
    1081 TAGGCACCGG GGAGCTGTTT TTTGGAGAAG GCTCTAGGCT GACCGTACTG GAGGACCTGA 
 ATCCGTGGCC CCTCGACAAA AAACCTCTTC CGAGATCCGA CTGGCATGAC CTCCTGGACT 
 
 ·  N  V  F   P  P  E   V  A  V  F   E  P  S   E  A  E   I  S  H  T  
    1141 AAAACGTGTT CCCACCCGAG GTCGCTGTGT TTGAGCCATC AGAAGCAGAG ATCTCCCACA 
 TTTTGCACAA GGGTGGGCTC CAGCGACACA AACTCGGTAG TCTTCGTCTC TAGAGGGTGT 
 
 ·  Q  K  A   T  L  V   C  L  A  T   G  F  Y   P  D  H   V  E  L  S  
    1201 CCCAAAAGGC CACACTGGTG TGCCTGGCCA CAGGCTTCTA CCCCGACCAC GTGGAGCTGA 
 GGGTTTTCCG GTGTGACCAC ACGGACCGGT GTCCGAAGAT GGGGCTGGTG CACCTCGACT 
 
 ·  W  W  V   N  G  K   E  V  H  S   G  V  C   T  D  P   Q  P  L  K  
    1261 GCTGGTGGGT GAATGGGAAG GAGGTGCACA GTGGGGTCTG CACAGACCCG CAGCCCCTCA 
 CGACCACCCA CTTACCCTTC CTCCACGTGT CACCCCAGAC GTGTCTGGGC GTCGGGGAGT 
 
 ·  E  Q  P   A  L  N   D  S  R  Y   A  L  S   S  R  L   R  V  S  A  
    1321 AGGAGCAGCC CGCCCTCAAT GACTCCAGAT ACGCTCTGAG CAGCCGCCTG AGGGTCTCGG 
 TCCTCGTCGG GCGGGAGTTA CTGAGGTCTA TGCGAGACTC GTCGGCGGAC TCCCAGAGCC 
 
 ·  T  F  W   Q  D  P   R  N  H  F   R  C  Q   V  Q  F   Y  G  L  S  
    1381 CCACCTTCTG GCAGGACCCC CGCAACCACT TCCGCTGTCA AGTCCAGTTC TACGGGCTCT 
 GGTGGAAGAC CGTCCTGGGG GCGTTGGTGA AGGCGACAGT TCAGGTCAAG ATGCCCGAGA 
 
 ·  E  N  D   E  W  T   Q  D  R  A   K  P  V   T  Q  I   V  S  A  E  
    1441 CGGAGAATGA CGAGTGGACC CAGGATAGGG CCAAACCCGT CACCCAGATC GTCAGCGCCG 
 GCCTCTTACT GCTCACCTGG GTCCTATCCC GGTTTGGGCA GTGGGTCTAG CAGTCGCGGC 
 
                         NotI 
                       ~~~~~~~~ 
 ·  A  W  G   R  A  D   A  A  A  S   R  I  H   H  H  H   * 
    1501 AGGCCTGGGG TAGAGCAGAC GCGGCCGCAT CTAGAATTCA CCATCATCAC TAG 
 TCCGGACCCC ATCTCGTCTG CGCCGGCGTA GATCTTAAGT GGTAGTAGTG ATC 
 
 
Figure 3.3. Sequence of Mel-5 wild-type TCR cloned into the phagemid vector 
pEX922. The amino acid residues encoding the pelB and bacteriophage M13 geneIII 
leader genes are highlighted in red and blue respectively. The six CDR loops, 
designated by the International Immunogenetics (IMGT) database (Lefranc, 
Giudicelli et al. 1999), are in bold and underlined. The TCR membrane-proximal 
cysteines in both the  and  chains have been removed. The introduced TCR 
stabilising constant region cysteines (at positions TRAC Thr 48 and TRBC Ser 57) 
are highlighted in green. The restriction enzyme sites used for molecular cloning are 
highlighted (NcoI, SfiI, BssHII and NotI). Asterisks show the location of stop codons 
including an amber codon (TAG) at the C-terminus of the beta chain. In suppressor 
(supE) strains of E. coli such as TG1 cells (as used in this work) protein translation 
continues through amber codons (at a reduced efficiency) with substitution of Gln. 
The TCR is linked to the hexahistidine tag. The sequence was analysed with Vector 
NTI Advance 11 (Invitrogen). 
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pG125 phagemid
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Figure 3.4. Map of phagemid vector pG125, for the construction of Mel-5 TCR 
phage display libraries. (A). Circular display. The vector encodes the Mel-5 TCR  
and  chains (V C /V C ). The C-terminal end of the  chain is fused to the N-
terminus of bacteriophage protein III (pIII). Transcription is under the control of the 
lacZ promoter. The vector includes both an E. coli (pUC19) and bacteriophage (M13) 
origin of replication to allow amplification in E. coli and phage. Other features 
include an ampicillin resistance gene, used for selection and maintenance of the 
plasmid and the gene encoding folding assistance chaperone Skp. The pelB and 
geneIII signal peptides direct the  and  chain-gIII fusion to the periplasm 
(respectively). The TCR genes are cloned between SfiI and NotI for display on the 
phage coat protein, pIII. (B). Linear display. The location of the oligonucleotides 
YOL13, YOL238, J195 and YOL22 used for construction of the alpha and beta chain 
libraries are highlighted. An amber codon is located between the His-tag and geneIII. 
The vector maps were constructed with Vector NTI Advance 11. 
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3.2.2 Generating library PCR fragments 
Libraries were assembled in which each of the six CDRs were individually targeted 
for mutagenesis producing TCRs with one wild-type and one mutated chain. The PCR 
strategy that outlines the construction of the Mel-5 TCR libraries is shown in Figure 
2.1 of Materials and Methods. Using pG125 as the template, PCR fragments were 
generated to flank each of the CDR regions to be mutated. A mutagenic primer was 
then designed which had four (for the CDR1 and CDR2 loops) and five codons (for 
the CDR3 loops) mutated with the NNK motif but also containing overlapping 
regions to allow stitching to the two flanking PCR fragments.  
Although the crystal structure of the Mel-5 TCR in complex with HLA-A*0201-
Melan-A/MART-1(26-35) has since become available (Cole, Yuan et al. 2009), this 
information was not available at the time of library construction. Therefore, 
overlapping mutagenic primers were designed to span the entire length of each CDR. 
For the CDR3 loops, the NNK motif was shifted every two residues to ensure 
complete coverage. The number of mutagenic primers was determined by the length 
of the CDR. The primers used for mutagenising the TCR chains are shown in Section 
2.4.1 of Materials and Methods. Following PCR amplification of the 24 initial 
fragments, 20 Units of DpnI endonuclease was added to digest methylated bacterial 
double-stranded DNA. This step reduced the level of bacterial template DNA, present 
in the PCR product, that could be co-purified with the PCR fragments. After a 2-hour 
incubation at 37 ºC, each fragment was analysed by agarose gel electrophoresis. In 
general, the  chain segments amplified equally, with the exception of PCRa5 which 
yielded substantially more product (Figure 3.5 A). The YOL22-amplified  chain 
segments produced a high yield of product, with PCRb15 being the exception (Figure 
3.5 B). The yield of the J195-amplified product varied.  
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B. 
 
 
Figure 3.5. Agarose gel photo of gel-purified Mel-5 TCR PCR fragments. (A).  
chain PCR fragments (1 l of each). Lane 1, HYP IV; lane 2, PCR a1; lane 3, PCR 
a2; lane 4, PCR a4; lane 5, PCR a5; lane 6, PCR a7; lane 7, PCR a8; lane 8, PCR a10; 
lane 9, PCR a11; lane 10, PCR a13; lane 11, PCR a14; lane 12, PCR a16; lane 13, 
PCR a17. (B).  chain PCR fragments (1 l of each). Lane 1, HYP IV; lane 2, PCR 
b1; lane 3, PCR b2; lane 4, PCR b4; lane 5, PCR b5; lane 6, PCR b7; lane 7, PCR b8; 
lane 8, PCR b10; lane 9, PCR b11; lane 10, PCR b13; lane 11, PCR b14; lane 12, 
PCR b16; lane 13, PCR b17.  
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3.2.3 Generating full-length  and  chain library PCR fragments 
The gel-purified PCR fragments (10-12 ng total DNA) (Figure 3.5 A and 3.5 B) and 
the mutagenic NNK primer (1 pM) were assembled into a three-way PCR stitch 
reaction which generated a full length PCR fragment suitable for cloning into the 
phage display in vector (Section 3.4.1.2 of Materials and Methods). The 3’ ends of the 
black fragment is complimentary to the 5’ ends of the NNK primer and the 3’ ends of 
this DNA linker was complimentary to the 5’ ends of the red fragment (Figure 2.1 of 
Materials and Methods).  
Whilst a single 4-NNK mutagenic primer was sufficient to randomise all positions 
of the CDR1 and CDR2 loops, four 5-NNK primers were required to randomise the 
CDR3 loops of both  and  chains. In addition to the test PCRs, PCRs were also set 
up to control for non-mutagenised background amplification of the template vector in 
which the NNK primer was omitted from the PCR mix. This meant for each SOE-
PCR, an additional (control) PCR was also prepared; this was identical except for the 
omission of the NNK primer. To assess amplification of parental DNA, 5 l of each 
PCR was resolved on a 1% (w/v) agarose gel (Figure 3.6 A and 3.6 B). Amplification 
of mutagenised  chain segments with primers YOL13 and YOL238 (Section 2.3.1 in 
Materials and Methods) yielded a product of ~850 bp. Amplification of mutagenised 
 chain segments with primers J195 and YOL22 produced a product of ~1100 bp. 
Amplification of full-length  and  gene segments yielded a significant amount of 
product compared to the control reactions. The remainder of each test PCR was 
analysed by agarose gel electrophoresis and DNA bands of the desired size were gel-
purified (Figure 3.6 C).  
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A. 
 
  
B. 
 
 
C.  
 
 
Figure 3.6. Agarose gel photos of overlapping stitch Mel-5 TCR library PCR 
fragments. (A).  chain PCR test and control reactions. Lane 1, HYP I; lane 2, PCR 
a1 + a2 + NNK primer; lane 3, PCR a4 + a5 + NNK primer; lane 4, PCR a7 + a8 + 
NNK primer; lane 5, PCR a10 + a11 + NNK primer; lane 6, PCR a13 + a14 + NNK 
primer; lane 7, PCR a16 + a17 + NNK primer; lane 8,  no sample; lane 9, PCR a1 + 
a2 - NNK primer; lane 3, PCR a4 + a5 - NNK primer; lane 4, PCR a7 + a8 - NNK 
primer; lane 5, PCR a10 + a11 - NNK primer; lane 6, PCR a13 + a14 - NNK primer; 
lane 7, PCR a16 + a17 - NNK primer. (B).  chain PCR test and control reactions. 
Lane 1, HYP I; lane 2, PCR b1 + b2 + NNK primer; lane 3, PCR b4 + b5 + NNK 
primer; lane 4, PCR b7 + b8 + NNK primer; lane 5, PCR b10 + b11 + NNK primer; 
lane 6, PCR b13 + b14 + NNK primer; lane 7, PCR b16 + b17 + NNK primer; lane 8,  
no sample; lane 9, PCR b1 + b2 - NNK primer; lane 3, PCR b4 + b5 - NNK primer; 
lane 4, PCR b7 + b8 - NNK primer; lane 5, PCR b10 + b11 - NNK primer; lane 6, 
PCR b13 + b14 - NNK primer; lane 7, PCR b16 + b17 - NNK primer. (C). Gel-
purified  and  chain stitch library PCR fragments. Lane 1, HYP I; lane 2, PCR a3; 
lane 3, PCR a6; lane 4, PCR a9; lane 5, PCR a12; lane 6, PCR a15; lane 7, PCR a18; 
lane 8, PCR b3; lane 9, PCR b6; lane 10, PCR b9; lane 11, PCR b12; lane 12, PCR 
b15; lane 13, PCR b18. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1000 
600 
400 
1500 
2000 
800 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1000 
600 
400 
1500 
2000 
800 
1 2 3 4 5 6 7 8 9 10 11 12 13 
1000 
600 
400 
1500 
800 
Chapter 3 
 176 
3.2.4 Generating bacterial libraries 
The gel-purified library SOE-PCR products were subsequently digested with SfiI for 
the six  chain segments  (PCR a3, a6, a9, a12, a15 and a18)  and BssHII-NotI for the 
six  chain segments (PCR b3, b6, b9, b12, b15 and b18) (Section 2.4.1.3 of Materials 
and Methods).  To reduce the level of background of non-recombinant clones, the 
vector and insert fragments were over-digested with five times the recommended 
amount of restriction enzymes. Gel-purified digested PCR fragments were analysed 
by agarose gel electrophoresis (Figure 3.7). Digesting the stitch PCRs removed ~200 
bp from the  fragments and ~350 bp from the  fragments to yield fragments of the 
expected size; ~650 bp for the  chains and ~750 bp for the  chains.  
 
 
 
 
 
Figure 3.7. Agarose gel photo of gel-purified digested stitch Mel-5 TCR library 
PCRs. Lane 1, HYP IV; lane 2, PCR a3; lane 3, PCR a6; lane 4, PCR a9; lane 5, PCR 
a12; lane 6, PCR a15; lane 7, PCR a18; lane 8, Hyperladder IV; lane 9, PCR b3; lane 
10, PCR b6; lane 11, PCR b9; lane 12, PCR b12; lane 13, PCR b15; lane 14, PCR 
b18; lane 15, Hyperladder IV. 
 
 
 
To monitor the efficiency of vector and insert digests, a pilot ligation was set up 
for each of the twelve SOE-PCR library products using a scaled down amount of 
DNA (~80 ng total DNA) (Section 2.4.1.4 Materials and Methods). Transformation of 
E. coli XL1-blue cells yielded an acceptably low level of background for the vector 
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only control (1-20%) and so, large scale ligations were prepared (5-7 g total DNA 
per ligation). Each of the twelve SOE-PCR products were ligated separately into 
pG125 (with T4 DNA ligase) as SfiI fragments for the TCR CDR mutated libraries 
and as BssHII-NotI digested fragments for the CDR mutated libraries (Section 
2.4.1.4 of Materials and Methods). This generated libraries in which only one of the 
two TCR chains was mutated in a single construct; mutated TCR  chain libraries 
were spliced with the wild-type TCR  chain and, conversely, mutated TCR  chain 
libraries were spliced with the wild-type TCR  chain. 
NNK degeneracy allows for the substitution of all 20 amino acids encoded by 32 
codons. The theoretical protein diversity of a library with four residues fully 
randomised (as in the CDR1 and CDR2 libraries) is 20
4
 = 1.6 x 10
5
 and for five 
residues it is 20
5
 = 3.2 x 10
6
. The CDR3 loops are mutated by four 5-NNK 
oligonucleotides and so the theoretical protein diversity is 4 x (20
5
) = 1.28 x 10
7
.  
TG1 electrocompetent E. coli cells were transformed with 200-300 ng of each of the 
twelve ligated DNA products to generate libraries of approximately 0.4 to 1 x 10
8
 
clones (Section 2.4.1.4 of Materials and Methods). Libraries having this diversity are 
therefore theoretically sufficient to encompass the entire repertoire of potential 
mutations.  
Library integrity was assessed by DNA sequence analysis. Randomly selected 
colonies were PCR amplified with primers YOL13 and YOL22; four colonies were 
analysed for the CDR1  and CDR2  libraries and ten colonies analysed for the 
CDR3  library. Similarly, four colonies were analysed for the CDR1  (although one 
of the sequences was of poor quality and is not shown) and CDR2  libraries and ten 
colonies analysed for the CDR3  library. Sequence analysis of each library revealed a 
broad diversity of mutations spanning each of the targeted CDRs (Table 3.1 A and 3.1 
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B). Additionally, but equally important, the TCR fragments were all in-frame. A 
number of the clones (CDR2 -1, CDR3 -4 and CDR3 -7) contained an amber codon 
and were translated as Gln in suppressor strains of E. coli (such as TG1). As a result 
the library size and diversity was not compromised by their inclusion. Amber codons 
probably occur when a higher expression level of certain TCRs is toxic for bacteria. 
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A. 
 CDR1 (R28-Q31) 
CDR1 _wt R  G  S  Q   
cgaggttcccag 
CDR1 _1 N  I  H  G   
aatattcatggt 
CDR1 _2 S  R  Y  G   
tcgcgttatggg 
CDR1 _3 W  X  A  H   
tggnaggctcat 
CDR1 _4 S  G  S  S   
tctggttcgtct 
 
 CDR2 (I50-N53) 
CDR2 _wt I  Y  S  N   
atatactccaat 
CDR2 _1 W  T  Q  C 
tggacgtagtgt 
CDR2 _2 G  P  G  L   
ggtcctggtttg 
CDR2 _3 A  G  L  E   
gctggtctggag 
CDR2 _4 G  G  N  L   
gggggtaatctg 
 
 CDR3 (A90-T98) 
CDR3 _wt A  V  N  V  A  G  K  S  T   
gccgtgaacgttgcaggcaaatcaacc 
CDR3 _1 G  T  G  I  W  G  K  S  T   
gggacgggtatttggggcaaatcaacc 
CDR3 _2 S  L  K  G  G  G  K  S  T   
tctttgaagggtgggggcaaatcaacc 
CDR3 _3 A  P  G  R  L  G  K  S  T   
gcgccgggggggcttggcaaatcaacc 
CDR3 _4 V  T  T  G  Q  G  K  S  T   
gttactactgggtagggcaaatcaacc 
CDR3 _5 A  W  P  G  G  G  K  S  T   
gccactgctgggtagggcaaatcaacc 
CDR3 _6 A  F  A  C  C  P  K  S  T   
gcctgtgcgtgttgtcctaaatcaacc 
CDR3 _7 A  H  I  N  L  Q  K  S  T   
gcccatgttcatctttagaaatcaacc 
CDR3 _8 A  V  N  P  D  I  G  V  T   
gccgtgaacccngatattggggttacc 
CDR3 _9 A  V  N  V  R  K  M  I  V   
gccgtgaacgttcggaagatgattgtg 
CDR3 _10 A  V  N  V  I  V  G  R  P   
gccgtgaacgttattgtgggtaggcct 
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B.  
 
 CDR1 (T28-P31) 
CDR1 _wt T  S  N  P   
acatcaaacccc 
CDR1 _1 G  A  A  G   
ggtgctgcgggt 
CDR1 _2 W  V  G  G   
tgggttgggggg 
CDR1 _3 T  Y  F  P   
acttattttcct 
 
 CDR2 (V51-G54) 
CDR2 _wt V  G  I  G   
gttggtattggc 
CDR2 _1 H  A  S  L   
catgcttcgttg 
CDR2 _2 T  L  W  V   
actttgtgggtg 
CDR2 _3 I  T  A  F   
attactgctttt 
CDR2 _4 S  A  K  F   
agtgcgaagttt 
 
 CDR3 (A92-L103) 
CDR3 _wt A  W  S  E  T  G  L  G  T  G  E  L   
gcctggtccgagacagggttaggcaccggggagctg 
CDR3 _1 Q  V  Q  A  V  G  L  G  T  G  E  L   
taggtgtaggcggttgggttaggcaccggggagctg 
CDR3 _2 G  H  V  R  R  G  L  G  T  G  E  L   
gggcatgtgaggagggggttaggcaccggggagctg 
CDR3 _3 A  W  W  F  A  P  C  G  T  G  E  L   
gcctggtggtttgctccgtgtggcaccggggagctg 
CDR3 _4 A  W  N  L  F  L  L  G  T  G  E  L   
gcctggaatctttttcttttgggcaccggggagctg 
CDR3 _5 A  W  S  E  N  T  V  V  T  G  E  L   
gcctggtccgagaatactgttgttactggggagctg 
CDR3 _6 A  W  S  E  F  N  R  E  R  G  E  L   
gcctggtccgagtttaatcgggagcggggggagctg 
CDR3 _7 A  W  S  E  L  R  A  L  F  G  E  L   
gcctggtccgagctgagggcgctgttcggggagctg 
CDR3 _8 A  W  S  E  T  G  L  W  D  S  G  S   
gcctggtccgagacagggttatgggattcggggtcg 
CDR3 _9 A  W  S  E  T  G  L  S  M  Q  Y  N   
gcctggtccgagacagggttaagtatgcagtataat 
CDR3 _10 A  W  S  E  T  G  L  F  H  V  I  C   
gcctggtccgagacagggttatttcatgttatttgt 
 
 
Table 3.1. Sequence analysis of Mel-5 TCR phage display NNK libraries. (A). 
Alpha chain libraries: CDR1 , CDR2  and CDR3 . (B). Beta chain libraries: 
CDR1 , CDR2  and CDR3 . Nucleotides marked with an “n” and amino acid 
residue marked with an “X” are undefined because the DNA sample is mixed and 
contains more than one DNA template. Amino acids that differ from wild-type are 
highlighted in red. Nucleotides that differ from wild-type are highlighted in blue. Q, 
Amber codon. wt, wild-type. International Immunogenetics (IMGT) nomenclature 
(Lefranc, Giudicelli et al. 1999). 
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3.3 Phage selections and screening  
Phage was separately prepared from each of the twelve E. coli TG1 transformations as 
described in Section 2.5.1 and 2.5.2 of Materials and Methods and then pooled into 
four libraries for panning: (1) CDR1  (SOE-PCR 3a) + CDR2  (6a); (2) CDR3  (9a 
+ 12a + 15a + 18a); (3) CDR1  (3b) + CDR2  (9a); (4) CDR3  (9b + 12b + 15b + 
18b) (Table 3.1). Briefly, 50 mL of 2xYT growth media supplemented with ampicillin 
(100 g/ml final concentration) and 2% glucose (w/v)  was inoculated separately with 
each of the twelve E. coli TG1 bacterial glycerol stocks to an OD600 of 0.05-0.08. The 
12 cultures were incubated at 37°C with shaking until an of OD600 0.3-0.5 was 
reached. Phage was rescued by infection with helper phage and grown in kanamycin-
containing media overnight at 26°C with shaking. The following day, the 12 cultures 
were pelleted and the phage supernatant was precipitated twice with polyethylene 
glycol (PEG)/NaCl (Section 2.5.2 of Materials and Methods). After resuspending 
each precipitated phage pellet in 1 mL PBS, the phage was divided into the four 
libraries described above for panning.    
Panning was performed against the TAA, Melan-A/MART-1(26-35), bound in the 
context of biotinylated HLA-A*0201. The quality and stability of the antigen is 
critical to the success of affinity maturation. A limitation of many antigenic peptides 
derived from TAAs is that they are not always optimal for binding to HLA in that 
they do not contain the dominant anchor residues. This results in a low binding 
affinity of these peptides in the groove of the HLA molecule. Modification of the 
anchor residues to generate heteroclitic peptides enhances the binding affinity of the 
peptide in the HLA groove stabilising the complex. The wild-type peptide binds 
weakly to the HLA-A*0201 heavy chain and so forms relatively unstable complexes 
(Valmori, Fonteneau et al. 1998). A heteroclitic version of the Melan-A/MART-1(26-
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35) peptide was used in all panning and ELISA screening experiments. The variant 
peptide contains an Ala27Leu substitution at position 2 from the N-terminus 
(ELAGIGILTV). Soluble HLA-A*0201-Melan-A/MART-1(26-35) was prepared from 
E. coli expressed inclusion bodies and synthetic peptide (Garboczi, Hung et al. 1992) 
and biotinylated with the BirA enzyme (O'Callaghan C, Byford et al. 1999).  
Three cycles of panning were performed as described in Section 2.5.4 of Materials 
and Methods. Phage (100 l) was pre-blocked with 3% Marvel-PBS and then 
incubated with 100 nM biotinylated HLA-A*0201-Melan-A/MART-1(26-35). The 
phage:HLA-A*0201-Melan-A/MART-1(26-35) complexes were rescued with 100 l 
streptavidin-coated paramagnetic beads. The beads were washed two times with PBS 
containing 3% Marvel (w/v) (MPBS), five times with PBS containing 0.1% Tween-20 
(v/v) (PBST) and further two times with PBS to remove non-binding or weakly 
binding variants. Phage displayed TCRs were eluted with 0.1 M Triethylamine and 
then neutralised with 1 M Tris (pH 7.4). Eluted phage was used to infect early log 
phase E. coli TG1 cells prior to plating on ampicillin-containing agar plates 
supplemented with 2% glucose (v/v). Overnight incubation at 30°C completed one 
round of selection. A total of three cycles of panning were performed under identical 
conditions. 
 
3.3.1 Monoclonal phage ELISA  
The output titre for each round of selection was determined and, following the third 
round, a ten-fold increase was observed for each of the four libraries. To screen 
monoclonal phage TCRs, individual clones were rescued by transferring ninety-five 
ampicillin-resistant E. coli TG1 colonies from each of the four libraries to the wells of 
sterile 96-well microtitre plates. Glycerol stocks of each of the 96-well libraries were 
prepared (master-plate) for storage at -80°C. Fresh 96-well cultures were grown from 
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the master-plates and phage was rescued by infection with helper phage and grown in 
kanamycin-containing media overnight at 26°C with shaking as described in Section 
2.5.1 of Materials and Methods. The following day, the cultures were pelleted and the 
supernatant containing monoclonal phage TCRs were screened for binding to 
immobilised biotinylated HLA-A*0201-Melan-A/MART-1(26-35) in an ELISA assay 
as described in Section 2.5.5 of Materials and Methods. Antigen-binding phage were 
detected with an anti-M13 antibody and a phosphatase-labelled anti-rabbit IgG 
monoclonal antibody. The phage were scored as ELISA positive if the absorbance at 
650 nm was at least two-times higher than the background absorbance value at 650 
nm.  
The only library to yield antigen-binding phage was the CDR3  library (Figure 
3.8). From this population, thirty-three positive clones (a frequency of ~35%) showed 
binding to HLA-A*0201-Melan-A/MART-1(26-35). Considerable variation in the level 
of expression of the positive-binding TCRs was observed with differences in the 
ELISA signal between the clones. Six out of the thirty-three clones (23, 28, 40, 59, 60 
and 83) failed to satisfy the antigen-binding absorbance criteria, but were deemed 
ELISA positive based on visual appearance of the developed ELISA plate.   
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Figure 3.8. Monoclonal phage ELISA screen of Mel-5 TCR CDR3  library Pan 3 
output. Following the third round of selection, ninety-five random colonies were 
screened by ELISA for binding to immobilised HLA-A*0201-Melan-A/MART-1(26-
35) (ELAGIGILTV). The cut-off for defining positive binding is indicated with a red 
dotted line. B, background. 
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3.3.2 Inhibition phage ELISA at 100 nM inhibitor 
The thirty-three positive HLA-A*0201-Melan-A/MART-1(26-35) binders selected from 
the CDR3  library were further characterised in an inhibition phage ELISA at 100 
nM HLA-A*0201-Melan-A/MART-1(26-35) to determine if any of the TCRs 
demonstrated competitive inhibition (Section 2.5.5 of Materials and Methods). The 
phage supernatant (as used in Figure 3.8) was incubated with 100 nM non-
biotinylated-HLA-A*0201-Melan-A/MART-1(26-35) for 1 h prior to adding to ELISA 
plates immobilised with HLA-A*0201-Melan-A/MART-1(26-35). High affinity binding 
phages are removed from the solution giving a reduction in ELISA signal. Inhibition 
was measured as a percentage reduction in signal and was calculated using the 
following formula: 100 - (Abs 650 nm sample with inhibitor ÷ Abs 650 nm sample 
without inhibitor x 100). 
The inhibition values for the thirty-three clones are shown in Table 3.2. Of the 33 
clones tested, inhibition values for 19 were calculated: 7/19 demonstrated >90% 
inhibition; 9/19 60-90% inhibition and 3/19 28-60% inhibition. It was noticeable that 
there was an overall reduction in the ELISA signal for each of the thirty-three clones 
compared to the values recorded in Figure 3.8. Overnight storage of the phage 
supernatant prior to this assay may have resulted in proteolysis of the phage displayed 
TCRs, reducing the amount of functional TCR in each well. Several of the clones 
showed almost no detectable binding to HLA-A*0201-Melan-A/MART-1(26-35) and so 
the  inhibition levels could not be calculated. 
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Clone 
number 
Abs @ 650 nm  
+ 0 nM inhib. 
Abs @ 650 nm  
+ 100 nM inhib. 
% Inhib. @ 
100 nM 
3 0.069 0.000 99 
6 0.021 0.003 nd 
9 0.071 0.010 86 
10 0.268 0.057 79 
13 0.031 0.001 nd 
17 0.119 0.022 82 
19 0.034 0.007 nd 
23 0.002 0.023 nd 
25 0.283 0.026 91 
28 0.014 0.000 nd 
29 0.015 -0.006 nd 
30 0.030 0.008 nd 
39 0.109 0.067 39 
40 0.020 0.003 nd 
41 0.142 0.079 44 
42 0.798 0.063 92 
44 0.143 0.018 87 
47 0.012 0.002 nd 
50 0.040 1.0101* nd 
51 0.362 0.092 75 
59 0.015 0.008 42 
60 0.015 -0.001 nd 
61 0.359 0.257 28 
64 0.149 0.022 85 
65 0.160 0.040 75 
77 0.186 0.017 91 
80 0.117 0.006 95 
82 0.149 0.025 84 
83 0.031 0.004 nd 
88 0.082 0.007 91 
89 0.107 0.008 93 
91 0.040 0.001 nd 
93 0.164 0.026 84 
    
Table 3.2. Inhibition phage ELISA of Mel-5 TCR CDR3  variants at a 
concentration of 100 nM inhibitor. The phage supernatant was incubated with 100 
nM non-biotinylated-HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) for 1 h 
prior to adding to ELISA plates immobilised with HLA-A*0201-Melan-A/MART-
1(26-35) (ELAGIGILTV). Absorbance (Abs) was measured at 650 nm. Percentage 
inhibition (% Inhib.) is measured as the percentage reduction in ELISA signal. The 
background absorbance value was subtracted from all readings before % Inhib. was 
calculated. *The Abs reading at 650 nm + 100 nM inhib. for clone is an outlier and 
probably due to a pipetting error. nd, not determined. 
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3.3.3 Sequencing analysis of the Pan 3 output 
The 33 CDR3  mutated clones were sequenced with primers YOL13 and YOL22 
(Table 3.3). One failed to produce sequence of sufficient quality and so was excluded 
from the analysis. Of the rest, 16 unique TCRs were identified. With the exception of 
clone 51, in which a Met at residue 48 in framework 2 was substituted for lle, no other 
mutations were observed outside of the targeted CDR3 region. Analysis of the 
variants showed a selection towards consensus sequences. It was apparent that certain 
residues were preferred at particular positions: Val
93
 was frequently substituted for 
Ser, Asp or Pro; Ala
94
 was changed to Gly in almost all of the mutated TCRs (in 26 of 
32 clones); the wild-type residue at position Gly
95
 was retained in 50 % of the 
sequenced clones; some variation was observed at position Lys
96
, which was 
substituted equally for a hydrophilic (His or Arg) or a hydrophobic (Leu or Tyr) 
residue; Leu was predominantly found at residue Ser
97
 (in 21 of 32 clones); Thr
98
 was 
commonly substituted for Leu. Several common motifs were seen; a central Gly
94
-
Gly
95
 motif was found in almost half of the sequenced clones and a G
94
X
95
X
96
L
97
 
motif was found in 18 of 32 sequenced clones. 
Multiple codon usage provides an indication of library diversity. For example, in 
the D
93
G
94
G
95
R
96
L
97
 motif, Gly
94
 is encoded by codons ggt or ggg, Arg
96
 is encoded 
by cgg or cgt and Leu
97
 is encoded by ttg or ctt. A second example, in the 
P
93
G
94
G
95
L
96
L
97
 motif, Gly
94
 is encoded by codons ggt or ggg, the wild-type residue 
Gly
95
 is encoded by codons ggt or ggc (as in the parental DNA template) and Leu
97
 is 
encoded by ttg or ctt. A third example, in the L
93
S
94
P
95
G
96
L
97
 motif, Ser
94
 is encoded 
by agt or tcg and Pro
95
 is encoded by ccg or cct.  
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Clone 
Number 
CDR3 (V91-T98) Frequency 
wt 
 
V  N  V  A  G  K  S  T 
gtgaacgttgcaggcaaatcaacc 
 
17 
 
V  N  S  G  N  H  M  T 
gtgaactctggtaatcatatgacc 
5 
19 
 
V  N  S  G  N  H  M  T 
gtgaactctggtaatcatatgacc 
83 
 
V  N  S  G  N  H  M  T 
gtgaactctggtaatcatatgacc 
64 
 
V  N  S  G  N  H  M  T 
gtgaactctggtaatcatatgacc 
39 
 
X  N  S  G  X  H  M  T 
gngaactctggtnatcatatgacc 
25 
 
V  N  D  G  G  R  L  T 
gtgaacgatggtggtcggttgacc 
5 
42 
 
V  N  D  G  G  R  L  T 
gtgaacgatgggggtcgtcttacc 
77 
 
V  N  D  G  G  R  L  T 
gtgaacgatgggggtcgtcttacc 
44 
 
V  N  D  G  G  R  L  T 
gtgaacgatgggggtcgtcttacc 
50 
 
V  N  D  G  G  R  L  T 
gtgaacgatgggggtcgtcttacc 
9 
 
V  N  P  G  G  L  L  T 
gtgaacccgggtggtttgttgacc 
3 
47 
 
V  N  P  G  G  L  L  T 
gtgaacccgggggggcttcttacc 
13 
 
V  N  P  G  G  L  L  T 
gtgaacccgggggggcttcttacc 
3 V  N  L  S  P  G  L  T 
gtgaacctgagtccgggtttgacc 
3 
28 
 
V  N  L  S  P  G  L  T 
gtgaacctgagtccgggtttgacc 
60 
 
V  N  L  S  P  G  L  T 
gtgaacctgtcgcctggtttgacc 
51 
 
V  N  V  G  G  Y  L  L 
gtgaacgttggtgggtatttgttg 
3 
82 
 
V  N  V  G  G  Y  L  L 
gtgaacgttggtgggtatttgttg 
65 
 
V  N  V  G  G  Y  L  L 
gtgaacgttggtgggtatttgttg 
29 
 
V  N  P  G  G  V  L  T 
gtgaacccggggggggtgttgacc 
2 
89 
 
V  N  P  G  G  F  L  T 
gtgaacccgggtggttttctgacc 
59 
 
V  N  N  G  M  P  S  T 
gtgaacaatggtatgccgtctacc 
2 
80 
 
V  N  N  G  M  P  S  T 
gtgaacaatggtatgccgtctacc 
10 
 
V  N  V  G  G  Y  L  S 
gtgaacgttgggggttatttgtcg 
1 
61 
 
V  N  V  G  G  L  L  R 
gtgaacgttggtgggttgttgagg 
1 
41 
 
V  N  N  P  T  L  A  T 
gtgaacaatcctacgctggctacc 
1 
40 
 
V  N  N  G  L  P  Q  T 
gtgaacaatggtctgcctcagacc 
1 
6 V  N  V  A  M  H  I  L 1 
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 gtgaacgttgcgatgcatattttg 
88 
 
V  N  V  G  V  I  L  R 
gtgaacgttggggtgattctgcgt 
1 
23 
 
S  G  Y  L  G  K  S  T 
gtcngggtatcttggnaaatcaacc 
1 
30 
 
V  N  P  G  L  I  L  T 
gtgaaccctgggctgattttgacc 
1 
91 
 
V  N  V  G  L  I  L  L 
gtgaacgttggtttgattctgctg 
1 
 
Table 3.3. Mel-5 TCR variants selected from the CDR3  libraries. Sequences are 
grouped according to frequency. Nucleotides marked with an “n” and the 
corresponding amino acid residue marked with an “X” are unknown because the DNA 
sample is mixed and contains more than one DNA template. Amino acids that differ 
from wild-type are highlighted in red. Blue lettering indicates alternative codon usage 
compared to the parental sequence. International Immunogenetics (IMGT) 
nomenclature (Lefranc, Giudicelli et al. 1999). 
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3.3.4 Inhibition and specificity phage ELISA  
Sequence analysis of the 33 Mel-5 TCR CDR3  variants guided the selection of ten 
unique clones to further characterise in an inhibition ELISA at two concentrations of 
inhibitor (5 nM and 50 nM) (Table 3.4). A new batch of phage was produced for each 
of the 10 clones from the E. coli TG1 glycerol stock master-plate prepared in section 
3.3.1.  
Of the ten clones analysed, only clone 89 failed to show any detectable binding to 
HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) despite having demonstrated 
binding in the previous ELISA (Table 3.3).  
Whilst several of the clones demonstrated a high level of inhibition at both 
concentrations of inhibitor, the clones could not be accurately ranked according by 
affinity because the level of displayed TCR varied amongst the clones. For example, 
the % inhibition values would imply that clone 59 was the highest affinity clone and 
clone 51 the lowest. However, this assumption would be erroneous because the level 
of TCR display for clone 51 (inferred from absorbance 650 nm values) is ~8-fold 
higher than for clone 59.  
In the same experiment, the ten clones were analysed for specificity against a panel 
of three non-cognate peptide HLA-A*0201 complexes: MUC-1(167-175) 
(ALGSTAPPV), HIV GAG(77-85) (SLYNTVATL) and NY-ESO(157-165) 
(SLLMWITQC) (Figure 3.9). All clones maintained specificity for HLA-A*0201-
Melan-A/MART-1(26-35) (ELAGIGILTV); no detectable binding to the three non-
cognate peptide HLA-A*0201 molecules was observed.  
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Clone 
number 
Abs @    
650 nm 
+ 0 nM 
inhib. 
Abs @    
650 nm  
+ 50 nM  
inhib. 
% Inhib. 
@ 50 nM 
Abs @      
650 nm       
+ 5 nM 
inhib. 
% Inhib.  
@ 5 nM 
3 0.286 0.036 87 0.215 25 
9 0.172 0.039 77 0.108 37 
17 1.050 0.317 70 0.878 16 
29 0.176 0.056 68 0.131 26 
42 0.859 0.291 66 0.775 10 
51 0.969 0.355 63 0.789 19 
59 0.127 0.012 91 0.058 54 
88 0.295 0.050 83 0.258 13 
89 -0.002 0.003 nd 0.001 nd 
91 0.123 0.021 83 0.114 7 
 
Table 3.4. Inhibition phage ELISA of Mel-5 TCR CDR3  variants at a 
concentration of 50 nM and 5 nM inhibitor. The phage supernatant was incubated 
with the appropriate concentration of non-biotinylated-HLA-A*0201-Melan-
A/MART-1(26-35) (ELAGIGILTV) prior to adding to ELISA plates immobilised with 
HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV). % Inhib. is measured as the 
percentage reduction in ELISA signal. The background absorbance value was 
subtracted from all readings before % Inhib. calculated. nd, not determined. 
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Figure 3.9. Specificity phage ELISA screen of Mel-5 TCR CDR3  variants. 
Specificity analysis against cognate pHLA: HLA-A*0201-Melan-A/MART-1(26-35) 
(ELAGIGILTV) and non-cognate pHLA: HLA-A*0201-MUC-1(167-175) 
(ALGSTAPPV), HLA-A*0201-HIV GAG(77-85) (SLYNTVATL)  and HLA-A*0201-
NY-ESO(157-165) (SLLMWITQC). The background value is indicated with a red dotted 
line.  
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3.4 Characterisation of first generation Mel-5 TCRs 
3.4.1 Soluble expression of Mel-5 TCRs 
The nine Mel-5 CDR3  mutated TCRs that showed specific binding to HLA-
A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) (Figure 3.9) were cloned into the 
expression plasmid pGMT7 for expression in E. coli strain BL21 (DE3) pLysS as 
described in Section 3.6.3 of Materials and Methods. The nine TCR mutants were 
renamed for the subsequent E. coli expression work: clone 42 = MELa1; clone 51 = 
MELa2; clone 29 = MELa3; clone 9 = MELa4; clone 17 = MELa5; clone 3 = MELa6; 
clone 88 = MELa7; clone 59 = MELa8; clone 91 = MELa9.  
The E. coli TG1 glycerol stock 96-well master-plate for the Mel-5 TCR CDR3  
Pan 3 output (from Section 3.3.1) was used as the template to PCR amplify the nine 
mutated V  domains. The primers TRAV12-2 and SalI Rev (Section 2.6.3 of 
Materials and Methods) were used to amplify the complete TCR V  domain together 
with the first 20 amino acid residues of the TCR C  (TRAC*01) domain. All PCR 
products were resolved on a 1.5% (w/v) agarose gel. The desired ~380 bp fragment 
was gel-purified and digested with restriction enzymes ClaI and SalI. Digested V  
domains were ligated into a modified version of pGMT7 (pEX954) containing a 
complete ds-bond engineered TCR C  (TRAC*01) domain. Following transformation 
of chemically-competent E. coli XL1-Blue cells, DNA from three ampicillin-resistant 
colonies was isolated and the DNA sequenced with the T7 primer (Section 2.6.3 of 
Materials and Methods).  
A sequence-verified clone for each of MEL1a-MEL9a, containing a full-length 
V /C  TCR chain, was transformed into chemically-competent E. coli BL21 (DE3) 
pLysS cells. The wild-type Mel-5 TCR  chain containing a ds-bond engineered TCR 
C  (TRBC*01) domain was cloned separately into pGMT7 (pG176) and transformed 
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into E. coli BL21 (DE3) pLysS cells. One litre cultures were set up for each of the 
nine mutated Mel-5 TCR  chains and the Mel-5 wild-type TCR  chain (bwt) 
(Section 2.6.4 of Materials and Methods). Following induction with IPTG, the 
cultures were pelleted and inclusion bodies (IBs) were prepared as described in 
Section 2.6.5 of Materials and Methods. Soluble TCR was refolded by rapid dilution 
in a refold buffer containing 5 M urea and 0.4 M L-arginine and a redox pair (Section 
2.6.8 of Materials and Methods). After dialysing against deionised water and then 10 
mM Tris pH 8.1, samples were loaded onto a POROS 50HQ column. A salt gradient 
was applied to the column to elute the TCR. Refolded TCR was further purified by 
gel-filtration on a Superdex 75PG 26/60 column (Section 2.6.8 of Materials and 
Methods). Purified Mel-5 TCR was analysed by Coomassie stained SDS PAGE under 
reducing and non-reducing conditions. 
 
3.4.2 Kinetic analysis of Mel-5 TCRs 
Surface plasmon resonance (SPR) studies with BIAcore provided quantitative 
measures of TCR-pHLA binding and dissociation kinetics as described in Section 2.7 
of Materials and Methods. Table 3.5 provides the kinetic values of parental and 
affinity-matured TCRs. Briefly, biotinylated pHLA-A*0201-Melan-A/MART-1(26-35) 
monomer was immobilised onto streptavidin-coupled CM-5 sensor chips up to 200 
response units (RU) and biotin-blocked. TCRs were analysed using a single injection 
of TCR (in kinetic conditions) at a concentration ten-fold higher than the predicted KD 
as described in Section 2.7 of Materials and Methods. 
Each of the Mel-5 TCR CDR3  mutants was improved in affinity for HLA-
A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) (Table 3.5 A). The KD values for 
the mutants ranged from 6.4 nM to 120 nM with half-life values of between 1.8 and 
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4.9 minutes. The highest affinity clone, MELa1bwt was improved ~2800-fold in 
affinity above the wild-type TCR (MELawtbwt). Retention of the wild-type Gly at 
position 95 in the highest affinity clones may be required to allow the CDR3  loop to 
adopt a conformation necessary for improved binding to cognate pHLA.    
Having selected on the common heteroclitic 10mer Melan-A/MART-1(26-35) 
peptide (ELAGIGILTV), I next tested whether binding to the wild-type peptide was 
maintained. Although the heteroclitic 10mer peptide was used in phage selections, a 
wild-type 9mer Melan-A/MART-1(27-35) peptide (AAGIGILTV), demonstrated that 
the binding affinity of the high affinity TCR (MELa1bwt) was largely unaffected; the 
calculated KD was 6.4 nM for the heteroclitic peptide versus 7.8 nM for the wild-type 
peptide (Table 3.5 B).  
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A. 
 
Clone ID TCR F2 CDR3 (V93-T98) Freq Kon (M
-1
 s
-1
) Koff (s
-1
) 
KD  
(nM) 
T1/2  
(min) 
KD (parent) 
KD (mutant) 
MELawtbwt IMF VAGKST - nd nd 18000 nd 1 
MELa1bwt IIF DGGRLT 5 5.08 x 10
5
 3.26 x 10
-3
 6.4 3.5 2812.5 
MELa2bwt IMF VGGYLL 3 5.01 x 10
5
 6.07 x 10
-3
 12 1.9 1500 
MELa3bwt IMF PGGVLT 1 3.18 x 10
5
 6.58 x 10
-3
 21 1.8 857.1 
MELa4bwt IMF PGGLLT 3 2.58 x 10
5
 5.72 x 10
-3
 22 2.0 818.2 
MELa5bwt IMF SGNHMT 5 2.20 x 10
5
 5.08 x 10
-3
 23 2.3 782.6 
MELa6bwt IMF LSPGLT 3 1.05 x 10
5
 2.38 x 10
-3
 23 4.9 782.6 
MELa7bwt IMF VGVILR 1 1.66 x 10
5
 4.49 x 10
-3
 27 2.6 666.7 
MELa8bwt IMF NGMPST 2 5.61 x 10
5
 4.36 x 10
-3
 77 2.6 233.8 
MELa9bwt IMF VGLILL 1 3.82 x 10
4
 4.57 x 10
-3
 120 2.5 150 
 
 
B. 
 
 
 
 
Table 3.5. Binding kinetics of Mel-5 TCR CDR3  mutants from first generation affinity enhancement. (A). Binding kinetics of 
MELa1bwt-MELa9bwt TCRs were measured by SPR on a BIAcore T100. HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) was 
immobilised on the biosensor chip. Control response values to a non-cognate pHLA: HLA-A*0201-hTERT(540-548) were subtracted from each 
reading prior to analysis. The ratio of KD values indicates the fold increase in binding affinity as compared to the wild-type (parent), Mel-5 TCR. 
Red lettering indicates residues mutated from the parental sequence. TCR F2, = TCR  framework 2. Freq, = number of repeated sequences 
within the population of clones analysed. nd, not determined. (B). Binding affinity of MELa1bwt to the 10mer heteroclitic Melan-A/MART-1(26-
35) (ELAGIGILTV) peptide was compared to the 9mer wild-type Melan-A/MART-1(27-35) (AAGIGILTV) peptide by SPR. International 
Immunogenetics (IMGT) nomenclature (Lefranc, Giudicelli et al. 1999). (Data kindly provided by Dr. E. Baston). 
 
 
Melan-A/MART-1(26-35) (AAGIGILTV) Melan-A/MART-1(27-35) ( ELAGIGILTV ) 
Kon (M
-1
 s
-1
) Koff (s
-1
) 
KD 
(nM) 
T1/2 
(sec) 
Kon (M
-1
 s
-1
) Koff (s
-1
) 
KD 
(nM) 
T1/2 
(sec) 
MELa1bwt 4.68 x 10
5
 3.65 x 10
-3
   7.8  190 7.31 x 10
4
 1.16 x 10
-2
   6.4  59 
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3.5 Generating Mel-5 TCR template for second generation libraries 
Mel-5 TCR CDR3  clones with affinities up to 6.4 nM (MELa1bwt) were isolated 
from the first round selection libraries. In an effort to generate Mel-5 TCR mutants 
with sub-nanomolar affinity, additional mutated TCR libraries required construction. 
Engineering antibodies for high affinity through a CDR-walking approach has proved 
highly successful (Yang, Green et al. 1995; Schier, McCall et al. 1996; Pavoni, Flego 
et al. 2006). It was therefore hypothesised that whilst only CDR3  mutated clones 
were isolated using the wild-type Mel-5 TCR as template, building libraries on an 
enhanced-affinity clone might lead to the isolation of mutations in other CDR loops. 
The highest affinity clone (MELa1) from the first generation libraries was chosen 
as one of the two templates on which to introduce further mutations. Because it was 
unknown which would be the optimal affinity clone to use as a framework on which 
to build further mutagenic libraries, a clone exhibiting a KD in the high nanomolar 
range was sought. Unfortunately, such a clone was not isolated from the CDR3  
library Pan 3 output.  
To identify a clone possessing optimal binding kinetics, a panel of four templates 
were generated by back-mutating, to wild-type, each residue in the MELa1 CDR3  
motif that differed from the parent clone. In this way, it was possible to examine the 
role that the individual CDR3  residues play in the interactions with HLA-A*0201-
Melan-A/MART-1(26-35). The MELa1 motif is: DGGRL and the panel of back-mutants 
include: MELa1a, VGGRL; MELa1b, DAGRL; MELa1c, DGGKL and MELa1d, 
DGGRS (the back-mutated wild-type residue is underlined).  
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3.5.1 Cloning and refolding of back-mutated MELa1 TCRs 
Using the pGMT7:MELa1 E. coli expression plasmid (Section 3.5) as template and 
four pairs of complimentary primers (Section 2.6.3 of Materials and Methods) to 
reintroduce the desired wild-type residue, the four E. coli expression plasmids 
MELa1a, MELa1b, MELa1c and MELa1d were generated. Sequence analysis 
confirmed the desired CDR3  motif of each clone.  
E. coli BL21 (DE3) pLysS cells were transformed with each of the four CDR3  
back-mutated constructs, protein expression was induced with IPTG and inclusion 
bodies purified as described in Section 2.6.4 and 2.6.5 of Materials and Methods. 
Purified IBs were analysed by SDS-PAGE as described in Section 2.6.6 of Materials 
and Methods (Figure 3.10). An over-expressed protein corresponding to the Mel-5 
TCR  chain (MELa1a-MELa1d) was seen at the expected molecular weight of ~23 
kilodaltons (kDa).  
 
 
 
Figure 3.10. Coomassie-stained reducing SDS PAGE analysis of MELa1 back-
mutated inclusion bodies. Lane 1, Bio-Rad Molecular Weight Marker (MWM) 
kilodaltons; lane 2, no sample; lane 3, MELa1a 5 l; lane 4, MELa1a 10 l; lane 5, 
MELa1b 5 l; lane 6, MELa1b 10 l; lane 7, MELa1c 5 l; lane 8, MELa1c 10 l; 
lane 9, MELa1d 5 l; lane 10, MELa1d 10 l. 
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Each of the back-mutated  chains was refolded with the wild-type Mel-5 TCR  
chain as described in Section 2.6.8 of Materials and Methods and each of the four 
TCR refolds was subjected to anion exchange chromatography followed by gel-
filtration chromatography. The chromatography profiles for each of the TCRs 
followed a similar pattern (data not shown). Purification of the four TCRs is 
exemplified by TCR MELa1abwt. MELa1abwt was purified by anion exchange 
chromatography on a POROS 50HQ column (Figure 3.11 A). A salt gradient was 
applied to the column to elute the TCR in 1 ml fractions. Three peaks of eluted 
protein were collected (P1, P2 and P3). The disulphide-linked TCR (dsTCR) elutes at 
a known conductivity and it was therefore predicted that peak 3 (P3) contained the 
refolded TCR. Three eluted fractions from P3 (fraction, Fr. 1, 2 and 3) were analysed 
by Coomassie stained SDS PAGE under non-reducing (Figure 3.11 B) and reducing 
conditions (Figure 3.11 C). A single band of ~45 kDa corresponding to the dsTCR 
can be seen (Figure 3.11 B) which upon reduction runs as separate  and  chains of 
~23 kDa and ~28 kDa respectively (Figure 3.11 C). The fraction containing the most 
protein (Fr. 2) was further purified by gel-filtration on a Superdex 75PG 26/60 (S75) 
column equilibrated with HEPES-buffered-saline-EP (HBS-EP) solution. A slight 
shoulder of aggregated protein can be seen at an elution volume between 8 and 10 ml. 
Four 0.5 ml peak fractions (Fr. 1, 2, 3 and 4) were collected (Figure 3.12 A). Each 
fraction was analysed by Coomassie stained SDS PAGE under non-reducing (Figure 
3.12 B) and reducing conditions (Figure 3.12 C) revealing high purity of TCR.  
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Figure 3.11. Purification of MELa1a by anion exchange chromatography. (A). 
Elution profile of MELa1abwt from Poros HQ column (highlighted in blue). Salt 
gradient shown in red. Absorbance at 280 nm converted into mAu (left Y-axis). Salt 
gradient converted into conductivity, mS/cm (right Y-axis). (B). Coomassie-stained 
SDS PAGE analysis of peak 3 (P3) fractions (Fr.) 1, 2 and 3 non-reducing. (C). 
Reducing. The lane order is the same for both gels. Lane 1, BioRad MWM (kDa); 
lane 2, fraction 1; lane 3, fraction 2; lane 4, fraction 3.  and  chains are highlighted. 
dsTCR, disulphide-linked TCR. 
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Figure 3.12. Purification of MELa1abwt by gel-filtration chromatography. (A). 
Superdex 75 profile. Collected fractions 1-4 are highlighted. Absorbance at 280 nm 
converted into mAu. (B). Coomassie-stained SDS PAGE analysis fractions (Fr.) 1, 2, 
3 and 4 under non-reducing conditions. (C). Coomassie-stained SDS PAGE analysis 
fractions 1, 2, 3 and 4 under reducing conditions. The lane order is the same for both 
gels. Lane 1, BioRad MWM (kDa); lane 2, no sample; lane 3, fraction 1; lane 4, 
fraction 2; lane 5, fraction 3; lane 6, fraction 4.  and  chains are highlighted. 
dsTCR, disulphide-linked TCR. 
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3.5.2 Kinetic analysis of back-mutated MELa1 TCRs   
Dissociation rate (KD) constants for the four MELa1 back-mutated TCRs binding to 
HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) were determined by SPR 
analysis on a BIAcore 3000 as outlined in Section 2.7 of Materials and Methods. 
Briefly, a separate streptavidin-coupled flow cells of a CM-5 sensor chip were coated 
with up to 1000 RU of HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) and 
HLA-A*0201-PSCA(14-22) (ALQPGTALL). The non-cognate antigen, HLA-A*0201-
PSCA(14-22), was used to control for non-specific binding. S75 fractions 2, 3 and 4 
were pooled (~1.5 ml volume) for each TCR and concentrated to ~0.1 ml in a YM-10 
spin column. The concentration of each TCR was calculated: MELa1abwt, 1.93 
mg/ml (58.88 M); MELa1bbwt, 2.65 mg/ml (80.85 M); MELa1cbwt, 2.87 mg/ml 
(87.56 M) and MELa1dbwt, 1.90 mg/ml (57.97 M). A ten-point serial dilution of 
each TCR was flowed over both pHLA complexes and the RU value at each 
concentration was measured. RU values for non-specific binding to HLA-A*0201-
PSCA(14-22) were subtracted from RU values for specific binding to HLA-A*0201-
Melan-A/MART-1(26-35). Equilibrium binding constants were calculated by plotting 
the RU values for specific binding against the protein concentrations using a least-
squares fit to the Langmuir equation, assuming a 1:1 interaction (Figure 3.13).  
Substituting each of the mutated residues in the MELa1 clone for the 
corresponding wild-type residue in the parent clone had a dramatic effect on the 
binding affinity for HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV). The 
binding affinity of MELa1 was reduced up to ~900-fold. By serendipity, the panel of 
back-mutated TCRs exhibited the desired binding kinetics suitable to use as templates 
for second generation libraries: MELa1a, 2.36 M; MELa1b, 5.9 M; MELa1c, 0.45 
M and MELa1d, 1.5 M.  
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Figure 3.13. Equilibrium-binding analysis of MELa1 back-mutants at 25°C. 
Serial dilutions of soluble TCR were flowed over CM-5 biosensor chips coated with 
~1000 RUs of cognate and non-cognate pHLA complexes. RU values at each TCR 
concentration were measured. Using a non-linear curve fitting equation the 
equilibrium KD of each TCR for HLA-A*0201-Melan-A/MART-1(26-35) 
(ELAGIGILTV) was calculated. (A). MELa1abwt (VGGRL). (B). MELa1bbwt 
(DAGRL). (C). MELa1cbwt (DGGKL). (D). MELa1dbwt (DGGRS).  
 
 
 
 
 
 
KD = 2.36 M ± 0.01 KD = 5.9 M ± 0.35 
KD = 0.45 M ± 0.02 KD = 1.5 M ± 0.06 
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3.6 Design and construction of second generation libraries 
Two clones were chosen as templates for further mutagenesis: one isolated directly 
from the first generation libraries (MELa1) and the second, a modified version of this 
clone (MELa1c), which exhibited binding affinities against HLA-A*0201-Melan-
A/MART-1(26-35) (ELAGIGILTV) of 6.4 nM and 450 nM respectively. 
 
3.6.1 Cloning the Mela1c TCR into the phagemid vector 
The phagemid vector encoding the MELa1 CDR3  mutant already existed in the 
phagemid vector and was designated pG396. The MELa1c mutant was cloned into the 
phagemid vector, pG125, by SOE-PCR as described in Section 2.3.1 of Materials and 
Methods. Fragment A, encoding the mutated MELa1c CDR3  motif was amplified 
from the E. coli expression plasmid, pG246 (pGMT7 containing the MELa1c  chain) 
with primers Nat22 and YOL237. Fragments B, C and D were prepared previously for 
cloning the Mel-5 wild-type TCR (Section 3.2). The final SOE-PCR product was 
ligated into pG125 and designated pG397. 
 
3.6.2 Generating DNA libraries 
Second generation libraries were constructed by SOE-PCR following the strategy 
used to build the first generation libraries (Section 2.4.1 of Materials and Methods). 
Several of the primers used to construct the first generation libraries were used to 
build second generation libraries. However, additional NNK oligonucleotides were 
designed to ensure more comprehensive coverage across particular CDRs; one more 
for each of CDR1 , CDR1  and CDR2  and two extra for CDR3  (Figure 2.2 of 
Materials and Methods). The NNK-mutagenised CDRs were cloned onto both the 
MELa1 (pG396, KD 6.4 nM) and MELa1c (pG397, KD 450 nM) frameworks. The 
CDR1  and CDR2  libraries were constructed by SOE-PCR using either phagemid 
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vector pG396 or pG397 as template to introduce the mutated CDR3  motif (MELa1 
or MELa1c) into the PCR splice product and were cloned as SfiI fragments into 
pG125. The CDR1 , CDR2  and CDR3  libraries were built by SOE-PCR using 
pG125 as template and were cloned as BssHII-NotI fragments into both pG396 and 
pG397.  
The gel-purified digested and  chain fragments used in the ligation reactions are 
shown in Figure 3.14. In Figure 3.14 A, a single band of ~650 bp can be observed that 
corresponds to the SfiI digested  chain fragments. PCR fragments amplified from 
pG396 are distinguished from fragments amplified from pG397 using the designated 
nomenclature a or à respectively. Additionally, a single band (~6.2 kbp) can be seen 
for the linearised phagemid vector pG125. In Figure 3.14 B and 3.14 C, a single band 
of ~750 bp can be observed corresponding to the BssHII-NotI digested  chain 
fragments together with digested phagemid vectors pG396 (Figure 3.14 B) and pG397 
(Figure 3.14 C).     
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A. 
 
 
B. 
 
 
C. 
 
 
Figure 3.14. Agarose gel photo of gel-purified digested Mel-5 TCR SOE-PCR 
second generation library fragments and phagemid vectors. (A).  chain library 
PCRs digested with SfiI. Lane 1, HYP I; lane 2, phagemid vector pG125; lane 3, PCR 
a3; lane 4, PCR a6; lane 5, PCR a6; lane 6, PCR à3; lane 7, PCR à6; lane 8, PCR à6; 
lane 9, a9; lane 10, PCR a9; lane 11, PCR à9; lane 12, PCR à9. Fragments generated 
using pG396 as template are shown as “a” and fragments generated using pG397 as 
template are shown as “à”. (B).  chain library PCRs digested with BssHII-NotI. Lane 
1, HYP I; lane 2, phagemid vector pG396; lane 3, PCR b3; lane 4, PCR b6; lane 5, 
PCR b9; lane 6, PCR b12; lane 7, PCR b15; lane 8, PCR b18; lane 9, b21; lane 10, 
PCR b24; lane 11, PCR b27; lane 12, PCR b30. (C).  chain library PCRs digested 
with BssHII-NotI. Lane 1, HYP I; lane 2, phagemid vector pG397; lane 3, PCR b3; 
lane 4, PCR b6; lane 5, PCR b9; lane 6, PCR b12; lane 7, PCR b15; lane 8, PCR b18; 
lane 9, b21; lane 10, PCR b24; lane 11, PCR b27; lane 12, PCR b30. 
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3.6.3 Generating bacterial libraries 
Electrocompetent E. coli TG1 cells were transformed with 200-300 ng of each of the 
ten ligated DNA products (Section 2.4.1.4 of Materials and Methods) to yield libraries 
containing 1 to 3 x 10
8
 TCR clones. Sequence analysis of random clones from each 
electroporation revealed that ligations 5, 6 and 9 (  chain libraries built on the MELa1 
framework) contained a high level of MELa1 template contamination (sequence data 
not shown). Isolation of high affinity clone MELa1 from the first generation libraries 
indicates the fitness of this TCR in terms of its ability to be displayed on the surface 
of phage. Library contamination with such a clone could compromise the enrichment 
for higher affinity clones. Libraries comprising ligations 5, 6 and 9 were therefore 
discarded.  
The potential for contamination of phage display libraries with parental template 
DNA requires consideration. Contamination can originate from a variety of sources. 
First, bacterial plasmid DNA can be co-purified with the initial PCR fragments and 
provide a source of template for PCR amplification. This source of contamination can 
be reduced by using DpnI endonuclease to specifically digest methylated bacterial 
double-stranded DNA. Second, excessive PCR extension times in the cycling 
reaction. In the Mel-5 TCR library strategy, the initial two PCR fragments are 
generated with one of the two stitch flanking primers. If the PCR extension times are 
too long, the PCR product will be extended to include the second stitch flanking 
priming site. In the subsequent stitch reaction, that includes both external primers, 
amplification of parental DNA is possible.   
The four libraries taken forward into the panning experiments are shown in Section 
2.4.1.4 of Materials and Methods. Each of these libraries contained sufficient 
diversity across each of the CDRs, as assessed by sequence analysis (data not shown).  
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3.7 Phage selections and screening 
The methods used for the selection and screening of high affinity binders were based 
on those described in Section 3.3 with several modifications. In an effort to isolate 
mutants with improved affinity exceeding that of the first generation clone, more 
stringent selection conditions were adopted.  
Following one cycle of panning with 100 nM HLA-A*0201-Melan-A/MART-1(26-
35) complexes, the concentration of HLA antigen was lowered 2-fold (50 nM) for Pan 
2 and a further 5-fold (10 nM) for Pan 3. For the affinity maturation of antibodies it 
has been demonstrated that reduction of the antigen concentration helps ensure that 
selection for higher affinity scFv occurs, rather than selection for scFv that express 
well on phage or are less toxic to E. coli (Hawkins, Russell et al. 1992; Schier, 
McCall et al. 1996).  
Additionally, off-rate selection was performed during the final two cycles of 
panning as described in Section 2.5.4 of Materials and Methods. In off-rate selection 
clones with lower affinity will dissociate from the bead:pHLA complexes quicker 
than clones with a reduced off-rate. Thus lower affinity clones will be sequestered by 
the excess of non-biotinylated pHLA in solution enriching for higher affinity clones 
retained bound to the beads. The off-rate method involved incubating the phage 
clones with biotinylated pHLA under equilibrium conditions, followed by washing 
and incubation with a 10-fold (in Pan 2) or 100-fold (in Pan 3) excess of non-
biotinylated pHLA.  
The phage:pHLA complexes were rescued with 50 l of streptavidin-coated 
paramagnetic beads. The washing and elution conditions were as described in section 
3.4. Eluted phage was used to infect early log phase TG1 cells prior to plating on YTE 
agar containing 100 g/ml ampicillin and 2%  glucose. Overnight incubation at 30°C 
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completed one cycle of selection. A total of three cycles of panning against 
biotinylated HLA-A*0201-Melan-A/MART-1(26-35) complexes were performed.  
 
3.7.1 Characterisation of phage clones: phage ELISA and sequencing  
Following the third cycle of panning, ninety-three monoclonal phage TCRs from each 
of the four libraries were screened for binding to immobilised biotinylated HLA-
A*0201-Melan-A/MART-1(26-35) complexes. Affinity ranking of the binders was 
determined by incubating the phage supernatant with 5 nM (for library 1) or 10 nM 
(for library 2, 3 and 4) non-biotinylated-HLA-A*0201-Melan-A/MART-1(26-35) 
complexes at room temperature for 1 h prior to adding to HLA-A*0201-Melan-A-
coated plates. Figure 3.15 provides an example inhibition phage ELISA plate from the 
Pan 3 output for library 4 (CDR3  built on MELa1c). Monoclonal phage TCRs for 
both MELa1bwt (KD 6.4 nM) and MELa1cbwt (KD 450 nM) were prepared in the 
same 96-well format to allow direct comparison of improvements in affinity over 
these clones (Figure 3.15). The % inhibition value at 10 nM inhibitor was ~90% and 
~40% for MELa1bwt and MELa1cbwt respectively. The % inhibition value at 5 nM 
inhibitor was ~50-60% for MELa1bwt (MELa1c was not tested at 5 nM inhibitor).  
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Figure 3.15. Representative inhibition phage ELISA at a concentration of 10 nM 
inhibitor. Data shown is for 46 individual clones from library 4 (CDR3  built on 
MELa1c). The remaining 47 phage-TCR clones were assayed on a second ELISA 
plate (data not shown). The phage supernatant was incubated with 10 nM non-
biotinylated-HLA-A*0201-Melan-A/MART-1(26-35) (ELAGIGILTV) for 1 h prior to 
adding to ELISA plates immobilised with HLA-A*0201-Melan-A/MART-1(26-35) 
(ELAGIGILTV). The ELISA signal for MELa1bwt and MELa1cbwt TCRs are 
highlighted in red. The % inhibition value at 10 nM inhibitor for these TCRs was 
~90% and ~40% respectively. 
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A selection of antigen-binding clones were further analysed by DNA sequencing of 
the CDR genes (Table 3.6). It should be noted that binders from library 2 showed no 
inhibition at 5 nM inhibitor and were therefore not sequenced. Sequence analysis of 
twenty-two binders from library 1 that gave the highest % inhibition in ELISA signal 
showed that 36% (8 out of 22) was the parental clone (MELa1) (Table 3.6 A). 
Enrichment for this clone that had been isolated from the first generation libraries, 
clearly illustrated an inherent fitness in terms of affinity and expression. As such, it 
was not surprising to see this level of background binding in the Pan 3 output. Despite 
these concerns, however, a number of unique sequences were isolated. Library 1 (a 
mixture of mutated CDR1  and CDR2  segments) was dominated by CDR1  
mutants; 11 sequenced clones converged to 8 variants. Residues at particular positions 
were preferred: Asp
27
 was frequently substituted for a hydrophobic aromatic residue, 
predominantly Phe; the wild-type residues at position Gly
29
, Ser
30
 and Gln
31
 were 
frequently retained (~92%, ~70% and 100% of the sequenced clones). Of the 14 
sequenced clones 9 contained an amber stop codon, suppressible to Gln. A single 
CDR2  variant was isolated from library 1 which retained a wild-type residue at 
position Tyr
51
. Clone MELa23 contains a non-targeted mutation, Tyr to His in alpha 
framework 3. From the % inhibition data it was difficult to assess any improvement in 
affinity over the background clone (MELa1); % inhibition for all variants was in a 
similar range and compared closely to MELa1. Without BIAcore data it was not 
possible to discriminate between the mutants and the parental clone.  
Sequence analysis of the library 3 output (Table 3.6 B) revealed a dramatic 
enrichment for a consensus CDR2  motif: a central Gly-Pro couplet flanked by a 
hydrophobic aromatic pair (Tyr, Phe or Trp). All selected clones contain a Leu to Pro 
substitution in beta framework 2. Clone MELb3 also contains a non-targeted 
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mutation, Val to Ala in beta framework 3. The % inhibition at 10 nM was greater for 
each of the mutants compared to the framework clone: 85-90% versus 60% for 
MELa1c. Although a single sequence dominated the output (MELb1), the % 
inhibition for all CDR2  mutants was measured within a narrow range (85-90%). If 
this comparable level of inhibition translates to similar binding affinities, it would 
indicate that enrichment for clone MELb1 is likely the result of improvements in 
expression in addition to affinity.  
Sequence analysis of twenty ELISA positive clones from library 4 (Table 3.6 C) 
showed that the output was comprised of mutants derived from two overlapping 
oligonucleotides (Nat241 and Nat36; Figure 2.2 of Materials and Methods) displaced 
by one codon: Group A, MELb10-MELb14 mutated at residue positions  Gly
99
Leu
103
 
and Group B, MELb5-MELb9 mutated at residue positions Thr
100
Phe
104
. Common to 
both groups a clear preference for a consensus motif can be observed: Glu
102
Leu
103
 
were substituted for a Gly-Trp pair in all sequenced clones. The wild-type residue at 
position Gly
101
 was retained in over half of the sequenced clones. In Group A, Thr
100
 
was substituted equally for a Met or Val. Position Phe
104
 was more permissive; five 
different residues were observed in this position. In Group B, Gly
99
 was substituted 
for Asn in all of the clones; Thr
100
 was substituted for a Thr, Leu or Val. Excluding 
clones MELb8 and MELb10 which contain non-targeted mutations in beta framework 
2 and beta framework 3 respectively, the % inhibition at 10 nM inhibitor is in the 
range of 70-80% compared to 60% for the parental clone (MELa1c). It is probable 
that the conserved central Gly-Trp pair is responsible for the apparent improvement in 
affinity over the base clone, MELa1c. 
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A.  
 
Clone 
Number 
CDR1 (D27-Q31) CDR2 (I50-N53) TCR F3 Freq 
% Inhib. 
@ 5 nM 
wt DRGSQ IYSN QYV - - 
MELa1 DRGSQ IYSN QYV 8 51-61 
MELa15 FQGSQ IYSN QYV 5 54-66 
MELa16 FLGSQ IYSN QYV 2 60 
MELa17 FQGAQ IYSN QYV 1 51 
MELa18 YQGAQ IYSN QYV 1 50 
MELa19 FQGSQ IYSN QYV 1 47 
MELa20 SIHAQ IYSN QYV 1 59 
MELa21 NLGSQ IYSN QYV 1 55 
MELa22 DFGAQ IYSN QYV 1 51 
MELa23 DRGSQ TYRE QHV 1 63 
 
 
B.  
 
Clone 
Number 
TCR F2 CDR2 (S50-I53) TCR F3 Freq 
% Inhib. 
@ 10 nM 
wt GLQ SVGI EVP - - 
MELa1c GLQ SVGI EVP - 60 
MELb1 GPQ YGPF EVP 16 85-90 
MELb2 GPQ FGPF EVP 3 85-90 
MELb3 GPQ FGPY EAP 4 85-90 
MELb4 GPQ WGPF EVP 1 85-90 
 
 
C.  
 
Clone 
Number 
TCR F2 CDR3 (G99-F104) TCR F3 Freq 
% Inhib. 
@ 10 nM 
wt GLQ GTGELF FIL - - 
MELa1c GLQ GTGELF FIL - 60 
MELb5 GLQ GMGGWQ FIL 3 80 
MELb6 GLQ GMGGWS FIL 1 78 
MELb7 GLQ GMGGWA FIL 1 79 
MELb8 GPQ GVGGWD FIL 1 82 
MELb9 GLQ GVGGWE FIL 3 80 
MELb10 GLQ NTSGWF FVL 2 83 
MELb11 GLQ NTNGWF FIL 1 83 
MELb12 GLQ NLGGWF FIL 3 79 
MELb13 GLQ NVSGWF FIL 4 75 
MELb14 GLQ NTTGWF FIL 1 73 
 
Table 3.6. Output clones obtained following three rounds of panning against 
biotinylated-HLA-A*0201-Melan-A/MART-1(26-35) complexes (100 nM in round 
1, followed by two subsequent cycles against 10 nM HLA). (A). Library 1: CDR1  
and CDR2  mutants on the MELa1bwt background. Clone MELa15 contains an 
amber codon (Q). Clone MELa23bwt has acquired a mutation in alpha framework 3 
(tyrosine to histidine). From soluble inhibition ELISA Library 1 clones showed 60-
63% inhibition compared to 56% for the background clone (MELa1) at 5 nM HLA-
A*0201-Melan-A/MART-1(26-35) complexes. (B). Library 3: CDR2  mutants on the 
MELa1cbwt background. All selected clones contain a leucine (L) to proline (P) 
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substitution in the beta framework 2. Clone MELb3 also contains a non-targeted 
mutation, valine (V) to alanine (A) in beta framework 3. (C). Library 4: CDR3  
mutants on the MELa1cbwt background. Clone MELb8 contains a non-targeted 
mutation, leucine (L) to proline (P) in beta framework 2. Clone MELb10 contains a 
non-targeted mutation, isoleucine (I) to valine (V) in beta framework 3.   From 
soluble inhibition ELISA library 3 and library 4 clones showed 75-89% inhibition 
compared to ~60% for the background clone (MELa1c) at 10 nM HLA-A*0201-
Melan-A/MART-1(26-35) complexes. Red lettering indicates residues mutated from the 
parental sequence. International Immunogenetics (IMGT) nomenclature (Lefranc, 
Giudicelli et al. 1999). 
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3.8 Characterisation of the second generation Mel-5 TCRs 
3.8.1 Soluble expression of Mel-5 TCRs 
PCR construction and ligation into the expression plasmid pGMT7 for expression in 
E. coli strain Rosetta (DE3) pLysS of 2  and 8  chain Mel-5 TCR mutants 
described in Table 3.9 was performed by Dr. A. Vuidepot and Dr. T. Mahon. The E. 
coli TG1 glycerol stock 96-well master-plates for the Mel-5 TCR Pan 3 output 
(Section 3.7.1) were used as the template to PCR amplify the two mutated V  
domains and eight mutated V  domains. Amber codons were replaced with Gln for 
TCR expression in the non-suppressor strain E. coli Rosetta (DE3) pLysS. The 
mutated V domains were amplified from the phagemid vector using primers 
TRAV12-2 and SalI Rev and cloned into pEX954 as ClaI-SalI fragments. The 
mutated V domains were amplified from the phagemid vector using primers 
TRBV30 and AgeI Rev and cloned as NdeI-AgeI fragments into  modified version of 
pGMT7 (pEX821) containing a complete wild-type TCR C  (TRBC*01) domain 
containing the introduced TCR chain stabilising mutation at position 57 (Ser to Cys 
substitution). To generate clone MELa24 the CDR1  segment from MELa16 was 
spliced onto the CDR2  region from MELa23 by SOE-PCR and cloned as a ClaI-SalI 
fragment into pEX954. To generate clone MELb15 the CDR2  segment from MELb1 
was spliced onto the CDR3  region from MELb5 by SOE-PCR and cloned as a  ClaI-
SalI fragment into pEX954. Similarly, MELb16 was generated by splicing the 
CDR2  segment from MELb4 onto the CDR3  region of MELb5 by SOE-PCR and 
cloned as an NdeI-AgeI fragment into pEX821. TCRs were refolded from purified 
inclusion bodies and purified as described in Section 2.6.4-2.6.8 of Materials and 
Methods. The goal of the affinity maturation of the Mel-5 TCR was to achieve the 
highest affinity clones from the pool of mutated CDR segments isolated from the 
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various phage libraries. Therefore, rather than refold the mutated  segments in the 
context of the chain with which they were isolated (MELa1c), mutated  chain CDR 
segments were refolded with the highest affinity  chain mutant (MELa1).  
 
3.8.2 Kinetic analysis of second generation Mel-5 TCRs 
Equilibrium binding constants were calculated from kinetic data following the 
methods outlined in Section 2.7 of Materials and Methods.  
Recruitment of CDR1  segments, MELa15 and MELa16 into the MELa1 clone 
yielded a modest 0.7 and 2-fold increase in affinity respectively (Table 3.7 A). This 
moderate improvement in affinity agreed with the phage inhibition ELISA data (Table 
3.8 A) that showed little if any difference in the % inhibition values between the 
mutants and MELa1. Whilst the affinity remained largely unchanged, up to a 5-fold 
reduction in off-rate was observed. Although addition of a CDR2  segment into the 
MELa1 clone resulted in a reduction in affinity (1.7-fold), the half-life of dissociation 
(T1/2) was increased by ~2-fold (Table 3.7 A) as a consequence of a reduced off-rate. 
This slight improvement in T1/2 may contribute to further increases in affinity when 
combined with other CDR segments.  
Recruitment of CDR2  segments into the MELa1 clone resulted in increases in 
affinity of between ~8 and 15-fold (Table 3.7 B). The highly conserved sequence of 
the mutants was reflected in almost identical binding kinetics. The mutated CDR2  
segment, MELb1, dominated the Pan 3 phage output (67% of sequenced clones) 
(Table 3.6 B) and although this enrichment conferred the highest affinity of all the 
mutants from this library, the difference was marginal (up to 2.5-fold). Selection of 
this clone is probably a consequence of affinity and more importantly, favourable 
expression. Addition of the CDR3  segments conferred similar improvements in 
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affinity to that of the CDR2  regions. The CDR3  mutations reside in two groups 
separated by a single residue: Group A, targeted positions G99-L103 and Group B, 
positions T100-F104. Mutations within the Group B region of the CDR loop 
conferred greater increases in affinity (up to 4.8-fold increase).   
Combining the CDR1  region from MELa16 with the CDR2  region from 
MELa23 yielded clone MELa24 with a 4.9-fold and 13,846-fold improvement in 
affinity compared to MELa1 and the wild-type TCR respectively (Table 3.7 C). 
Combining the most optimal CDR segments isolated from first and second generation 
phage libraries into a single clone generated a TCR with significantly enhanced 
affinity compared to the wild-type molecule; 1.8 million-fold increase in affinity 
(Table 3.7 C).    
CDRs were independently optimised and then combined in a single clone. This 
step-wise approach proved highly successful in generating ultra-high affinity TCRs 
with extremely long half-lives (Figure 3.16 A and 3.16 B). Additivity of the CDR 
segments was demonstrated and is most clearly illustrated by T1/2 values calculated 
for alpha chain mutants (Figure 3.16 B). Combining the alpha chain CDRs 
incrementally increased the T1/2. The mean fold increase in T1/2 for the addition of two 
mutated CDRs was 2.85-fold and for the addition of a third CDR segment was 8.6-
fold. Inclusion of beta chain CDR segments in a combination of five mutated CDRs 
increased the T1/2 by 1423-fold (setting the T1/2 value for MELa1 at 1). The on-rates 
remained largely unchanged; up to 14-fold variation (Figure 3.16 D). 
Improvements in affinity are dominated by decreases in off-rate; up to 1000-fold 
slower off-rate for the highest affinity clone compared to MELa1 (Figure 3.16 C; 3  
= MELa1 and the highest affinity clones are labelled 1 2 3 2 3 ).  
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A. 
Clone ID CDR1  CDR2  CDR3  CDR2  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (MELa1bwt) 
KD (mutant) 
KD (parent) 
KD (mutant) 
MELawtbwt DRGSQ IYSNG VAGKS SVGI GTGELF nd nd 18000 nd - 1 
MELa1bwt DRGSQ IYSNG DGGRL SVGI GTGELF 5.08 x 10
5
 3.26 x 10
-3
 6.4 3.5 1 2813 
MELa15bwt FQGSQ IYSNG DGGRL SVGI GTGELF 2.00 x 10
5
 1.21 x 10
-3
 6.1 9.5 0.7 2951 
MELa16bwt FLGSQ IYSNG DGGRL SVGI GTGELF 2.00 x 10
5
 6.56 x 10
-4
 3.2 17.5 2 5625 
MELa23bwt DRGSQ TYREG DGGRL SVGI GTGELF 1.70 x 10
5
 1.80 x 10
-3
 10.6 6.4 -1.7 1698 
 
 
B. 
 
Clone ID CDR1  CDR2  CDR3  CDR2  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (MELa1bwt) 
KD (mutant) 
KD (parent) 
KD (mutant) 
MELawtbwt DRGSQ IYSN VAGKS SVGI GTGELF nd nd 18000 nd - 1 
MELa1bwt DRGSQ IYSN DGGRL SVGI GTGELF 5.08 x 10
5
 3.26 x 10
-3
 6.4 3.5 1 2813 
MELa1b1 DRGSQ IYSN DGGRL YGPF GTGELF 5.46 x 10
5
 2.30 x 10
-4
 0.42 50.2 15.2 42857 
MELa1b2 DRGSQ IYSN DGGRL FGPF GTGELF 3.92 x 10
5
 2.04 x 10
-4
 0.52 57 12.3 34615 
MELa1b3 DRGSQ IYSN DGGRL FGPY GTGELF 2.69 x 10
5
 2.20 x 10
-4
 0.82 52.5 7.8 21951 
MELa1b4 DRGSQ IYSN DGGRL WGPF GTGELF 2.83 x 10
5
 1.73 x 10
-4
 0.61 66.7 10.5 29508 
MELa1b5 DRGSQ IYSN DGGRL SVGI GMGGWQ 3.87 x 10
5
 1.55 x 10
-4
 0.4 74 16 45000 
MELa1b9 DRGSQ IYSN DGGRL SVGI GVGGWE 3.63 x 10
5
 2.06 x 10
-4
 0.57 56 11.2 31579 
MELa1b12 DRGSQ IYSN DGGRL SVGI NLGGWF 1.14 x 10
5
 1.14 x 10
-4
 1 101 6.4 18000 
MELa1b13 DRGSQ IYSN DGGRL SVGI NVSGWF 8.40 x 10
4
 1.62 x 10
-4
 1.9 71 3.4 9474 
 
 
 
 
Chapter 3 
 219 
C. 
 
Clone ID CDR1  CDR2  CDR3  CDR2  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (MELa1bwt) 
KD (mutant) 
KD (parent) 
KD (mutant) 
MELawtbwt DRGSQ IYSN VAGKS SVGI GTGELF nd nd 18000 nd - 1 
MELa1bwt DRGSQ IYSN DGGRL SVGI GTGELF 5.08 x 10
5
 3.26 x 10
-3
 6.4 3.5 1 2813 
MELa24bwt FLGSQ TYRE DGGRL SVGI GTGELF 2.99 x 10
5
 3.85 x 10
-4
 1.3 30 4.9 13846 
MELa24b15 FLGSQ TYRE DGGRL YGPF GMGGWQ 2.85 x 10
5
 2.86 x 10
-6
 0.01 4020 640 1800000 
MELa24b16 FLGSQ TYRE DGGRL WGPF GMGGWQ 6.87 x 10
4
 1.94 x 10
-6
 0.028 5940 228.6 642857 
 
Table 3.7. Affinities and binding kinetics of Mel-5 TCR mutants isolated from second generation libraries. (A). Mutants isolated from 
CDR1  and CDR2  libraries built on the MELa1 framework. (B). Mutants isolated from CDR2  and CDR3  libraries built on the MELa1c 
framework were refolded with the highest affinity  chain MELa1. (C). Combination of the most optimal  and  chain CDR segments. The 
ratio of KD parent and mutant KD gives the overall improvement in affinity from the starting Mel-5 wild-type TCR. Kon and Koff were determined 
by SPR in a BIAcore using purified refolded TCR and KD calculated. nd, not determined. Q, Amber codon. (Data kindly provided by Dr. A. 
Vuidepot and Dr. T. Mahon).  
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Figure 3.16. Affinities and binding kinetics of Mel-5 TCR CDR segments isolated 
from first and second generation libraries. Mutated CDR regions were combined in 
a step-wise manner to enhance the binding affinity of the engineered Mel-5 TCR for 
HLA-A*0201-Melan-A/MART-1(26-35). (A). Equilibrium dissociation constant (KD). 
(B). Dissociation half-life (T1/2). (C). Association rate constant (Kon). (D). 
Dissociation rate constant (Koff).   
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4.1 Introduction 
This chapter further explores the sequential optimisation strategy that was 
successfully employed to affinity mature the Mel-5 TCR (Chapter 3). This type of 
CDR walking strategy, in which CDR segments are independently optimised and then 
recombined, is based on the assumption that non-interacting mutations will be 
additive (Wells 1990). Although this optimisation method has proved successful in 
antibody affinity maturation, the additive effects of enhanced-affinity antibody CDR 
segments are often unpredictable (Yang, Green et al. 1995; Chen, Wiesmann et al. 
1999). The aim of this chapter was to determine the generality of the CDR walking 
based method for the affinity maturation of TCRs.  
The focus of this chapter is the affinity maturation of the gp100 TCR that 
recognises the melanoma-specific epitope derived from HLA-A*0201-gp100280-288 
(Cox, Skipper et al. 1994). The gp100 TCR was isolated from a gp100-specific human 
CD8
+
 T-cell clone that recognizes the YLEPGPVTA peptide in complex with HLA-
A*0201 and was kindly provided by Cassian Yee (Fred Hutchinson Cancer Research 
Centre, Seattle WA, USA). The wild-type TCR  and  chains were expressed 
separately in E. coli and the TCR was refolded from inclusion bodies. The affinity of 
interaction against the wild-type peptide (YLEPGPVTA) and heteroclitic variant 
peptide (YLEPGPVTV) was determined as 26 M (Aleksic, Liddy et al. 2012; Liddy, 
Bossi et al. 2012) and 22 M respectively (unpublished). 
 
4.2 First-generation gp100 TCR affinity maturation phage libraries 
First-generation libraries were kindly provided by Dr. N. Harwood. The phagemid 
vector pG159 for the phage display of the gp100 TCR (specific for HLA-A*0201 in 
complex with the gp100(280-288) peptide) was constructed as described in section 3.2 
using V  and V  specific primers to amplify the wild-type gp100 TCR  and  
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chains. The templates used to generate the fragments were E. coli expression plasmids 
encoding the wild-type  and  chains. The gp100 TCR  chain V domain is encoded 
by TRAV17*01 and TRAJ29*01 gene segments. The  C region is encoded by 
TRAC*01 gene segment. The gp100 TCR  chain V domain is encoded by 
TRBV19*01, TRBJ2-7*01 and TRBD1*01 gene segments. The  C region is 
encoded by TRBC1*01 segments. In the final construct, the  and  chains contain 
the engineered ds cysteines (in the mTCR format). The 3’ end of the TCR  chain is 
fused in frame to the 5’ end of the bacteriophage M13 geneIII. The pelB and geneIII 
leader sequences are fused to the 5’ end of the  and  chains respectively as 
illustrated in Figure 3.4. The sequence of the wild-type gp100 TCR NcoI-NotI 
phagemid fragment is shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 224 
                     
             NcoI 
                             pelB leader gene                    ~~ 
  M  K  Y  L   L  P  T   A  A  A   G  L  L  L   L  A  A   Q  P  A 
       1 ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTCGCGGC CCAGCCGGCC 
 TACTTTATGG ATAACGGATG CCGTCGGCGA CCTAACAATA ATGAGCGCCG GGTCGGCCGG 
 
 NcoI 
 ~~~~ 
  M  A  S  Q   Q  G  E   E  D  P   Q  A  L  S   I  Q  E   G  E  N 
      61 ATGGCCAGTC AACAAGGAGA AGAAGATCCT CAGGCCTTGA GCATCCAGGA GGGTGAAAAT 
 TACCGGTCAG TTGTTCCTCT TCTTCTAGGA GTCCGGAACT CGTAGGTCCT CCCACTTTTA 
 
        CDR1  
  A  T  M  N   C  S  Y   K  T  S   I  N  N  L   Q  W  Y   R  Q  N 
     121 GCCACCATGA ACTGCAGTTA CAAAACTAGT ATAAACAATT TACAGTGGTA TAGACAAAAT 
 CGGTGGTACT TGACGTCAAT GTTTTGATCA TATTTGTTAA ATGTCACCAT ATCTGTTTTA 
 
           CDR2  
  S  G  R  G   L  V  H   L  I  L   I  R  S  N   E  R  E   K  H  S 
     181 TCAGGTAGAG GCCTTGTCCA CCTAATTTTA ATACGTTCAA ATGAAAGAGA GAAACACAGT 
 AGTCCATCTC CGGAACAGGT GGATTAAAAT TATGCAAGTT TACTTTCTCT CTTTGTGTCA 
 
  G  R  L  R   V  T  L   D  T  S   K  K  S  S   S  L  L   I  T  A 
     241 GGAAGATTAA GAGTCACGCT TGACACTTCC AAGAAAAGCA GTTCCTTGTT GATCACGGCT 
 CCTTCTAATT CTCAGTGCGA ACTGTGAAGG TTCTTTTCGT CAAGGAACAA CTAGTGCCGA 
 
                CDR3                                                  
  S  R  A  A   D  T  A   S  Y  F   C  A  T  D   G  D  T   P  L  V 
     301 TCCCGGGCAG CAGACACTGC TTCTTACTTC TGTGCTACGG ACGGAGACAC ACCTCTTGTC 
 AGGGCCCGTC GTCTGTGACG AAGAATGAAG ACACGATGCC TGCCTCTGTG TGGAGAACAG 
 
  F  G  K  G   T  R  L   S  V  I   A  N  I  Q   K  P  D   P  A  V 
     361 TTTGGAAAGG GCACAAGACT TTCTGTGATT GCAAATATCC AGAAGCCTGA CCCTGCCGTG 
 AAACCTTTCC CGTGTTCTGA AAGACACTAA CGTTTATAGG TCTTCGGACT GGGACGGCAC 
 
  Y  Q  L  R   D  S  K   S  S  D   K  S  V  C   L  F  T   D  F  D 
     421 TACCAGCTGA GAGACTCTAA GTCGAGTGAC AAGTCTGTCT GCCTATTCAC CGATTTTGAT 
 ATGGTCGACT CTCTGAGATT CAGCTCACTG TTCAGACAGA CGGATAAGTG GCTAAAACTA 
 
  S  Q  T  N   V  S  Q   S  K  D   S  D  V  Y   I  T  D   K  C  V 
     481 TCTCAAACAA ATGTGTCACA AAGTAAGGAT TCTGATGTGT ATATCACAGA CAAATGTGTG 
 AGAGTTTGTT TACACAGTGT TTCATTCCTA AGACTACACA TATAGTGTCT GTTTACACAC 
 
  L  D  M  R   S  M  D   F  K  S   N  S  A  V   A  W  S   N  K  S 
     541 CTAGACATGA GGTCTATGGA CTTCAAGAGC AACAGTGCTG TGGCCTGGAG CAACAAATCT 
 GATCTGTACT CCAGATACCT GAAGTTCTCG TTGTCACGAC ACCGGACCTC GTTGTTTAGA 
 
  D  F  A  C   A  N  A   F  N  N   S  I  I  P   E  D  T   F  F  P 
     601 GACTTTGCAT GTGCAAACGC CTTCAACAAC AGCATTATTC CAGAAGACAC CTTCTTCCCC 
 CTGAAACGTA CACGTTTGCG GAAGTTGTTG TCGTAATAAG GTCTTCTGTG GAAGAAGGGG 
 
  S  P  E  S   S  *  * 
     661 AGCCCAGAAA GTTCCTAATA ACCTAGGTTA ATTAAGAATT CTTTAAGAAG GGGATATACA 
 TCGGGTCTTT CAAGGATTAT TGGATCCAAT TAATTCTTAA GAAATTCTTC CCCTATATGT 
 
                            gIII leader gene 
   M  K  K   L  L  F  A   I  P  L   V  V  P   F  Y  S  H   S  A  Q  
     721 TATGAAAAAA TTATTATTCG CAATTCCTTT AGTTGTTCCT TTCTATTCTC ACAGCGCGCA 
 ATACTTTTTT AATAATAAGC GTTAAGGAAA TCAACAAGGA AAGATAAGAG TGTCGCGCGT 
 
 · D  G  G   I  T  Q  S   P  K  Y   L  F  R   K  E  G  Q   N  V  T  
     781 GGATGGTGGA ATCACTCAGT CCCCAAAGTA CCTGTTCAGA AAGGAAGGAC AGAATGTGAC 
 CCTACCACCT TAGTGAGTCA GGGGTTTCAT GGACAAGTCT TTCCTTCCTG TCTTACACTG 
 
         CDR1  
 · L  S  C   E  Q  N  L   N  H  D   A  M  Y   W  Y  R  Q   D  P  G  
     841 CCTGAGTTGT GAACAGAATT TGAACCACGA TGCCATGTAC TGGTACCGAC AGGACCCAGG 
 GGACTCAACA CTTGTCTTAA ACTTGGTGCT ACGGTACATG ACCATGGCTG TCCTGGGTCC 
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                             CDR2  
 · Q  G  L   R  L  I  Y   Y  S  Q   I  V  N   D  F  Q  K   G  D  I  
     901 GCAAGGGCTG AGATTGATCT ACTACTCACA GATAGTAAAT GACTTTCAGA AAGGAGATAT 
 CGTTCCCGAC TCTAACTAGA TGATGAGTGT CTATCATTTA CTGAAAGTCT TTCCTCTATA 
 
 · A  E  G   Y  S  V  S   R  E  K   K  E  S   F  P  L  T   V  T  S  
     961 AGCTGAAGGG TACAGCGTCT CTCGGGAGAA GAAGGAATCC TTTCCTCTCA CTGTGACATC 
 TCGACTTCCC ATGTCGCAGA GAGCCCTCTT CTTCCTTAGG AAAGGAGAGT GACACTGTAG 
 
                
                 CDR3  
 · A  Q  K   N  P  T  A   F  Y  L   C  A  S   S  I  G  G   P  Y  E  
    1021 GGCCCAAAAG AACCCGACAG CTTTCTATCT CTGTGCCAGT AGTATAGGGG GCCCCTACGA 
 CCGGGTTTTC TTGGGCTGTC GAAAGATAGA GACACGGTCA TCATATCCCC CGGGGATGCT 
 
 · Q  Y  F   G  P  G  T   R  L  T   V  T  E   D  L  K  N   V  F  P  
    1081 GCAGTACTTC GGGCCGGGCA CCAGGCTCAC GGTCACAGAG GACCTGAAAA ACGTGTTCCC 
 CGTCATGAAG CCCGGCCCGT GGTCCGAGTG CCAGTGTCTC CTGGACTTTT TGCACAAGGG 
 
 · P  E  V   A  V  F  E   P  S  E   A  E  I   S  H  T  Q   K  A  T  
    1141 ACCCGAGGTC GCTGTGTTTG AGCCATCAGA AGCAGAGATC TCCCACACCC AAAAGGCCAC 
 TGGGCTCCAG CGACACAAAC TCGGTAGTCT TCGTCTCTAG AGGGTGTGGG TTTTCCGGTG 
 
 · L  V  C   L  A  T  G   F  Y  P   D  H  V   E  L  S  W   W  V  N  
    1201 ACTGGTGTGC CTGGCCACCG GTTTCTACCC CGACCACGTG GAGCTGAGCT GGTGGGTGAA 
 TGACCACACG GACCGGTGGC CAAAGATGGG GCTGGTGCAC CTCGACTCGA CCACCCACTT 
 
 · G  K  E   V  H  S  G   V  C  T   D  P  Q   P  L  K  E   Q  P  A  
    1261 TGGGAAGGAG GTGCACAGTG GGGTCTGCAC AGACCCGCAG CCCCTCAAGG AGCAGCCCGC 
 ACCCTTCCTC CACGTGTCAC CCCAGACGTG TCTGGGCGTC GGGGAGTTCC TCGTCGGGCG 
 
 · L  N  D   S  R  Y  A   L  S  S   R  L  R   V  S  A  T   F  W  Q  
    1321 CCTCAATGAC TCCAGATACG CTCTGAGCAG CCGCCTGAGG GTCTCGGCCA CCTTCTGGCA 
 GGAGTTACTG AGGTCTATGC GAGACTCGTC GGCGGACTCC CAGAGCCGGT GGAAGACCGT 
 
 · D  P  R   N  H  F  R   C  Q  V   Q  F  Y   G  L  S  E   N  D  E  
    1381 GGACCCCCGC AACCACTTCC GCTGTCAAGT CCAGTTCTAC GGGCTCTCGG AAAATGACGA 
 CCTGGGGGCG TTGGTGAAGG CGACAGTTCA GGTCAAGATG CCCGAGAGCC TTTTACTGCT 
 
 · W  T  Q   D  R  A  K   P  V  T   Q  I  V   S  A  E  A   W  G  R  
    1441 GTGGACCCAG GATAGGGCCA AACCCGTCAC CCAGATCGTC AGCGCCGAGG CCTGGGGTAG 
 CACCTGGGTC CTATCCCGGT TTGGGCAGTG GGTCTAGCAG TCGCGGCTCC GGACCCCATC 
 
          NotI 
        ~~~~~~~~~ 
 · A  D  A   A  A  S  R   I  H  H   H  H  * 
    1501 AGCAGACGCG GCCGCATCTA GAATTCACCA TCATCACTAG 
 TCGTCTGCGC CGGCGTAGAT CTTAAGTGGT AGTAGTGATC 
 
 
Figure 4.1. Sequence of gp100 wild-type TCR cloned into the phagemid vector 
pEX922. The amino acid residues encoding the pelB and bacteriophage M13 gene III 
leader genes are highlighted in red and blue respectively. The six CDR loops, 
designated by the International Immunogenetics (IMGT) database (Lefranc, 
Giudicelli et al. 1999), are in bold and underlined. The TCR membrane-proximal 
cysteines in both the  and  chains have been removed. The introduced TCR 
stabilising constant region cysteines (at positions TRAC threonine 48 and TRBC 
serine 57) are highlighted in bright green. An N4K mutation has been introduced into 
C  by PCR error (shown in violet). The restriction enzyme sites used for molecular 
cloning purposes are highlighted (NcoI and NotI). Asterisks show the location of TAA 
and TAG (amber) stop codons. The sequence was analysed with Vector NTI Advance 
11.  
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Libraries were assembled in which each of the six CDRs were individually 
targeted for mutagenesis resulting in TCRs with one wild-type and one mutant chain 
as described in section 3.3. Panning was performed against the TAA, gp100(280-288), 
bound in the context of biotinylated HLA-A*0201. To increase the stability of the 
pHLA complex, a heteroclitic version of the gp100(280-288) peptide was used in all 
panning and ELISA screening experiments. The variant peptide contains an 
Ala288Val substitution (YLEPGPVTV). Three cycles of panning were performed 
against HLA-A*0201-gp100(280-288) peptide. Antigen binding clones were exclusively 
isolated from the CDR2  library.  
Seven CDR2  variants were expressed in E. coli Rosetta (DE3) pLysS cells and 
refolded with the gp100 TCR wild-type  chain. Purified refolded TCR was subjected 
to SPR on a BIAcore instrument. Equilibrium binding constants were calculated from 
kinetic data following the methods outlined in Section 2.7 of Materials and Methods. 
The affinity of interaction between the CDR2  mutants and the wild-type 
(YLEPGPVTA) and variant peptide (YLEPGPVTV) was substantially improved 
compared to the parental TCR; ~5000-fold and ~3800-fold improvement for clone 
GPawtb1 respectively (Table 4.1). The affinities were in the range of ~5-39 nM (wild-
type peptide) and ~6-45 nM (heteroclitic peptide) compared to 26 M (wild-type 
peptide) and 22 M (heteroclitic peptide) for the wild-type TCR. The T1/2 values were 
in the range of ~1-5 minutes. Importantly, the affinity engineered gp100 TCRs bound 
both the wild-type and heteroclitic peptide ligands with comparable kinetics (Table 
4.1) providing support for the use of the HLA-stabilising peptide variant for all further 
experiments. 
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Clone ID Peptide CDR2  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
GPawtbwt wt SQIVND nd nd 26000 nd 1 
 het  nd nd 22000 nd 1 
        
GPawtb1 wt SWAQGD 4.77 x 10
5
 2.47 x 10
-3
 5.18 4.6 5019 
 het  4 x 10
5
 2.33 x 10
-3
 5.83 4.9 3773.6 
        
GPawtb2 wt SWGVGD 2.88 x 10
5
 1.09 x 10
-2
 37.8 1.1 687.8 
 het  3.05 x 10
5
 1.02 x 10
-2
 33.4 1.13 658.7 
        
GPawtb3 wt SWAQGH 3.2 x 10
5
 4.71 x 10
-3
 14.7 2.44 1768.7 
 het  3.71 x 10
5
 4.47 x 10
-3
 12 2.57 1833.3 
        
GPawtb4 wt SWAYGH 2.84 x 10
5
 3.13 x 10
-3
 19.5  3.67 1333.3 
 het  3.16 x 10
5
 3.02 x 10
-3
 9.5 3.8 2736.8 
        
GPawtb5 wt SWAVGN 2.99 x 10
5
 5.82 x 10
-3
 19.5 1.97 1333.3 
 het  2.32 x 10
5
 5.81 x 10
-3
 25 1.98 880 
        
GPawtb6 wt SWAQFD 1.25 x 10
5
 3.41 x 10
-3
 27.2 3.3 955.9 
 het  3.53 x 10
5
 3.33 x 10
-3
 9.44 3.4 2330.6 
        
GPawtb7 wt SWGTGD 3.44 x 10
5
 1.33 x 10
-2
 38.7 0.87 671.8 
 het  2.78 x 10
5
 1.24 x 10
-2
 44.6 0.9 493.3 
 
Table 4.1. Affinities and binding kinetics of gp100 TCR mutants isolated from 
first-generation libraries. Mutants isolated from CDR2  libraries built on the wild-
type framework. Kon and Koff were determined by SPR in a BIAcore using purified 
refolded TCR and KD calculated. Binding against HLA-A*0201-gp100(280-288) wild-
type (wt) peptide (YLEPGPVTA) and heteroclitic (het) peptide (YLEPGPVTV). nd, 
not determined. (Data kindly provided by J. Gaverret).  
 
 
 
As had been observed with the Mel-5 TCR, mutants isolated from the first-
generation affinity maturation libraries did not possess the required binding kinetics 
for suitability as protein therapeutics. Using an enhanced affinity mutant as the 
template for second-generation mutagenesis had proved a successful strategy for 
isolating high affinity Mel-5 TCRs. The aim was to establish whether this was a 
generic method to increase the affinity of TCRs using a stepwise strategy. Here, clone 
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GPb7 (having the weakest affinity from the first-generation phage output) was used as 
the template to build further CDR-targeted phage libraries. 
 
4.3 Design and construction of second-generation gp100 TCR libraries 
Following on from the affinity maturation of the Mel-5 TCR, a number of 
modifications to the method for generating and cloning mutagenised gp100 TCR 
fragments were implemented. First, the SOE-PCR strategy was adapted; rather than 
introducing mutations into the CDR loop using a linking NNK oligonucleotide as 
illustrated in Figure 5, here the NNK primer was used to amplify one of the two PCR 
fragments. This modification simplified the assembly step by reducing the number of 
fragments from three to two. Second, instead of cloning a mutagenised  or  chain 
segment into a phagemid bearing the corresponding wild-type chain, here a 
mutagenised  or  chain fragment was spliced onto the corresponding wild-type 
chain by SOE-PCR. In this way, the final pull-through PCR could be performed with 
two primers (YOL13 and YOL22) compatible to the 5’ NcoI or 3’ NotI segments of 
the amplified TCR gene fragments. Therefore each could be conveniently cloned into 
the phagemid vector as NcoI-NotI fragments. Third, in an attempt to reduce further 
the potential contamination of library PCRs with parent DNA (in addition to the 
DpnI-treatment of the PCR fragments), the phagemid vector template was linearised 
separately with NcoI and NotI. Fourth, SOE-PCR fragments were sequenced before 
progressing to the digestion and ligation steps to assess quality and to monitor for 
parental DNA contamination.  
 
4.3.1 Generating library PCR fragments 
Linearising the template DNA was performed to reduce the level of background 
amplification of parental DNA. Fragments generated with the YOL13 primer using 
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NotI cut template were not extended beyond the NotI site and so the YOL22 priming 
site was not present in the PCR product. Likewise, YOL22 fragments amplified from 
NcoI digested DNA were not extended past the NcoI site and so prevented the 
synthesis of the YOL13 priming site. This step reduced the amount of non-
mutagenised parental DNA amplified in the SOE-PCR reaction with YOL13-YOL22. 
This is of particular importance when using an affinity-enhanced clone which could 
be enriched over other mutants if present at high levels in the library population. 
The phagemid vector containing the wild-type gp100  chain and the affinity-
enhanced CDR2  mutant, GPb7, was linearised separately with NcoI and NotI and 
gel-purified. Purified plasmids were quantitated by agarose gel electrophoresis 
(Figure 4.2) and diluted to ~2 ng/ l for PCR. The NotI linearised plasmid was used as 
the template for PCRs set up with the YOL13 forward primer and NcoI linearised 
plasmid was used as the template for PCRs set up with the YOL22 reverse primer.  
 
 
 
 
 
Figure 4.2. Ethidium bromide stained agarose gel photo of gel-purified linearised 
phagemid vector pEX922:GPawtb7. Lane 1, Hyperladder I size of bands in bp; lane 
2, pEX922:gp100awtb12 digested with NcoI; lane 3, pEX922:gp100awtb7 digested 
with NotI. 1% (w/v) agarose gel. 
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Three independent libraries were constructed within the context of clone GPb7 
CDR2  mutant. The CDR loops targeted for NNK mutagenesis were CDR2 , 
CDR3  and CDR3 . For each library overlapping 5-NNK oligonucleotides were 
designed to span the entire CDR: two for CDR2 , three for CDR3  and four for 
CDR3 . The number of NNK primers was dictated by the CDR length. Using the 
strategy depicted in Figure 2.3 of Materials and Methods as a guide and the primer set 
in Section 2.4.2 of Materials and Methods, eighteen PCR fragments were generated. 
As can be seen from Figure 2.3 of Materials and Methods there is no fragment a4. 
Instead the fragment amplified with YOL13-Nat53 (a1) was used in the SOE-PCR 
with fragments a2 and a5. The primer that had been designed specifically for 
amplification with YOL13 to generate fragment a4 failed to yield a product and so 
PCR a1 was used as a substitute. Fragments a2 and a5 generated with NNK primers 
Nat54 and Nat55 respectively only differ by a 3 bp shift at the 5’ end and so fragment 
a1 would anneal to both with comparable efficiency. PCR fragments of the expected 
size were gel-purified and 1 l of each was resolved on a 1% (w/v) agarose gel 
(Figure 4.3). The PCR fragments were all of the desired size and could be quanititated 
using the Hyperladder I DNA ladder as a guide. 
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Figure 4.3. Ethidium bromide stained agarose gel photo of gel-purified gp100 
TCR library PCR fragments. Lane 1, HYP I; lane 2, PCR fragment a1; lane 3, PCR 
a2; lane 4, PCR a5; lane 5, PCR a7; lane 6, PCR a8; lane 7, PCR a10; lane 8, PCR 
a11; lane 9, PCR a13; lane 10, PCR a14; lane 11, PCR b1; lane 12, PCR b2; lane 13, 
PCR fragment b4; lane 14, PCR b5; lane 15, PCR b7; lane 16, PCR b8; lane 17, PCR 
b10; lane 18, PCR b11; lane 19, HYP I. 1% (w/v) agarose gel. 
 
 
 
 
4.3.2 Generating full-length  and  chain library PCR fragments 
TCR fragments containing mutagenised CDR segments were assembled by SOE-
PCR: equimolar amounts of each of the two PCR fragments (~10-12 ng total DNA) 
were added together with the external primers YOL13 and YOL22 and amplified 
through 30 cycles of PCR with Expand polymerase (Roche) (Section 2.4.2.1 of 
Materials and Methods). Amplification of background parental template was assessed 
by setting up control PCRs with YOL13 and YOL22 in which one or other of the two 
fragments was excluded. An equal volume of each PCR was resolved on a 1% (w/v) 
agarose gel (Figure 4.4 A and 4.4 B). A dominant band of the desired size (~1800 bp) 
was observed for each of the SOE-PCR reactions. Background amplification of 
template DNA was almost undetectable. A faint band was seen at ~600-700 bp for 
each of the stitch PCRs but was eliminated following gel-purification of the ~1800 bp 
product (Figure 4.4 C).  
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Figure 4.4. Photo of ethidium bromide agarose gel of overlapping stitch gp100 
TCR library PCR fragments. (A). Lane 1, HYP I; lane 2, PCR a1 only; lane 3, PCR 
a2 only; lane 4, PCR a1 + a2; lane 5, PCR a5 only; lane 6, PCR a1 + a5; lane 7, PCR 
a7 only; lane 8, PCR a8 only; lane 9, PCR a7 + a8; lane 10, PCR a10 only; lane 11, 
PCR a11 only; lane 12, PCR a10 + a11; lane 13, PCR a13 only; lane 14, PCR a14 
only; lane 15, PCR a13 + a14; lane 16, b1 only; lane 17, b2 only; lane 18 PCR b1 + 
b2; lane19, HYP I. (B). Lane 1, HYP I; lane 2, PCR b4 only; lane 3, PCR a5 only; 
lane 4, PCR b4 + b5; lane 5, PCR b7 only; lane 6, PCR b8 only; lane 7, PCR b7 + b8; 
lane 8, PCR b10 only; lane 9, PCR b11; lane 10, PCR b10 + b11; lane 11, no template 
control; lane 12, no sample; lane 13, HYP I. (C). Agarose gel photo of gel-purified 
alpha and beta chain stitch library PCR fragments. Lane 1, HYP I; lane 2, PCR a3; 
lane 3, PCR a6; lane 4, PCR a9; lane 5, PCR a12; lane 6, PCR a15; lane 7, PCR b3; 
lane 8, PCR b6; lane 9, PCR b9; lane 10, PCR b12; lane 11, HYP I. 1% (w/v) agarose 
gel. 
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4.3.3 Polyclonal sequencing of library PCR fragments 
Contamination of the library population, as monitored by sequence analysis, had 
proved to be a concern during the Mel-5 TCR second-generation library construction 
(Section 3.7.1). As a result, two of the libraries were discarded from the panning 
experiments. In this example, library integrity was not assessed until after the 
electroporation step. In the affinity maturation of the gp100 TCR, we used polyclonal 
sequencing of the undigested stitch products to assess, far earlier in the process, the 
quality of each library.  
Figure 4.5 illustrates the polyclonal sequencing of two individual 5-NNK stitch 
products: PCR fragment a3 (Figure 4.5 A) and PCR fragment a15 (Figure 4.5 B). The 
chromatogram shows a central mutated region that is flanked by parental sequence. 
The targeted region is mutated with a 5-NNK motif where N represents each of the 
four nucleotides and K represents nucleotides G or T. At position N each of the four 
nucleotide traces can be seen and at position K only G and T are present. Multiple 
nucleotides at a single position results in a reduction in the chromatogram signal at 
that position. Both chromatogram traces shown in Figure 24 depict polyclonal library 
sequence that was considered of sufficient quality to progress to the next stage of 
library construction. Polyclonal sequences showing either the NNK trace overlapping 
into the parental sequence or parental sequence overlapping the mutated region would 
be discarded. Polyclonal sequencing of the nine stitched library fragments showed no 
detectable parental contamination and each was of sufficient quality to proceed to the 
next stage of the library build.  
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A. 
 
 
 
 
 
B. 
 
 
 
Figure 4.5. Examples of polyclonal sequencing of mutagenised gp100 TCR CDR 
loops using NNK oligonucleotides. SOE-PCR fragments amplified with YOL13-
YOL22 were sequenced. NNK mutagenised regions are flanked by monoclonal non-
mutagenised template DNA. (A). PCR a3 (CDR2  segment). (B). PCR a15 (CDR3  
segment).  
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4.3.4 Generating bacterial libraries 
Libraries targeting CDR2  (library 1), CDR3  (library 2) and CDR3  (library 3) 
were cloned into the phagemid vector pEX922 as NcoI-NotI fragments as described in 
Section 2.4.2 of Materials and Methods. Figure 4.6 illustrates the purity of the 
digested vector and library fragments used in the ligation reactions. A single sharp 
band can be observed for the phagemid vector pEX922 and for each of the ten library 
fragments. Electrocompetent E. coli TG1 cells were transformed separately with each 
of the three libraries to yield individual CDR libraries containing between 10
8
 and 10
9
 
independent transformants. Ten randomly selected colonies from each of the three 
libraries were PCR amplified with primers YOL13 and YOL22. The integrity and 
diversity of the gp100 TCR libraries was confirmed by DNA sequencing to reveal a 
broad diversity of mutations spanning each of the targeted CDRs (data not shown).  
 
 
 
 
 
Figure 4.6.  Ethidium bromide stained agarose gel photo of gp100 TCR gel-
purified NcoI-NotI digested stitch library PCRs and pEX922 phagemid vector. 
Lane 1, HYP I; lane 2, pEX922; lane 3, PCR a3; lane 4, PCR a6; lane 5, PCR a9; lane 
6, PCR a12; lane 7, PCR a15; lane 8, PCR b3; lane 9, PCR b6; lane 10, PCR b9; lane 
11, PCR b12; lane 12, HYP I. 1% (w/v) agarose gel. 
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4.4 Phage selections and screening 
The GPawtb7 mutant that was used as the framework on which to introduce mutations 
into the CDR2 , CDR3  and CDR3  loops binds to HLA-A*0201-gp100(280-288) with 
a KD value of 44.6 nM. The concentration of antigen used in panning was chosen on 
the basis of this affinity. Three cycles of panning against 10 nM biotinylated HLA-
A*0201-gp100(280-288) variant peptide (YLEPGPVTV) were performed with increased 
number of washes at each round (Section 3.5.4 of Materials and Methods). The output 
titre for each round of selection was estimated and following the third round of 
panning a significant increase was observed for each library: a 10-fold for library 1, a 
14-fold for library 2 and a 30-fold for library 3.  
Individual ampicillin-resistant E. coli TG1 colonies were picked from each of the 
library outputs and grown in a sterile 96-well tissue culture plate containing 100 l 
growth media supplemented with ampicillin and 2% glucose (master-plates). As a 
control, a single E. coli TG1 colony bearing the GPawtb7 clone was grown in each of 
the three plates. Phage was rescued by infection with helper phage and grown in 
kanamycin-containing media overnight at 26°C with shaking as outlined in Section 
2.5.1 of Materials and Methods. The following day, the cultures were pelleted and the 
supernatant containing monoclonal-phage-TCRs were screened in an inhibition phage 
ELISA at 5 nM HLA-A*0201-gp100(280-288) variant peptide (YLEPGPVTV) to 
determine if any of the TCRs demonstrated competitive inhibition. Antigen-binding 
phage clones were obtained from all three libraries.  
 
4.4.1 ELISA screening of crude phage supernatant 
Twenty clones from each library demonstrating the highest % inhibition at 5 nM 
inhibitor were sequenced. Sequence analysis of library 1 revealed mutations in 
CDR3  rather than in the region intentionally mutated (CDR2 ). Of the 20 
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sequenced clones, 10 contained a single point mutation within CDR3  (data not 
shown). Enrichment of the CDR3  single point mutant resulted from contamination 
of library 1 with library 2 during library construction. Contamination was at a low 
level since sequencing of ten unselected variants revealed ten unique sequences (data 
not shown). The remaining library 1 sequenced clones were clone GPb7.  
Of the sequenced library 2 output (Table 4.2 A), 50% was enriched for clone GPb7 
and 50% for five unique clones. Clones GPa1 and GPa2 were represented by multiple 
copies (four and two copies respectively). Each of the clones retained at least two 
wild-type residues. In all cases wild-type residues at positions Thr
95
 and Pro
96
 were 
retained through alternative codon usage compared to the parental sequence. With the 
exception of clone GPa6, in which an Asp at residue 6 in C  was substituted for Gly, 
no other mutations were observed outside of the targeted CDR3 region. The % 
inhibition at 5 nM was greater for each of the mutants compared to the framework 
clone (GPb7): 55-74% for the mutants versus 30% for GPb7.   
Dramatic sequence convergence was observed in library 3 (Table 4.2 B). Of the 
twenty sequenced clones, nineteen contained the motif G
96
A
97
P
98
Y
99
 in which Ala
97
 
was the only residue mutated from wild-type. Introduction of a Tyr at position Ile
95
 
produced a significant increase in the % inhibition in clone GPb13; 90% compared to 
38% of the framework clone. Addition of the Ala
97
 substitution further enhanced the 
apparent affinity demonstrated by clone GPb12; from 90% for GPb13 to 100% for 
GPb12. Thus highlighting the importance of the G97A substitution for affinity 
enhancement. Clone GPb8 which contained an Ala at position 97 and a Pro at position 
100 dominated the library 3 output (55% of sequenced clones).  
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A. 
 
Clone 
Number 
CDR3 (D94-G102) C  Freq 
% Inhib. 
@ 5 nM 
GPb7 D  T  P  L  V  F  G  K  G 
gacacacctcttgtctttggaaagggc 
K  P  D 
aagcctgac 
10 30 
GPa1 S  T  P  L  M  F  G  K  G 
tcgactcctttgatgtttggaaagggc 
K  P  D 
aagcctgac 
4 55 
GPa2 D  T  P  L  A  F  G  K  G 
gacacacctcttgcctttggaaagggc 
K  P  D 
aagcctgac 
2 55 
GPa3 S  T  P  M  Q  F  G  K  G 
tcgactccgatgcagtttggaaagggc 
K  P  D 
aagcctgac 
1 59 
GPa4 R  T  P  M  S  F  G  K  G 
cggactcctatgagttttggaaagggc 
K  P  D 
aagcctgac 
1 57 
GPa5 T  T  P  L  G  F  G  K  D 
acgacgccgcttggttttggaaaggac 
K  P  D 
aagcctgac 
1 74 
GPa6 D  T  P  L  V  F  G  K  G 
gacacacctcttgtctttggaaagggc  
K  P  G 
aagcctggc 
1 58 
 
 
 
B. 
 
Clone 
Number 
CDR3 (S94-E100) Freq 
% Inhib. 
@ 5 nM 
GPb7 S  I  G  G  P  Y  E   
agtatagggggcccctacgag   
- 38 
GPb8 S  I  G  A  P  Y  P   
agtataggtgcgccgtatccg  
11 83 
GPb9 S  H  G  A  P  Y  E   
tctcatggggctccgtacgag  
3 87 
GPb10 S  I  G  A  P  Y  Q   
agtataggtgctccgtatcag  
2 83 
GPb11 S  S  G  A  P  Y  E   
tcgtcgggggcgccgtacgag  
1 80 
GPb12 S  W  G  A  P  Y  E   
agttggggtgctccttacgag  
1 100 
GPb13 S  Y  G  G  P  Y  E   
agttatggggggccgtacgag  
1 90 
GPb14 S  V  G  A  P  Y  E   
agtgtgggggcgccgtacgag  
1 76 
 
Table 4.2. Output clones obtained following three rounds of panning against 10 
nM biotinylated-HLA-A*0201-gp100(280-288) complexes. (A). Library 2: CDR3  
mutants on the GPb7 background. Clone GPa6 has acquired a mutation in C  (Asp to 
Gly). From soluble inhibition ELISA library 2 clones showed 55-74% inhibition 
compared to 30% for the background clone (GPb7) at 5 nM HLA-A*0201-gp100(280-
288) complexes. (B). Library 3: CDR3  mutants on the GPb7 background. From 
soluble inhibition ELISA library 3 showed 76-100% inhibition compared to 38% for 
the background clone (GPb7) at 5 nM HLA-A*0201-gp100(280-288) complexes. Red 
lettering indicates residues mutated from the parental sequence. Blue lettering 
indicates alternative codon usage compared to the parental sequence. The  and  
chain fragments are denoted by the letter a or b respectively. International 
Immunogenetics (IMGT) nomenclature (Lefranc, Giudicelli et al. 1999). 
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4.4.2 ELISA screening of purified phage supernatant 
To more accurately characterise the Pan 3 output, phage supernatant was purified for 
a selection of clones. Fifty ml of growth media containing 100 g/ml ampicillin and 
2% glucose (w/v) was inoculated with clones GPa1, GPa2, GPa3, GPa4, GPb8 and 
the framework clone GPb7 from the E. coli TG1 glycerol master-plates (Section 4.4). 
Phage was rescued by infection with helper phage and grown in kanamycin-
containing media overnight at 26°C with shaking. The following day, the cultures 
were pelleted and the supernatant containing monoclonal phage TCRs was twice 
precipitated with PEG/NaCl as described in Section 2.5.2 of Materials and Methods. 
The phage pellet was resuspended in a final volume of 1 ml PBS. To control for 
variation in the TCR display levels, a preliminary antigen binding phage ELISA was 
performed as outlined in Section 2.5.5 of Materials and Methods. A 7-point doubling 
dilution series of each phage sample was prepared in PBS (from 1:4 to 1:256). The 
purpose of the ELISA was to determine a phage dilution that produced an absorbance 
650 nm reading of ~1.0. In the subsequent inhibition ELISA the amount of TCR-
displaying phage could be normalised and so the % inhibition values could be more 
accurately compared independent of expression levels. One salient point from Figure 
4.7 is the variation of TCR display levels between the clones. It can be surmised that 
the dominance of clone GPb8 in the Pan 3 output is due to the fitness of this clone in 
terms of both expression and affinity. The ELISA signal at each of the dilution points 
is >2-fold higher than the other clones. The ELISA is designed to measure the display 
of functional correctly folded TCR and so it can be concluded that a greater 
proportion of phage particles are displaying this TCR variant compared to the other 
clones. The sample dilution that produced an absorbance value at 650 nm of ~1.0 
were: 1:4 (GPb7 and GPa4); 1:8 (GPa2 and GPa3); 1:16 (GPa1) and 1:64 (GPb8). 
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Figure 4.7. Titration of gp100 TCR purified phage samples in a antigen-binding 
ELISA. Streptavidin-coated Nunc-Maxisorp plates were immobilised with 0.5 g 
biotinylated HLA-A*0201-gp100(280-288) (YLEPGPVTV). A doubling dilution series 
of PEG-precipitated phage was prepared in 6% MPBS. Antigen-binding phage were 
detected with an anti-M13 antibody and a phosphatase-labelled anti-rabbit IgG 
monoclonal antibody. ELISA signals were measured as an absorbance at 650 nm. The 
dotted line indicates an absorbance at 650 nm of 1. The background absorbance value 
was subtracted from all readings before % Inhib. was calculated. The  and  chain 
fragments are denoted by the letter a or b respectively. 
 
 
 
 
 
 
 
 
 
Chapter 4 
 241 
An inhibition ELISA was performed at 5, 10, 25 and 50 nM inhibitor using a phage 
dilution that gave an absorbance of ~1.0 (Figure 4.8). Normalising the level of TCR-
displaying phage in each of the samples made it now possible to assess improvements 
in affinity by comparison with the inhibition profile of the framework clone GPb7. 
The inhibition profiles of each of the mutants provided evidence for improvements in 
affinity over the framework clone GPb7. Inclusion of the CDR3  segments (GPa1, 
GPa2, GPa3 and GPa4) into the GPb7 clone produced a similar increase in apparent 
antigen-binding affinity as judged by % inhibition. The improvement in relative 
affinity over clone GPb7 is illustrated by comparing the average % inhibition value 
(at 10 nM inhibitor) for the mutated  chains against the framework clone: ~70% 
versus 45% respectively. The recruitment of a CDR3  (GPb8) segment into clone 
GPb7 produced a more significant improvement in the apparent affinity; ~90% 
inhibition at 10 nM inhibitor compared to 45% for clone GPb7. The dilution curve for 
clone GPb8 (Figure 4.7) and the inhibition profile (Figure 4.8) supported the 
hypothesis that GPb8 was selected for both expression and affinity.    
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Figure 4.8. Inhibition phage ELISA of gp100 TCR CDR3  and CDR3  variants 
at a concentration of 50, 25, 10 and 5 nM inhibitor. All phage samples were diluted 
to give an absorbance at 650 nm of ~1 in an antigen binding phage ELISA. GPb7 is 
the first-generation enhanced affinity CDR2  mutant upon which second-generation 
mutants were built. The PEG-precipitated phage samples were incubated with the 
appropriate concentration of non-biotinylated HLA-A*0201-gp100(280-288) 
(YLEPGPVTV) prior to adding to ELISA plates immobilised with HLA-A*0201-
gp100(280-288) (YLEPGPVTV). % Inhib. is measured as the percentage reduction in 
ELISA signal. The background absorbance value was subtracted from all readings 
before % Inhib. was calculated. The  and  chain fragments are denoted by the letter 
a or b respectively.  
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4.5 Characterisation of the second-generation gp100 TCRs 
4.5.1 Soluble expression of gp100 TCRs 
Three mutated  (GPa1, GPa3 and GPa5) and three mutated  (GPb8, GPb9 and 
GPb12) CDR segments were selected for kinetic analysis by SPR. The CDR3  
segments were cloned both in combination with the CDR2  segment from GPb7 (as 
selected from library 3) and also in combination with the highest affinity CDR2  
segment (GPb1) from the first-generation affinity maturation libraries (Table 4.1). All 
chains were cloned into the expression plasmid pGMT7 (pEX954 for the  chain and 
pEX821 for the  chain) for expression in E. coli strain Rosetta (DE3) pLysS. TCRs 
were refolded from inclusion bodies and purified by anion exchange chromatography 
followed by size exclusion chromatography as outlined in Section 2.6.4-2.6.8 of 
Materials and Methods.  
 
4.5.2 Kinetic analysis of gp100 TCRs 
Purified refolded TCR was subjected to SPR on a BIAcore instrument. Equilibrium 
binding constants were calculated from kinetic data following the methods outlined in 
Section 2.7 of Materials and Methods.  
Recruitment of CDR3  segments into TCR clone GPawtb7 increased the affinity 
up to 8-fold (Table 4.3 A). Inclusion of the CDR3  segments GPb8 and GPb9 into 
clone GPb7 had a greater effect on the binding affinity; increasing the KD by 10 and 
26-fold respectively. However, recruitment of CDR3  segment GPb10 into clone 
GPawtb7 had a more striking effect on the affinity; increasing it by ~200-fold. This 
represents a 10-fold increase in affinity compared to clone GPb9. Clones GPb9 and 
GPb12 differ by only a single residue; an Ile at position 95 is substituted for His in 
GPb9 and for Trp in GPb12. Addition of a large bulky hydrophobic side chain at this 
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position is likely to be responsible for the dramatic affinity enhancement observed 
with this clone. 
Combining the most optimal  and  chain segments isolated from first and 
second-generation libraries further improved the binding affinity in an additive 
manner (Table 4.3 B). The CDR3  clone with the longest T1/2, GPa3, was refolded 
with three  chain double mutants, GPb15, GP16 and GPb17. To generate the  chain 
mutants each of the CDR3  variants (GPb8, GPb9 and GPb12) were combined with 
the highest affinity CDR segment from the first-generation libraries, GPb1 (CDR2 ). 
Although the increase in affinity between GPb1 and GPb7 was only moderate (~8-
fold), we have shown that even minor CDR-derived improvements can enhance 
binding affinity in a step-wise manner. Generating TCR clone GPa3b17, comprising 
only three engineered CDRs, resulted in a ~1.7 million-fold increase in binding 
affinity compared to the wild-type (parental) TCR. 
Mutagenesis of individual CDR segments has proved a successful strategy to 
improve the binding affinity of the gp100 TCR for its cognate pHLA. Engineering of 
separate CDRs has enhanced the affinity and half-life by incremental steps (Figure 4.9 
A and 4.9 B). Combination of affinity enhanced CDRs has generated TCRs with 
significantly improved binding affinities. Improvements in affinity are almost 
exclusively driven by decreases in off-rates rather than alterations to on-rates which 
remain largely unchanged (Figure 4.9 C and 4.9 D). A comparison of the weakest 
affinity first-generation mutant, GPb7 with the highest affinity combined mutant, 
GPa3b17 illustrates this point. Only a two-fold variation in on-rate was observed 
compared to a 1850-fold variation in off-rate (Table 4.3) between the two mutants. 
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A. 
 
Clone ID CDR3  CDR2  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (GPawtb7) 
KD (mutant) 
KD (parent) 
KD (mutant) 
GPawtbwt DTPLVFGKG SQIVND IGGPYE nd nd 22000 nd - 1 
GPawtb7 DTPLVFGKG SWGTGD IGGPYE 2.78 x 10
5
 1.24 x 10
-2
 44.6 0.9 1 493.3 
GPa1b7 STPLMFGKG SWGTGD IGGPYE 4.55 x 10
5
 2.85 x 10
-3
 6.26 4 7.1 3514.4 
GPa3b7 STPMQFGKG SWGTGD IGGPYE 4.36 x 10
5
 2.49 x 10
-3
 5.71 4.6 7.8 3852.9 
GPa5b7 TTPLGFGKD SWGTGD IGGPYE 5.33 x 10
5
 2.82 x 10
-3
 5.3 4 8.4 4150.9 
GPawtb8 DTPLVFGKG SWGTGD IGAPYP 1.72 x 10
5
 7.05 x 10
-4
 4.11 16.3 10.9 5352.8 
GPawtb9 DTPLVFGKG SWGTGD HGAPYE 3.28 x 10
5
 5.6 x 10
-4
 1.71 20.5 26.1 12865.4 
GPawtb12 DTPLVFGKG SWGTGD WGAPYE 4.87 x 10
5
 9.93 x 10
-5
 0.2 115 223 110000 
 
B. 
 
Clone ID CDR3  CDR2  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
GPawtbwt DTPLVFGKG SQIVND IGGPYE nd nd 22000 nd 1 
GPawtb1 DTPLVFGKG SWAQGD IGGPYE 4 x 10
5
 2.33 x 10
-3
 5.83 4.9 3773.6 
GPa3b15 STPMQFGKG SWAQGD IGAPYP 6.21 x 10
5
 2.35 x 10
-5
 0.038 486 578947.4 
GPa3b16 STPMQFGKG SWAQGD HGAPYE 4.47 x 10
5
 3.75 x 10
-5
 0.084 306 261904.8 
GPa3b17 STPMQFGKG SWAQGD WGAPYE 5.31 x 10
5
 6.7 x 10
-6
 0.013 1716 1692307.7 
 
Table 4.3. Affinities and binding kinetics of gp100 TCR mutants isolated from second-generation libraries. (A). Second-generation phage 
output. Mutants isolated from CDR3 , CDR2  and CDR3  libraries built on the GPb7 framework. (B). Combination of the most optimal alpha 
and beta chain CDR segments obtained from both first and second-generation phage libraries. GPb1 was the highest affinity clone isolated from 
the first-generation library selections. The ratio of KD parent and mutant KD gives the overall improvement in affinity from the starting gp100 
wild-type TCR. Kon and Koff were determined by SPR in a BIAcore using purified refolded TCR and KD calculated. Binding was measured 
against the HLA-A*0201-gp100(280-288) (YLEPGPVTV) ligand. nd, not determined. (Data kindly provided by J. Gavarret).  
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Figure 4.9. Affinities and binding kinetics of gp100 TCR CDR segments isolated 
from first and second-generation libraries. Mutated CDR regions were combined 
in a step-wise manner to enhance the binding affinity of the engineered gp100 TCR 
for HLA-A*0201-gp100(280-288) (YLEPGPVTV). (A). Equilibrium dissociation 
constant (KD). (B). Dissociation half-life (T1/2). (C). Association rate constant (Kon). 
(D). Dissociation rate constant (Koff).   
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EXPLORING PHAGE DISPLAY METHODOLOGIES TO ISOLATE AN 
HLA-A1-RESTRICTED HIGH AFFINITY T CELL RECEPTOR AGAINST 
THE MAGE-A3168-176 TUMOUR ASSOCIATED ANTIGEN 
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5.1 Introduction 
The MAGE-A3-EB81-103 T-cell clone was kindly supplied by Pierre Coulie 
(University of Louvian, Brussels, Belgium) (Karanikas, Lurquin et al. 2003). The 
MAGE-A3-EB81-103 T-cell clone recognises the TAA epitope derived from MAGE-
A3(168-176) (EVDPIGHLY) presented in the context of the HLA-A*0101 complex.  
Of the TCRs described in this thesis, the MAGE-A3-EB81-103 TCR (hereafter 
referred to as the MAGE-A3 TCR) exhibits the lowest affinity for its cognate pHLA 
with a KD of 248 M. The affinity is 14-fold and 9.5-fold weaker than the wild-type 
Mel-5 (KD of 18 M) and gp100 (KD of 26 M) TCRs, respectively.  
In this chapter, the affinity-maturation of the MAGE-A3 TCR will be described. 
Moreover, the off-target activity of the first-generation MAGE-A3 TCR mutants will 
be addressed through exploring various features of the phage display system. This 
will include investigating the format of the TCR (native versus mTCR), the number of 
consecutive CDR residues randomised (5-NNK versus 6-NNK) and the use of 
subtractive panning of phage libraries on mammalian cells to remove off-target 
binders and enrich for target-specific binders.   
The Mel-5 and gp100 TCRs were displayed on the bacteriophage surface in the 
engineered mTCR format in which the membrane-proximal C  and C  cysteines 
(native) were removed and a C-region cysteine pair was introduced (Boulter, Glick et 
al. 2003). Whilst, intuitively it was believed that the engineered disulphide (ds)-
format would favour the display on the bacteriophage surface, by stabilising the 
interaction between the  and  chains, the opposite was demonstrated. We have 
shown, using a (limited) panel of TCRs containing the native C-region cysteine pair, 
that the display is enhanced over the ds-engineered equivalent. Since a greater 
proportion of the phage population display a TCR available for interaction with pHLA 
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ligand, it was hypothesised that increasing the efficiency of display using the native 
ds-format would increase the likelihood of isolating high affinity MAGE-A3 TCR 
mutants. 
 
5.2 Design and construction of MAGE-A3 TCR libraries 
5.2.1 Cloning the MAGE-A3 wild-type TCR into the phagemid vector 
The phagemid vector pIM160 for the phage display of the MAGE-A3 TCR (specific 
for HLA-A*0101 in complex with the MAGE-A3(168-176) peptide) was constructed as 
described in Section 2.3 of Materials and Methods using V  and V  specific primers 
(primers J135 and J155) to amplify the wild-type MAGE-A3 TCR  and  chains. 
The template used to amplify the variable fragments was cDNA isolated from the 
MAGE-A3-EB81-103 T-cell clone (cDNA was provided by Dr. B. Cameron). The 
C  and C  domains were amplified from the phagemid vector pG484 encoding TCR 
C-regions in the native format; in which the engineered ds-cysteines were replaced 
with wild-type residues and the native membrane-proximal cysteines were introduced. 
The MAGE-A3 TCR  chain V domain is encoded by TRAV21*01 and TRAJ28*01 
gene segments. The  C region is encoded by TRAC*01. The MAGE-A3 TCR  
chain V domain is encoded by TRBV5-1*01, TRBJ2-7*01 and TRBD1*01 gene 
segments. The  C region is encoded by TRBC1*01. The sequence of the wild-type 
MAGE-A3 TCR NcoI-NotI phagemid fragment is shown in Figure 5.1.  
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                                                              NcoI 
                    pelB leader gene                           ~~ 
  M  K  Y  L   L  P  T   A  A  A   G  L  L  L   L  A  A   Q  P  A 
       1 ATGAAATACC TATTGCCTAC GGCAGCCGCT GGATTGTTAT TACTCGCGGC CCAGCCGGCC 
 TACTTTATGG ATAACGGATG CCGTCGGCGA CCTAACAATA ATGAGCGCCG GGTCGGCCGG 
  
          NcoI 
 ~~~~ 
  M  A  K  Q   E  V  T   Q  I  P   A  A  L  S   V  P  E   G  E  N 
      61 ATGGCCAAAC AGGAGGTGAC GCAGATTCCT GCAGCTCTGA GTGTCCCAGA AGGAGAAAAC 
 TACCGGTTTG TCCTCCACTG CGTCTAAGGA CGTCGAGACT CACAGGGTCT TCCTCTTTTG 
 
                                          CDR1  
  L  V  L  N   C  S  F   T  D  S   A  I  Y  N   L  Q  W   F  R  Q 
     121 TTGGTTCTCA ACTGCAGTTT CACTGATAGC GCTATTTACA ACCTCCAGTG GTTTAGGCAG 
 AACCAAGAGT TGACGTCAAA GTGACTATCG CGATAAATGT TGGAGGTCAC CAAATCCGTC 
 
                                                                            CDR2  
  D  P  G  K   G  L  T   S  L  L   L  I  Q  S   S  Q  R   E  Q  T 
     181 GACCCTGGGA AAGGTCTCAC ATCTCTGTTG CTTATTCAGT CAAGTCAGAG AGAGCAAACA 
 CTGGGACCCT TTCCAGAGTG TAGAGACAAC GAATAAGTCA GTTCAGTCTC TCTCGTTTGT 
 
  S  G  R  L   N  A  S   L  D  K   S  S  G  R   S  T  L   Y  I  A 
     241 AGTGGAAGAC TTAATGCCTC GCTGGATAAA TCATCAGGAC GTAGTACTTT ATACATTGCA 
 TCACCTTCTG AATTACGGAG CGACCTATTT AGTAGTCCTG CATCATGAAA TATGTAACGT 
 
                                                                                           CDR3  
  A  S  Q  P   G  D  S   A  T  Y   L  C  A  V   R  P  G   G  A  G 
     301 GCTTCTCAGC CTGGTGACTC AGCCACCTAC CTCTGTGCTG TGAGGCCGGG AGGGGCTGGG 
 CGAAGAGTCG GACCACTGAG TCGGTGGATG GAGACACGAC ACTCCGGCCC TCCCCGACCC 
 
  S  Y  Q  L   T  F  G   K  G  T   K  L  S  V   I  P  N   I  Q  N 
     361 AGTTACCAAC TCACTTTCGG GAAGGGGACC AAACTCTCGG TCATACCAAA TATCCAGAAC 
 TCAATGGTTG AGTGAAAGCC CTTCCCCTGG TTTGAGAGCC AGTATGGTTT ATAGGTCTTG 
 
  P  D  P  A   V  Y  Q   L  R  D   S  K  S  S   D  K  S   V  C  L 
     421 CCTGACCCTG CCGTGTACCA GCTGAGAGAC TCTAAATCCA GTGACAAGTC TGTCTGCCTA 
 GGACTGGGAC GGCACATGGT CGACTCTCTG AGATTTAGGT CACTGTTCAG ACAGACGGAT 
 
  F  T  D  F   D  S  Q   T  N  V   S  Q  S  K   D  S  D   V  Y  I 
     481 TTCACCGATT TTGATTCTCA AACAAATGTG TCACAAAGTA AGGATTCTGA TGTGTATATC 
 AAGTGGCTAA AACTAAGAGT TTGTTTACAC AGTGTTTCAT TCCTAAGACT ACACATATAG 
 
  T  D  K  T   V  L  D   M  R  S   M  D  F  K   S  N  S   A  V  A 
     541 ACAGACAAAA CCGTGCTAGA CATGAGGTCT ATGGACTTCA AGAGCAACAG TGCTGTGGCC 
 TGTCTGTTTT GGCACGATCT GTACTCCAGA TACCTGAAGT TCTCGTTGTC ACGACACCGG 
 
  W  S  N  K   S  D  F   A  C  A   N  A  F  N   N  S  I   I  P  E 
     601 TGGAGCAACA AATCTGACTT TGCATGTGCA AACGCCTTCA ACAACAGCAT TATTCCAGAA 
 ACCTCGTTGT TTAGACTGAA ACGTACACGT TTGCGGAAGT TGTTGTCGTA ATAAGGTCTT 
 
                                           AvrII 
                                           ~~~~~~~ 
  D  T  F  F   P  S  P   E  S  S   C  *  * 
     661 GACACCTTCT TCCCCAGCCC AGAAAGTTCC TGTTAATAAC CTAGGTTAAT TAAGAATTCT 
 CTGTGGAAGA AGGGGTCGGG TCTTTCAAGG ACAATTATTG GATCCAATTA ATTCTTAAGA 
 
                                                                              gIII leader gene 
                      M   K  K  L   L  F  A   I  P  L  V   A  P  F  
     721 TTAAGAAGGG GATATACATA TGAAAAAATT ATTATTCGCA ATTCCTTTAG TTGCTCCTTT 
 AATTCTTCCC CTATATGTAT ACTTTTTTAA TAATAAGCGT TAAGGAAATC AACGAGGAAA 
 
 · Y  S  H   S  A  Q  K   A  G  V   T  Q  T   P  R  Y  L   I  K  T  
     781 CTATTCTCAC AGCGCGCAGA AGGCTGGAGT CACTCAAACT CCAAGATATC TGATCAAAAC 
 GATAAGAGTG TCGCGCGTCT TCCGACCTCA GTGAGTTTGA GGTTCTATAG ACTAGTTTTG 
 
                                                                                       CDR1  
 · R  G  Q   Q  V  T  L   S  C  S   P  I  S   G  H  R  S   V  S  W  
     841 GAGAGGACAG CAAGTGACAC TGAGCTGCTC CCCTATCTCT GGGCATAGGA GTGTATCCTG 
 CTCTCCTGTC GTTCACTGTG ACTCGACGAG GGGATAGAGA CCCGTATCCT CACATAGGAC 
 
                 
Chapter 5 
 251 
                                                                                                    CDR2  
 · Y  Q  Q   T  P  G  Q   G  L  Q   F  L  F   E  Y  F  S   E  T  Q  
     901 GTACCAACAG ACCCCAGGAC AGGGCCTTCA GTTCCTCTTT GAATACTTCA GTGAGACACA 
 CATGGTTGTC TGGGGTCCTG TCCCGGAAGT CAAGGAGAAA CTTATGAAGT CACTCTGTGT 
 
 · R  N  K   G  N  F  P   G  R  F   S  G  R   Q  F  S  N   S  R  S  
     961 GAGAAACAAA GGAAACTTCC CTGGTCGATT CTCAGGGCGC CAGTTCTCTA ACTCTCGCTC 
 CTCTTTGTTT CCTTTGAAGG GACCAGCTAA GAGTCCCGCG GTCAAGAGAT TGAGAGCGAG 
 
                                                                                                          CDR3  
 · E  M  N   V  S  T  L   E  L  G   D  S  A   L  Y  L  C   A  S  S  
    1021 TGAGATGAAT GTGAGCACCT TGGAGCTGGG GGACTCGGCC CTTTATCTTT GCGCCAGCAG 
 ACTCTACTTA CACTCGTGGA ACCTCGACCC CCTGAGCCGG GAAATAGAAA CGCGGTCGTC 
 
 · P  N  M   A  D  E  Q   Y  F  G   P  G  T   R  L  T  V   T  E  D  
    1081 CCCGAACATG GCCGACGAGC AGTACTTCGG GCCGGGCACC AGGCTCACGG TCACAGAGGA 
 GGGCTTGTAC CGGCTGCTCG TCATGAAGCC CGGCCCGTGG TCCGAGTGCC AGTGTCTCCT 
 
 · L  K  N   V  F  P  P   E  V  A   V  F  E   P  S  E  A   E  I  S  
    1141 CCTGAAAAAC GTGTTCCCAC CCGAGGTCGC TGTGTTTGAG CCATCAGAAG CAGAGATCTC 
 GGACTTTTTG CACAAGGGTG GGCTCCAGCG ACACAAACTC GGTAGTCTTC GTCTCTAGAG 
 
 · H  T  Q   K  A  T  L   V  C  L   A  T  G   F  Y  P  D   H  V  E  
    1201 CCACACCCAA AAGGCCACAC TGGTGTGCCT GGCCACAGGC TTCTACCCCG ACCACGTGGA 
 GGTGTGGGTT TTCCGGTGTG ACCACACGGA CCGGTGTCCG AAGATGGGGC TGGTGCACCT 
 
 · L  S  W   W  V  N  G   K  E  V   H  S  G   V  S  T  D   P  Q  P  
    1261 GCTGAGCTGG TGGGTGAATG GGAAGGAGGT GCACAGTGGG GTCTCCACAG ACCCGCAGCC 
 CGACTCGACC ACCCACTTAC CCTTCCTCCA CGTGTCACCC CAGAGGTGTC TGGGCGTCGG 
 
 · L  K  E   Q  P  A  L   N  D  S   R  Y  A   L  S  S  R   L  R  V  
    1321 CCTCAAGGAG CAGCCCGCCC TCAATGACTC CAGATACGCT CTGAGCAGCC GCCTGAGGGT 
 GGAGTTCCTC GTCGGGCGGG AGTTACTGAG GTCTATGCGA GACTCGTCGG CGGACTCCCA 
 
 · S  A  T   F  W  Q  D   P  R  N   H  F  R   C  Q  V  Q   F  Y  G  
    1381 CTCGGCCACC TTCTGGCAGG ACCCCCGCAA CCACTTCCGC TGTCAAGTCC AGTTCTACGG 
 GAGCCGGTGG AAGACCGTCC TGGGGGCGTT GGTGAAGGCG ACAGTTCAGG TCAAGATGCC 
 
 · L  S  E   N  D  E  W   T  Q  D   R  A  K   P  V  T  Q   I  V  S  
    1441 GCTCTCGGAG AATGACGAGT GGACCCAGGA TAGGGCCAAA CCCGTCACCC AGATCGTCAG 
 CGAGAGCCTC TTACTGCTCA CCTGGGTCCT ATCCCGGTTT GGGCAGTGGG TCTAGCAGTC 
 
                                 NotI 
                               ~~~~~~~~~ 
 · A  E  A   W  G  R  A   D  C  A   A  A  S   R  I  H  H   H  H  *  
    1501 CGCCGAGGCC TGGGGTAGAG CAGACTGTGC GGCCGCATCT AGAATTCACC ATCATCACTA 
 GCGGCTCCGG ACCCCATCTC GTCTGACACG CCGGCGTAGA TCTTAAGTGG TAGTAGTGAT 
 
 · * 
    1561 G 
 C 
 
 
Figure 5.1. Sequence of wild-type MAGE TCR (recognising the epitope derived 
from the MAGE-A3168-176) cloned into the phagemid vector pEX922. The amino 
acid residues encoding the pelB and bacteriophage M13 geneIII leader genes are 
highlighted in red and blue respectively. The six CDR loops, designated by the 
International Immunogenetics (IMGT) database (Lefranc, Giudicelli et al. 1999), are 
in bold and underlined. The TCR membrane-proximal cysteines in both the  and  
chains are highlighted in bold purple. The restriction enzyme sites used for molecular 
cloning purposes are highlighted (NcoI, AvrII and NotI). Asterisks show the location 
of stop codons including an amber codon (TAG) at the C-terminus of the beta chain. 
A V12A mutation has been introduced into the geneIII leader sequence by PCR error 
(shown in bold and underlined). The sequence was analysed with Vector NTI 
Advance 11 (Invitrogen).  
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5.2.2 Generating DNA and bacterial libraries 
Libraries were assembled in which each of the six CDRs were individually targeted 
for mutagenesis producing TCRs with one wild-type and one mutant chain as 
described in Section 2.4.3 Materials and Methods. The PCR strategy is outlined in 
Figure 2.4 of Materials and Methods. The phagemid vector pIM160 was linearised 
separately with NcoI and NotI and gel-purified. Purified plasmids were quantitated by 
agarose gel electrophoresis and diluted to ~2 ng/ l for PCR. The NotI linearised 
plasmid was used as the template for YOL13 PCRs and NcoI linearised plasmid was 
used as the template for YOL22 PCRs. 
The DNA fragments used to generate the MAGE-A3 TCR libraries are shown in 
Figure 5.2. For each library, overlapping 5-NNK oligonucleotides were designed to 
span the entire CDR: two for CDR1 , one for CDR2 , five for CDR3 , one for 
CDR1 , two for CDR2  and four for CDR3 . Following the strategy depicted in 
Figure 2.4 of Materials and Methods and the primer set and methods outlined in 
Section 2.4.3 of Materials and Methods PCR fragments were generated. PCR 
fragments of the expected size were gel-purified and 1 l of each was resolved on a 
1% (w/v) agarose gel (Figure 5.2 A and 5.2 B).  
TCR fragments containing mutagenised CDR segments were assembled by SOE-
PCR: equimolar amounts of each of the two PCR fragments (~13 ng total DNA) were 
added together with the external primers YOL13 and YOL22 and amplified through 
30 cycles of PCR with Expand polymerase. Amplification of background parental 
template was assessed by setting up control PCRs with YOL13 and YOL22 in which 
one or other of the two fragments was excluded. An equal volume of each PCR was 
resolved on a 1% (w/v) agarose gel (Figure 5.2 C and 5.2 D). A dominant band of the 
expected size (~1800 bp) was observed for each of the SOE-PCR reactions. 
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Background amplification of template DNA was almost undetectable. The fifteen 
SOE-PCR fragments (~1800 bp) were excised from the gel, purified and analysed by 
agarose gel electrophoresis (Figure 5.2 E). Each of the purified stitch PCRs were 
sequenced with primers YOL13 and YOL22. Polyclonal sequencing (data not shown) 
demonstrated sufficient integrity of the libraries to proceed to the next stages of 
library construction. Each library fragment was digested with NcoI-NotI to generate a 
~1500 bp product; gel-purified fragments were analysed by agarose gel 
electrophoresis (Figure 5.2 F). 
Libraries targeting each of the six CDRs were cloned into the phagemid vector 
pEX922 as NcoI-NotI fragments as described in Section 2.4.3.1 of Materials and 
Methods. Electrocompetent E. coli TG1 cells were transformed separately with each 
of the six libraries. Multiple electroporations were performed for each of the libraries 
(ten CDR1 , six CDR2 , twenty CDR3 , six CDR1 , ten CDR2  and twenty 
CDR3 ) to yield individual CDR libraries containing between 10
8
 and 10
9
 
independent transformants. Eight randomly selected colonies from each of the six 
libraries were PCR amplified with primers YOL13 and YOL22. The integrity and 
diversity of the MAGE-A3 TCR libraries was confirmed by DNA sequencing to 
reveal a broad diversity of mutations spanning each of the targeted CDRs (data not 
shown). 
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Figure 5.2. Ethidium bromide stained agarose gel photos of MAGE TCR library 
construction. (A). Gel-purified  chain library PCR fragments. Lane 1, HYP I; lane 
2, PCR fragment a1; lane 3, a2; lane 4, a4; lane 5, a5; lane 6, a7; lane 7, a8; lane 8, 
a10; lane 9, a11; lane 10, a13; lane 11, a14; lane 12, a16 ; lane 13, a17; lane 14, a19; 
lane 15, a20; lane 16, a22; lane 17, a23. (B). Gel-purified  chain library PCR 
fragments. Lane 1, HYP I; lane 2, PCR fragment b1; lane 3, b2; lane 4, b4; lane 5, b5; 
lane 6, b7; lane 7, b8; lane 8, b10; lane 9, b11; lane 10, b13; lane 11, b14; lane 12, b16 
; lane 13, b17; lane 14, b19; lane 15, b20. (C). Overlapping stitch  chain library PCR 
fragments. Lane 1, HYP I; lane 2, PCR fragment a1 only; lane 3, PCR a2 only; lane 4, 
PCR a1 + a2; lane 5, a4 only; lane 6, a5 only; lane 7, a4 + a5; lane 8, a7 only; lane 9, 
a8 only; lane 10, a7 + a8; lane 11, a10 only; lane 12, a11 only; lane 13, a10 + a11; 
lane 14, a13 only; lane 15, a14 only; lane 16, a13 + a14; lane 17, a16 only; lane 18 
a17 only; lane 19, a16 + a17; lane 20, HYP I; lane 21, a19 only; lane 22, a20 only; 
lane 23, a19 + a20; lane 24, a22 only; lane 25, a23 only; lane 26, a22 + a23; lane 27, 
HYP I. (D). Overlapping stitch  chain library PCR fragments. Lane 1, HYP I; lane 2, 
PCR b1 only; lane 3, PCR b2 only; lane 4, PCR b1 + b2; lane 5, b4 only; lane 6, b5 
only; lane 7, b4 + b5; lane 8, b7 only; lane 9, b8 only; lane 10, b7 + b8; lane 11, b10 
only; lane 12, b11 only; lane 13, b10 + b11; lane 14, b13 only; lane 15, b14 only; lane 
16, b13 + b14; lane 17, b16 only; lane 18, b17 only; lane 19, b16 + b17; lane 20, HYP 
I; lane 21, b19 only; lane 22, b20 only; lane 23, b19 + b20; lane 24, blank; lane 25, 
blank; lane 26, blank; lane 27, HYP I. (E). Gel-purified  and  chain SOE-PCR 
fragments. Lane 1, HYP I; lane 2, PCR a3; lane 3, a6; lane 4, a9; lane 5, a12; lane 6, 
a15; lane 7, a18; lane 8, a21; lane 9, a24; lane 10, b3; lane 11, b6; lane 12, b9; lane 
13, b12; lane 14, b15; lane 15, b18; lane 16, b21. (F). Gel-purified NcoI-NotI digested 
 and  chain SOE-PCR fragments. Lane order the same as for gel (E). 
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5.3 Phage selections and screening 
Phage was separately prepared from each of the six libraries as outlined in Section 
2.5.1 and 2.5.2 of Materials and Methods. Panning was performed against the TAA, 
MAGE-A3(168-176), bound in the context of biotinylated HLA-A*0101. Rather than 
using an HLA-stabilising peptide as employed in the Mel-5 and gp100 TCR affinity 
maturation projects, the wild-type MAGE-A3(168-176) peptide bound in the HLA-
A*0101 was sufficiently stable for panning and screening experiments. A total of 
three cycles of panning on 100 nM HLA-A*0101-MAGE-A3(168-176) complexes were 
performed under identical conditions as described in Section 2.5.4 of Materials and 
Methods. 
The output titre for each round of selection was estimated and following the third 
round of panning a significant increase was observed for library 2 (CDR2 ) and 
library 5 (CDR2 ): ~100-fold for library 2 and 17-fold for library 5. The output titre 
for each of the other four libraries remained unchanged from the previous selection 
cycle and so were not analysed.  
Phage was rescued from ninety-three individual ampicillin-resistant E. coli TG1 
colonies from both the CDR2  and CDR2  library outputs as described in Section 
2.5.1 of Materials and Methods. A single E. coli TG1 colony bearing the MAGE-A3 
wild-type clone was grown in each of the two plates. Monoclonal-phage-TCRs were 
screened in an inhibition phage ELISA at 200 nM HLA-A*0101-MAGE-A3(168-176) 
(EVDPIGHLY) to determine if any of the TCRs demonstrated competitive inhibition.  
 
5.3.1 Inhibition phage ELISA 
From the population of CDR2  clones picked, 82 ELISA-positive clones were 
obtained, representing a hit frequency of ~88%. Even more striking was the 100% 
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ELISA-positive hit frequency observed for the CDR2  library clones. Unsurprisingly, 
the wild-type MAGE-A3 TCR failed to produce a signal reflecting the low affinity 
pHLA interaction. A total of eighteen clones from library 2 and nineteen clones from 
library 5 that gave the highest % inhibition readings were sequenced with primers 
YOL13 and J195. A clear convergence to particular mutations was evident in both 
library outputs (Table 5.1). The CDR2  output clones had converged exclusively to 
the following motif: Y
49
X
50
R
51
P
52
Y/F
53
. Similarly, the CDR2  clones showed 
remarkable convergence to the following mutations: T
50
D
51
X
52
L
53
L
54
 in all sequenced 
clones. The average % inhibition value at 200 nM inhibitor for the CDR2  mutants 
was ~30% and for the CDR2  mutants ~40%.   
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A. 
 
Clone 
Number 
CDR2 (L49-S53) Freq. 
% Inhib. 
@ 200 nM 
wt L  I  Q  S  S   
cttattcagtcaagt 
- - 
MAGEa1 Y  F  R  P  F   
tattttcggccgttt 
6 28 
MAGEa2 Y  M  R  P  F   
tatatgcggccgttt 
3 29 
MAGEa3 Y  I  R  P  Y   
tatattcggccgtat 
2 31 
MAGEa4 Y  L  R  P  Y   
tatctgcggccgtat 
1 33 
MAGEa5 Y  L  R  P  F   
tatttgcggccgttt 
1 25 
MAGEa6 Y  V  R  P  Y 
tatgttaggccttat   
1 26 
MAGEa7 Y  H  R  P  Y   
tatcataggccttat 
1 31 
 
B. 
 
Clone 
Number 
CDR2 (F50-Q54) Freq. 
% Inhib. 
@ 200 nM 
wt F  S  E  T  Q 
ttcagtgagacacag 
- - 
MAGEb1 T  D  L  L  L 
acggatcttttgttg 
4 38 
MAGEb2 T  D  M  L  L 
acggatatgttgttg 
1  86* 
MAGEb3 T  D  S  L  L 
acggatagtttgttg 
3 34 
MAGEb4 T  D  G  L  L 
acggatggtctgctg 
3 41 
MAGEb5 T  D  T  L  L 
acggatactttgttg 
2 24 
MAGEb6 T  D  R  L  L 
actgataggttgttg 
1 37 
MAGEb7 T  D  H  L  L 
acggatcatttgttg 
1 49 
MAGEb8 T  D  A  L  L 
actgatgcgcttttg 
1 44 
 
 
Table 5.1. Output clones obtained following three rounds of panning against 
biotinylated-HLA-A*0101-MAGE(168-176) (EVDPIGHLY) complexes. (A). Library 
2: CDR2  mutants. Eighteen clones were sequenced; 3 contained mixed templates 
and are not included in the analysis. (B). Library 5: CDR2  mutants. Red lettering 
indicates residues mutated from the parental sequence. Nineteen clones were 
sequenced; 3 contained mixed templates and are not included in the analysis. Freq., 
the number of copies in the sequenced pool. For repeated sequences, the % inhib. 
represents the average value between the repeats. *The Abs reading for MAGEb2 was 
significantly lower than the readings for the other clones. 
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5.4 Constructing CDR2 :CDR2  crossing library 
A crossing library is assembled by splicing two independent libraries (CDR2  and 
CDR2 so that a new library of TCRs is generated in which two CDRs are mutated 
within the same molecule (CDR2 :CDR2 ). Crossing libraries were constructed (as 
described in Section 2.4.3.2 of Materials and Methods) firstly to identify an 
improved-affinity clone on which to construct second -generation libraries and 
secondly to ascertain if the mutations in the two CDR segments were additive.  
Although it is difficult to accurately predict the affinity of a TCR mutant based on 
phage inhibition ELISA data alone, in combination with BIAcore data of previous 
TCRs, such assays do provide an affinity window for a panel of novel clones. The 
phage inhibition ELISA data and BIAcore measurements, compiled for the Mel-5 and 
gp100 TCRs provided a guide against which to compare the MAGE-A3 TCR 
mutants. Whilst the comparisons did not account for variation in TCR-display levels, 
quality and stability of pHLA antigen or HLA-restriction, they were informative 
nonetheless. 
Mel-5 TCR clone MELa1bwt (KD value of 6.4 nM) and gp100 TCR clone GPa1b7 
(KD value of 6.26 nM) exhibited inhibition values of 50-60% at 5 nM inhibitor. Mel-5 
TCR clone MELa1cbwt (KD value of 450 nM) gave an inhibition  level of  60% at 10 
nM inhibitor. Guided by this information, it was anticipated that the MAGE-A3 TCR 
single CDR mutants would exhibit KD values in the low micromolar range. If these 
predications were confirmed by BIAcore analysis, TCRs demonstrating such a kinetic 
profile would be unsuitable for therapeutic application or as template for second 
maturation libraries. It was envisaged that recruiting two mutated CDR segments into 
the same molecule would provide the necessary improvement in affinity to satisfy 
these requirements.    
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DNA was isolated from the CDR2  and CDR2  Pan 3 bacterial glycerol stocks 
using the QIAprep spin miniprep kit (Qiagen) as described in Section 2.4.3.2 of 
Materials and Methods and 10 g of each was digested with NcoI-AvrII to excise  
chain library fragments from the CDR2  libraries and wild-type  chains from the 
CDR2  libraries (see Figure 5.1 for location of restriction enzyme sites). Digests were 
resolved on a 1% agarose gel. The NcoI-AvrII fragment (~640 bp) from the CDR2  
library miniprep DNA was cloned into the NcoI-AvrII digested CDR2  library 
miniprep DNA (~6.2 kbp) to generate TCRs mutated in both CDR2  and CDR2  
loops. The 5 g ligation reaction was used to transform electrocompetent E. coli TG1 
cells and yielded 10
8
 discrete transformants. 
 
5.4.1 Phage selection and screening 
Since the Pan 3 output of both the CDR2  and CDR2  libraries was highly enriched 
as assessed by sequence analysis (Table 5.1) only a single cycle of selection at 100 
nM biotinylated HLA-A*0101-MAGE-A3(168-176) was performed. Monoclonal-phage- 
TCRs were prepared from a representative set of ninety CDR2 :CDR2  
transformants together with two separate E. coli TG1 colonies bearing single CDR 
mutated clones MAGEa1bwt (CDR2 ) and MAGEawtb1 (CDR2 ). Of the 
population of clones that were screened in an inhibition phage ELISA at 200 nM 
HLA-A*0101-MAGE-A3(168-176) (EVDPIGHLY), 84 ELISA-positive clones were 
obtained, representing a 93% hit-rate. Encouragingly, combining mutated CDR2  and 
CDR2  segments into the same TCR molecule increased the % inhibition compared 
to the single CDR mutated clones. Clones MAGEa1bwt and MAGEawtb1 exhibited 
inhibition values of 37% and 26% respectively, whereas the double-mutants displayed 
inhibition values in the range of 66-94% at the same concentration of inhibitor.  
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Twenty-four clones that demonstrated the highest % inhibition at 200 nM inhibitor 
were sequenced with primers YOL13 and J195 (Table 5.2). Sequence analysis of the 
double-CDR-mutated clones confirmed the strong selective enrichment of mutations 
present in the Pan 3 output shown in Table 5.1. Of the seven CDR2  mutants shown 
in Table 5.1 A, five were re-selected in combination with a mutated CDR2  segment 
(Table 5.2). Of the eight mutated CDR2  regions obtained from the individual CDR 
libraries (Table 5.1 B), six were re-isolated in association with a mutated 
CDR2 segment (Table 5.2). The  chain segments contained the consensus 
sequence Y
49
X
50
R
51
P
52
Y/F
53 
with the exception of clones MAGEa8, MAGEa12 and 
MAGEa13 which varied in two, four or one of these conserved positions respectively. 
The  chain segments also maintained the consensus sequence T
50
D
51
X
52
L
53
L
54
 
shown in Table 18B with the exception of clones MAGEb12 and MAGEb13 which 
varied in one and three positions respectively.  
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Clone 
Number 
CDR2 (L49-S53) CDR2 (F50-Q54) 
% Inhib. 
@ 200 nM 
wt L I Q S S F S E T Q - 
MAGEa1bwt Y F R P F F S E T Q 37 
MAGEawtb1 L I Q S S T D L L L 26 
MAGEa3b6 Y I R P Y T D R L L 77 
MAGEa4b6 Y L R P Y T D R L L 83 
MAGEa8b6 Y L G A Y T D R L L 66 
MAGEa9b3 Y I R P F T D S L L 80 
MAGEa10b3 Y F R P Y T D S L L 69 
MAGEa3b3 Y I R P Y T D S L L 69 
MAGEa4b4 Y L R P Y T D G L L 69 
MAGEa11b4 Y M R P Y T D G L L 94 
MAGEa11b1 Y M R P Y T D L L L 70 
MAGEa12b1 G F I N Q T D L L L 97 
MAGEa11b1 Y M R P Y T D L L L 67 
MAGEa13b9 Y Y L P Y T D F L L 67 
MAGEa6b9 Y V R P Y T D F L L 88 
MAGEa1b10 Y F R P F T D D L L 72 
MAGEa7b11 Y H R P Y T D A L L 71 
MAGEa9b7 Y I R P F T D H L L 70 
MAGEa9b12 Y I R P F T S S L L 70 
MAGEa6b9 Y V R P Y T D F L L 70 
MAGEa14b13 Y S R P Y Q D G M L 68 
 
Table 5.2. Output clones obtained from the crossed Pan 3 CDR2 :CDR2  
libraries. The Pan 3 CDR2  library output was cloned as NcoI-AvrII fragments into 
the  Pan 3 CDR2  output so that each phagemid vector construct encoded a TCR 
mutated in both CDR2  and CDR2  segments. Following one cycle of panning 
against biotinylated-HLA-A*0101-MAGE(168-176) complexes phage was prepared 
from 90 individual ampicillin-resistant clones and analysed in a phage inhibition 
ELISA with 200 nM non-biotinylated HLA-A*0101-MAGE(168-176) antigen. Twenty-
four clones demonstrating the highest level of inhibition were sequenced of which 
five failed to yield readable sequence. Clones MAGEa1bwt and MAGEawtb1 were 
also analysed to provide inhibition values for single-mutated CDR mutants. Clones 
MAGEa12 and MAGEb13 contain an amber codon (Q). Red lettering indicates wild-
type residues retained from the parental sequence. In the Clone Number heading, a = 
 chain and b =  chain. 
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5.5 Kinetic analysis of first-generation MAGE-A3 TCRs 
Since the enrichment for particular CDR2  and CDR2  sequences was so dramatic, it 
was proposed that characterisation of a limited panel of mutants would provide 
sufficient information regarding the binding kinetics of the entire phage selection 
output. Three  chain (MAGEa1, MAGEa2 and MAGEa6) and three  chain 
(MAGEb1, MAGEb2 and MAGEb9) mutants were cloned into pEX954 for the 
chains and pEX821 for the  chains for expression in E. coli strain Rosetta (DE3) 
pLysS. Soluble TCR was refolded from denatured inclusion bodies as described in 
Section 2.6 of Materials and Methods. BIAcore experiments were performed under 
kinetic conditions as described in Section 2.7 of Materials and Methods. Recruiting  
and  chain segments into the MAGE-A3 TCR increased the affinity up to ~7000-fold 
(KD of 35 nM) and ~4000-fold (KD of 61 nM) respectively (Table 5.3 A). Clone 
MAGEa1bwt and clone MAGEa2bwt differ by a single residue in CDR2 ; S51F and 
S51M respectively. Since single residue differences within the CDR motif accounted 
for only minor variation in affinity the importance of the conserved residues in 
affinity improvements were therefore highlighted. Combining mutated CDR2  and 
CDR2  segments to generate clone MAGEa6b9 yielded a significant improvement in 
the affinity; >3.5 million-fold increase over the wild-type TCR. Such a dramatic 
improvement in affinity was not anticipated from the phage inhibition ELISA results 
(Table 5.1 and 5.2) or from the affinity maturation of the Mel-5 and gp100 TCRs. The 
highest affinity TCR generated by the combination of two mutated CDR segments 
was 400 pM for the Mel-5 TCR, 200 pM for the gp100 TCR and was 67 pM for the 
MAGE-A3 TCR (Table 5.3 B). This represented affinity improvements over the wild-
type TCR of 45,000-fold, 415,000-fold and 3,701,492-fold respectively. 
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A.  
Clone ID CDR2  CDR2  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt LIQSS FSETQ nd nd 248000 nd 1 
MAGEa1bwt YFRPF   FSETQ 2.75 x 10
5
 9.60 x 10
-3
 35 1.2 7085.7 
MAGEa2bwt YMRPF   FSETQ 2.43 x 10
5
 1.51 x 10
-2
 62 0.77 4000 
MAGEa6bwt YVRPY   FSETQ 5.49 x 10
5
 1.04 x 10
-2
 190 1.1 1305.3 
MAGEawtb1 LIQSS TDLLL 4.24 x 10
5
 2.58 x 10
-3
 60.8 4.4 4079 
MAGEawtb2 LIQSS TDMLL 3.29 x 10
5
 5.55 x 10
-2
 169 2 1467.5 
MAGEawtb9 LIQSS TDFLL 4.47 x 10
5
 3.87 x 10
-2
 86.5 2.9 2867.1 
 
 
 
B. 
 
Clone ID CDR2  CDR2  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt LIQSS FSETQ nd nd 248000 nd 1 
MAGEa1b1 YFRPF   TDLLL 2.81 x 10
5
 2.83 x 10
-5
 0.1005 417 2467661.7 
MAGEa6b9 YVRPY   TDFLL 3.38 x 10
5
 2.17 x 10
-5
 0.067 546 3701492.5 
 
Table 5.3. Affinities and binding kinetics of MAGE TCR mutants isolated from first-generation libraries. (A). Phage output. Mutants 
isolated from CDR2  and CDR2  libraries. (B). Combination of the most optimal alpha and beta chain CDR segments. Kon and Koff were 
determined by SPR in a BIAcore using purified refolded TCR and KD calculated. nd, not determined. In the Clone Number, a = alpha chain, b = 
beta chain and wt = wild-type. HLA-A*0101-MAGE(168-176) (EVDPIGHLY) and HLA-A*0101-M1(58-66) (GILGFVFTL) were used as test and 
control antigen respectively. (Data kindly provided by J. Gavarret). 
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5.6 Cellular testing of clone MAGEa6b9 in T-cell redirection assays 
Hitherto, the engineering of soluble TCRs to generate high affinity molecules against 
TAA targets has been described. To enable therapeutic utility an associated effector 
function is necessary since in a soluble form the TCR is uncoupled from the naturally-
occurring function, i.e. the T-cell.  
Clone MAGEa6b9 was reformatted into a bispecific molecule capable of targeting 
two distinct cell surface proteins by fusing a CD3-specific scFv to the high affinity 
TCR  chain. To evaluate the mechanism of action of MAGEa6b9-anti-CD3-scFv 
two components of the proteins intended function were examined; redirected T-cell 
activation and target cell lysis. Experiments were performed by Dr. N. Hassan. 
Activation of T-cells was investigated by measuring release of pro-inflammatory 
cytokines; target cell lysis was determined by assessing the release of metabolic 
enzymes or the triggering of apoptotic enzymes in dying cells. Utilising these assay 
systems it was shown that MAGEa6b9-anti-CD3-scFv potently redirected T-cells 
against MAGE
 
antigen positive targets. However, a significant level of activity 
against MAGE
 
antigen negative targets was also measured (Figure 5.3). This was 
deemed too high to be clinically acceptable.  
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Figure 5.3. MAGEa6b9-anti-CD3-scFv redirected T-cell activation in the 
presence of MAGE-positive tumour cells. HLA-A*0101
+
/MAGE-A3
+
 (▼ A375) 
and   HLA-A*0101
+
/MAGE-A3
-
 (▼ HEP2) cell-lines were incubated with CD8+ T-
cells derived from normal donors and increasing concentrations of MAGEa6b9-anti-
CD3-scFv in a granzyme B release ELISPOT assay. Controls included A375 cells + 
CD8
+
 T-cells (▼) and HEP2 cells + CD8+ T-cells (▲). Data points represent mean of 
triplicate values. Error bars are standard error of mean (SEM). Assays were performed 
overnight at 37
o
C and 5% CO2. (Data kindly provided by Dr. N. Hassan). 
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5.7 Second -generation MAGE-A3 TCR libraries 
5.7.1 Addressing the off-target activity of clone MAGEa6b9  
An overview of both the first and second -generation libraries is provided in Figure 
5.4. It was hypothesised that increasing the affinity of the MAGE-A3 TCR through 
mutations exclusively within the germline-encoded CDR2 loops could enhance the 
affinity for the HLA-A*0101 heavy chain by increasing off-target binding in a 
peptide-independent manner. Although BIAcore experiments had indicated initial 
specificity of the MAGEa6b9 TCR with no detectable binding to HLA-A*0101-
M1(58-66) (GILGFVFTL), such experiments are not representative of the complexity of  
the cellular milieu.  
Selectively altering the amino acid residues of the CDR3 which interact with the 
peptide as it lies in the HLA groove, could redress the compromised specificity 
observed with clone MAGEa6b9. Three strategies were devised to target the CDR3 
loops for mutagenesis (Table 5.4). These strategies addressed several features of the 
phage display process: (1) the format of the TCR (native or mTCR), (2) the number of 
consecutive residues mutated (5-NNK or 6-NNK) and (3) the selection conditions 
(subtractive panning on human primary cells followed by selection on soluble pHLA).  
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Figure 5.4. Schematic overview of the affinity maturation of the MAGE-A3 TCR. 
First-generation libraries targeted all six CDR loops with 5-NNK oligonucleotides 
using the wild-type MAGE-A3 TCR (native format) as template. Phage-ELISA 
screening identified mutations exclusively in the CDR2 loops of the  and  chains. 
Combination of the CDR2  and CDR2  segments produced clone MAGEa6b9 with a 
KD of 67 pM and a T1/2 of ~9 hours. The off-target binding activity of MAGEa6b9 
was deemed unacceptable and required further engineering. Back mutation of clones 
MAGEa6 and MAGEb2 generated clones MAGEa6a and MAGEb2a with KD values 
of 6.55 M and 9.43 M respectively suitable for use as second -generation 
templates. Three second -generation strategies were investigated to isolate CDR3 
mutations; exploring the TCR format, the number of residues simultaneously mutated 
and the panning conditions. 
 First generation libraries
All CDRs targeted
KD 190 nM MAGEa6 MAGEb2       KD 169 nM
KD 6.55 M MAGEa6a MAGEb2a     KD 9.43 M
Back mutated
Hits
Second generation libraries
CDR3 loops targeted
Strategy 1
Native TCR
MAGEa6a, MAGEb2a
5
pHLA
Strategy 2
mTCR
MAGEa6a, MAGEb2a, wt
5
pHLA
Strategy 3
Native TCR
MAGEa6a
6
Cells and pHLA
Format:
Template:
NNK:
Panning:
CDR2 CDR2
KD 67 pM MAGEa6b9
Back mutants
Clones MAGEa1-a14 Clones MAGEb1-b13
Best combination
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Strategy ds-format 
Targeted  
CDR 
Framework NNK Panning strategy 
Sequence 
analysis 
1 Native 
CDR3  
CDR3  
MAGEa6a 
MAGEb2a 
5 3 cycles against HLA-A*0101-MAGE(168-176) Normal 
2 mTCR 
CDR3  
CDR3  
wt 
MAGEa6a 
MAGEb2a 
5 3 cycles against HLA-A*0101-MAGE(168-176) 
Deep 
sequencing 
of TCR  
chain 
3 Native 
CDR3  
CDR3  
MAGEa6a 6 
 
(a) 3 cycles of subtractive panning on HLA-A1
+
 
MAGE
-
 human primary cell lines followed by 
panning against HLA-A*0101-MAGE(168-176) 
 
(b) 3 cycles against HLA-A*0101-MAGE(168-176) 
 
Deep 
sequencing 
of TCR  
chain 
 
Table 5.4. Outline of selection strategies employed to isolate MAGE-A3 TCR CDR3 mutations. ds-format: TCR constant domains 
containing the membrane-proximal cysteine pair in the native format or TCR constant domains containing the engineered cysteine pair in the 
mTCR format. Targeted CDR: CDR3 domains exclusively targeted. Framework: mutated CDR3 libraries built in the context of the wt TCR 
chains, enhanced-affinity clone MAGEa6a (CDR2  mutant) or enhanced-affinity clone MAGEb2a (CDR2  mutant). NNK: 5 or 6 residues 
targeted with the NNK motif.  
 
 
 
Chapter 5 
 269 
5.8 Strategy 1 - Exploring the native TCR format on enhanced-affinity 
framework 
The first-generation MAGE-A3 TCR libraries built in the context of the wild-type 
framework had failed to yield high affinity CDR3 mutants. Using an enhanced-
affinity clone from the first maturation libraries for further mutagenesis had proved a 
fruitful strategy in isolating mutations in further CDR loops for both the Mel-5 and 
gp100 TCRs. Mutations within the CDR2 loops had been identified from first 
maturation MAGE-A3 TCR libraries. Based on the engineering of the Mel-5 and 
gp100 TCRs, enhanced-affinity CDR2  and CDR2  MAGE-A3 TCRs were used as 
template to obtain mutations in the CDR3 loops. The enhanced-affinity MAGE TCR 
templates were first cloned in the native TCR format and the CDR3 loops were 
subsequently mutated using overlapping 5-NNK oligonucleotides. 
  
5.8.1 Cloning the MAGEa6a and MAGEb2a TCRs into the phagemid vectors 
The binding kinetics of MAGEa6 (KD of 190 nM and T1/2 of 66 seconds) and 
MAGEb2 (KD of 170 nM and T1/2 of 120 seconds) were deemed unsuitable to use as 
templates for further mutagenesis. Whilst it had proved difficult to isolate novel 
mutations in the Mel-5 TCR using the highest affinity clone MELa1 as template (KD 
of 6.4 nM and T1/2 of 210 s), using a back-mutated version (KD of 450 nM), provided 
a more optimal framework to isolate further mutations.  
Consequently, a panel of back-mutated TCRs, based on clones MAGEa6 
(YVRPY) and MAGEb2 (TDMLL) was generated by Dr. A. Bennett. Each mutated 
residue in the CDR2 loop was sequentially reverted to wild-type to produce eight 
separate E. coli expression plasmids designated MAGEa6a-a6d and MAGEb2a-b2d. 
TCRs were refolded from denatured inclusion bodies and purified ds-linked TCRs 
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were subjected SPR analysis on a BIAcore3000. Equilibrium binding constants (KD) 
of 6.55 M for MAGEa6abwt and 9.43 M for MAGEawtb2a were calculated.  
Clones MAGEa6a (LVRPY) and MAGEb2a (TDMTL) did not exist in the 
phagemid format and required engineering. The phagemid vectors pIM194 and 
pIM195 encoding the back-mutated TCR segments MAGEa6a and MAGEb2a 
respectively, were constructed by SOE-PCR as described in Section 2.3.2 of Materials 
and Methods.  
 
5.8.2 Design and construction of Strategy 1 libraries  
Mutated CDR3  and CDR3  libraries were constructed on both the MAGEa6a and 
MAGEb2a frameworks (a total of four independent libraries) as described in Section 
2.4.3 of Materials and Methods. NcoI and NotI digested pIM194 and pIM195 
phagemid vectors were used as template and CDR3 segments were mutated using 5-
NNK oligonucleotides listed in Section 2.4.3 of Materials and Methods and following 
the PCR strategy depicted in Figure 2.5 of Materials and Methods. In addition to the 
first-generation primers, an extra NNK primer was designed to increase coverage of 
both the CDR3  (primer Nat100) and CDR3  (primer Nat102) segments (Section 
2.4.3 of Materials and Methods). SOE-PCR-generated library fragments (six CDR3  
and five CDR3 ) were cloned into pEX922 as NcoI-NotI fragments to yield libraries 
comprising 10
8
-10
9
 transformants. Sequencing of ten random clones showed diversity 
across each CDR (data not shown).   
 
5.8.3 Phage selection and screening 
Three cycles of panning against biotinylated HLA-A*0101-MAGE-A3(168-176) were 
performed as described in Section 2.5.4 of Materials and Methods. The stringency of 
selection was increased with each round: decreased antigen concentration, decreased 
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phage input and increased number of washes (Table 5.5). The output titre for each 
round of selection was estimated and following the third round of panning up to a 10-
fold increase was observed for libraries 1, 2 and 4 (Table 5.5).  
Pan 3 phage from individual ampicillin-resistant E. coli TG1 colonies was rescued 
together with a single E. coli TG1 colony bearing enhanced-affinity clones MAGEa6, 
MAGEa6a and MAGEb2a (grown in each of the four plates). Monoclonal phage 
TCRs were screened in an inhibition phage ELISA at 200 nM biotinylated HLA-
A*0101-MAGE-A3(168-176) to determine if any of the TCRs demonstrated competitive 
inhibition. Antigen-binding phage clones were obtained from all four libraries. 
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  Pan 1  
100 nM pHLA 
7 washes 
Pan 2 
80 nM pHLA 
9 washes 
Pan 3 
50 nM pHLA 
9 washes 
Library Targeted CDR:Template 
Input  
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
1 CDR3 :MAGEa6a 6 x 10
11
 5 x 10
5
 2 x 10
11
 1.5 x 10
6
 1 x 10
11
 1.5 x 10
7
 
2 CDR3 :MAGEb2a 6 x 10
11
 5 x 10
5
 2 x 10
11
 4 x 10
7
 1 x 10
11
 3.6 x 10
8
 
3 CDR3 :MAGEa6a 6 x 10
11
 5 x 10
5
 2 x 10
11
 9 x 10
6
 1 x 10
11
 1.3 x 10
7
 
4 CDR3 :MAGEb2a 6 x 10
11
 3 x 10
5
 2 x 10
11
 7 x 10
6
 1 x 10
11
 6 x 10
7
 
 
Table 5.5. MAGE-A3 TCR CDR3 Strategy 1 library selections. Three cycles of selection against biotinylated HLA-A*0101-MAGE(168-176) 
antigen were performed. The stringency of the panning conditions was increased with each round; pHLA concentration was decreased and the 
number of washes increased. To estimate the phage titre, the input phage preparation was diluted 50-fold in PBS and the absorption at 260 nm 
was measured. The phage titres were estimated according to the following empirical formula: phage ml
-1
 = Abs260 x phage dilution x 22.14 x 
10
10
 (Lee, Iorno et al. 2007). The output phage titres were estimated by infecting log-phase E. coli TG1 cells with eluted phage and plating onto 
agar plates supplemented with ampicillin and 2% glucose and incubated overnight at 30 ºC as described in Section 2.5.4 of Materials and 
Methods. The estimation of phage titre determined using either method correlated closely (data not shown). In order to reduce potential 
proteolysis of the display TCR, the input phage was titred using the Abs260 method to allow a cycle of selection to be performed on the day of 
phage precipitation. Thus reducing potential proteolysis of the displayed TCR.      
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5.8.4 Primary screening of crude phage supernatant 
Twenty clones from each library demonstrating the highest % inhibition at 200 nM 
inhibitor were sequenced (Table 5.6). The Pan 3 output for library 2 (Table 5.6 B) and 
library 4 (Table 5.6 D) built on MAGEb2a were enriched for a non-designed  TCR 
combination; clone MAGEa6b2a (19 out of 20 and 3 out of 20 sequenced clones 
respectively). The presence of this clone in the two libraries was the result of a PCR-
splice reaction between the MAGEa6 chain and the MAGEb2a chain that 
occurred during library construction. The MAGEa6b2a clone was not seen in the 
sequencing of either pre-selected libraries. Such a degree of enrichment for this clone 
in library 2 (95%) indicated a lack of CDR3  mutants in the context of MAGEb2a 
with improved binding kinetics compared to clone MAGEa6b2a. Assuming that 
library 4 (built on the same template as library 2) contained a similar level of 
MAGEa6b2a contamination, the presence of 85% unique CDR3  clones in the Pan 3 
output suggested an improved fitness over the contaminating splice variant. 
Of the 20 sequenced clones from library 1 (Table 5.6 A), one was of poor quality 
and so was not included in the analysis. The remaining sequences converged to 7 
unique clones with several being represented by multiple copies. Fourteen sequenced 
clones shared a common motif: P-F-X
101
-V-X
103
, where X
101
 was mutated to a Tyr or 
Phe and X
103
 mutated to a Val, Lys or Arg. In clone MAGEa21, the wild-type Ser
99
 
was retained but also included the Y
100
 to Phe and L
102
 to Val substitutions common 
to all clones. Although an S99P substitution was seen in 14 out of 19 sequenced 
clones, S
99
 was also substituted for an Ala in several clones. The % inhibition values 
at 200 nM inhibitor for the selected library 1 clones were in a similar range (86-91%) 
to that observed for clone MAGEa6 (86%). This relatedness in phage inhibition 
ELISA would imply that they also shared similar affinity values. The back mutated 
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TCRs MAGEa6a and MAGEb2a failed to produce a signal reflecting the low affinity 
pHLA interaction. The nucleotides highlighted in blue (Table 5.6) indicate alternative 
codon usage; multiple codon usage provides confidence of library diversity. The 
single unique clone from library 2 (Table 5.6 B), MAGEa22 demonstrated an 
inhibition value higher than the reference clone, MAGEa6. As the output was 
dominated by the contaminant clone MAGEa6b2a, it was likely that this mutant was 
selected based on improvements in affinity. Of the 20 sequenced clones from library 
3, 11 shared the consensus QVS motif (residues 97-99). All variants conferred an 
increase in the level of inhibition compared to clone MAGEa6 reflecting a potential 
improvement in affinity over the parental clone. The affinity of clone MAGEa6a is 
too weak to exhibit a signal in this system indicating that the ELISA positive clones 
were of higher affinity. A second group of mutants, derived from a separate NNK 
primer was isolated yielding inhibition values in excess of that registered for clone 
MAGEa6. In this collection, five individual sequences had converged to three clones. 
This subset showed a strong preference for particular substitutions: S94G and M97E. 
In all cases, the wild-type Asn
96
 was retained. The 17 sequenced clones from library 4 
(Table 5.6 D), excluding the 3 non-designed MAGEa6b2a sequences, converged to 9 
unique mutants. Second -generation libraries were built on more than one framework 
with the aim to satisfy two objectives: (1) to increase the opportunity of isolating 
improved-affinity mutants and (2) to identify clones with varied sequence. The 
CDR3  libraries were constructed on the MAGEa6a (Table 5.6 C) and MAGEb2a 
(Table 5.6 D) templates. Although common to both outputs was a Q
97
V
98
 motif, a 
diverse sequence output was obtained from overlapping mutations covering as total of 
8 residues. Clone MAGEb30 (containing the Q
97
V
98 
motif) dominated the output (45 
% of sequenced clones). All clones contained an amber codon.  
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A. 
 
Clone 
Number 
CDR3 (S99-T103) Freq. 
% Inhib. 
@ 200 nM 
wt S  Y  Q  L  T 
agttaccaactcact 
- - 
MAGEa6 S  Y  Q  L  T 
agttaccaactcact 
- 86 
MAGEa15* P  F  Y  V  V 
cctttttatgtggtg 
6 89 
MAGEa16* P  F  Y  V  K 
cctttttatgtgaag 
3 91 
MAGEa17 P  F  Y  V  R 
ccgttttatgttcgg 
5 90 
MAGEa18* P  F  F  V  V 
cctttttttgtggtt 
3 90 
MAGEa19 A  F  Y  V  R 
gctttttatgttagg 
1 89 
MAGEa20 A  F  Y  V  V 
gcgttttatgtggtt 
1 88 
MAGEa21 S  F  A  V  V 
gtctttgctgtggtt 
1 86 
 
 
 
B. 
 
Clone 
Number 
CDR3 (G95-S99) Freq. 
% Inhib. 
@ 200 nM 
wt G  G  A  G  S 
ggaggggctgggagt 
- - 
MAGEa6 G  G  A  G  S 
ggaggggctgggagt 
- 86 
MAGEa22* S  Q  S  G  R 
agtcagtcgggtagg 
1 97 
 
 
 
C. 
 
Clone 
Number 
CDR3 (S94-E100) Freq. 
% Inhib. 
@ 200 nM 
wt S  P  N  M  A  D  E  
agcccgaacatggccgacgag 
- - 
MAGEa6 S  P  N  M  A  D  E  
agcccgaacatggccgacgag 
- 86 
MAGEb14* G  R  N  E  A  D  E  
ggtaggaatgaggccgacgag 
2 94 
MAGEb15 G  L  N  M  A  D  E  
ggtcttaatatggccgacgag 
2 92 
MAGEb16 G  L  N  E  A  D  E 
ggtttgaatgaggccgacgag 
1 97 
MAGEb17 G  I  N  E  A  D  E 
gggattaatgaggccgacgag 
1 94 
MAGEb18 S  E  W  Q  V  S  E 
agcgagtggcaggtgtctgag 
1 98 
MAGEb19 S  E  W  Q  V  S  E 1 98 
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agcgagtggtaggtgtctgag 
MAGEb20 S  E  H  Q  V  S  E 
agcgagcattaggtgtcggag 
2 99 
MAGEb21 S  K  Y  Q  V  S  E 
agcaagtattaggtgagtgag 
1 92 
MAGEb22* S  K  H  Q  V  S  E 
agcaagcattaggtgtctgag 
1 97 
MAGEb23 S  R  Y  Q  V  S  E 
agcaggtattaggtgagtgag 
1 99 
MAGEb24 S  L  G  Q  V  S  E 
agcttggggtaggtttcggag 
1 97 
MAGEb25 S  Q  Y  Q  V  S  E 
agccagtatcaggtttcggag 
1 99 
MAGEb26* S  Y  N  L  A  S  E 
agctataatcttgcgtctgag 
1 96 
MAGEb27 S  V  G  Q  V  S  E 
agcgttggtcaggtgtcggag 
1 93 
MAGEb28* S  M  Y  Q  V  S  E 
agcatgtattaggtgagtgag 
1 99 
MAGEb29* S  P  H  Q  V  G  R 
agcccgcattaggttggtcgt 
1 98 
 
 
 
D. 
 
Clone 
Number 
CDR3 (S93-E100) Freq. 
% Inhib. 
@ 200 nM 
wt S  S  P  N  M  A  D  E  
agcagcccgaacatggccgacgag 
- - 
MAGEa6 S  S  P  N  M  A  D  E  
agcagcccgaacatggccgacgag 
- 86 
MAGEb30 S  S  P  N  Q  V  D  G 
agcagcccgaattaggttgatggg 
9 98 
MAGEb31 S  S  P  N  Q  V  D  G 
agcagcccgaaccaggtggatggt 
1 96 
MAGEb32* S  S  Y  V  L  A  M  E 
agcagctatgttttggcgatggag 
1 100 
MAGEb33* S  S  Y  V  L  V  A  E 
agcagctatgttttggttgcggag 
1 97 
MAGEb34* S  S  Y  V  L  A  D  E 
agcagctatgtgcttgctgatgag 
1 92 
MAGEb35 G  S  Y  V  L  A  D  E 
gggtcgtatgtgttggccgacgag 
1 100 
MAGEb36* G  S  Y  T  L  A  D  E 
gggtcgtatacgttggccgacgag 
1 98 
MAGEb37* S  N  L  N  G  A  D  E 
tcgaatcttaatggtgccgacgag 
1 97 
MAGEb38* S  N  R  N  G  A  D  E 
tcgaatcggaatggggccgacgag 
1 75 
 
Table 5.6. Output clones obtained after three cycles of panning against 
biotinylated HLA-A*0101-MAGE(168-176) antigen.  A phage inhibition ELISA was 
performed at 200 nM non-biotinylated HLA-A*0101-MAGE(168-176) antigen. Twenty 
clones showing the highest % inhibition level were sequenced from each library. (A). 
Library 1: MAGE-A3 TCR CDR3  library built on clone MAGEa6a (CDR2  
mutant; KD of 6.55 M).  (B). Library 2: MAGE-A3 TCR CDR3  library built on 
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clone MAGEb2a (CDR2  mutant; KD of 9.43 M). Library 2 was contaminated with 
the high affinity clone MAGEa6b2a. Of the 20 sequenced clones, only one clone 
contained mutations in the targeted CDR3  region. (C). Library 3: MAGE-A3 TCR 
CDR3  library built on clone MAGEa6a. One out of twenty sequenced clones was of 
poor quality and so was not included in the analysis. (D). Library 4: MAGE-A3 TCR 
CDR3  library built on clone MAGEb2a. Library 4 contained a low level 
contamination of high affinity clone MAGEa6b2a (3 out of 20). Amino acids that 
differ from wt are highlighted in bold and red. Nucleotides highlighted in blue 
indicate alternate codon usage between clones sharing the same amino acid sequence. 
Q, amber codon. wt, wild-type. * Clones selected for further analysis in secondary 
phage ELISA screen (section 5.8.5). 
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5.8.5 Secondary screening of purified phage supernatant 
To more precisely establish affinity improvement over the parental clones, a phage 
ELISA was performed at three concentrations of inhibitor (200, 100 and 20 nM). 
Phage was PEG precipitated from 10 ml culture supernatant for the 16 clones 
highlighted in Table 5.6 (Section 2.5.1 and 2.5.2 of Materials and Methods): four 
CDR3  and twelve CDR3  mutants. Additionally, phage was prepared for clone 
MAGEa6 as a reference. 
A preliminary ELISA was performed to determine the dilution of phage that would 
generate a similar level of signal between clones of Abs650 ~1.0 (data not shown). A 
subsequent inhibition ELISA was performed using the dilution of phage (1.75-fold) 
determined from the first ELISA that produced an Abs650 ~1.0. The % reduction in 
signal was measured at 200, 100 and 20 nM inhibitor (Figure 5.5). Using the 
inhibition profile measured for the reference clone MAGEa6 (with a KD of 190 nM), 
it was possible to assess the relative affinity of each of the test mutants. 
Several of the TCR variants (MAGEa22, MAGEb28, MAGE32 and MAGE36) 
registered inhibition values similar to or in excess of the reference clone MAGEa6. A 
number of clones (MAGEa15, MAGEa16, MAGEa18 and MAGEb38) failed to yield 
inhibition values  similar to those measured in the primary screen (Table 5.6). This 
may reflect a discrepancy in the amount of displayed TCR assayed in the primary 
screen compared to the secondary screen. Having normalised the TCR display level in 
the secondary screen the inhibition profiles are more informative (Figure 5.5).  
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                     R         a6a          b2a               a6a                                   b2a 
 
 
Figure 5.5. Inhibition phage ELISA of MAGE-A3 TCR CDR3  and CDR3  
variants at a concentration of 200, 100 and 20 nM inhibitor. The CDR3 libraries 
were built in the context of enhanced-affinity clones MAGEa6a (a6a) and MAGEb2a 
(b2a); clones are grouped accordingly. High affinity clone MAGEa6 was included in 
the ELISA as the reference (R). The PEG-precipitated phage samples were incubated 
with the appropriate concentration of non-biotinylated HLA-A*0101-MAGE(168-176) 
antigen prior to adding to ELISA plates immobilised with HLA-A*0101-MAGE(168-
176) antigen. % Inhib. is measured as the percentage reduction in ELISA signal. The 
background absorbance value was subtracted from all readings before % Inhib. was 
calculated.  
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5.8.6 Kinetic analysis of Strategy 1 TCRs  
To assess the contribution of the CDR3 segments to improvements in affinity, four  
chain (three isolated in the context of MAGEa6a and one in the context of MAGEb2a) 
and eleven  chain (five selected in the context of MAGEa6a and six in the context of 
MAGEb2a) mutants were cloned onto the wild-type MAGE-A3 TCR framework and 
named MAGEa’ or MAGEb’ (Table 5.7 A-D). One  chain (MAGEa22) and one  
chain (MAGEb28) mutant were also cloned in the context of the enhanced-affinity 
mutant on which they were isolated (Table 5.7 E). PCR fragments were ligated into 
pEX954 for the chains and pEX821 for the  chains for expression in E. coli strain 
Rosetta (DE3) pLysS. Soluble TCR was refolded from denatured inclusion bodies as 
described in Section 2.6.4 and 2.6.5 of Materials and Methods and binding affinity 
analysis was performed on a BIAcore3000 as described in Section of Materials and 
Methods. Based on the kinetic data obtained from BIAcore experiments, the most 
optimal CDR3  and CDR3  segments were combined (Table 5.7 F).  
For libraries 1, 2 and 3 the hierarchy of mutants determined by phage inhibition 
ELISA was largely maintained when affinities were determined by SPR. Comparison 
of phage ELISA data and BIAcore data was not possible for the library 4 output as 4 
out of 6 clones aggregated during refolding or failed to show any detectable binding 
as measured by BIAcore.  
A selection of the mutants (highlighted in Table 5.7) was refolded firstly in the 
context of the wild-type MAGE-A3 TCR. The CDR3  segments isolated in the 
context of MAGEa6a (library 1) increased the affinity of the wild-type MAGE-A3 
TCR up to ~1000-fold (Table 5.7 A). However, the soluble protein produced from this 
clone (MAGEa18’) aggregated and so binding kinetic data was not accurate. Proteins 
from the other two clones that were tested (MAGEa15’ and MAGEa16’) shared 
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similar binding kinetics; with improvements in affinity of ~40-fold and ~60-fold 
respectively. 
Although the library 2 output (built on the MAGEb2a framework) was enriched for 
the non-designed mutant MAGEa6b2a, the single unique CDR3  variant isolated 
(MAGEa22’) improved the affinity of the wild-type MAGE-A3 TCR; up to ~1000-
fold (Table 5.7 B).  
The CDR3  segments isolated in the context of MAGEa6a (library 3) increased 
the affinity of the wild-type MAGE-A3 TCR up to ~145-fold (Table 5.7 C). The three 
clones that gave the greatest improvement in affinity shared a QV motif highlighting 
the importance of these residues to the binding.  
Of the six CDR3  segments isolated in the context of MAGEb2a (library 4) only 
two produced measurable kinetics; although one (MAGEb38’) aggregated upon 
purification (Table 5.7 D). Whilst each of the four remaining mutants (MAGEb32’,  
MAGEb34’, MAGEb36’ and MAGEb37’) had registered a positive signal in the 
phage ELISA in the context of the MAGEb2a segment (Table 5.6 D), they failed to 
show any detectable binding when refolded on the wild-type framework (Table 5.7 
D).  
Two of the mutants were subsequently refolded in the context of the enhanced-
affinity TCR on which they were isolated: MAGEa18 (built on MAGEa6a) and 
MAGEb28 (built on MAGEb2a). Improvements in affinity of ~25-fold and ~15-fold 
were observed over the parental clones MAGEa6a and MAGEb2a respectively (Table 
5.7 E). Although additivity of CDR segments was demonstrated for clone MAGEb28  
(KD of 1.7 M on wild-type TCR and 0.6 M on MAGEb2a), this was not observed 
for clone MAGEa18. Clone MAGEa18 on the wild-type TCR framework gave a KD 
of 230 nM and 257 nM on MAGEa6a. One explanation for this unexpected result was 
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that MAGEa18 refolded in the context of the wild-type TCR yielded aggregated 
protein leading to an inaccurate KD of 257 nM.  
The most optimal CDR3 segments were combined; a representative mutant was 
chosen from each of the four libraries (Table 5.7 F). Combining the highest affinity 
CDR3  clone from library 2 (MAGEa22’) with the highest affinity CDR3  clones 
from library 3, increased the affinity up to a further 100-fold over MAGEa22’. 
However, cooperative association of enhanced-affinity CDR segments was not always 
observed. Combining MAGEa22’ with MAGEb38’ reduced the affinity ~100-fold 
over MAGEa22’. Combining MAGEa18’ and MAGEb38’ resulted in loss of 
detectable binding. Clone MAGEa38’ refolded with the wild-type  chain formed 
aggregates upon purification and as such does not represent an optimal  chain 
folding partner.  
Strategy 1 successfully identified mutations in the CDR3 domains that increased 
the affinity over the wild-type TCR. Combining CDR3  and CDR3  mutated 
segments further improved the affinity up to ~100,000-fold. The aim of the second -
generation libraries was not only to identify high affinity CDR3 mutations, but 
moreover, to isolate a variety of CDR3 mutations. As such, further strategies were 
pursued in order to realise these objectives.   
Based on the binding kinetic data obtained for the CDR3 mutants refolded in the 
context of the wild-type TCR, it is not surprising that the first maturation libraries 
(built on the wild-type framework), failed to yield mutations in the CDR3 loops. The 
design of the phage ELISA allows detection of TCR/pHLA interactions with 
dissociation rate constant KD <1 M.  
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A. 
 
Clone ID CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt SYQLT 248000 nd 1 
MAGEa15’bwt PFYVV 5800 0.15 42.8 
MAGEa16’bwt PFYVK 3800 0.15 65.3 
MAGEa18’bwt PFFVV 230 12.6a 1078.3 
 
 
B. 
 
Clone ID CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt GGAGS 248000 nd 1 
MAGEa22’bwt SQSGR 230 0.9 1078.3 
 
 
C. 
 
Clone ID CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt SPNMADE 248000 nd 1 
MAGEawtb14’ GRNEADE 21000 nd 11.8 
MAGEawtb22’ SKHQVSE 2000 0.11 124 
MAGEawtb26’ SYNLASE 21000 nd 11.8 
MAGEawtb28’ SMYQVSE 1700 0.1 145.9 
MAGEawtb29’ SPHQVGR 2500 4 99.2 
 
 
D. 
 
Clone ID CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt SSPNMAD 248000 nd 1 
MAGEawtb32’ SSYVLAM b - - 
MAGEawtb33’ SSYVLVA 35000 nd 7.1 
MAGEawtb34’ SSYVLAD nb - - 
MAGEawtb36’ GSYTLAD nb - - 
MAGEawtb37’ SNLNGAD nb - - 
MAGEawtb38’ SNRNGAD 5500 10.6a 45.1 
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E. 
 
Clone ID CDR2  CDR3  CDR2  CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEa6abwt LVRPY SYQLT FSETQ PNMAD 6550 nd 1 
MAGEa18bwt LVRPY PFFVV FSETQ PNMAD 257 1.8 24.5 
MAGEawtb2a LIQSS SYQLT TDMTL PNMAD 9430 nd 1 
MAGEawtb28 LIQSS SYQLT TDMTL MYQVS 626 0.7 15.1 
 
 
F.  
 
Clone ID CDR3  CDR3  
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt GGAGSSYQLT SSPNMADE   248000 nd - 
MAGEa22’b22’ SQSGRSYQLT SSKHQVSE 3.4 15.7 72941.2 
MAGEa22’b28’ SQSGRSYQLT SSMYQVSE 3.4 13.5 72941.2 
MAGEa22’b29’ SQSGRSYQLT SSPHQVGR 2.3 12.5 107826.1 
MAGEa18’b38’ GGAGSPFFVV SNRNGADE nb - - 
MAGEa22’b38’ SQSGRSYQLT SNRNGADE 22500 1.2 11 
 
Table 5.7. Binding affinities of MAGE-A3 TCR mutants isolated from Strategy 1 
CDR3 libraries. (A). Library 1 (MAGEa6a) mutated CDR3  segments refolded with 
wt  chain. (B). Library 2 (MAGEb2a) mutated CDR3  segments refolded with wt  
chain. (C). Library 3 (MAGEa6a) mutated CDR3  segments refolded with wt  
chain. (D). Library 4 (MAGEb2a) mutated CDR3  segments refolded with wt  
chain. (E). Mutated CDR3 segments refolded in the context of the enhanced-affinity 
clones MAGEa6a and MAGEb2a on which they were selected. (F). Combination of 
the most optimal  and  chain CDR3 segments. Q, amber codon. wt, wild-type. KD 
values were determined by SPR in a BIAcore using purified refolded TCR. nd, not 
determined. ’Indicates mutated CDR3 segment cloned in the context of the wt 
framework and not the enhanced-affinity CDR2 mutant on which they were isolated.
 
a
Aggregation of refolded TCR. 
b
Instability of refolded TCR. nb, no binding observed. 
(Data kindly provided by Dr. A. Powlesland and Dr. A. Legg). 
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5.9 Strategy 2 - Exploring the mTCR format on enhanced-affinity framework 
Up until this point the MAGE-A3 TCR mutagenic libraries had been constructed on 
the native disulphide bond TCR framework. It was unclear how the positioning of the 
inter-chain disulphide cysteines would influence the composition of the phage display 
selection output. Whereas the mTCR cysteines fix the TCR  and  chains in a more 
rigid structure, the native TCR retains a degree of conformational flexibility possibly 
contributing to increased promiscuity. Strategy 2 aimed to explore the impact of the 
TCR format on the variation of mutants isolated.   
 
5.9.1 Cloning the wild-type MAGE-A3 TCR (mTCR format) into the phagemid 
vector 
The phagemid vector pLAS0282 for the display of the MAGE-A3 TCR in the mTCR 
format was constructed as described in Section 2.3 of Materials and Methods. MAGE-
A3 TCR PCR fragments A (V ), B (V ), C (C  containing mTCR cysteine) and D 
(C  containing mTCR cysteine) (all fragments from Section 2.3 of Materials and 
Methods) were amplified by SOE-PCR with primers J135 and YOL22. The full-
length V C /V C  product was cloned into pEX922 as an NcoI-NotI fragment. A 
sequence-verified clone was used for library construction. Fragment C containing a 
wild-type geneIII leader sequence was used in the construction of pLA0282; the 
geneIII leader sequence from phagemid pIM160 contained a point mutation (Figure 
5.1).  
 
5.9.2 Design and construction of Strategy 2 libraries 
In this strategy, an alternative method for generating mutagenised TCR libraries was 
adopted. In the normal approach, two PCR fragments are generated for each 
overlapping NNK oligonucleotide which are subsequently stitched by SOE-PCR. To 
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construct MAGE-A3 TCR CDR3  and CDR3  libraries on two separate frameworks 
using this method would require 24 individual and 12 SOE-PCRs for each CDR; a 
total of 72 PCRs. As CDR3  and CDR3  libraries had already been built, albeit in the 
native format (Section 5.3 and Section 5.9.3), this material could be used as template 
to generate Strategy 2 libraries.  
A PCR approach was designed to convert CDR3  and CDR3  libraries from the 
native format into the mTCR format (Figure 2.6 of Materials and Methods). The 
CDR3  libraries to be reformatted were library 3 (built on the wild-type framework; 
Section 5.3) and library 1 (on the MAGEa6a framework; Section 5.9.3). The CDR3  
libraries built in the context of MAGEb2a were contaminated with the non-designed 
clone MAGEa3b2a and so were excluded from further libraries (Table 5.6 B).  The 
CDR3 libraries to be reformatted were library 6 (built on the wild-type framework; 
Section 5.3) and library 4 (on the MAGEb2a framework; Section 5.9.3). Whilst the 
CDR3  library built in the context of MAGEa6a had yielded several high affinity 
clones that refolded with a high degree of efficiency, the CDR3  library built on 
MAGEb2a had not. Therefore it was of interest to mine this library further for 
potential high affinity mutants. A total of two CDR3  and two CDR3  libraries were 
reformatted. The schematic diagram in Figure 2.6 of Materials and Methods and the 
design outlined in Section 2.4.3.3 of Materials and Methods describe the strategy 
employed. In brief, the V  and V  library fragments were amplified from the 
appropriate CDR3  and CDR3  library E. coli TG1 glycerol stocks using a reverse 
C  or C  primer located upstream of the native constant region cysteine. Full-length 
V C and V C  domains were assembled by splicing onto the variable domain 
library fragment, a C  or C  region containing the mTCR cysteines. The two CDR3  
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and two CDR3  library SOE-PCR products were cloned into pLAS0282 as NcoI-
AvrII and AvrII-NotI fragments respectively to yield libraries containing 10
9
 
independent transformants. Five randomly selected colonies from each of the four 
libraries were PCR amplified with primers YOL13 and YOL22. The integrity and 
diversity of the MAGE-A3 TCR libraries was confirmed by DNA sequencing to 
reveal a broad diversity of mutations spanning each of the targeted CDRs (data not 
shown). 
 
5.9.3 Phage selection and screening 
The libraries were affinity-selected three times against biotinylated HLA-A*0101-
MAGE-A3(168-176); the antigen concentration was decreased  and the number of 
washes were increased with each round (Table 5.8). The output titre for each round of 
selection was estimated. Following the third round of panning the output increased 
10-fold for library 1, 20-fold for library 2 and 100-fold for library 4. The output of 
library 3 decreased by ~2-fold indicating a failure to enrich for high affinity clones 
(Table 5.8). Phage was prepared from individual ampicillin-resistant colonies as 
described in Section 2.5.1 and 2.5.2 of Materials and Methods. Monoclonal-phage-
TCRs were screened in an inhibition phage ELISA at 100 nM biotinylated HLA-
A*0101-MAGE-A3(168-176) to determine if any of the TCRs demonstrated competitive 
inhibition.  
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 Pan 1  
100 nM pHLA 
7 washes 
Pan 2 
50 nM pHLA 
7 washes 
Pan 3 
50 nM pHLA 
9 washes 
Library Targeted CDR Framework 
Input  
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
1 CDR3  wt 1.5 x 10
11
 1 x 10
6
 1 x 10
11
 5 x 10
4
 1 x 10
11
 5 x 10
5
 
2 CDR3  a6a 1.5 x 10
11
 1 x 10
6
 1 x 10
11
 1 x 10
6
 1 x 10
11
 2 x 10
7
 
3 CDR3  wt 1.5 x 10
11
 4 x 10
5
 1 x 10
11
 1 x 10
5
 1 x 10
11
 4 x 10
4
 
4 CDR3  b2a 1.5 x 10
11
 4 x 10
5
 1 x 10
11
 5 x 10
5
 1 x 10
11
 5 x 10
7
 
 
Table 5.8. MAGE-A3 TCR CDR3 Strategy 2 library selections. CDR3  and CDR3  libraries were built on either wt, MAGEa6a or 
MAGEb2a frameworks. Three cycles of selection against biotinylated HLA-A*0101-MAGE(168-176) antigen were performed. The stringency of 
the panning conditions was increased with each round; pHLA concentration was decreased and the number of washes increased.  
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5.9.4 Phage inhibition ELISA 
ELISA positive clones were obtained from all libraries except library 3, as expected 
from the decreasing output (Table 5.8) Twenty clones from library 1, 2 and 4 
demonstrating the highest % inhibition at 100 nM inhibitor were sequenced (Table 
5.9). Sequencing of the library 1 output showed a contamination with high affinity 
CDR2  library clones (from the first-generation libraries) and so the data is not 
shown. The sequencing data illustrated  in Table 5.9 A shows that four of the mutants 
that were isolated in the native TCR format (Strategy 1 Table 5.6 A) were also 
identified in the mTCR format. Common to both the re-selected and unique library 2 
clones was a P
99
F
100
 motif. Selection of this motif encoded by two overlapping 5-
NNK oligonucleotides (residues A
97
-Q
101
 or S
99
-T
103
) illustrated the importance of 
this combination to improvements in affinity.  
The sequencing data shown in Table 5.9 B shows that three of the mutants that 
were isolated in the native TCR format (Strategy 1 Table 5.6 D) were also identified 
in the mTCR format (MAGEb30, MAGEb34 and MAGEb37). Clones MAGEb37, 
MAGEb39, MAGEb40 and MAGEb41 showed a preference for an Asn at positions 
94 and 96 and a Gly at position 97. Of these four clones only MAGEb37 was isolated 
from Strategy 1 selections.  
Although converting the CDR3  and CDR3  libraries from the native into the 
mTCR format identified a number of unique mutants, the clear overlap between the 
clones isolated from the two strategies indicated minimal influence of the TCR format 
on the selection of MAGE-A3 TCR mutants.  
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A.  
 
Clone 
Number 
CDR3 (A97-T103) Freq. 
% Inhib. 
@ 100 nM 
Isolated from 
 Strategy 1 
wt A  G  S  Y  Q  L  T 
gctgggagttaccaactcact 
- -  
MAGEa15 A  G  P  F  Y  V  V 
gctgggcctttttatgtggtt 
6 82  
MAGEa23 A  G  P  F  Y  V  Q 
gctgggcctttttatgttcag 
1 57  
MAGEa17 A  G  P  F  Y  V  R 
gctgggcctttttatgtgcgt 
2 83  
MAGEa18 A  G  P  F  F  V  V 
gctgggcctttttttgttgtg 
1 82  
MAGEa21 A  G  S  F  A  V  V 
gctgggagttttgctgttgtt 
3 71  
MAGEa24 A  G  S  F  A  T  K 
gctgggagttttgcgactaag 
1 39  
MAGEa25 V  G  P  F  N  L  T 
gttggtccgtttaatctcact 
1 58  
MAGEa26 A  G  P  F  F  V  R 
gctgggcctttttttgttcgt 
1 78  
MAGEa27 V  G  P  F  P  L  T 
ttggtccttttcctctcact 
1 85  
MAGEa28 V  G  S  F  E  L  T 
gtggggagttttgagctcact 
1 78  
MAGEa29 A  G  P  F  Y  V  K 
gctgggccgttttatgtgaag 
1 74  
 
 
B. 
 
Clone 
Number 
CDR3 (S93-E100) Freq. 
% Inhib. 
@ 100 nM 
Isolated from 
 Strategy 1 
wt S  S  P  N  M  A  D  E  
agcagcccgaacatggccgacgag 
- - 
 
MAGEb39 T  N  L  N  G  A  D  E 
acgaatttgaatggggccgacgag 
6 66  
MAGEb37 S  N  L  N  G  A  D  E 
tcgaatctgaatggggccgacgag 
4 92  
MAGEb40 S  N  M  N  G  A  D  E 
tctaatatgaatggtgccgacgag 
1 91  
MAGEb41 G  N  L  N  G  A  D  E 
ggtaatttgaatggtgccgacgag 
1 68  
MAGEb30 S  S  P  N  Q  V  D  G 
agcagcccgaattaggtggatgga 
4 95  
MAGEb34 S  S  Y  V  L  A  D  E 
agttcttatgtgttggccgacgag 
3 80 
MAGEb42 S  S  Y  V  L  S  M  E 
agcagctatgttcttagtatggag 
1 86 
 
Table 5.9. Strategy 2 output clones obtained after three cycles of panning against 
biotinylated HLA-A*0101-MAGE(168-176) antigen.  A phage inhibition ELISA was 
performed at 100 nM non-biotinylated HLA-A*0101-MAGE(168-176) antigen. Twenty 
clones showing the highest % inhibition were sequenced from each library. (A). 
Library 2: MAGE-A3 TCR CDR3  library built on clone MAGEa6a. One sequence 
contained a mixture of templates and so was not included in the analysis. (B). Library 
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4: MAGE-A3 TCR CDR3  library built on clone MAGEb2a. Library 1 pan 3 output 
was contaminated with CDR2  library mutants from the first-generation libraries. 
Library 3 yielded no ELISA positive clones. Amino acids that differ from wt are 
highlighted in bold and red. Nucleotides highlighted in blue indicate alternate codon 
usage between clones sharing the same amino acid sequence. Q, amber codon. wt, 
wild-type. Clones isolated from Strategy 1 library selections are indicated. 
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5.9.5 Deep sequencing of library 4 Pan 0 and Pan 3 outputs 
Whilst high affinity TCR mutants had been successfully isolated from sequencing a 
relatively small number of clones, in order to capture a more complete picture of the 
enrichment of mutated CDR3  segments, a deep sequencing approach was explored. 
Using the high throughput sequencing services of Adaptive Biotechnologies on the 
Illumina GAII System (Robins, Campregher et al. 2009), ~90,000 Pan 0 and ~360,000 
Pan 3 CDR3  sequences were obtained. The top 24 most enriched clones are shown 
in Table 5.10. Although three of the five most enriched clones were also identified by 
phage ELISA (Table 5.9), an additional collection of novel mutants were sequenced. 
Clones MAGEb34 and MAGEb39 dominated the Pan 3 output; ~60% of sequenced 
clones (~1500-fold and ~800-fold enrichment respectively).  
Whilst the 24 clones shown in Table 5.10, derived from 4 out of the 5 overlapping 
5-NNK primers used to generate the CDR3  libraries, suggests a paucity of 
mutational hot-spots, remarkably, there was a clear preference for certain residues at 
some positions: P
95
 was frequently substituted for Tyr or Leu; N
96
 was changed to Val 
or Tyr; M
97
 was substituted for Gln, Phe or Leu (collectively represented in 75% of 
sequences); A
97
 was substituted for Val in half of the sequenced clones; D
99
 was 
changed to Gly, Ser or Leu. Two motifs were also frequently isolated: Q
97 
V
98
 (~33% 
of sequenced clones) and Y
95 
V
96
 (~17% of sequenced clones).   
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Clone 
Number 
CDR3 (C91-E100) 
Pan 0 
% of total 
Pan 3 
% of total 
Fold  
increase 
Identified  
by ELISA 
wt CASSPNMADE 3.83443 0.12149 0.03 - 
MAGEb34 CASSYVLADE 0.01143 17.09598 1495.76 
MAGEb42 CASNFGQVDE 0.00085 0.84545 998.60 
MAGEb39 CATNLNGADE 0.05630 45.64693 810.76 
MAGEb43 CASTVHQVGE 0.00212 0.89267 421.75 
MAGEb18 CASSEWQVSE 0.00085 0.25181 297.43 
MAGEb44 CASSWQPPYE 0.00339 0.96714 285.58  
MAGEb45 CASSPYPDLS 0.00127 0.29922 235.61  
MAGEb46 CASSMWQVSE 0.00127 0.25546 201.16  
MAGEb47 CASSYVLASE 0.00339 0.39883 117.77  
MAGEb48 CASSPNQVDA 0.00127 0.10479 82.52  
MAGEb49 CASSPYPILS 0.00085 0.05988 70.73  
MAGEb50   CASSLLSVVADE 0.00085 0.05911 69.82  
MAGEb51 CASSVQDPLE 0.00085 0.04299 50.78  
MAGEb52 CASSFVLADE 0.00169 0.07447 43.98  
MAGEb53 CASNVGQVGE 0.00381 0.14472 37.98  
MAGEb54 CASSYVLANE 0.00381 0.07313 19.19  
MAGEb55 CASSSSIVSE 0.00085 0.01516 17.91  
MAGEb56 CASSPYPNLG 0.00085 0.01497 17.68  
MAGEb57 CASSYNLVGE 0.00085 0.01132 13.38  
MAGEb58 CASSSMEVSE 0.00212 0.02764 13.06  
MAGEb59 CASSLLQVSE 0.00085 0.00960 11.33  
MAGEb60 CASSYVLADD 0.00085 0.00844 9.97  
MAGEb61 CASSMFQVSE 0.00127 0.00902 7.10  
MAGEb37 CASNLNGADE 0.00423 0.01209 2.86  
 
Table 5.10. MAGE-A3 TCR Strategy 2 deep sequencing of library 4 Pan 0 and 
Pan 3 outputs. 10 g DNA was isolated from Pan 0 and Pan 3 library 4 (CDR3 ) E. 
coli TG1 glycerol stocks. Sequencing of the Pan 0 and Pan 3 outputs on the Illumina 
GAII System generated 93,903 and 365,309 sequences respectively. The frequency of 
each sequence has been converted into a % of the total number of sequences. 
Enrichment of sequences is shown as the fold-increase at Pan 3. Identification of 
clones based on phage inhibition ELISA data (Table 5.9 B) is shown ( or ). Data 
kindly provided by Adaptive Biotechnologies (Seattle, USA). 
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5.9.6 Kinetic analysis of Strategy 2 TCRs 
A subset of  CDR3 mutants identified from the Strategy 2 output were refolded and 
TCR-pHLA binding analysed by BIAcore (Table 5.11). The clones were chosen 
based on isolation frequency or uniqueness of sequence compared to Strategy 1. Two 
CDR3  mutants (containing the MAGEa6a mutated segment) were refolded with the 
wild-type  chain. A single CDR3  mutant (containing the MAGEb2a mutated 
segment) was refolded with the wild-type  chain. Recruiting the CDR3  segments 
(unique to Strategy 2) into the MAGEa6a clone increased the KD by ~30-fold; 
representing ~1000-fold improvement over the wild-type TCR. Recruiting the CDR3  
segment MAGEb30 (highly represented in the Strategy 1 and 2 outputs) into the 
MAGEb2a clone increased the KD by ~850-fold; representing ~22500-fold 
improvement over the wild-type TCR. However, clone MAGEb34 (muated  
CDR3 refolded in the context of the wild-type TCR, failed to exhibit detectable 
binding to HLA-A*0101-MAGE(168-176) (data not shown). This CDR3  segment had 
yielded an ELISA positive signal in the context of MAGEb2a (Table 5.9 B), 
indicating co-operative binding between the mutated CDR2  and CDR3  segments. 
However, a lack of cooperativity between the wild-type CDR2  and mutated CDR3  
culminated in abolished binding.  
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A.  
 
Clone ID CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
KD (MAGEa6a) 
KD (mutant) 
MAGEawtbwt AGSYQLT nd nd 248000 nd 1 - 
MAGEa6abwt AGSYQLT nd nd 6550 nd 37.9 1 
MAGEa24bwt AGSFATK 1.19 x 10
5
 2.69 x 10
-2
 226 0.43 1097.3 29 
MAGEa25bwt VGPFNLT 3.93 x 10
5
 9.03 x 10
-3
 230 1.3 1078.3 28.5 
 
 
B. 
 
Clone ID CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
KD (MAGEb2a) 
KD (mutant) 
MAGEawtbwt PNMADE nd nd 248000 nd 1 - 
MAGEawtb2a PNMADE nd nd 9430 nd 26.3 1 
MAGEawtb30 PNQVDG 5.43 x 10
4
 5.84 x 10
-4
 11 19.8 22545.5 857.3 
 
Table 5.11. Binding affinities of MAGE-A3 TCR mutants isolated from Strategy 2 CDR3 libraries. (A). Library 2: MAGE-A3 TCR 
CDR3  mutant segments cloned in the context of MAGEa6a and refolded with wt  chain. (B). Library 4: MAGE-A3 TCR CDR3  mutant 
segment cloned in the context of MAGEb2a and refolded with wt  chain.  Q, amber codon. wt, wild-type. KD values were determined by SPR 
in a BIAcore using purified refolded TCR. nd, not determined. nb, no binding observed. (Data kindly provided by Dr. A. Legg). 
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5.10 Strategy 3 - Exploring subtractive panning on human primary cell lines 
The MAGE-A3 TCR mutants isolated from the first-generation libraries (Section 5.7) 
demonstrated off-target activity against several human primary cell lines including 
HEP2 (human hepatocyte) and HDMEC3 (human microvascular endothelial cells) 
cell lines. The cell lines are HLA-A*0101 positive but MAGE antigen negative. In 
this context, identification of the exact antigen target on the cell surface is of little 
importance.  
Selection of phage displayed antigens against cell surface receptors performed on 
adherent mammalian cells has proven successful (Liu, Teng et al. 2005; Wang, Liu et 
al. 2011). Panning on whole cells such as against primary cell suspensions of organs 
and tissues or selections against immortalised cell lines is reviewed in (Molek, 
Strukelj et al. 2011). It was hypothesised that preselecting the phage library against 
one or both of HEP2 and HDMEC3 cell lines at each cycle of panning would deplete 
the pool of cross-reactive phage-TCRs. Completing one cycle of panning against 
biotinylated HLA-A*0101-MAGE(168-176) should enrich for specific binders. The 
schematic shown in Figure 5.6 illustrates the strategy employed to deplete the phage 
library population of cross-reactive MAGE-A3 TCRs. Each cycle of panning is 
divided into two parallel selection approaches: (A). Pre-selection of phage libraries on 
human primary cell lines followed by selection on biotinylated HLA-A*0101-
MAGE(168-176) (designated subtractive panning) or (B). Selection exclusively on 
biotinylated HLA-A*0101-MAGE(168-176) (designated normal panning).  
 
 
 
 
Chapter 5 
 297 
Elute
1. HEP2
Amplify
Analyse
Next cycle
Phage library
2. HDMEC3
Discard 
cells
3. pHLA
Wash
3 cycles
Discard 
cells
Elute
Amplify
Analyse
Next cycle
Phage library
pHLA
Wash
3 cycles
A.
B.
 
 
Figure 5.6. Schematic diagram of MAGE-A3 TCR Strategy 3 panning strategies. 
(A). Subtractive panning against human primary cell lines (HLA-A1
+
 MAGE
-
). 1. 
Pre-blocked phage (1 x 10
11
) was incubated with the HEP2 (human hepatocyte) cell 
line (~2 x 10
6
) for 1 h at room temperature (RT). 2. Cells were pelleted at 4,000 rpm 
(RT) and phage supernatant (pSN) incubated with the HDMEC3 (human 
microvascular endothelial cells) cell line (~2 x 10
6
) for 1 h at RT (only for Pan 1). 3. 
Cells were pelleted at 4,000 rpm (RT) and pSN was panned against biotinylated HLA-
A*0101-MAGE(168-176) (pHLA-MAGE-bio). (B). Normal panning against pHLA-
MAGE-bio. Three cycles of both selection strategies were performed in parallel. 
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5.10.1 Design and construction of Strategy 3 libraries 
The CDR3  and CDR3  loops were mutated using overlapping 6-NNK 
oligonucleotides and phagemid vector pIM194 (MAGEa6a) as template. Libraries 
were kindly provided by Dr. Y. Li. Library fragments were assembled by SOE-PCR 
as described in Section 2.4.2 and 2.4.3 of Materials and Methods. Transformation of 
electrocompetent E. coli TG1 cells with each library ligation mixture yielded libraries 
with a complexity of ~10
10
 TCR members.  
 
5.10.2 Phage selection and screening 
Phage was subjected to three cycles of subtractive or normal panning as shown in 
Figure 5.6 following the methods described in Section 2.5.4 of Materials and 
Methods. In the subtractive panning, 1 x 10
11
 phage was incubated with 2 x 10
6
 HEP2 
cells for 1 hour at room temperature. Following centrifugation to pellet the cells, 
phage was incubated for a further hour with 2 x 10
6
 HDMEC3 cells. In Pan 2 and 3, 
phage was incubated with only HEP2 cells. The cells were pelleted and the depleted 
phage population was panned against biotinylated HLA-A*0101-MAGE(168-176). In 
parallel, the phage was also treated to the normal conditions of panning against 
biotinylated HLA-A*0101-MAGE(168-176).  
The output titre for each round of selection was estimated. Following the third 
round of panning the output increased between 20 and 30-fold for each library (Table 
5.12). The outputs consistently were lower for the subtractive panning compared to 
the normal panning reflecting the more stringent conditions of selection. Phage was 
prepared from 96-individual ampicillin-resistant colonies as described in Section 2.5.1 
and 2.5.2 of Materials and Methods. Monoclonal phage TCRs were screened in an 
inhibition phage ELISA at 100 nM biotinylated HLA-A*0101-MAGE-A3(168-176) to 
determine if any of the TCRs demonstrated competitive inhibition. 
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   Pan 1 Pan 2 Pan 3 
Library Targeted CDR Panning 
Input  
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
Input 
phage ml
-1
 
Output 
cfu ml
-1
 
1 CDR3  Subtractive 1 x 10
11
 8 x 10
4
 1 x 10
11
 1.7 x 10
6
 5 x 10
10
 3 x 10
7
 
2 CDR3  Normal 1 x 10
11 1 x 105 1 x 1011 3.2 x 106 5 x 1010 1 x 108 
3 CDR3  Subtractive 1 x 10
11 1 x 105 1 x 1011 1.5 x 106 5 x 1010 4 x 107 
4 CDR3  Normal 1 x 10
11 3 x 105 1 x 1011 2.1 x 106 5 x 1010 5 x 107 
 
Table 5.12. MAGE-A3 TCR CDR3 Strategy 3 library selections. CDR3  and CDR3  libraries were built on the MAGEa6a framework. For 
the subtractive panning, a pre-selection step against HEP2 cells and HDMEC3 cells (in Pan 1 only) was included in each of three cycles of 
panning against biotinylated HLA-A*0101-MAGE(168-176) antigen. In parallel, three cycles of panning against biotinylated HLA-A*0101-
MAGE(168-176) antigen was also performed. 
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5.10.3 Phage inhibition ELISA 
ELISA positive clones were obtained from each of the four libraries. Sequencing of 
library 1 and 2 (CDR3 ), however, showed complete enrichment for a non-designed 
clone MAGEa6ab2a (data not shown). Sequencing of library 3 and 4 (CDR3 ) also 
showed enrichment for clone MAGEa6ab2a but at a lower frequency (~50% of total 
sequences) (Table 5.13). Significant convergence was observed for both the 
subtractive and normal panning outputs.  M
97 
N
98
 was frequently substituted for Gln-
Val in the subtractive (~67% of sequenced clones) and normal panning (50%) 
outputs. Furthermore, a Q-V-S/G motif at positions 97-99 was observed in both 
outputs (~60% subtractive and ~70% normal). The QV and QVS/G mutations derived 
from up to three overlapping 6-NNK primers illustrated the importance of these 
changes to the fitness of the phage-TCR clone. Positions surrounding this motif were 
more permissive. The QV motif was also identified using 5-NNK oligonucleotides in 
both Strategy 1 and 2 further highlighting the value of these substitutions to the 
selection of this clone. Clone MAGEb18 (Table 5.13 B) was also isolated from 
Strategy 2 libraries using 5-NNK primers (Table 5.10). Selection of this clone from 
both the 5-NNK and 6-NNK libraries (irrespective of the TCR format) reflects the 
influence of these mutations on expression and affinity.  
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A.  
Clone 
Number 
CDR3 (S94-Y102) Freq. 
% Inhib. 
@ 100 nM 
wt SPNMADEQY - - 
MAGEa6ab2a SPNMADEQY 14 74 
MAGEb62 AAGQVSEQY 1 77 
MAGEb63 ARYQVSEQY 1 80 
MAGEb64 GEMLVTEQY 1 71 
MAGEb65 SRYEVGRQY 1 87 
MAGEb66 SVGQVTGQY 1 79 
MAGEb67 SVFQVSEQY 1 88 
MAGEb68 SMTQVGRQY 1 83 
MAGEb69 SVGQVSRQY 1 86 
MAGEb70 SRDQVSQQY 1 53 
MAGEb71 SWGQVSRQY 1 83 
MAGEb72 SKDQVGRQY 1 80 
MAGEb73 SRAQVGRQY 1 86 
MAGEb74 SKEQVSEQY 1 88 
MAGEb75 SPNQVGWSQ 1 95 
MAGEb76 SPNQVGLSH 1 86 
MAGEb77 SPNLASGID 1 66 
MAGEb78 SPNQVGRAQ 1 83 
MAGEb79 SPNLADGVT 1 24 
 
B.  
Clone 
Number 
CDR3 (S94-Y102) Freq. 
% Inhib. 
@ 100 nM 
wt SPNMADEQY - - 
MAGEa6ab2a SPNMADEQY 18 74 
MAGEb80  ARFQVSEQY 1 87 
MAGEb81 GINEASEQY 1 68 
MAGEb82 SREQVSSQY 1 74 
MAGEb83 SKEQVGRQY 1 83 
MAGEb84 SYNLASGQY 1 69 
MAGEb18 SEWQVSEQY 1 83 
MAGEb85 SQDQVGRQY 1 83 
MAGEb86 SKFQVDQQY 1 81 
MAGEb87 SYGQVGRQY 1 84 
MAGEb88 SEHQVSRQY 1 91 
MAGEb89 SQGQVDRQY 1 85 
MAGEb90 SPNQVGLSV 1 67 
MAGEb91 SPNQVGLAQ 1 84 
MAGEb92 SPNQVGLSV 1 78 
 
Table 5.13. MAGE-A3 TCR Strategy 3 output clones obtained after three cycles 
of panning. A phage inhibition ELISA was performed at 100 nM non-biotinylated 
HLA-A*0101-MAGE(168-176) antigen. Thirty-two clones showing the highest % 
inhibition were sequenced from each library. (A). Library 3: subtractive panning; 44% 
non-designed PCR splice clone MAGEa6ab2a. (B). Library 4: normal panning; 56% 
non-designed PCR splice clone MAGEa6ab2a. Library 1 and library 2 were 
contaminated with the non-designed PCR splice clone MAGEa6ab2a; no CDR3  
mutants were identified. Amino acids that differ from wild-type are highlighted in 
bold and red. Q, amber codon. wt, wild-type. 
5.10.4 Deep sequencing of library 3 and library 4 Pan 3 outputs 
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Sequencing of 32 ELISA positive clones from the subtractive and normal panning Pan 
3 outputs (Table 5.13) failed to uncover any significant differences between the 
selection strategies. Through deep sequencing a considerably larger pool of clones, it 
was hoped to identify variants unique to the subtractive panning output. In total, 
~140,000 CDR3  sequences from the subtractive panning (library 3) and ~170,000 
sequences from the normal panning (library 4) were obtained.  
The frequency of each clone was converted into a % of the total number of 
sequences (Figure 5.7). There were three groups of clones: those isolated exclusively 
in the subtractive panning output (x-axis, blue triangles), those isolated exclusively in 
the normal panning output (y-axis, green triangles) and those isolated in both outputs 
(red dots). Representing the Pan 3 outputs in this way helped guide the choice of 
mutants to further characterise. An example of the mutants identified solely in the 
subtractive panning output are listed in Figure 5.7. A single outlier sequence is also 
depicted which represents the non-designed clone MAGEa6ab2a. 
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Figure 5.7. MAGE-A3 TCR Strategy 3 deep sequencing comparison of the Pan 3 
outputs of library 3 (subtractive panning) and library 4 (normal panning). 10 g 
of DNA was isolated from E. coli TG1 glycerol stocks of the Pan 3 outputs of library 
3 (subtractive) and library 4 (normal). Sequencing of the pan 3 outputs of library 3 
and library 4 on the Illumina GAII System generated 142,881 and 174,324 sequences 
respectively. The frequency of each sequence has been converted into a % of the total 
number of sequences. The sequences along the x-axis (blue triangles) represent 
mutants identified exclusively in the subtractive panning output. The sequences along 
the y-axis (green triangles) represent mutants identified exclusively in the normal 
panning output. Those sequences along the diagonal (red dots) represent mutants 
identified in both pan 3 library outputs. Of the clones circled along the x-axis three 
were characterised further by BIAcore. The clone indicated with an arrow is 
MAGEa6ab2a (non-designed PCR splice product). Data kindly provided by Adaptive 
Biotechnologies (Seattle, USA).  
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5.10.5 Kinetic analysis of Strategy 3 TCRs 
A comprehensive number of CDR3  mutants identified by phage ELISA and a select 
group of CDR3  mutants identified from deep sequencing were refolded and analysed 
by SPR on a BIAcore3000 as described in Section 2.7 of Materials and Methods 
(Table 5.14). Eleven CDR3  segments isolated from the subtractive panning were 
refolded with MAGEa6a and yielded improvements of up to ~10,000-fold over 
MAGEa6a and ~370,000-fold over the wild-type TCR (Table 5.14 A). Seven CDR3  
segments isolated from the normal panning were refolded with MAGEa6a and yielded 
improvements of up to ~13,500-fold over MAGEa6a and ~510,000-fold over the 
wild-type TCR (Table 5.14 B). The range of affinity was comparable between the two 
selection approaches; KD of 0.663-29.4 nM for clones from the subtractive panning 
and KD of 0.486-39.5 nM for clones from the normal panning.  
In an attempt to generate the highest affinity MAGE-A3 TCR (including a CDR3  
segment), MAGEb18 and MAGEb79 were refolded with the highest affinity  chain 
segment MAGEa26 (a combination of MAGEa6 and MAGEa18). In addition, the 
most abundant CDR3  clones identified from deep sequencing of the subtractive 
panning output were also refolded with MAGEa26. Whilst combining MAGEb18 and 
MAGEa26 was favourable in terms of a half-life gain (5-fold increase), recruiting 
MAGEb79 was not. A lack of cooperativity between the MAGEb79 and MAGEa26 
resulted in a ~13-fold decrease in half-life. Combining MAGEb93, MAGEb96 and 
MAGEb97 with MAGEa26 yielded increases in affinity over the wild-type TCR of 
~110,000-fold, ~177,000-fold and ~59,000-fold respectively.  
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A.  
Clone ID CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
KD (MAGEa6a) 
KD (mutant) 
MAGEawtbwt SPNMADEQY nd nd 248000 nd 1 - 
MAGEa6abwt SPNMADEQY nd nd 6550 nd 37.9 1 
MAGEb62 AAGQVSEQY 3.08 x 10
5
 2.35 x 10
-3
 7.63 4.9 33972.6 897.3 
MAGEb63 ARYQVSEQY 2.35 x 10
5
 8.1 x 10
-4
 3.45 14.3 71884.1 1927.5 
MAGEb64 GEMLVTEQY 2.86 x 10
5
 2.2 x 10
-3
 7.7 5.3 32207.8 850.6 
MAGEb65 SRYEVGRQY 9.18 x 10
5
 3.55 x 10
-3
 3.9 3.3 63589.7 1679.5 
MAGEb66 SVGQVTGQY 2.97 x 10
5
 1.16 x 10
-3
 3.9 10 63589.7 1679.5 
MAGEb67 SVFQVSEQY 3.58 x 10
5
 2.37 x 10
-3
 6.62 4.9 37462.2 989.4 
MAGEb68 SMTQVGRQY 3.27 x 10
5
 1.47 x 10
-3
 4.5 7.9 55111.1 1455.6 
MAGEb71 SWGQVSRQY 1.15 x 10
5
 7.61 x 10
-4
 0.663 15.2 374057.3 9879.3 
MAGEb73 SPNQVGWSQ 3.64 x 10
5
 1.89 x 10
-3
 5.19 6.1 47784.2 1262 
MAGEb75 SPNLASGID 1.53 x 10
5
 4.49 x 10
-3
 29.4 2.6 8435.4 222.8 
MAGEb77 SPNLADGVT 1.32 x 10
5
 2.84 x 10
-3
 21.6 4 11481.5 303.2 
 
B. 
Clone ID CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
KD (MAGEa6a) 
KD (mutant) 
MAGEawtbwt PNMADEQY nd nd 248000 nd 1 - 
MAGEa6abwt PNMADEQY nd nd 6550 nd 37.9 1 
MAGEb78 ARFQVSEQ 3.43 x 10
5
 1.06 x 10
-3
 3.09 10.9 80258.9 2119.7 
MAGEb79 GINEASEQ 1.88 x 10
5
 9.15 x 10
-5
 0.486 126 510288.1 13477.4 
MAGEb82 YNLASGQY 3.01 x 10
5
 3.92 x 10
-3
 13 2.9 19076.9 503.8 
MAGEb18 EWQVSEQY 2.3 x 10
5
 4.79 x 10
-4
 2.1 24 118095.2 3119 
MAGEb85 KFQVDQQY 2.52 x 10
5
 1.3 x 10
-3
 5.2 8.9 47692.3 1259.6 
MAGEb88 QGQVDRQY 3.77 x 10
5
 1.01 x 10
-3
 2.7 11.4 91851.9 2425.9 
MAGEb89 PNQVGLSV 1.7 x 10
5
 6.72 x 10
-3
 39.5 1.7 6278.5 165.8 
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C. 
Clone ID CDR2  CDR3  CDR3  
Kon 
(M
-1
 s
-1
) 
Koff 
(s
-1
) 
KD 
(nM) 
T1/2 
(min) 
KD (parent) 
KD (mutant) 
MAGEawtbwt LIQSS SYQLT PNMADEQY nd nd 248000 nd 1 
MAGEa26b79 YVRPY PFFVV GINEASEQ 8.23 x 10
4
 1.15 x 10
-3
 14 10.1 17714.3 
MAGEa26b18 YVRPY PFFVV EWQVSEQY 6.11 x 104 9.37 x 10-5 1.5 122.4 161039 
MAGEa26b93* YVRPY PFFVV FNMATGQY 8.87 x 104 3.77 x 10-4 2.2 30.6 110714.3 
MAGEa26b94* YVRPY PFFVV RLQIDRQY 1 x 105 1.4 x 10-4 1.4 81.6 177142.9 
MAGEa26b95* YVRPY PFFVV KDQIGRQY 7.6 x 104 3.18 x 10-4 4.2 36.1 59047.6 
 
Table 5.14. Binding affinities of MAGE-A3 TCR mutants isolated from Strategy 3 CDR3  libraries. (A). Library 3 (subtractive): MAGE-
A3 TCR CDR3  mutant segments refolded in the context of MAGEa6a on which they were selected. (B). Library 4 (normal): MAGE-A3 TCR 
CDR3  mutant segments refolded in the context of MAGEa6a on which they were selected. (C). Most optimal  chain segments 
(MAGEa6/MAGEa18) combined with the most optimal CDR3  chain segments identified either by phage inhibition ELISA or through deep 
sequencing (*). Q, amber codon. wt, wild-type. KD values were determined by SPR in a BIAcore using purified refolded TCR. nd, not 
determined. nb, no binding observed. (Data kindly provided by Dr. P. Todorov, Dr. A. Legg and Dr. A. Powlesland).   
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5.11 MAGE-A3 TCR clinical candidates 
Mutated TCRs were reformatted as fusion molecules to an anti-CD3-scFv and tested 
in T-cell redirection assays. Five MAGE-A3 TCR clones (in addition to MAGEa6b9) 
(Table 5.15), selected through a combination of binding affinity and potency (initial 
T-cell redirection experiments), were taken forward for more detailed in vitro cellular 
testing. Mutated CDR segments identified from the first-generation libraries and from 
the three second-generation libraries are represented in at least one of the fusion 
molecules.  
 
 
 
 
Clone Number CDR1  CDR2  CDR3  CDR1  CDR2  CDR3  
wt DSAIYN LIQSS SYQLT SGHRS FSETQ 
 
SPNMADE 
 
MAGEa6b9 DSAIYN YVRPY
a SYQLT SGHRS TDFLL
a 
 
SPNMADE 
 
MAGEa26b7 DSAIYN YVRPY
a PFFVVbc SGHRS TDFLL
a 
 
SPNMADE 
 
MAGEa26b96 DSAIYN YVRPY
a PFFVVbc SGHRS FSFLLa 
 
SPNMADE 
 
MAGEa26b97 DSAIYN YVRPY
a PFFVVbc SGHRS TDFTQa 
 
SPNMADE 
 
MAGEa26b93 DSAIYN YVRPY
a PFFVVbc SGHRS FSETQ 
 
SFNMATGd 
 
MAGEa26b79 DSAIYN YVRPY
a PFFVVbc SGHRS FSETQ 
 
GINEASEd 
 
 
Table 5.15. List of potential MAGE-A3 TCR clinical candidates. 
a
Segments 
isolated from first-generation libraries; 
b
Segments isolated from Strategy 1 libraries; 
c
Segments isolated from Strategy 2 libraries; 
d
Segments isolated from Strategy 3 
libraries.  
 
 
Chapter 6 
 308 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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6.1 TCRs, a suitable protein scaffold? 
A protein scaffold is a polypeptide fold comprising surface exposed loops that form a 
sizeable target binding interface that is permissive to sequence variation within a 
geometrically constrained structure (Skerra 2000). Scaffold proteins can be divided 
into two distinct groups: (1) scaffolds with -helical frameworks and (2) scaffolds 
with -sheet frameworks (Hosse, Rothe et al. 2006). Whilst numerous examples of -
helical secondary structural scaffolds are reported in the literature, including 
affibodies and ankyrin domain repeats reviewed in (Hosse, Rothe et al. 2006; Nuttall 
and Walsh 2008; Gebauer and Skerra 2009), the -sheet framework is the most 
prevalent scaffold used for library construction. Since the magic bullet theory was 
proposed over a century ago (Ehrlich 1906), antibodies have been the paradigm of 
binding proteins with desired specificities. Antibodies, for the most part, fulfil the 
criteria required for a suitable molecular scaffold; most significantly they possess an 
inherently prescribed binding function. The constant (C) and variable (V) domains are 
barrel-shaped structures consisting of two antiparallel -sheets packed tightly against 
each other. In the C domains, each sheet consists of 4-strands and 3-strands 
respectively. The V domains consist of a total of 9 strands of 4 and 5-strands 
respectively. The characteristic -sheet secondary structure is known as the Ig fold 
(Janeway, Travers et al. 2001). Six hypervariable loops (CDRs), one set of three loops 
from each variable domain of light and heavy chain, supported by the -barrel 
structure, come together in close spatial proximity, to form an extended contiguous 
combining site. The ability of antibodies to recognise a nearly infinite array of 
antigenic determinants is due to their capacity to tolerate huge sequence heterogeneity 
within the antigen-binding loops, most notably within the third CDR. The well 
conserved structurally stable -sheet Ig fold that supports the CDR loops provides an 
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ideal scaffold on which to introduce sequence variation for the purpose of affinity 
engineering or reshaping target specificity.  
The other receptor arm of the adaptive immune response is the T-cell receptor. The 
overall structure of the TCR is remarkably similar to the Fab fragment. Three of the 
four domains comprise -sheet secondary structure, typical to the Ig fold organisation; 
the C  domain, however, forms a non-classical Ig fold due to the loss of a top -
sheet. Akin to the antigen-binding loops of antibodies, the CDR loops of TCR 
molecules can also accommodate significant sequence diversity. Since TCRs and 
antibodies share structurally similar architecture, related to a common antigen-binding 
function, there is a good rationale for applying the same engineering methodologies 
employed successfully to antibodies. However, the production of soluble TCRs has 
proven challenging. In contrast to antibodies, TCRs are not naturally expressed as 
soluble proteins and the ectodomains are highly unstable in the absence of the natural 
inter-chain disulphide bond. Several strategies have been explored to stabilise the  
and  chains including single-chain TCRs (Chung, Wucherpfennig et al. 1994; 
Schodin, Schlueter et al. 1996) or fusions to the fos/jun leucine zipper domains 
(Willcox, Gao et al. 1999). More recently, a TCR format has been designed in which 
a non-native cysteine pair is introduced at the interface between the TCR constant 
domains (Boulter, Glick et al. 2003) and has proven a generic method for producing 
extremely stable TCRs in high yields.  
 
6.2 Technical parameters affecting TCR phage display 
Phage display is a powerful tool for isolating proteins with desirable target binding 
characteristics from libraries with diversities of millions or billions of variants. 
Although phage display follows a well-established method (Smith 1985), there 
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remains scope within the system for extensive fine tuning in order to tailor the 
parameters towards different binding partners. The process is defined by four 
principal steps: first, generating molecular diversity; second, applying a selective 
pressure; third, amplifying the enriched phage population; fourth, analysis of the 
selective output. 
 
6.2.1 Library quality 
The simplest method to introduce random mutations is to use an NNN oligonucleotide 
primer that encodes an equal mixture of the four nucleotides at each position of the 
codon. This strategy, however, suffers from a biased representation of certain amino 
acids since out of the 64 possible codon combinations, Leu, Arg or Ser use 18 and one 
each for Trp or Met. In addition, the 3 nonsense (stop) codons will result in chain 
termination in ~5% of sequences. These issues are to a large extent alleviated by 
using two degenerative mixes of nucleotides N, at codon position one and two and K 
at position three (where N represents a 25% mix each of A, C, G or T and K 
represents a 50% mix each of G or T). The benefit to library quality by using NNK 
oligonucleotides is two-fold: first, it reduces the number of codons from 64 to 32 
(whilst still encoding all 20 amino acids) giving each amino acid a more even chance 
to incorporate into the library; second, it eliminates 2 of 3 stop codons thus reducing 
the amount of truncated protein within the library; the remaining stop codon TAG is 
translated as Gln in suppressor strains of E. coli. However, this approach still causes 
an uneven distribution of amino acids in the constructed library. Whilst this type of 
oligonucleotide directed mutagenesis was sufficient to isolate high affinity binders 
described for the Mel-5, gp100 and MAGE-A3 TCRs (Chapters 1, 2 and 3 
respectively), the most efficient method of incorporating an equal distribution of 
mutations is to use trinucleotide phosphoramidites (Virnekas, Ge et al. 1994; 
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Knappik, Ge et al. 2000). Trinucleotide building-blocks allow greater control over 
sequence variation so that stop codons, frame-shift mutations and codon bias are all 
eliminated. However, in the case of TCRs, removal of amber codons from the library 
pool may in fact be deleterious to the isolation of tighter binding clones, since their 
enrichment in several libraries suggests an inherent toxicity of the TCR molecule to 
E.coli. The advent of presynthesised trinucleotide triplets provides a means to 
augment library quality by minimising codon redundancy and eliminating codon bias. 
However, in the absence of the appropriate experiments it is not certain what 
additional benefit this would confer on the engineering of the TCRs described here. 
The chief objective in constructing a phage display library is to maximise diversity 
whilst minimising background parental template contamination. Several procedures 
were modified during the engineering of the three TCRs so that the lessons learnt 
from the Mel-5 TCR affinity maturation (Chapter 3) were implemented during the 
gp100 (Chapter 4) and MAGE-A3 (Chapter 5) TCR library builds. For example, in 
addition to DpnI treating the initial PCR products to reduce the amount of bacterially 
propagated plasmid DNA, the DNA template was linearised with either NcoI or NotI 
restriction endonuclease. This step was designed to prevent PCR extension beyond 
either the NcoI or NotI restriction site that would result in synthesis of the SOE-PCR 
flanking primer sites YOL13 or YOL22 respectively. In effect, the parental DNA 
template would be synthesised including both YOL13 and YOL22 stitching primer 
sites available to act as template during the SOE-PCR reaction. In spite of these 
modifications, parental TCR was enriched during the second-generation affinity 
maturation of the gp100 TCR (Chapter 4; Table 4.2) and thus the benefit to the library 
integrity is unclear. Moreover, it illustrates the challenge of isolating high affinity 
TCRs from an already improved affinity framework.  
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Furthermore, a number of additional steps were implemented to standardise and 
thus simplify the process of library construction. The number of fragments spliced 
together by SOE-PCR was reduced from 3 to 2 in both the gp100 and MAGE-A3 
TCR library builds to increase the efficiency of amplification. Moreover, the strategy 
of assembling and digesting the PCR fragments was redesigned for the gp100 and 
MAGE-A3 TCRs. The SOE-PCRs were performed using the same flanking primers 
(YOL13 and YOL22) to permit digestion of the PCR products with the same 
restriction endonucleases (NcoI and NotI) irrespective of CDR or TCR identity. 
Additionally, a quality control check point was introduced by sequencing the SOE-
PCR products before restriction digests were performed (as exemplified in Chapter 4; 
Figure 4.5). Hence, DNA of poor quality could be resynthesised rather than blindly 
proceeding with restriction digests, ligations and transformations.   
Background binding between target and display system is inherent to all molecular 
display strategies and can lead to a propensity of false-positives and confusing 
outputs. In the phage panning experiments described in Chapter 2; Section 2.5, the 
helper phage M13K07 was used to rescue the phagemid pEX922 encoding 
heterodimeric TCR molecules. In this system, phage-TCR:pHLA complexes were 
eluted from the streptavidin-coated magnetic beads under alkaline conditions using 
triethylamine (TEA). Bearing in mind that the majority of phage particles express 
only wild-type pIII proteins derived from the helper phage, indiscriminate elution 
(with TEA) of both wild-type and recombinant pIII proteins contributes to the 
background binding of bald phage that do not express recombinant fusions. Whilst the 
engineering of the TCRs in this work did not appear to suffer from this phenomenon, 
consideration must be given to alternative strategies with the potential to improve the 
system. One approach is to use a protease-cleavable helper phage (called KM13) that 
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has a trypsin cleavage sequence introduced between the D2 and D3 domains of the 
pIII protein in conjunction with an engineered phagemid that has a trypsin cleavage 
site interposed between the gene of interest and gIII (Kristensen and Winter 1998). 
Wild-type pIII proteins derived from the helper phage KM13 are susceptible to 
protease cleavage rendering phage that do not express a recombinant fusion protein 
non-infective since all three domains of the pIII protein (D1, D2 and D3) are required 
for infection. Therefore, the role of trypsin protease is two-fold: first, it elutes phage 
by cleaving the trypsin site between the protein of interest and the pIII protein and, 
second, it reduces the background infectivity of trypsin-sensitive KM13 helper phage 
(Lee, Iorno et al. 2007; Schofield, Pope et al. 2007; Pansri, Jaruseranee et al. 2009). 
 
6.2.2 Size of library 
The affinity of antibodies isolated from naïve libraries generally correlates to the size 
of the library. Whilst a small phage library with 3 x 10
7
 clones built by the group of 
Greg Winter yielded antibodies with affinities of 10
6-7
 M
-1
 (Marks, Hoogenboom et al. 
1991; Griffiths, Malmqvist et al. 1993), Vaughan et al. (Vaughan, Williams et al. 
1996) isolated antibodies with affinities of  10
8-10
 M
-1
 from a very large library of 10
10
 
members. In terms of lead optimisation, however, constructing libraries of this size 
may not be imperative to a successful outcome. Naïve antibody libraries comprise 
multiple chains from the natural repertoire of which a significant proportion will be 
redundant or incompatible. By comparison, manipulating the sequence of a well 
characterised single TCR  and  chain framework, as in affinity maturation, leads to 
more frequent productive combinations thus negating the demand for very large 
libraries. It is notable that although the Mel-5 TCR libraries (Chapter 3; Section 3.2.4) 
were 10-fold smaller than the gp100 (Chapter 4; Section 4.3.4) and MAGE-A3 
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(Chapter 5; Section 5.2.2) TCR libraries, clones with comparable affinities (in the low 
nanomolar range) were isolated. Strikingly, from a small yeast display TCR CDR3  
library (10
5
 mutants) built using a single 5-NNS degenerative oligonucleotide, clones 
with up to a 100-fold improvement in affinity over the parent molecule were obtained 
(Holler, Holman et al. 2000). In affinity maturation, the library size required to ensure 
coverage of the potential mutated sequence space is dictated by the number of 
consecutive amino acids mutated. Typically, the CDR3 is randomised using five 
overlapping 5-NNK degenerative oligonucleotides. The theoretical diversity of such a 
library is 1.7 x 10
8
 (32
5
 x 5) and a library size of 10
9
 should be sufficient to represent 
the library. Wu et al. (Wu, Beuerlein et al. 1998) used a more reductionist approach to 
isolate high affinity binders. By separately introducing all 20 amino acids at each 
position across all CDRs a far smaller library was required. This strategy identified 
mutations from a library of only 2,592 sequences that individually conferred up to a 
13-fold gain in affinity. Whilst small libraries can yield affinity-enhancing mutations, 
a limitation of this method, however, is the potential lack of cooperativity between 
mutations that have been isolated individually. This is overcome by mutating multiple 
consecutive residues within the same molecule (a strategy used for engineering the 
TCRs in this thesis) and allowing the process of Darwinian selection to identify 
molecules with the most optimised combination of residues.   
 
6.2.3 Display levels 
The low affinity interaction of TCR and pHLA prevents the detection of wild-type 
TCR on the surface of phage using a pHLA binding ELISA since a positive readout is 
limited to interactions with affinity values of <1 M. Despite efforts to monitor TCR 
display by Western blot using a pIII-specific antibody (data not shown); these 
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analyses remain unreliable and inconclusive. As a consequence, engineering studies 
are often initiated in the absence of confirmed display. 
Bothmann and Pluckthun (Bothmann and Pluckthun 1998) demonstrated that the 
E. coli periplasmic chaperone Skp improved the amount of correctly folded scFv 
protein (most notably aggregation prone and toxic fragments) on the phage surface. 
Encouraged by their finding together with supporting results from our lab that 
demonstrated an increased level of surface display (data not shown), the gene 
encoding for Skp was coexpressed on the same phagemid as the TCR. Having 
observed no significant effect on the productive phage surface display of a murine 
scTCR through coexpression of Skp, Loset et al. (Loset, Lunde et al. 2007) turned 
their attention to the role played by a second E. coli periplasmic factor, FkpA 
(Bothmann and Pluckthun 2000) in the display of TCRs. In the absence of specific 
soluble pMHC antigen, Loset et al. (Loset, Lunde et al. 2007) used a panel of anti-
TCR mAbs, predominantly -chain specific to detect TCR surface expression. Whilst 
coexpression of FkpA on the same phagemid as the -dsTCR (analogous to the 
mTCR format) increased mAb reactivity, intact  TCR assembly was ambiguous 
since the antibodies were directed towards the  chain only. Although these results do 
not provide irrevocable evidence for a role played by FkpA in improving periplasmic 
folding of TCR heterodimers, the clear benefit to the expression of scTCRs 
advocates further evaluation in our system with access to specific pHLA ligands.   
The TCR format, whether native or engineered (mTCR), had little effect on the 
MAGE-A3 TCR selective output (Chapter 5; Section 5.9). However, a direct 
comparison between the two formats is not possible since the phagemid pG484 
(encoding the wild-type MAGE-A3 TCR in the native format) contained a valine to 
alanine substitution in the geneIII leader sequence (Chapter 5; Figure 5.1) that was 
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corrected in phagemid pLAS0282 (encoding the wild-type MAGE-A3 TCR in the 
mTCR format). Western blot and phage ELISA analysis of the display of the MAGE-
A3 TCR clone MAGEawtb1 (Chapter 5; Table 5.3) in the native versus the mTCR 
format with and without the geneIII mutation, demonstrates a clear hierarchy of 
expression levels (data not shown). The native TCR format in combination with a 
wild-type geneIII leader sequence supports the highest level of display whereas, the 
mTCR format in conjunction with a mutated gIII leader sequence supports the lowest. 
Inclusion of a mutated geneIII leader sequence in partnership with the native TCR 
format (Chapter 5; Section 5.8; Strategy 1) reduces the expression level in line with 
that observed for the wild-type geneIII leader sequence and mTCR format (Chapter 5; 
Section 5.9; Strategy 2). In effect, the wild-type geneIII leader sequence compensates 
for the reduced TCR display level conferred by the mTCR format. For the engineering 
of the libraries described in Section 5.9, it would have been more instructive to have 
retained the alanine geneIII leader sequence mutation. What effect would reducing the 
level of display have on the selective output? Conversely, what effect would 
increasing the level of display through correcting the geneIII leader mutation have on 
the selective output in either the first-generation libraries (Chapter 5; Section 5.2) or 
Strategy 1 libraries (Chapter 5; Section 5.8)? The introduction of the non-designed 
geneIII leader sequence mutation may have been fortuitous, since high levels of TCR 
expression are not well tolerated in E. coli which may well have been detrimental to 
the selective output.  
 
6.2.4 Quality of the pHLA antigen 
The outcome of a TCR affinity engineering project is largely, but not exclusively 
influenced by the efficiency of the wild-type TCR refold and the quality and stability 
of the pHLA complex. Whilst optimisation of TCR refolding represents a significant 
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obstacle, modification of the pHLA molecule to enhance stability is often a more 
fruitful exercise. It is well acknowledged that mutations in the peptide sequence at so-
called anchor positions can stabilise the complex by fastening the peptide into the 
HLA binding groove (Hunt, Henderson et al. 1992; Parker, Bednarek et al. 1992; 
Parkhurst, Salgaller et al. 1996; Valmori, Fonteneau et al. 1998). For the affinity 
maturation of the Mel-5 (Chapter 3) and gp100 (Chapter 4) TCRs, a heteroclitic 
peptide variant was used, whereas for the MAGE-A3 (Chapter 5) TCR engineering, 
the wild-type peptide was employed because it folded with high efficiency into a 
stable molecule. Indeed, a first attempt at isolating high affinity gp100 TCR mutants 
failed in selections performed with the wild-type peptide (data not shown). The 
preferred peptide binding motif for HLA-A*0201 is xLxxxxxxV/L and for HLA-
A*0101 is xxD/G
 
xxxxxY. Whilst the wild-type MAGE-A3(168-176) peptide satisfies 
both the preferred anchor residues at P3 and P9 (EVDPIGHLY), the wild-type Melan-
A/MART-1(26-35) and gp100(280-288) peptides do not (at P2 and PC); only containing 
one of the two preferred residues (EAAGIGILTV and YLEPGPVTA respectively). 
Accordingly, heteroclitic variants of both the Melan-A/MART-1(26-35) and gp100(280-
288) peptides were designed; ELAGIGILTV and YLEPGPVTV respectively. It is 
important that modification of the peptide to improve binding to the HLA molecule is 
not deleterious to recognition by the TCR. It is noteworthy that the wild-type and 
improved affinity gp100 TCRs bind to the wild-type and heteroclitic variant peptides 
with comparable affinity (Chapter 4; Table 4.1). 
 
6.2.5 Library selection - specificity 
Having established the off-target activity of the highest affinity MAGE-A3 TCR 
clone (MAGEa6b9) against human primary cells (HEP2 and HDMEC3) (Chapter 5; 
Figure 5.3), three protein engineering strategies were designed to identify novel 
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mutations harnessed with adequate potency yet devoid of the cross-reactivity profile 
attributed to MAGEa6b9. It was hypothesised that the binding specificity could be 
augmented by preselecting the CDR3 libraries against an undesired target. In the third 
strategy (Chapter 5; Section 5.10) each cycle of panning started with a depletion (or 
subtractive) step in which the phage was incubated with 2 x 10
6
 human primary cells 
(HEP2 or HDMEC3). Whilst the cell surface antigenic component responsible for 
MAGEa6b9 binding was unknown, the HEP2 and HDMEC3 cells provided a suitable 
target (Chapter 5; Figure 5.3). The effectiveness of this type of strategy hinges on a 
number of factors. Consideration must be given to the level and accessibility of 
antigen expressed at the cell surface, since the density of antigen may well be lower 
than the KD of any of the off-target binders in the library. Moreover, the antigen may 
be inaccessible to interaction due to steric hindrance caused by the presence of other 
cell surface molecules. The impact of the subtractive panning procedure on the 
CDR3  library output was scrutinised through deep sequencing of ~150,000 
sequences from each selection method (Chapter 5; Section 5.10.3). The consequence 
of the modifications in the panning procedure is shown in Figure 5.7 which highlights 
a group of mutants in the subtractive output divergent from those selected through the 
normal panning method. Whilst this data does not provide unequivocal evidence for 
the success of this approach, it does at least provide a plethora of novel mutants for 
biophysical and cellular characterisation.   
 
6.2.6 Why do some CDRs not yield high affinity? Second-generation libraries  
Antibodies selected from natural repertoire libraries have already been through a 
process of affinity optimisation (somatic hypermutation) akin to the first round of in 
vitro affinity engineering described here for TCRs. The isolated antibody fragments 
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that act as scaffolds for in vitro affinity maturation are therefore of high affinity and 
require only moderate fine tuning to satisfy clinical development criteria. By 
comparison, the natural affinity of TCRs is much lower than for antibodies and 
therefore substantial improvement in affinity is required to bring TCRs into a similar 
affinity window from which antibodies enter the process of lead optimisation.  
Isolation of mutations in more than one CDR generally requires the construction of 
second-generation libraries, in which an enhanced-affinity first-generation mutant is 
used as template for further CDR mutagenesis. Of the three TCRs described here and 
the three TCRs engineered previously in our group (Li, Moysey et al. 2005; Purbhoo, 
Li et al. 2007), only two yielded mutations in more than one CDR from first-
generation libraries. Whilst the reasons for this are not fully understood there are 
several possible explanations.  
One reasoning is that whilst not all CDR loops are conducive to accommodating 
mutations in the context of the wild-type structure, conformational adjustment of the 
loops that result from the mutation of a single CDR, repositions the loops so that new 
pHLA contacts are made. These novel contacts at the TCR-pHLA interface are now 
accessible to modification through site directed mutagenesis that were not available in 
the wild-type structure. The structure of the high affinity A6c134 TCR supports this 
hypothesis, which shows that mutations in the CDR3  loop increase the number of 
contacts between the  chain and the Tax peptide (D. K. Cole, manuscript in 
preparation). It is conceivable that  chain libraries built on a high affinity  chain 
framework would yield mutations in the  chain that were not identified in the 
context of the wild-type TCR (Li, Moysey et al. 2005).  
A second explanation is that high affinity binders are not present in the starting 
library population. However, based on the deep sequencing analysis of one of the Pan 
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0 (preselected) MAGE-A3 TCR libraries (data not shown) which shows a wide 
distribution and high diversity of mutations, this is unlikely. A more plausible 
explanation is that a selective loss of low affinity binders occurs during the selection 
process (de Bruin, Spelt et al. 1999). The binding kinetics of the selective output of 
the MAGE-A3 TCR Strategy 1 libraries endorses this notion (Chapter 5; Table 5.7). 
Enrichment for consensus sequences in the context of an affinity enhanced clone was 
observed (Chapter 5; Table 5.6). Whilst the mutated CDR segments conferred 
considerable improvements in affinity over the wild-type TCR of between 7 and 145-
fold (KD of 35-1.7 M; Chapter 5; Table 5.7) (excluding clone MAGEa22 with a KD 
of 230 nM), affinities in this range are not permissive to TCR capture during a 
solution-based selection approach and justifies the absence of such phages in the 
output described in Chapter 5; Section 5.3. It is noteworthy that the cut-off for 
detection of specific binding of TCR with cognate pHLA in a phage ELISA assay is 
approximately 1 M (data not shown) and therefore it is likely that the selection of 
TCR mutants during the panning process is limited by this affinity value, i.e. there is a 
diminished probability of capturing TCRs with KD values >1 M.  Without a surgical 
examination of each mutated CDR segment it is not possible to assess whether the 
affinity of mutations obtained from second-generation selections, as a general rule, 
fall below this detection threshold. It would be intriguing, for example, to determine 
the affinity of the Mel-5 TCR CDR1  segment (as described in Chapter 3) that in 
combination with clone MELa1 (KD value of 6.4 nM) contributes to an affinity of 3.2 
nM  attributed to clone MELa16 (Table 3.7). Likewise, it would be compelling to 
calculate the affinity of the gp100 TCR CDR3  segment (discussed in Chapter 4) that, 
when refolded in the context of clone GPb7 (KD value of 44.6 nM), affords an affinity 
of 4.11 nM measured for clone GPb8 (Table 4.3). If, indeed, these biophysical 
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determinations indicated affinities unfavourable to capture from the first-generation 
libraries, the question is, what modifications could be implemented to the panning 
strategy to permit complete mining of the sequence space? Moreover, how can these 
low affinity binders be retained in the selective output? One possible solution would 
be to use an alternative helper phage to rescue the phage TCR libraries. The 
traditional helper phage, M13K07 (as used here), supplies all the necessary proteins 
required for phage assembly; in addition, it also provides a source of pIII protein. 
Since the phagemid also supplies pIII (as a recombinant fusion protein), a competition 
for incorporation into the assembling phage particle is set up between the wild-type 
pIII (helper phage) and recombinant pIII (phagemid). Because the wild-type pIII is 
incorporated more efficiently than the recombinant pIII, less than 10% of phages have 
a single fusion protein displayed on the phage surface with the overwhelming 
majority displaying only wild-type pIII. Whilst monovalent display is conducive to 
the isolation of high affinity binders, low affinity binders may slip through the net. To 
increase the display level of recombinant pIII fusions on the phage surface, Rondot et 
al. (Rondot, Koch et al. 2001) produced a  modified helper phage, called Hyperphage, 
that has a partial deletion of the pIII gene so that the only supply of pIII protein is 
from the phagemid. The resulting phages have up to five copies of pIII carrying a 
fusion protein. The effect on the selection process is two-fold: first, it reduces the 
background of phage displaying only pIII from the helper phage; second, and more 
importantly, it increases the avidity effect that may lead to the capture of lower 
affinity binders.    
It is curious that certain CDRs are resistant to affinity engineering, despite being 
selected in the context of an enhanced-affinity first-generation mutant. For example, 
three CDRs were targeted for the gp100 TCR (Chapter 4; Section 4.4), namely 
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CDR2 , CDR3  and CDR3  (built on GPb7; a CDR2  mutant) yet high affinity 
clones were recovered from only the CDR3  and CDR3  libraries. An inspection of 
the crystal structure of the TCR-pHLA complex may offer a possible explanation for 
this. Recent findings from our lab (Dr. A. Knox; unpublished observations) have 
demonstrated the importance of structural information to the rational design of phage 
display libraries. The cocrystal structure showed that two of the CDRs were spatially 
too distant from the pHLA surface to mediate contact. Guided by this information, 
two and three randomised NNK amino acid residues were inserted into the relevant 
CDR loops and subjected to several cycles of phage display panning. Remarkably, 
creating novel contacts through bridging the gap between the TCR and pHLA 
molecule, conferred substantial gains in affinity.     
 
6.3 Phage output - Binding affinity 
Protein-protein interactions are fundamental to most biological processes (Pawson 
and Nash 2000) and as consequence there is much interest in unravelling the 
molecular mechanisms underlying these interactions with the aim to exploit this 
knowledge to affinity engineer a number of these molecules for targeting purposes. T-
cells express on their surface the TCR which recognises antigen in association 
with MHC molecules. Differences in the CDR regions of the TCR domains, 
specifically variation in length and amino acid composition, account for the diversity 
of peptide specificity demonstrated by T-cells. Tumour associated antigens (TAAs), 
which are not expressed on normal tissue or expressed at a low level in a few tissues, 
constitute suitable targets for therapeutic agents. Peptides derived from TAAs, so-
called tumour associated peptide antigens (TAPAs), are presented on the surface of 
tumour cells in the context of MHC class I complexes. Optimal binding of soluble 
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TCR therapeutics to extremely low numbers of pMHC, typically 1-100 pMHC 
complexes per target cell (Purbhoo, Irvine et al. 2004), requires engineering to 
overcome the inherently low affinity TCR-pMHC interaction (KD = 0.1-500 M) 
(Cole, Pumphrey et al. 2007; Aleksic, Liddy et al. 2012). The ability to generate very 
high affinity TCRs is essential for their use as soluble therapeutics as, naturally, their 
affinities are too low to be useful when applied as monovalent targeting agents.  
In the work described in this thesis, site-directed mutagenesis has proven to be a 
successful strategy for targeting each of the six CDRs for engineering ultra-high 
affinity TCRs. The aim of this study was to generate high affinity TCRs that 
recognise the melanoma-specific epitopes, including peptides derived from Melan-
A/MART-126-35 (Chapter 3), gp100280-288 (Chapter 4) and MAGE-A3168-176 (Chapter 
5). The TCRs specific for these epitopes were designated Mel-5, gp100 and MAGE-
A3 respectively and as wild-type molecules demonstrated binding affinities (KD 
values) for their cognate pHLA antigens of 18 M, 26 M and 248 M respectively 
(Aleksic, Liddy et al. 2012; Liddy, Bossi et al. 2012). 
Using an in vitro directed evolution strategy and phage display, TCRs containing 
mutagenised CDR loops were expressed on the surface of bacteriophage as fusions to 
the phage coat protein pIII.  Following enrichment of antigen-binding molecules, in a 
process of biopanning, the selective output was analysed by phage-ELISA for binding 
to pHLA. This method successfully identified mutated TCRs with improved affinity 
for pHLA. TCRs with the best combinations of mutated CDRs were shown to bind 
their cognate pHLA antigens with significantly improved KD values of 10 pM (Mel-5 
TCR-Melan-A/MART-126-35) (Chapter 3; Section 3.8.3), 13 pM (gp100 TCR-
gp100280-288) (Chapter 4; Section 4.5.2) and 67 pM (MAGE-A3 TCR-MAGE-A3168-
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176) (Chapter 5; Section 5.5). The TCRs displaying these affinities are now in the 
range of affinity matured antibodies and potentially can have therapeutic application.  
Two biophysical properties of the affinity-enhanced TCRs emerge (Chapter 3; 
Figure 3.16, Chapter 4; Figure 4.9 and Chapter 5; Table 5.3). First, in agreement with 
the affinity maturation of antibodies (Hawkins, Russell et al. 1992; Yang, Green et al. 
1995; Thompson, Pope et al. 1996), improvements in affinity are almost exclusively 
driven by decreases in off-rates and the affinity gains correlate well with extended T1/2 
values (several hours). This observation confirms the findings of the engineered 1G4 
TCR in which T1/2 values of up to ~17 hours were reported (Li, Moysey et al. 2005). 
Second, on-rates between the improved affinity mutants remain largely unchanged. 
There are two possible explanations for this. First, wild-type TCRs possess extremely 
fast on-rates and so engineering for improvements present a significant challenge. 
Second, the underlying principle of affinity maturation of proteins by phage display 
favours the selection of binders with slower dissociation rate constants. This is 
particularly apparent when using off-rate selection strategies (Hawkins, Russell et al. 
1992; Yang, Green et al. 1995; Chen, Wiesmann et al. 1999) as employed in the 
engineering of the Mel-5 (Chapter 3, Section 3.7) and gp100 TCRs. In these 
experiments a large excess of non-biotinylated, and, therefore, soluble, antigen is 
added to the panning reaction. The non-biotinylated antigen acts as a competitor and 
captures any binding molecules that dissociate from the biotinylated antigen. The 
probability of a binder dissociating from antigen is largely determined by its 
dissociation rate constant. The excess of non-biotinylated antigen prevents molecules 
with fast off-rates re-binding to biotinylated antigen and so binders with the slowest 
off-rates in the pre-selected library pool are enriched (Hawkins, Russell et al. 1992). 
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 Using a combinatorial strategy, individual mutated affinity-enhanced CDRs were 
spliced into the same TCR molecule in a stepwise manner to further increase binding 
affinity. As a general rule, combining mutated CDRs improved binding affinity in an 
additive fashion; a feature not always evident for antibodies (Yang, Green et al. 
1995). Whilst the initial affinity gain conferred by a single CDR segment was 
significant (~2,000-fold; average value between the three TCRs) (Chapter 3; Table 
3.7, Chapter 4; Table 4.3 and Chapter 5; Table 5.3), affinity gains at each subsequent 
step were generally in smaller increments, about 40-fold. An exception was clone 
MAGEa6b9, which produced a ~3.7 million-fold improvement over the parent 
MAGE-A3 TCR by inclusion of a second CDR segment (Chapter 5; Table 5.3). The 
cumulative effect on the affinity of the inclusion of up to five mutated CDR segments 
translated to astounding improvements over the wild-type TCR of approximately 1.8 
million-fold, 1.7 million-fold and 3.7 million-fold respectively for the Mel-5 (Chapter 
3; Table 3.7), gp100 (Chapter 4; Table 4.3) and MAGE-A3 (Chapter 5; Table 5.3) 
TCRs. The capacity of TCRs to accommodate affinity-enhancing mutations in 
multiple CDRs in the same molecule indicates that the geometry of interaction 
between TCR and pHLA is unaffected by these changes. Indeed, superimposition of 
the wild-type and high affinity 1G4 TCR (Dunn, Rizkallah et al. 2006; Sami, 
Rizkallah et al. 2007) in complex with cognate pHLA provides supporting evidence 
for this and moreover, indicates that the high affinity mutations have not driven the 
binding away from the peptide.  
In view of experiences with antibody affinity engineering, such a dramatic gain in 
affinity through a combination of as few as two mutated CDRs was not predicted. 
Antibody engineering has yielded less striking improvements over the wild-type 
antibody of 228-fold (Lowe, Gerhardt et al. 2011), 420-fold (Yang, Green et al. 1995) 
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and 5,000-fold (Steidl, Ratsch et al. 2008). However, it must be remembered that the 
affinity of wild-type antibodies can be several orders of magnitude higher than TCRs 
and as such improvements in affinity from an already high affinity background is 
often more challenging. Engineering of the murine 2C scTCR generated up to a 750-
fold improvement in affinity over the wild-type TCR for a single CDR2  segment. 
However, additive binding between different CDR mutants was not tested (Chlewicki, 
Holler et al. 2005). 
The TCRs described in this thesis have been shown to be capable of detecting 
antigen expressed on the surface of human tumour cell lines following previously 
described methods (Purbhoo, Sutton et al. 2006) (Chapter 6; Figure 6.1). Briefly, 
cancer cells were incubated with biotinylated TCR followed by streptavidin-PE. 
Based on the assumption that a single PE fluorescence corresponds to a single TCR-
peptide-HLA complex, the following epitope numbers were determined: Mel526 cell 
line expresses ~118 Melan-A/MART-1(26-35) (EAAGIGILTV) and ~33 gp100(280-288) 
(YLEPGPVTA) epitopes and A375 cell line expresses ~39 MAGE-A3(168-176) 
(EVDPIGHLY) epitopes. Soluble protein therapeutics have been designed which 
combine the tumour targeting capability shown in Figure 6.1 (Chapter 6) with an 
effector function by fusing the high affinity TCR to an anti-CD3 scFv moiety. The 
therapeutic mode of action of the high affinity TCR-anti-CD3 scFv fusions (so-called 
ImmTACs; immune-mobilising monoclonal TCRs against cancer) is described in our 
recent publication (Liddy, Bossi et al. 2012). 
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Figure 6.1. Imaging of individual peptide-HLA antigens on human tumour cell lines with high affinity TCRs. (A). Melan-A/MART-1(26-35) 
(EAAGIGILTV)/HLA-A2 antigens (Ags) on Mel 526 melanoma cell line using high affinity MELa24b15 TCR-biotinylated (bio) monomers and 
streptavidin-PE; (B). gp100(280-288) (YLEPGPVTA)/HLA-A2 Ags on Mel 526 cell line using high affinity GPa3b17 TCR-bio monomers and 
streptavidin- PE; (C). MAGE-A3(168-176) (EVDPIGHLY)/HLA-A1 Ags on A375 melanoma cell line using high affinity MAGEa6b9 TCR-bio 
monomers and streptavidin-PE. Each dot on the fluorescent images represents a single streptavidin-PE/TCR/Ag-HLA complex. Cells stained 
with control TCR-bio monomers and streptavidin-PE only are shown as controls. Cells shown are representative of the brightest 10% found 
among each staining condition. Bar, 10 m. (Data kindly provided by Dr. G. Bossi). 
A. 
B. 
C. 
Control TCR 
Phase contrast Phase contrast Fluorescence Fluorescence 
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6.4 Phage output - Sequence analysis 
The sequence of antibody CDRs, although hypervariable, are biased towards certain 
amino acid residues. These include hydrophobic aromatic residues (tyrosine, 
tryptophan and phenylalanine), polar residues (arginine and histidine) and small 
residues (glycine, serine and alanine). The abundance of these residues at the binding 
interface may indicate an intrinsic suitability in forming antigen-binding sites, in 
which glycine and serine act as conformation residues and tyrosine, tryptophan and 
phenylalanine as the contact residues (Padlan 1994; Zemlin, Klinger et al. 2003; 
Fellouse, Wiesmann et al. 2004; Birtalan, Fisher et al. 2010). The structural similarity 
between antibodies and TCRs would imply that analogous patterns of protein-protein 
interactions may exist. However, the fact that T-cells are deselected during thymic 
education based on affinity parameters, argues against the desire for aromatic residues 
in the TCR antigen-binding loops since their inclusion may result in too strong 
interactions.     
Subjecting the phage TCR libraries to three cycles of selective pressure was 
sufficient to obtain high affinity clones. Indeed, the selection output for each TCR 
revealed remarkable convergence to consensus sequences. Analysis of the Mel-5 TCR 
CDR3  output showed that 30 sequenced clones collapsed to 9 unique mutants 
(Chapter 3; Table 3.5). Likewise, the 22 sequenced CDR1  clones converged to 9 
unique mutants and the CDR3  from 20 to 10 unique clones Table 3.6 (Chapter 3).    
Notably, there was a prevalence of glycine residues in the CDR loops of both the 
engineered Mel-5 (Chapter 3; Table 3.3 and 3.6) and gp100 (Chapter 4; Table 4.1 and 
4.2) TCRs. Enrichment for small residues such as glycine may indicate that flexibility 
is crucial to allow a conformation that is suitable for high affinity binding. For the 
Mel-5 TCR (Chapter 3), three of the four mutated CDRs that yielded enhanced-
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affinity mutants contained at least one glycine residue (Chapter 3; Table 3.7). Glycine 
residues were either retained from the wild-type Mel-5 TCR or preferentially selected 
in place of the wild-type residue. For CDR1 , the wild-type glycine residue was 
retained in 7/8 clones (Chapter 3; Table 3.6). For CDR3 , a glycine residue was 
retained from the wild-type TCR in 4/9 clones and substituted for the wild-type 
residue in the remaining five mutants (Chapter 3; Table 3.5). The CDR2  clones were 
all selected with a glycine in place of the wild-type residue. The CDR3  clones all 
contained a glycine residue either retained from the wild-type clone (6/10) or 
introduced for the wild-type residue (4/10) (Chapter3; Table 3.6). Interestingly, in the 
fourth CDR loop that yielded improved affinity mutants, CDR2 , a wild-type glycine 
residue was located immediately adjacent to the targeted NNK region. In total, the 
CDR1 , CDR3 , CDR2  and CDR3  clones contain up to one, two, one and three 
glycine residues respectively.  
A similar pattern emerged from the gp100 TCR affinity maturation (Chapter 4). 
Whilst the CDR3  selection output yielded only a single clone containing a glycine 
residue, both the CDR2  and CDR3  clones were substantially enriched for a glycine 
residue (86% and 100% of sequenced clones respectively) (Chapter 4; Table 4.2). The 
glycine residue was either retained from the wild-type parent TCR (CDR3 ) or 
selected in preference to the wild-type residue (CDR2 ) (Chapter 4; Table 4.3).  
The pattern was not as evident in the MAGE-A3 TCR output (Chapter 5). Of the 
fifteen sequenced CDR2 clones, only three CDR2  clones contained a glycine residue 
(Chapter 5; Table 5.1). The selection of glycine-containing clones was more 
noticeable for the second-generation mutants, yet far less striking compared with the 
Mel-5 and gp100 TCRs. Although an average of ~20% CDR3  and ~50% CDR3  
second-generation clones were enriched for glycine residues, a more rigorous 
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dissection of these mutants is required to determine the importance of glycine residues 
for the binding affinity. 
Engineering of the 1G4 TCR for high affinity (Li, Moysey et al. 2005) identified 
glycine residues as key components of the CDR3  phage selection output. Indeed, at 
least one of the two wild-type glycine residues was retained in the centre of the 
mutated motif in all but one of the high affinity clones. 
A propensity for glycine residues has also been observed in the CDR3  loop of the 
engineered yeast-displayed murine single-chain 2C TCR (Holler, Holman et al. 2000). 
Of the fifteen isolated mutants, nine contained a glycine residue in the centre of the 
mutated CDR3  motif which in combination with a stretch of four additional mutated 
residues conferred a 100-fold improvement in affinity compared with the parent 2C 
TCR. In agreement with these findings, Kranz and co-workers (Chlewicki, Holler et 
al. 2005) further demonstrated the importance of glycine residues to the binding 
affinity of the 2C TCR. They found that each of the CDR3  mutants isolated from 
engineering the 2C TCR retained two glycine residues. It is noteworthy that the wild-
type CDR3  contains four adjacent glycine residues, possibly indicating a level of 
flexibility required for antigen-binding. The retention of two wild-type glycine 
residues provided sufficient loop flexibility to accommodate two residue substitutions 
that conferred a ~90-fold increase in affinity over the parent TCR.  
The role of glycine residues in affording high affinity binding to the 2C TCR was 
further demonstrated by Kieke et al. (Kieke, Sundberg et al. 2001). The flexibility of 
the 2C TCR CDR2  loop due to two glycine residues was presumed critical for 
antigen-binding function since complete randomisation of the loop to increase the 
affinity for staphylococcal enterotoxin C3 (SEC3) generated mutants in which the two 
wild-type glycines were retained.  
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The contribution of the unique flexibility of glycine to the affinity of antibodies has 
also been widely explored (Fellouse, Esaki et al. 2007; Birtalan, Zhang et al. 2008). 
Sidhu and co-workers (Fellouse, Esaki et al. 2007) attributed a key role for glycine in 
the antigen-binding function of an anti-hVEGF Fab antibody. The HCDR3 loop was 
diversified using a spiked oligonucleotide strategy, in which the phage libraries were 
biased in favour of tyrosine, serine and glycine residues. Birtalan et al. (Birtalan, 
Zhang et al. 2008) also constructed anti-hVEGF Fab HCDR3 libraries in which 
diversity was added to the simplified binary tyrosine/serine background (Fellouse, Li 
et al. 2005) by introducing glycine, arginine or both. In each study, glycine residues 
were found in the majority of the selected antigen-binding clones in multiple 
positions. Taken together, these results suggest a critical role for glycine residues in 
providing conformational versatility that permits antigen recognition and high affinity 
binding. The prevalence of glycine residues in the HCDR3 loops of high affinity 
antibodies is supported by its high abundance in naïve antibodies in which it is the 
second most common residue after tyrosine (Zemlin, Klinger et al. 2003).  
Accordingly, an alternative strategy to the blanket NNK mutagenesis approach, in 
which consecutive residues are mutated, would be to retain wild-type glycine residues 
and only target the adjacent amino acids. Whilst all 20 amino acids are encoded by 
degenerative NNK oligonucleotides, permitting the representation of wild-type 
residues in the initial phage library pool, limiting the library complexity by mutating 
fewer residues may offer benefits to library quality and composition. The only caveat 
to this strategy is that favourable substitutions of wild-type glycine residues would be 
overlooked, as illustrated in the case of the Mel-5 TCR CDR2  mutants (Chapter 3; 
Table 3.6).       
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The aromatic residues tyrosine, phenylalanine and tryptophan played a prominent 
role in mediating high affinity binding for each of the TCRs engineered in this thesis, 
most notably for the Mel-5 and gp100 TCRs (Chapter 6; Table 6.1). For the Mel-5 
TCR, there was a dramatic enrichment for CDR3  clones containing a tryptophan 
residue (90% of sequenced clones). Interestingly, all of the CDR2  clones contained 
at least one aromatic residue. Over half of the CDR1  clones contained a 
phenylalanine. Of note, enrichment of an aromatic residue was frequently 
accompanied by a glycine residue. 
 
 
 
Table 6.1. Frequency of the aromatic amino acid residues in the Pan 3 selection 
output of the Mel-5, gp100 and MAGE-A3 TCRs. Single letter amino acid 
nomenclature used: Y, tyrosine; F, phenylalanine; W, tryptophan; G, glycine. G/Y, 
G/F or G/W: Frequency of G in combination with Y, F or W in the same CDR. The 
mutagenised CDR is indicated.   
 
 
 
TCR CDR 
Total  
clones 
Y F W G/Y G/F G/W 
 1  8 1 5 0 0 5 0 
 2  1 1 0 0 1 0 0 
Mel-5 3  9 1 0 0 1 0 0 
 2  4 2 4 1 2 4 1 
 3  10 0 0 9 0 0 0 
 3  6 0 6 0 0 6 0 
gp100 2  7 1 1 7 1 0 6 
 3  7 7 0 1 7 0 1 
 2  7 7 3 0 0 0 0 
MAGE-A3 3  15 7 14 0 7 14 0 
 2  8 0 0 0 0 0 0 
  61 14 9 5 4 0 2 
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The frequency of aromatic residues in the gp100 TCR output was even more 
striking (Chapter 6; Table 6.1): all sequenced CDR3  clones contained a 
phenylalanine residue; all CDR2  clones were enriched for a tryptophan residue; all 
CDR3  clones contained a tyrosine residue in addition to a single clone that contained 
a tryptophan residue. With the exception of a single CDR2  clone, which contained a 
phenylalanine residue, the selection of an aromatic residue was in combination with a 
glycine residue.  
Excluding the CDR2  output, the MAGE-A3 TCR clones from CDR2 , CDR3  
and CDR3 , were preferentially selected to a lesser or greater extent for the presence 
of an aromatic residue (Chapter 6; Table 6.1). Most notably, >90% of CDR3  clones 
contained a phenylalanine in conjunction with a glycine residue, of which over half 
include a tyrosine residue. The presence of a glycine residue may provide 
conformational mobility that allows bulky residues, such as tyrosine, phenylalanine 
and tryptophan to achieve an optimal fit. 
Interestingly, a prevalence of aromatic residues in the CDRs of affinity matured 
TCRs has previously been reported. The (~90-fold) improved affinity murine 2C 
scTCR described earlier (Chlewicki, Holler et al. 2005), contained a phenylalanine 
residue in combination with a pair of glycine residues in the CDR3  loop. Also, Dunn 
et al. (Dunn, Rizkallah et al. 2006) isolated high affinity 1G4 TCR clones that were 
greatly enriched for tryptophan  residues in the CDR2  loop that were frequently 
found in combination with a glycine residue. 
Notably, in antibody engineering, Sidhu and colleagues (Fellouse, Li et al. 2005) 
also demonstrated the importance of tyrosine residues in mediating high affinity 
antigen recognition by constructing an anti-hVEGF Fab framework phage library in 
which binary tyrosine/serine diversity was introduced into four CDRs. Remarkably, 
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antibodies with high affinity and specificity were isolated, revealing that a minimal 
number of contacts are sufficient for binding. A follow-up study reported from the 
same lab (Birtalan, Zhang et al. 2008) showed that introduction of glycine residues 
into the simplified diversity tyrosine/serine background combined successfully with 
tyrosine to mediate high affinity binding. Furthermore, tyrosine residues in the 
HCDR3 loop of the G8 Fab (Hulsmeyer, Chames et al. 2005) have been shown to 
play a pivotal role in the interaction with the HLA-A1-MAGE-A1 complex since the 
high affinity derivative Hyb3, retained four of the six tyrosine residues. Accordingly, 
structural analysis showed the tyrosine-rich HCDR3 loop (FHYYYY) formed a clamp 
over the HLA 1 helix.    
Besides glycine, tyrosine, tryptophan and phenylalanine several other residues 
were selectively enriched following engineering of the Mel-5 (Chapter 3; Table 3.5 
and 3.7), gp100 (Chapter 4; Table 4.3) and MAGE-A3 (Chapter 5; Table 5.1) TCRs 
commonly including proline and to a lesser extent leucine and arginine.  
Interestingly, in the Mel-5 TCR maturation, a leucine to proline substitution was 
preferentially selected at position 44 (outside of the targeted CDR region) in all of the 
CDR2  clones and in a single clone from the CDR3  output (Chapter 3; Table 3.6). 
Because the two libraries were independently constructed using CDR2  or CDR3  
specific primers, the L44P substitution would appear to be advantageous in terms of 
expression or binding affinity. Prevalence for a proline residue in the CDR loops was 
observed in all three TCRs. Mel-5 TCR: in addition to the L44P substitution in  
framework 2, a proline residue was selected for in all of the CDR2  clones (Chapter 
3; Table 3.6); gp100 TCR: a single proline residue was retained from the wild-type 
sequence in all of the CDR3  and CDR3  mutants (Chapter 4; Table 4.2); MAGE-A3 
TCR: a proline residue was introduced into each of the selected CDR2  clones 
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(Chapter 5; Table 5.1) and highly enriched in the CDR3  mutants (Chapter 5; Table 
5.6 and 5.9). The presence of a proline residue could have some effect on the 
geometry of these loops, yet without structural information its precise role in the 
antigen-binding domains is unclear.   
Additionally, amber codons were frequently found in the CDR regions of the 
selective output of all three TCRs; a phenomenon that has been observed in both 
antibody (Shinohara and Fukuda 2002; Rinderknecht, Villa et al. 2010) and TCR 
affinity engineering (Dunn, Rizkallah et al. 2006). The amber stop codon is 
transcribed as a glutamine residue in suppressor strains of E. coli (such as TG1 cells 
used in this work) with an efficiency of 10-20%. Krebber et al. (Krebber, Burmester 
et al. 1996) demonstrated that inserting an amber stop codon between the gene of 
interest and geneIII in a phagemid vector reduced the amount of fusion protein 
produced thus limiting the negative effect on bacterial cell growth. Furthermore, 
Paschke and Hohne  (Paschke and Hohne 2005) showed that introduction of an amber 
codon in the pelB leader sequence conferred elevated display levels of the protein of 
interest by reducing the expression of pIII. Enrichment for an amber codon in many of 
the TCRs described in this thesis and in TCRs engineered previously by our group 
(Dunn, Rizkallah et al. 2006) perhaps indicates the toxic character of the pIII-TCR 
fusion proteins or alternatively may demonstrate an improvement in affinity sufficient 
to compensate for reduced expression. 
Dissection of the mutated CDR segments to assess the affinity gains attributable to 
particular residues would be highly informative. One method to achieve this would be 
to revert back to wild-type each of the mutated residues as described for the MELa1 
CDR3  mutant (Chapter 3; Section 3.5). In this example, the importance of Gly
92
 to 
the affinity of the MELa1 clone was demonstrated by substituting for the wild-type 
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alanine residue at this position. The outcome of this mutation was a dramatic ~900-
fold reduction in the affinity (Chapter 3; Figure 3.13) endorsing the role of glycine 
residues to the binding affinity as described above. By comparison, the contribution of 
Arg
94
 to the affinity of the MELa1 clone was far less significant since substitution for 
the wild-type lysine reduced the affinity by ~70-fold (Chapter 3; Figure 3.13). 
Finally, it is interesting to note that Shiroishi et al. (Shiroishi, Tsumoto et al. 2007) 
suggest that the lower number of tyrosine residues participating at the TCR-pMHC 
interface compared with antibodies may account for the differences in binding affinity 
between these two structurally related molecules. The scattering of tyrosine residues 
in the high affinity TCRs described in this thesis provides some support to this notion.  
 
6.5 What is the structural basis of high affinity? 
Several factors, most likely working synergistically, contribute to the high affinity 
binding of the engineered Mel-5, gp100 and MAGE-A3 TCR mutants; these include 
improved shape complimentarity (SC), additional number of interfacial hydrogen 
bonds, van der Waals interactions, increased buried hydrophobic surface area and 
exclusion of water molecules (Lo Conte, Chothia et al. 1999). 
Following the completion of the Mel-5 TCR affinity engineering project, the 
structure of the wild-type Mel-5 TCR in complex with HLA-A*0201-Melan-
A/MART-126-35, (ELAGIGILTV) has been solved (Cole, Yuan et al. 2009). In the 
absence of a structure of at least one of the high affinity Mel-5 TCRs, it is difficult to 
assess which mutations directly contribute to the affinity improvements. However, the 
structure of the wild-type Mel-5 TCR provides a framework to identify key binding 
contacts between the TCR, the ELA peptide and the HLA surface which may assist in 
the interpretation of the high affinity interactions. The Mel-5 TCR binds to the N-
terminus of the peptide as observed for the A6 TCR (in complex with HLA-A2-Tax) 
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which also uses the TRAV12-2 gene (Ding, Smith et al. 1998). Unusually, the Mel-5 
TCR (Cole, Yuan et al. 2009) CDR3  makes a minimal contact with the peptide, with 
TCR residue Asn
92
 making only a single electrostatic interaction with ELA peptide 
residue Gly
P4
. The CDR1  loop plays a more dominant role in contacting the ELA 
peptide, with TCR residue Gln
31
 making a significant network of contacts to ELA 
peptide residues Glu
P1
, Leu
P2
, Gly
P4
 and Ile
P5
. More specifically, the CDR1  loop 
uses side chain atoms to contact the peptide. Cole et al. (Cole, Yuan et al. 2009) 
suggest that changes to the sequence of this loop would therefore not be well tolerated 
and may well abrogate TCR recognition of peptide. The results of the Mel-5 TCR 
affinity maturation (Chapter 3) lend credence to this hypothesis. The CDR1  
mutations are predominantly at positions 27 and 28, whilst Gln
31
 remains invariant 
(except when replaced with an amber codon, suppressible to Gln) (Chapter 3; Table 
3.6). Mutation of Gln
31
 likely results in loss of peptide binding and therefore such 
mutants were not selected during the panning process. Although residue Arg
28
 in the 
wild-type TCR makes four electrostatic interactions with the MHC surface, it is 
mutated in all CDR1  clones (Chapter 3; Table 3.6). The introduction of a 
phenylalanine or tyrosine residue at position 27 in over half of the clones may well 
compensate for the loss of these MHC contacts. Interestingly, the mutations isolated 
at positions 27 and 28 conferred only modest improvements in affinity (up to 2-fold) 
(Chapter 3; Table 3.7) and may have been selected on the basis of reduced expression 
mediated by an amber codon at position 28. Since the CDR3  loop makes minimal 
contact with the peptide it is surprising that affinity-enhancing mutations within this 
region were identified (Chapter 3; Table 3.3). Presumably, the mutated high affinity 
alpha chains make substantially more contacts with the peptide compared with the 
wild-type Mel-5 TCR. By contrast, the CDR3  loop makes a total of ten contacts 
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(five hydrogen bonds and five van de Waals interactions) between TCR residues 
Thr
96
, Leu
98
 and Gly
99
 and ELA peptide residues Ala
P3
, Gly
P4
, Ile
P5
, Gly
P6
, Ile
P7
 and 
Thr
P9
. Because the CDR3  loop largely makes contact with the ELA peptide main 
chain Cole et al. (Cole, Yuan et al. 2009) proposed the loop would be tolerant to 
changes to its sequence without the loss of peptide recognition. Accordingly, 
engineering of the CDR3  loop yielded mutants with significant changes from the 
wild-type sequence. Most notably, a leucine residue at position 103 was substituted 
for a tryptophan residue in all sequenced clones (Chapter 3; Table 3.6). Preference for 
a tryptophan residue conferred a substantial gain in affinity of up to 16-fold (Chapter 
3; Table 3.7). The CDR2  loop makes no contact with the ELA peptide and only a 
single electrostatic interaction between TCR residue Tyr
51
 and the MHC residue 
His
151
. Only a single CDR2  mutant was isolated and interestingly retained the 
residue Tyr
51
.  
The structures of the high affinity 1G4 TCR (Sami, Rizkallah et al. 2007) and the 
A6 TCR (D.K. Cole, manuscript in preparation) are now available and offer structural 
suggestions for the observed high affinity. Sami et al. (Sami, Rizkallah et al. 2007) 
showed that for the 1G4 TCR, increases in the shape complementarity  (SC) index 
(Lawrence and Colman 1993) of TCR/pMHC, TCR/peptide and TCR/Met
P4
Tyr
P5
 
peptide motif correlated well with increased affinity. Most strikingly were the 
observed increases in the SC index of the TCR/peptide, particularly when both CDR2 
and CDR3 mutations occurred simultaneously. The improved number of peptide 
contacts made as a consequence of the increased SC index provides a likely 
explanation for the increases in binding affinity and is in agreement with observations 
for the high affinity A6 TCR (D. K. Cole, manuscript in preparation). Whilst the 
geometry of the A6 TCR/HLA-A2-Tax interaction was largely unchanged between 
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the wild-type and high affinity TCRs, the affinity gains were therefore the result of 
other interactions. Indeed, an extra 28 van de Waals interactions were made between 
the high affinity TCR and the Tax peptide compared with the wild-type TCR. 
Although it seems likely that increases in the number of contacts made between the 
TCR and peptide are chiefly responsible for the high affinity binding, it would be 
hugely ambitious to predict the location and nature of these mutations and this is 
exemplified by the high affinity A6 TCR CDR3  mutant, A6c134 (M
99
S
100
A
101
Q
102
). 
Interestingly, the R102Q mutation resulted in the loss of 8 peptide contacts, attributed 
to the loss of a potential salt bridge forming between the Ser
100
 and Arg
102
 side chains. 
Indeed, the A6c134R (MSAR) derivative displayed higher binding affinity compared 
with A6c134 probably due the opening of the CDR3  loop to accommodate the Tax 
peptide residue Tyr
P5
. It is the combination of individual residues that generate high 
affinity binding and as such, the cooperativity between these residues, in the context 
of a multi-domain protein, cannot be predicted. It is also not possible to predict the 
effect mutations in one CDR loop will confer on the other non-targeted CDRs within 
the same or opposing chain. Although the A6c134 TCR  chain contained no 
mutations, the introduction of mutations in the  chain facilitated a number of 
additional contacts between the  chain and the Tax peptide compared with the wild-
type TCR.  
Kranz and colleagues have attempted to identify generic TCR mutations that are 
beneficial to protein expression (Richman, Aggen et al. 2009; Aggen, Chervin et al. 
2011). Whilst their studies highlighted common V-region mutations that permitted 
yeast surface display, many with clear structural advantages, a large number of 
changes however, were more difficult to comprehend. This provides a further 
example, in addition to those described earlier, of the challenge in designing rational 
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mutagenesis strategies that target only a specific collection of residues. For this 
reason, a directed evolution approach, in which mutations are enriched based on the 
Darwinian principle of selection, is the most effective method of identifying affinity-
enhancing mutations.  
The prevalence of aromatic residues in the pMHC binding loops of the affinity 
matured TCRs described in this thesis has been alluded to earlier (Chapter 6; Section 
6.4). Numerous studies have explored the unique properties of these residues that 
make them well suited for molecular recognition. Whilst most hydrophobic residues 
are mainly located in the interior of proteins, tyrosine and tryptophan are found in the 
interior and on the surface of proteins with similar frequency (Tsai, Lin et al. 1997). 
Studies of the amino acid composition of antibodies have highlighted the 
overabundance of aromatic residues, particularly tyrosine and tryptophan in the CDR 
loops that comprise the interface with the antigen (Padlan 1994; Bogan and Thorn 
1998; Lo Conte, Chothia et al. 1999). The frequency of tyrosine and tryptophan 
residues in the contact area has been attributed to their capacity to mediate multiple 
types of intermolecular interactions, including aromatic π interactions, hydrogen 
bonding via the hydroxyl group, van der Waals interactions and hydrophobic 
interactions (Bogan and Thorn 1998).  
The importance of aromatic residues in contributing to high affinity binding of the 
engineered 1G4 TCR has been demonstrated (Sami, Rizkallah et al. 2007). The role 
attributed to tyrosine residues in mediating key contacts between the TCR loops was 
two-fold. First, a V94L substitution in the high affinity CDR3  clone provided a more 
favourable contact with the aromatic ring of wild-type residue Tyr
100
 to enable the 
CDR3 loops to lock around the central peptide residues Met
P4
Trp
P5. Second, π ring 
stacking interactions between CDR1/CDR3  loops and peptide residue Trp
P5
 were 
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implicated in generating high affinity since a Y31D  substitution, that abrogated 
aromatic stacking, dramatically reduced binding affinity.  
More recently, a structure-based design was used to indentify affinity-enhancing 
mutations at the A6 TCR-HLA-Tax interface (Haidar, Pierce et al. 2009). Four 
mutations were identified that individually increased the affinity as much as 6-fold 
(for an D26W substitution) and in combination by nearly 100-fold. The mutations 
that increased the binding affinity were hydrophobic substitutions that improved 
complementarity and hydrophobic packing. A drawback, however, of structure-based 
approaches is that cooperativity between residues, frequently seen in the mutants 
selected from a directed evolution strategy, may not be observed since a selective 
pressure has not been applied. Haider et al. (Haidar, Pierce et al. 2009) combined the 
highest binding five point mutations (  chain motif W
26
F
27
T
28
M
51
T
100
) that 
individually improved the affinity for pMHC up to 6-fold. Surprisingly, the 
combination only yielded a ~9-fold gain in affinity over the wild-type TCR. Structure 
analysis suggested the side chains of W
26
 and T
28
 were incompatible. Accordingly, 
replacing the wild-type G
28
 produced a dramatic improvement in affinity of nearly 
100-fold.   
The nature of the antigenic peptide clearly plays an integral role in shaping the 
output of affinity selection strategies. In the case of the 1G4 TCR (Sami, Rizkallah et 
al. 2007), the CDR3 loops clamp around the central Met
P4
Tyr
P5
 peptide residues that 
protrude directly into the solvent. However, not all peptides present “interesting” 
residue side chains and instead present fairly flat antigenic surfaces as demonstrated 
by the HLA-A1-MAGE-A1 (EADPTGHSY) peptide complex recognised by the high 
affinity Fab-Hyb3 (Hulsmeyer, Chames et al. 2005). In this example, a lack of 
solvent-accessible peptide side chain contacts is alleviated by a density of water 
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molecules that mediate hydrogen bonding between Hyb3 CDR loops and the MAGE-
A1 peptide. The antibody makes 8 contacts with the MAGE-A1 peptide; 4 direct 
hydrogen bonds and 4 water-bridged contacts. This may provide a possible 
mechanism for the MAGE-A3 TCR (Chapter 5) to engage the HLA-A1-MAGE-A3 
(EVDPIGHLY) peptide complex in which six of the nine peptide residues are shared 
with MAGE-A1 epitope.  
 
6.6 Specificity 
A central feature underpinning T-cell function that appears implicitly paradoxical is, 
on the one hand, the capacity to discriminate between variant peptides with a high 
level of specificity, whilst on the other hand, the propensity to cross-react with a 
multitude of peptide ligands. A resolution to this incongruity is based on numerical 
considerations. Combinatorial rearrangement of TCR gene segments has the capacity 
to generate ~10
15
 unique TCRs. However, the final repertoire of TCRs that survive 
the culling process of thymic selection has been estimated to be around 25 million 
(Arstila, Casrouge et al. 1999). The total number of possible decamer peptides that 
can be generated from the 20 proteinogenic amino acids is >10
13
. Assuming that 1% 
of these peptides bind to MHC (~10
11
) and a single TCR can functionally recognise 
~10
6 
decamer peptides, a cross-reactivity frequency of only 1:100,000 manifests 
(Mason 1998; Sewell 2012; Wooldridge, Ekeruche-Makinde et al. 2012). Therefore, 
in terms of the number of possible peptides recognised, TCRs appear considerably 
cross-reactive, yet in terms of the frequency of peptides recognised in the context of 
the vast peptide universe, TCRs appear highly specific (Donermeyer, Weber et al. 
2006). 
A further enigma in the study of T-cell antigen recognition is the high specificity-
low affinity TCR-pMHC interaction. It is difficult to assign a generic definition to 
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specificity since there is no intrinsic unit of measurement. A determination of 
specificity is dependent on the design, conditions and stringency of the experimental 
model. In terms of three-dimensional (3D) biophysical analysis by surface plasmon 
resonance (SPR), binding affinities between TCR and variant pMHC ligands may 
indicate specificity based on defined kinetic parameters. Alternatively, in the context 
of a two-dimensional (2D) cellular environment, the interaction between a TCR and 
pMHC that is sufficient to induce productive intracellular signalling and activation 
provides a measure of T-cell responsiveness or specificity towards a given antigen.   It 
is important to distinguish between TCR intrinsic affinity which is a measure of the 
strength of binding of monomeric interactions between one TCR molecule and the 
pMHC ligand and TCR avidity, which is the combined synergistic outcome of 
multiple TCR-pMHC interactions that occur at the T-cell-APC contact zone.   
T-cell recognition is highly sensitive such that engagement with a single agonist 
pMHC ligand is sufficient for T-cell stimulation (Irvine, Purbhoo et al. 2002; 
Purbhoo, Irvine et al. 2004; Morris and Allen 2012). This level of sensitivity is all the 
more extraordinary considering the background of 10
5
 or so irrelevant pMHC 
molecules on the surface of antigen presenting cells (Yewdell 2001). The binding 
affinity between soluble TCR and pMHC, as determined by SPR, which is typically in 
the low micromolar range (Davis, Boniface et al. 1998; Cole, Pumphrey et al. 2007; 
Stone, Chervin et al. 2009), seemingly is not consistent with this observation. The 
mechanisms that govern such remarkable T-cell sensitivity are not fully understood. 
However, the 3D biophysical measurements do not account for the complexity of the 
synaptic environment. For example, a clear role in enhancing T-cell sensitivity has 
been attributed to CD8 co-receptor molecules (Wooldridge, van den Berg et al. 2005; 
Laugel, van den Berg et al. 2007; Cole, Laugel et al. 2012) and to the formation of 
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microclusters of multivalent TCRs at the TCR-pMHC interface (Schamel, Arechaga 
et al. 2005; Lillemeier, Mortelmaier et al. 2009). 
Measurements of the 2D TCR-pMHC interactions at the cell surface show that the 
kinetics differ markedly from the corresponding 3D (SPR) values (Huang, Zarnitsyna 
et al. 2010; Huppa, Axmann et al. 2010). These studies, which are seen by many 
researchers to more accurately reflect the T-cell-APC interaction, show the higher 
affinity TCR-pMHC kinetics are the result of significantly increased association rates. 
Huang et al. (Huang, Zarnitsyna et al. 2010) propose that the rapid kinetics allows the 
T-cell to sample a vast array of pMHC complexes with the sensitivity required to 
discriminate between variant ligands, since the fast off-rates associated with the 
breaking of bonds are recompensed by the rapid on-rates and the reforming of bonds. 
The resulting rapid serial engagement of the rare agonist pMHC molecules, against a 
background of self-pMHC, amplifies the binding signals that influence T-cell 
responsiveness.   
In general, there is a good correlation with T1/2 and the strength of T-cell activation 
(Davis, Boniface et al. 1998; Gascoigne, Zal et al. 2001; van der Merwe and Davis 
2003). Several TCR triggering models have been proposed to reconcile the low 
affinity TCR-pMHC interactions with the exquisite sensitivity of T-cell activation 
(van der Merwe and Dushek 2011). Kinetic models (McKeithan 1995; Rabinowitz, 
Beeson et al. 1996) suggest that potent T-cell activation is dictated by the duration of 
the TCR-pMHC interaction since sufficient time is required to allow completion of 
the intracellular signalling cascade that involves the multistep phosphorylation  of 
CD3 subunits (Kersh, Shaw et al. 1998). By contrast, the serial engagement model 
stipulates that the dissociation rates need to be sufficiently short to allow multiple 
TCRs to interact with the same pMHC (Valitutti, Muller et al. 1995; Valitutti and 
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Lanzavecchia 1997). Both models predict an optimal T1/2 for the TCR-pMHC 
interaction and that above or below an ‘affinity ceiling’, T-cell sensitivity is impaired 
(Sewell 2002; Schmid, Irving et al. 2010). The ‘affinity ceiling’ hypothesis has been 
challenged by Kranz and colleagues (Holler and Kranz 2003) since T-cells transfected 
with high affinity TCRs (T1/2 100-fold slower than the wild-type TCR) were potently 
activated. However, a caveat to these findings is that the T-cells bearing TCRs 
engineered with supraphysiological affinities lost peptide fine-specificity (Holler, 
Chlewicki et al. 2003). Moreover, a trade-off between T-cell potency as the TCR 
affinity increased and the increased number of stimulatory peptides that the T-cell 
could recognise was observed (Donermeyer, Weber et al. 2006). These findings 
impact significantly on the design of T-cell gene therapy strategies; it is imperative 
that the engineered TCRs do not exceed an affinity threshold above which off target 
activity against self-pMHCs is mediated. Morgan and colleagues (Zhao, Bennett et al. 
2007) in a recent study provided support for such a cautious approach. They 
demonstrated that increased off target activity correlated with increased TCR affinity, 
since CD8
+
 T-cells transfected with high affinity TCRs (ranging from 84 nM to 26 
pM) lysed T2 cells pulsed with noncognate peptide, whereas those transfected with a 
moderate affinity (4 M) TCR only lysed T2 cells pulsed with cognate peptide and 
not control targets.  
Despite these investigations into the effect of increasing TCR affinity on the 
potency of T-cell activation and antigen recognition have been made in the context of 
T-cell therapy, the observations provide clear support for the rationale behind 
engineering high affinity soluble TCRs as an efficient means to overcome the 
limitations of natural TCR-mediated antigen recognition. Whilst there are concerns 
regarding potential cross-reactivity of picomolar-affinity soluble TCR reagents to 
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non-target epitopes, our lab has recently demonstrated that target cell lysis is specific 
even at pMHC class I levels as low as 2-10 copies per cell and is restricted to cells 
presenting cognate pMHC complexes (Liddy, Bossi et al. 2012).   
 
6.7 Closing remarks and future perspectives 
The work presented here demonstrates that the phage display methodologies 
employed to increase antibody affinity can be successfully modified to the 
engineering of TCRs for high affinity. Importantly, picomolar affinity TCRs can be 
produced, commonly with T1/2 values of many hours, by combining multiple mutated 
CDR segments into the same molecule. This general observation is imperative to the 
successful application of TCRs as immune therapeutics since the antigenic peptides 
recognised by TCRs are presented at extremely low levels at the surface of tumour 
cells.  
Antibodies have become the benchmark for the targeted treatment of malignant 
cells. The membrane-bound targets for antibodies are intact proteins. By contrast, 
TCRs recognise the degradation products of intracellular proteins that are loaded onto 
MHC molecules and displayed at the cell surface for inspection by patrolling 
cytotoxic T-cells. This continuous process of peptide fragmentation and presentation 
which takes place in almost all cells generates an enormous repertoire of diverse 
TCR-accessible peptide targets that substantially exceeds the potential antibody 
targets. The development of high affinity TCR-based therapeutics provides the first 
tumour-targeting agent able to exploit this vast array of antigens inaccessible to any 
other naturally-occurring molecule. The first of these reagents is now being tested in 
clinical trials; if successful, the versatility of the TCR-pHLA platform potentially 
makes it relevant for virtually every form of cancer.  High affinity bispecific TCRs 
have potential beyond targeted cancer therapy. A similar approach of enhancing a 
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targeted immune response, could be used to selectively lyse virally-infected cells or 
alternatively, to dampen autoimmunity by conjugation of a high affinity TCR 
molecule to an immunosuppressive effector.  
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